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ABSTRACT	  
MOLECULAR	  MECHANISMS	  UNDERLYING	  THE	  MUSCLE	  RESPONSE	  TO	  
EXERCISE-­‐INDUCED	  MUSCLE	  DAMAGE	  IN	  CHRONIC	  CIGARETTE	  SMOKERS	  	  SEPTEMBER	  2015	  	  NINA	  A.	  MOORE,	  B.Mus,	  UNIVERSITY	  OF	  MASSACHUSETTS	  AMHERST	  	  M.S.,	  UNIVERSITY	  OF	  MASSACHUSETTS	  AMHERST	  	  Ph.D.,	  UNIVERSITY	  OF	  MASSACHUSETTS	  AMHERST	  	  Directed	  by:	  Priscilla	  M.	  Clarkson	  and	  Professor	  Lawrence	  M.	  Schwartz	  	  	  
Smoking increases risk for musculoskeletal injury and protracts healing. The 
underlying mechanisms have not been explored, yet dysregulated inflammatory responses 
may contribute. To investigate these risks, Study 1 of this dissertation monitored typical 
responses to muscle damaging eccentric	  contractions	  (ECC)	  in	  smokers	  and	  non-­‐smokers.	  Smokers	  experienced	  greater	  muscle	  fatigue	  both	  during	  and	  immediately	  after	  ECC	  and	  greater	  delayed	  hyperalgesia,	  a	  phenomenon	  known	  as	  delayed	  onset	  muscle	  soreness	  (DOMS),	  than	  did	  non-­‐smokers.	  DOMS	  (driven	  by	  inflammation)	  peaks	  48h	  after	  ECC,	  when	  there	  is	  a	  shift	  from	  pro-­‐	  to	  anti-­‐inflammatory	  signaling;	  thus	  I	  chose	  to	  investigate	  this	  time	  further	  in	  smokers.	  The	  “late	  inflammation”	  time	  point	  is	  relatively	  unstudied	  mechanistically.	  Therefore,	  in	  Study	  2	  I	  further	  characterized	  the	  post-­‐ECC	  muscle	  response	  in	  non-­‐smokers	  and	  focused	  on	  hyperalgesic	  pathways.	  Transcriptome	  analyses	  revealed	  greater	  proliferation	  and	  pro-­‐inflammatory	  signaling	  at	  3h,	  which	  returned	  to	  baseline	  by	  48h.	  Activity	  of	  key	  regulatory	  pathways	  canonical	  (p65)	  nuclear	  factor	  kappa-­‐beta	  (NFκB)	  and	  extracellular	  regulated	  kinase	  (ERK)1/2	  mimicked	  the	  pro-­‐	  (activated)	  to	  anti-­‐
	  viii	  
inflammatory	  (de-­‐activated)	  shift.	  In	  addition,	  nerve	  growth	  factor	  (NGF),	  a	  hyperalgesic-­‐modifier,	  was	  also	  induced.	  Further	  testing	  revealed	  suppressed	  48h	  p65	  activity.	  In	  Study	  3	  I	  tested	  these	  pathways,	  and	  non-­‐canonical	  NFκB	  (REL-­‐B)	  signaling	  (specifies	  oxidative	  muscle	  fibers),	  in	  skeletal	  muscle	  from	  smokers	  and	  non-­‐smokers	  48h	  post-­‐ECC.	  Smokers	  had	  fewer	  oxidative	  (Type	  I)	  muscle	  fibers.	  Further,	  REL-­‐B,	  enhanced	  in	  non-­‐smokers	  at	  48h,	  was	  suppressed	  in	  smokers.	  These	  findings	  may	  explain	  the	  greater	  fatigue	  in	  smokers,	  which	  can	  increase	  risk	  for	  injury.	  p65	  activity,	  suppressed	  at	  48h	  in	  non-­‐smokers,	  was	  unchanged	  in	  smokers,	  suggesting	  delayed	  pro-­‐inflammatory	  resolution.	  Active	  and	  total	  ERK	  levels	  were	  suppressed,	  overall,	  in	  smokers.	  While	  there	  were	  no	  differences	  in	  NGF	  levels	  or	  co-­‐localization	  with	  the	  TrkA	  receptor	  between	  smokers	  and	  non-­‐smokers,	  smokers	  did	  express	  higher	  p75NTR	  receptor	  levels,	  which	  may	  activate	  NFκB	  and	  promote	  hyperalgesia.	  NGF/p75NTR	  co-­‐localization	  at	  48h	  post-­‐ECC	  decreased	  in	  non-­‐smokers	  but	  increased	  in	  smokers.	  Higher	  DOMS,	  NGF,	  and	  NFκB	  signaling	  may	  indicate	  prolonged	  pro-­‐inflammatory	  signaling,	  delayed	  resolution,	  and	  protracted	  healing	  in	  smokers.	  This	  dissertation	  provides	  insights	  into	  mechanisms	  that	  appear	  to	  place	  smokers	  at	  greater	  risk	  for	  musculoskeletal	  injury	  and	  impaired	  healing.
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CHAPTER	  I	  
INTRODUCTION	  
Statement	  of	  the	  Problem	  Cigarette	  smoking	  is	  associated	  with	  increased	  risk	  for	  musculoskeletal	  injury	  (145,	  157)	  and	  prolonged	  healing	  (5,	  182).	  One	  common	  factor	  underlying	  many	  of	  the	  negative	  health	  consequences	  of	  smoking	  is	  a	  dysregulated	  inflammatory	  environment	  (23,	  71,	  81,	  101,	  320,	  329,	  348),	  which	  could	  contribute	  to	  increased	  musculoskeletal	  injury	  risk	  and	  delayed	  recovery.	  However,	  the	  precise	  molecular	  mechanisms	  linking	  smoking	  to	  increased	  injury	  risk	  are	  currently	  unknown.	  	  Muscle	  is	  a	  plastic	  tissue	  that	  undergoes	  constant	  change,	  either	  through	  normal	  protein	  turnover	  or,	  when	  exposed	  to	  exercise,	  by	  undergoing	  a	  highly	  coordinated	  program	  of	  remodeling.	  Remodeling	  can	  change	  muscle	  at	  structural	  and	  molecular	  levels,	  such	  as	  hypertrophy	  and	  fiber	  type	  shift,	  and	  consequently	  alters	  future	  function.	  When	  muscle	  is	  injured	  via	  strenuous	  exercise	  (especially	  muscle	  lengthening	  or	  eccentric	  exercise	  (ECC)),	  primary	  mechanical	  damage	  evokes	  a	  pro-­‐inflammatory	  response,	  which	  can	  then	  result	  in	  secondary	  damage.	  Secondary	  damage	  increases	  muscle	  breakdown,	  yet	  also	  stimulates	  repair	  and	  regeneration	  of	  the	  muscle.	  Repeated	  exposure	  to	  ECC	  results	  in	  adaptation,	  through	  which	  the	  muscle	  is	  strengthened	  and	  protected	  against	  future	  insult.	  Without	  secondary	  damage	  and	  inflammation,	  regeneration	  is	  delayed	  (190,	  221)	  and	  adaptation	  is	  attenuated	  (168,	  223).	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Secondary	  damage	  from	  inflammation	  can	  be	  categorized	  into	  two	  phases:	  early	  (~0-­‐2d	  after	  the	  initial	  insult)	  and	  late	  (≥2d),	  which	  can	  overlap	  around	  the	  2d	  post-­‐exercise	  time	  point.	  Under	  normal	  conditions,	  there	  is	  a	  balance	  between	  pro-­‐and	  anti-­‐inflammatory	  processes	  needed	  to	  maintain	  muscle	  homeostasis.	  In	  response	  to	  muscle	  injury,	  specifically	  exercise-­‐induced	  muscle	  damage	  (EIMD),	  the	  inflammatory	  balance	  tips	  to	  first	  favor	  pro-­‐inflammatory	  actions	  (early	  phase),	  then	  anti-­‐inflammatory	  ones	  (late	  phase),	  finally	  ending	  in	  resolution	  back	  to	  baseline.	  The	  shift	  between	  these	  phases,	  which	  occurs	  approximately	  2d	  post-­‐exercise,	  is	  an	  important	  time	  point	  in	  muscle	  regeneration.	  The	  majority	  of	  research	  into	  EIMD	  has	  focused	  on	  the	  gross	  responses	  to	  ECC	  such	  as	  strength	  loss,	  while	  fewer	  studies	  have	  examined	  molecular	  responses,	  mostly	  at	  early	  (<1d)	  time	  points.	  The	  early	  phase	  of	  secondary	  damage	  has	  been	  moderately	  well	  explored	  (137,	  214,	  267,	  313,	  323),	  while	  later	  time	  points	  (particularly	  around	  the	  2d	  inflammatory	  shifting	  point)	  remain	  largely	  unexplored.	  Understanding	  how	  inflammation	  successfully	  resolves	  after	  EIMD	  would	  help	  clinicians	  optimize	  healing.	  Smokers	  exhibit	  alterations	  to	  the	  immune	  and	  inflammatory	  systems	  and	  are	  more	  susceptible	  to	  infection	  and	  complications	  following	  injury	  or	  surgery	  (143,	  225).	  In	  smokers,	  cytokines	  and	  chemokines	  tend	  to	  promote	  pro-­‐inflammatory	  signaling	  and	  neutrophil	  and	  macrophage	  numbers	  are	  enhanced	  with	  conversely	  suppressed	  activity	  including	  phagocytosis,	  respiratory	  bursts,	  and	  cytokine	  release	  (17,	  23,	  305,	  320).	  Together,	  these	  alterations	  generally	  promote	  a	  more	  pro-­‐inflammatory	  environment	  in	  smokers.	  However,	  it	  is	  unknown	  how	  this	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dysregulated	  inflammatory	  environment	  could	  impact	  smokers’	  response	  to	  EIMD.	  It	  is	  possible	  that	  dysfunctional	  inflammation	  and	  disrupted	  molecular	  signaling	  impair	  myogenesis,	  leading	  to	  inadequate	  muscle	  repair	  in	  smokers,	  which	  may	  explain	  the	  increased	  risk	  for	  musculoskeletal	  injury.	  	  	  
Aims	  and	  Hypotheses	  The	  primary	  goal	  of	  this	  dissertation	  was	  to	  understand	  how	  smoking	  affects	  muscle	  damage	  and	  recovery.	  To	  do	  this,	  I	  used	  ECC	  as	  a	  safe	  and	  effective	  model	  of	  transient	  muscle	  injury	  that	  elicits	  delayed	  onset	  muscle	  soreness	  (DOMS),	  strength	  loss,	  and	  the	  release	  of	  muscle-­‐specific	  proteins	  into	  the	  blood.	  The	  following	  set	  of	  experiments	  was	  designed	  to	  test	  the	  effects	  of	  smoking	  on	  EIMD,	  from	  the	  functional	  level	  down	  to	  the	  molecular	  level.	  	  
Study	  I:	  Smoking	  Decreases	  Muscle	  Function	  During	  Eccentric	  Exercise	  	  
and	  Increases	  Delayed	  Onset	  Muscle	  Soreness	  The	  first	  goal	  of	  this	  dissertation	  was	  to	  determine	  if	  the	  functional	  responses	  of	  smokers	  following	  ECC	  differed	  from	  that	  of	  non-­‐smokers.	  I	  hypothesized	  that,	  compared	  to	  non-­‐smokers,	  smokers	  would	  have	  a	  more	  pronounced	  damage	  response,	  experiencing:	  1)	  greater	  early	  strength	  loss;	  2)	  more	  prolonged	  strength	  loss;	  3)	  greater	  creatine	  kinase	  release;	  and	  4)	  greater	  soreness	  (both	  peak	  and	  prolonged)	  in	  response	  to	  ECC.	  	  Smokers	  in	  this	  study	  experienced	  greater	  muscle	  fatigue,	  as	  indicated	  by	  strength	  loss	  during	  (10%	  higher	  strength	  loss	  in	  smokers	  during	  final	  exercise	  set)	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and	  shortly	  (5min	  post)	  after	  ECC	  (~15%	  higher	  strength	  loss	  in	  smokers).	  Smokers	  performed	  the	  same	  amount	  of	  work	  (but	  generated	  fewer	  high-­‐force	  contractions	  during	  exercise),	  yet	  experienced	  the	  same	  level	  of	  prolonged	  (1-­‐5d	  post)	  strength	  loss	  as	  compared	  to	  non-­‐smokers.	  Finally,	  smokers	  experienced	  a	  higher	  peak	  (~15%	  greater	  in	  smokers)	  and	  greater	  overall	  (all	  time	  points	  combined)	  soreness	  than	  non-­‐smokers	  after	  exercise.	  These	  results	  add	  to	  the	  existing	  body	  of	  knowledge	  on	  the	  consequences	  of	  smoking	  by	  showing	  greater	  early	  fatigue,	  greater	  soreness,	  and	  similar	  strength	  loss	  in	  response	  to	  fewer	  high-­‐force	  eccentric	  contractions—indicating	  increased	  susceptibility	  to	  EIMD	  in	  smokers.	  	  	  
Study	  II:	  Transcriptome	  Analysis	  of	  Skeletal	  Muscle	  at	  Early	  (3h)	  	  
and	  Late	  (48h)	  Time	  Points	  after	  Eccentric	  Exercise	  In	  Study	  1,	  I	  found	  that	  smokers	  have	  greater	  peak	  and	  overall	  DOMS	  post-­‐exercise	  as	  compared	  to	  non-­‐smokers.	  The	  next	  step	  was,	  therefore,	  to	  examine	  potential	  molecular	  mechanisms	  that	  could	  drive	  the	  differences	  seen	  in	  Study	  1.	  Inflammation	  is	  widely	  considered	  the	  driving	  force	  behind	  DOMS.	  Given	  the	  additional	  importance	  of	  inflammation	  to	  the	  muscle	  repair/regeneration	  program,	  understanding	  mechanistic	  changes	  underlying	  the	  associated	  inflammation	  and	  its	  resolution	  following	  EIMD	  is	  critical.	  	  Mechanisms	  underlying	  inflammatory	  changes	  in	  the	  days	  following	  ECC	  are	  poorly	  understood,	  therefore	  it	  was	  important	  to	  next	  generate	  an	  in	  depth	  description	  of	  early	  (3h)	  versus	  late	  (48h)	  time	  points	  post-­‐ECC	  in	  non-­‐smokers	  –	  to	  have	  a	  normal	  pattern	  of	  response	  to	  which	  I	  could	  compare	  smokers	  in	  a	  follow-­‐up	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study.	  Consequently,	  the	  second	  goal	  of	  this	  dissertation	  was	  to	  use	  skeletal	  muscle	  transcriptome	  data	  to	  identify	  molecular	  changes	  across	  early	  and	  late	  inflammatory	  phases	  after	  ECC,	  and	  to	  use	  these	  results	  to	  identify	  candidate	  genes	  and	  pathways	  important	  to	  EIMD	  inflammatory	  processes,	  especially	  those	  related	  to	  DOMS,	  in	  non-­‐smokers.	  This	  would	  generate	  a	  working	  model	  of	  “normal”	  EIMD,	  repair,	  and	  DOMS	  to	  which	  I	  could	  then	  compare	  to	  the	  responses	  of	  smokers	  in	  Study	  3.	  I	  hypothesized	  that:	  1)	  early	  pathways	  in	  skeletal	  muscle	  would	  involve	  stress-­‐response	  genes	  and	  immediate	  pro-­‐inflammatory	  pathways;	  2)	  later	  (at	  48h),	  inflammation	  would	  continue	  to	  be	  a	  dominant	  force	  in	  the	  ECC	  response,	  evolving	  from	  the	  pro-­‐inflammatory	  expression	  at	  early	  time	  points	  to	  anti-­‐inflammatory	  signaling	  at	  48h;	  and	  3)	  altered	  expression	  in	  other	  signaling	  pathways	  would	  become	  evident	  at	  the	  later	  time	  points,	  including	  vascularization/angiogenesis	  and	  muscle	  structure.	  	  Study	  2	  identified	  3h	  activation	  of	  the	  extracellular	  regulated	  kinase	  (ERK)1/2	  pathway	  that	  was	  suppressed	  by	  48h	  post-­‐ECC.	  The	  ERK1/2	  pathway	  affects	  inflammatory	  signaling	  and,	  more	  specifically,	  promotes	  proliferation.	  I	  further	  determined	  that	  the	  canonical	  (p65:	  REL-­‐A,	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A)	  nuclear	  factor	  kappa-­‐beta	  (NFκB)	  pathway	  is	  also	  altered	  during	  the	  later	  damage	  response,	  with	  similar	  activation	  patterns	  as	  I	  found	  for	  ERK1/2.	  The	  canonical	  NFκB	  pathway	  promotes	  (among	  other	  effects)	  pro-­‐inflammatory	  actions	  and	  proliferation,	  while	  the	  non-­‐canonical	  (REL-­‐B,	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  B)	  pathway	  promotes	  oxidative	  metabolism	  and	  may	  affect	  anti-­‐inflammatory	  signaling.	  Finally,	  I	  identified	  changes	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over	  time	  for	  the	  co-­‐localization	  of	  nerve	  growth	  factor	  (NGF)	  and	  its	  receptors:	  tyrosine	  receptor	  kinase	  A	  (TrkA,	  high	  binding	  affinity)	  and	  p75	  neurotrophin	  receptor	  (p75NTR,	  low	  binding	  affinity).	  NGF	  stimulates	  activity	  of	  the	  NFκB	  and	  ERK	  pathways,	  which	  in	  turn	  can	  drive	  NGF	  expression.	  Evidence	  indicates	  that	  NGF	  binding	  to	  its	  receptors	  is	  related	  to	  various	  types	  of	  hyperalgesia,	  including	  that	  induced	  by	  ECC.	  Overall,	  the	  findings	  from	  Study	  2	  add	  to	  current	  understanding	  of	  the	  EIMD	  response	  by	  characterizing	  the	  molecular	  responses	  at	  48h	  post-­‐exercise	  in	  healthy	  non-­‐smokers.	  Having	  established	  this	  “normal”	  pattern	  of	  response,	  I	  then	  sought	  to	  compare	  molecular	  changes	  in	  smokers	  to	  this	  established	  pattern	  (Study	  3),	  particularly	  at	  the	  later	  time	  point.	  
	  
Study	  III:	  Molecular	  Effects	  of	  Smoking	  on	  Skeletal	  Muscle	  	  
48h	  after	  Eccentric	  Exercise	  In	  Study	  2,	  I	  found	  that	  the	  activity	  of	  ERK1/2	  and	  canonical	  NFκB	  pathways,	  as	  well	  as	  the	  hyperalgesic	  mediator	  NGF,	  differed	  between	  early	  and	  late	  phases	  of	  EIMD.	  Components	  of	  these	  proposed	  pathways	  are	  altered	  in	  various	  cells/tissues	  in	  smokers	  (6,	  53,	  56,	  138,	  332,	  368),	  although	  their	  expression	  or	  activity	  in	  skeletal	  muscle	  remains	  unexplored.	  The	  final	  goal	  of	  this	  dissertation	  was	  to	  evaluate	  the	  molecular	  pathways	  identified	  in	  Study	  2	  in	  smokers	  at	  48h	  after	  ECC	  in	  newly	  collected	  skeletal	  muscle	  biopsies.	  I	  hypothesized	  that:	  1)	  smokers	  would	  have	  a	  greater	  proportion	  of	  Type	  II	  fibers	  and	  suppressed	  REL-­‐B	  activity	  at	  48h	  post-­‐ECC	  compared	  to	  non-­‐smokers;	  2)	  after	  ECC	  the	  activity	  of	  the	  canonical	  NFκB	  pathway	  would	  be	  suppressed	  in	  non-­‐smokers	  but	  not	  in	  smokers;	  3)	  nuclear	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activity	  of	  the	  ERK	  pathway	  would	  increase	  for	  non-­‐smokers	  while	  activity	  would	  be	  concentrated	  in	  the	  cytoplasm	  for	  smokers;	  and	  4)	  NGF	  levels	  and	  receptor	  co-­‐localization	  would	  be	  more	  pronounced	  in	  smokers	  versus	  non-­‐smokers.	  	  I	  found	  that	  non-­‐smokers	  had	  an	  equal	  ratio	  of	  Type	  I:Type	  II	  muscle	  fibers	  and	  increased	  activation	  of	  the	  non-­‐canonical	  (REL-­‐B)	  NFκB	  pathway	  after	  ECC.	  In	  contrast,	  smokers	  had	  a	  greater	  percentage	  of	  Type	  II	  (non-­‐oxidative)	  muscle	  fibers	  and	  no	  change	  to	  REL-­‐B	  activity.	  The	  REL-­‐B	  pathway	  stimulates	  oxidative	  metabolism,	  and	  indicates	  a	  signaling	  mechanism	  through	  which	  smoking	  may	  affect	  muscle	  fiber	  type,	  resulting	  in	  lower	  fatigue	  resistance	  and	  higher	  risk	  for	  injury	  in	  smokers.	  	  p65	  activity,	  suppressed	  post-­‐ECC	  in	  non-­‐smokers,	  did	  not	  change	  in	  smokers	  and	  thus	  could	  impede	  inflammatory	  resolution.	  Smokers	  had	  suppressed	  ERK	  activity	  in	  the	  cytosol	  and,	  in	  the	  nucleus,	  a	  diminished	  capacity	  for	  ERK	  activity	  due	  to	  lower	  total	  ERK,	  suggesting	  that	  smokers	  may	  have	  a	  blunted	  ERK	  response	  when	  a	  more	  substantial	  one	  is	  needed.	  NGF	  levels	  did	  not	  differ	  with	  exercise	  or	  smoking	  and,	  although	  smokers	  had	  greater	  TrkA	  expression,	  NGF/TrkA	  co-­‐localization	  was	  not	  affected	  by	  smoking	  or	  exercise.	  p75NTR	  protein	  expression	  was	  elevated	  in	  smokers	  but	  not	  with	  exercise.	  NGF/p75NTR	  co-­‐localization	  was	  greater	  than	  NGF/TrkA	  co-­‐localization	  in	  both	  groups.	  Further,	  NGF/p75NTR	  co-­‐localization	  was	  greater	  overall	  in	  smokers	  and,	  after	  ECC,	  decreased	  in	  non-­‐smokers	  but	  was	  enhanced	  in	  smokers.	  Altogether,	  these	  data	  suggest	  a	  mechanism	  through	  which	  smoking	  may	  prevent	  the	  resolution	  of	  NFκB	  activity,	  promoting	  further	  pro-­‐inflammatory	  activity,	  and	  enhance	  DOMS	  after	  EIMD.	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The	  findings	  from	  Study	  3	  add	  to	  our	  current	  understanding	  of	  muscle	  health	  and	  the	  EIMD	  response	  at	  48h	  post-­‐exercise	  in	  smokers.	  Further,	  they	  suggest	  mechanisms	  through	  which	  smoking	  leads	  to	  suppressed	  fatigue	  resistance	  during	  ECC	  and	  greater	  DOMS.	  Together,	  these	  data	  offer	  several	  means	  through	  which	  smoking	  could	  enhance	  susceptibility	  to	  injury.	  	  
Significance	  Smoking	  is	  still	  common	  in	  many	  parts	  of	  the	  world,	  and	  rates	  are	  higher	  among	  various	  groups	  including	  active	  duty	  military	  personnel.	  Smokers	  have	  a	  higher	  risk	  for	  musculoskeletal	  injury	  and	  disability,	  leading	  to	  loss	  of	  work	  and	  combat	  time,	  increased	  risk	  for	  future	  injury,	  and	  a	  high	  financial	  burden	  associated	  with	  loss	  of	  productivity	  and	  medical	  costs.	  Therefore,	  these	  data	  are	  of	  significant	  interest	  to	  public	  health.	  This	  line	  of	  research	  helps	  us	  understand	  why	  smokers	  are	  more	  susceptible	  to	  the	  negative	  effects	  of	  muscle	  stress.	  I	  have	  shown	  that	  smokers	  experience	  higher	  soreness	  (which	  could	  make	  smokers	  less	  prone	  to	  continue	  an	  exercise	  program),	  indicating	  a	  dysregulated	  inflammatory	  program	  post-­‐exercise,	  and	  suggest	  NGF,	  via	  the	  p75NTR	  receptor,	  is	  a	  mechanism	  to	  explain	  the	  greater	  soreness.	  	  Data	  from	  these	  studies	  may	  help	  explain	  increased	  risk	  for	  musculoskeletal	  injury	  in	  smokers,	  as	  well	  as	  provide	  insight	  into	  prolonged	  healing	  in	  smokers	  (5,	  143,	  157,	  317).	  In	  addition,	  I	  have	  added	  to	  our	  knowledge	  of	  the	  normal	  role	  of	  inflammatory	  signaling	  in	  muscle	  damage	  and	  remodeling	  through	  NFκB	  and	  NGF	  signaling.	  These	  data	  further	  inform	  the	  field	  about	  the	  signaling	  shifts	  that	  occur	  at	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48h	  post-­‐exercise,	  and	  how	  alterations	  to	  this	  shift	  may	  ultimately	  affect	  muscle	  repair	  and	  overall	  muscle	  health.
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CHAPTER	  II	  
LITERATURE	  REVIEW	  
Introduction	  	  Cigarette	  smoking	  is	  associated	  with	  a	  wide	  variety	  of	  negative	  health	  consequences,	  from	  increased	  susceptibility	  to	  viral	  and	  bacterial	  infection	  (64,	  153,	  253)	  to	  diseases	  such	  as	  chronic	  obstructive	  pulmonary	  disease	  (COPD)	  and	  an	  array	  of	  cancers	  (106,	  301).	  Less	  well	  characterized	  are	  the	  effects	  of	  chronic	  smoking	  on	  skeletal	  muscle.	  Epidemiological	  studies	  report	  increased	  risk	  of	  musculoskeletal	  injury	  and	  prolonged	  disability	  in	  smokers	  (5,	  145,	  182),	  though	  the	  cellular	  and	  molecular	  mechanisms	  driving	  these	  associations	  are	  not	  clear.	  	  Skeletal	  muscle	  is	  a	  plastic	  and	  resilient	  tissue	  that	  can	  adapt	  to	  a	  variety	  of	  conditions,	  including	  alterations	  to	  activity	  (15,	  142,	  323,	  380,	  381).	  Strenuous	  (typically	  novel)	  activity	  can	  damage	  muscle,	  which	  then	  undergoes	  repair	  during	  which	  irreparable	  tissue	  is	  removed,	  muscle	  progenitor	  cells	  fuse	  with	  surviving	  fibers,	  and	  new	  proteins	  are	  produced	  and	  incorporated	  into	  the	  contractile	  apparatus.	  Successful	  repair	  is	  often,	  but	  not	  always,	  complemented	  by	  muscle	  adaptation	  via	  the	  remodeling	  of	  existing	  fibers	  (380,	  383),	  resulting	  in	  attenuated	  future	  damage	  responses	  to	  similar	  stresses	  (77).	  	  Inflammation	  is	  vitally	  important	  in	  muscle	  repair	  and	  remodeling	  and	  changes	  in	  the	  inflammatory	  process	  are	  a	  potential	  mechanism	  by	  which	  smoking	  could	  increase	  injury	  risk.	  Both	  pro-­‐	  and	  anti-­‐inflammatory	  processes	  take	  place	  following	  the	  damage-­‐inducing	  stimuli	  in	  a	  time-­‐dependent	  manner,	  first	  to	  generally	  enhance,	  and	  later	  to	  quench	  inflammation	  and	  promote	  proliferation	  and	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healing.	  From	  0d	  to	  1-­‐2d	  following	  a	  damaging	  stimulus,	  the	  inflammatory	  environment	  is	  predominantly	  pro-­‐inflammatory,	  referred	  to	  throughout	  this	  dissertation	  as	  the	  “early”	  phase	  of	  inflammation.	  A	  large	  pro-­‐inflammatory	  response	  can	  create	  secondary	  damage,	  especially	  if	  unquenched.	  Quenching	  occurs	  as	  the	  muscle	  shifts	  into	  a	  second,	  anti-­‐inflammatory	  phase	  of	  inflammation	  (referred	  to	  throughout	  this	  dissertation	  as	  the	  “late”	  phase	  of	  inflammation),	  which	  also	  serves	  to	  stimulate	  repair	  and	  adaptation.	  The	  transition	  from	  early	  to	  late	  phase	  occurs	  ~2d	  after	  damage,	  though	  timing	  can	  vary	  depending	  on	  the	  stimulus	  and	  high	  inter-­‐subject	  variability.	  Without	  proper	  shifting	  of	  the	  inflammatory	  balance	  during	  recovery,	  repair	  can	  be	  delayed	  and	  adaptation	  attenuated	  (168,	  221,	  223,	  342).	  However,	  the	  mechanisms	  controlling	  damage	  and	  repair	  during	  this	  shift	  are	  poorly	  understood.	  	  Exposure	  to	  cigarette	  smoke	  can	  alter	  inflammation,	  affecting	  damage	  and	  repair	  responses.	  Higher	  rates	  of	  secondary	  complications	  after	  injury	  and	  surgery	  (infection,	  attenuated	  healing,	  longer	  time	  to	  recovery	  (163,	  182,	  316,	  317))	  occur	  in	  smokers,	  effects	  thought	  to	  be	  partially	  due	  to	  dysregulated	  inflammation	  (32,	  101,	  165,	  305,	  306,	  316,	  320).	  Recent	  experimental	  data	  showed	  that	  smoking	  suppressed	  inflammation	  and	  wound	  healing	  one	  week	  after	  a	  skin	  punch	  biopsy	  injury,	  while	  smoking	  cessation	  promoted	  a	  return	  to	  normal	  inflammatory	  responses	  and	  wound	  healing	  (317).	  With	  previous	  data	  regarding	  smoking	  and	  disability	  after	  musculoskeletal	  injury,	  these	  results	  suggest	  that	  dysregulated	  inflammation	  in	  smokers	  could	  be	  a	  possible	  mechanism	  through	  which	  smoking	  impairs	  healing,	  promotes	  disability,	  and	  increases	  the	  risk	  for	  future	  injury.	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The	  primary	  goal	  of	  this	  dissertation	  was	  to	  understand	  how	  smoking	  affects	  muscle	  damage	  and	  recovery.	  I	  first	  investigated	  the	  effects	  of	  smoking	  on	  skeletal	  muscle	  function	  and	  markers	  of	  damage	  following	  exercise.	  Second,	  I	  explored	  in-­‐depth	  the	  molecular	  processes	  that	  occur	  during	  the	  shift	  from	  “early”	  to	  “late”	  phases	  of	  inflammation	  after	  exercise	  to	  provide	  better	  context	  for	  understanding	  the	  final	  portion	  of	  my	  dissertation,	  which	  hypothesized	  that	  dysregulated	  inflammation	  during	  damage/repair	  in	  smokers	  causes	  greater	  damage	  and	  inhibits	  muscle	  repair.	  The	  following	  literature	  review	  provides	  a	  summary	  and	  discussion	  of	  smoking	  and	  injury	  risk,	  normal	  muscle	  damage	  and	  repair,	  and	  possible	  mechanisms	  by	  which	  smoking	  could	  modify	  damage	  and	  repair.	  	  	  
Cigarette	  Smoking	  Cigarette	  smoking	  has	  been	  associated	  with	  a	  variety	  of	  adverse	  health	  effects	  ranging	  from	  inflammatory	  airway	  diseases	  (such	  as	  chronic	  obstructive	  pulmonary	  disease)	  to	  cancer.	  Unless	  otherwise	  noted,	  most	  data	  discussed	  throughout	  this	  dissertation	  were	  collected	  from	  chronic	  smokers—those	  at	  greatest	  risk	  for	  negative	  consequences	  and	  who	  have	  been	  most	  studied.	  Smokers	  have	  greater	  susceptibility	  to	  and	  take	  longer	  to	  recover	  from	  viral	  and	  bacterial	  illness	  and	  infection	  (64,	  153,	  253),	  and	  experience	  impaired	  healing	  and	  greater	  risk	  of	  complications	  after	  injury	  and	  surgery	  (82,	  117,	  163).	  Risk	  for	  injury	  (212,	  237,	  285)	  and	  prolonged	  disability	  (182,	  363)	  are	  higher	  in	  smokers.	  Among	  these	  risks	  is	  an	  increased	  incidence	  of	  musculoskeletal	  injury	  and	  delayed	  return	  to	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normal	  activity	  (5,	  145,	  157,	  182,	  286,	  343),	  though	  the	  molecular	  mechanisms	  driving	  these	  effects	  are	  currently	  unknown.	  	  	  
Smoking	  and	  General	  Injury	  Risk	  Epidemiological	  data	  report	  approximately	  2-­‐fold	  greater	  risk	  for	  overall	  injury	  among	  smokers.	  This	  has	  been	  primarily	  described	  in	  the	  workplace	  (47-­‐49,	  212,	  237,	  285,	  293,	  339,	  343,	  354)	  and	  in	  the	  military	  (5,	  145,	  157,	  286).	  Wen	  and	  colleagues	  (366)	  reported	  that	  death	  resulting	  from	  injury	  is	  also	  more	  common	  in	  smokers	  than	  non-­‐smokers.	  This	  risk	  was	  dose-­‐dependent,	  such	  that	  those	  that	  smoked	  >20	  cigarettes	  per	  day	  had	  the	  greatest	  risk	  (>5	  times	  greater	  chance	  of	  death	  from	  a	  work-­‐related	  injury	  than	  that	  of	  non-­‐smokers).	  Higher	  rates	  of	  injury	  not	  resulting	  in	  death,	  including	  traumatic	  and	  repetitive	  strain	  injury,	  have	  also	  been	  well	  documented	  among	  smokers	  in	  the	  workplace	  across	  cultures.	  For	  example,	  a	  greater	  than	  2-­‐fold	  risk	  for	  injury	  incurred	  at	  work	  has	  been	  reported	  in	  smokers	  when	  compared	  to	  non-­‐smokers	  both	  in	  Northern	  France	  (47)	  and	  Great	  Britain	  (354).	  	  Similar	  rates	  of	  injury	  occur	  across	  professions	  with	  varying	  degrees	  of	  physical	  demand,	  including	  those	  working	  in	  agriculture	  (212),	  construction	  (48),	  railway	  laborers	  (49),	  manufacturing	  (237)	  and	  postal	  workers	  (293).	  Heightened	  risk	  for	  repetitive	  strain	  injury	  in	  the	  upper	  extremities	  has	  been	  reported	  (285,	  339)	  in	  smokers.	  Furthermore,	  worker’s	  compensation	  claims	  for	  back	  injury	  are	  higher	  in	  current	  smokers	  (adjusted	  odds-­‐ratio	  (OR):	  1.64)	  than	  former	  (OR:	  1.56)	  or	  non-­‐smokers	  (OR:	  1.00),	  suggesting	  a	  delayed	  recovery	  in	  smokers	  (363).	  Other	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data	  suggest	  that	  this	  effect	  is	  dose-­‐dependent,	  with	  time-­‐loss	  injury	  being	  lowest	  in	  light	  (<11	  cigarettes	  per	  day,	  OR:	  1.6)	  and	  highest	  in	  heavy	  male	  smokers	  (>20	  cigarettes	  per	  day,	  OR:	  2.8)(157).	  Women	  had	  similar	  risks,	  with	  even	  higher	  risks	  for	  heavy	  smokers	  (OR:	  4.4).	  	  	  
Smoking	  and	  Musculoskeletal	  Injury	  While	  the	  increased	  risk	  of	  general	  injury	  in	  smokers	  is	  important	  to	  public	  health,	  the	  incidence	  of	  musculoskeletal	  injury	  is	  of	  greatest	  interest	  to	  this	  dissertation.	  Increased	  risk	  for	  musculoskeletal	  injury	  in	  smokers	  is	  particularly	  notable	  in	  the	  military	  (5,	  145,	  157,	  182,	  286),	  where	  recruits	  and	  active	  duty	  service-­‐members	  are	  subjected	  to	  intense	  physical	  stresses.	  These	  effects	  are	  seen	  in	  both	  current	  and	  recent	  smokers	  (those	  who	  have	  recently	  quit,	  typically	  upon	  entering	  basic	  training),	  indicating	  that	  the	  mechanisms	  driving	  increased	  injury	  are,	  at	  least	  in	  part,	  persistent.	  During	  basic	  training,	  where	  smoking	  is	  not	  permitted,	  personnel	  who	  had	  smoked	  before	  entering	  training	  remained	  at	  increased	  risk	  for	  injury	  (5,	  157);	  among	  those	  who	  had	  quit	  within	  the	  past	  year,	  women	  continued	  to	  have	  a	  higher	  risk	  (OR:	  1.6),	  while	  injury	  risk	  in	  men	  decreased	  below	  that	  of	  non-­‐smokers	  (OR:	  0.7)	  (157).	  Altarac	  and	  colleagues	  (5)	  reported	  that	  risk	  varied	  depending	  on	  the	  type	  of	  injury	  between	  1.32	  (overuse)	  and	  1.62	  (traumatic)	  in	  men,	  with	  greater	  time	  lost	  from	  training	  after	  injury	  in	  smokers	  (OR:	  1.47	  for	  ≥	  6d	  lost).	  Injury	  risk	  was	  also	  dose-­‐dependent,	  with	  those	  who	  smoked	  the	  most	  in	  the	  past	  month	  (+1	  pack)	  having	  the	  greatest	  risk	  (adjusted	  OR:	  2.03)	  versus	  ≤	  ½	  pack	  having	  the	  smallest	  risk	  (adjusted	  OR:	  1.43).	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Increased	  risk	  for	  musculoskeletal	  injury	  has	  also	  been	  reported	  in	  current	  smokers	  within	  the	  military	  outside	  of	  basic	  training,	  when	  they	  are	  permitted	  to	  smoke	  (286).	  Injured	  active	  service	  members	  who	  smoked	  were	  more	  likely	  to	  be	  discharged	  due	  to	  physical	  disability	  after	  musculoskeletal	  injury	  (182).	  Rates	  of	  disability	  due	  to	  musculoskeletal	  injury	  are	  dose-­‐dependent,	  ranging	  from	  17.6%	  in	  heavy	  smokers	  down	  to	  12.2%	  in	  non-­‐smokers.	  Former	  smokers	  had	  a	  disability	  rate	  of	  10.3%,	  slightly	  but	  non-­‐significantly	  below	  that	  of	  non-­‐smokers	  (182).	  However,	  the	  injuries	  presented	  in	  the	  above	  studies	  were	  either	  joint-­‐related	  injuries	  or	  were	  not	  defined;	  therefore	  direct	  information	  on	  muscle-­‐specific	  injuries	  remains	  scarce.	  	  
Effects	  of	  Smoking	  on	  Skeletal	  Muscle	  To	  my	  knowledge,	  there	  are	  no	  published	  studies	  on	  the	  effects	  of	  smoking	  on	  direct	  skeletal	  muscle	  injury	  and	  recovery,	  although	  there	  have	  been	  a	  few	  retrospective	  studies	  reporting	  increased	  risk	  for	  complications	  in	  smokers	  after	  surgeries	  requiring	  muscle	  flaps	  (45,	  80).	  Among	  the	  complications	  reported	  were	  flap	  necrosis	  and	  donor	  site	  complications	  (45).	  There	  are	  a	  handful	  of	  reports	  regarding	  the	  effect	  of	  smoke	  on	  skeletal	  muscle	  function	  (19,	  162,	  227,	  290,	  347,	  370),	  reviewed	  in	  Degens	  (72).	  Together,	  these	  studies	  suggest	  that	  smokers	  have	  similar	  or	  slightly	  lower	  maximal	  muscle	  strength,	  may	  be	  more	  fatigable,	  and	  rely	  more	  heavily	  on	  anaerobic	  metabolism	  as	  compared	  to	  their	  non-­‐smoking	  peers.	  	  With	  regard	  to	  muscle	  function,	  mice	  exposed	  to	  nose-­‐only	  smoke	  generated	  ~20%	  less	  force	  at	  high	  frequency	  simulations	  in	  the	  soleus,	  although	  this	  difference	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did	  not	  reach	  significance	  (p=0.08)	  (290).	  In	  humans,	  studies	  have	  found	  smokers	  to	  have	  significantly	  lower	  strength	  in	  the	  quadriceps	  muscle	  group	  than	  non-­‐smokers	  (19,	  257).	  For	  example,	  in	  one	  study	  of	  middle-­‐aged	  healthy	  non-­‐smokers	  and	  smokers,	  the	  maximal	  voluntary	  contraction	  of	  their	  quadriceps	  was	  38.50±1.7	  and	  36.78±1.5kg,	  respectively.	  However,	  others	  have	  reported	  no	  difference	  between	  smokers	  and	  non-­‐smokers	  for	  muscle	  strength	  (370).	  	  Smoking	  may	  also	  impair	  other	  facets	  of	  muscle	  function,	  including	  fatigability.	  Skeletal	  muscle	  of	  smokers	  was	  more	  fatigable	  in	  response	  to	  electrical	  stimulation,	  though	  this	  was	  not	  related	  to	  level	  of	  smoking	  or	  respiratory	  function	  (370).	  However,	  mice	  exposed	  to	  cigarette	  smoke	  for	  6mo	  were	  not	  more	  fatigable	  with	  repeated	  electrical	  stimulation,	  although	  force	  production	  at	  each	  time	  point	  was	  slightly	  lower	  (290).	  Additional	  data	  are	  needed	  to	  clarify	  whether	  the	  skeletal	  muscle	  of	  smokers	  is	  more	  fatigable	  than	  non-­‐smokers.	  	  Although	  they	  did	  not	  have	  greater	  fatigability,	  mice	  from	  this	  and	  another	  study	  did	  present	  with	  a	  shift	  from	  Type	  IIa	  to	  IIx/b	  muscle	  fibers	  in	  the	  soleus	  after	  exposure	  to	  cigarette	  smoke	  (290,	  328),	  while	  several	  groups	  report	  smaller	  cross-­‐sectional	  area	  and/or	  percentage	  of	  low	  oxidative/high	  glycolytic	  muscle	  fibers	  in	  smokers	  (162,	  169,	  226,	  257,	  294,	  311).	  These	  physiological	  alterations	  to	  muscle	  suggest	  that	  skeletal	  muscle	  of	  smokers	  may	  not	  function	  in	  the	  same	  way	  as	  non-­‐smokers,	  yet	  mechanisms	  underlying	  these	  phenomena	  remain	  undiscovered.	  	  Three	  studies	  may	  shed	  some	  light	  on	  these	  findings	  and	  lend	  a	  clue	  to	  why	  smokers	  are	  at	  higher	  risk	  for	  injury.	  First,	  under	  non-­‐exercised	  conditions,	  protein	  synthesis	  appears	  to	  be	  suppressed	  in	  smokers	  as	  compared	  to	  non-­‐smokers	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(fractional	  synthesis	  rate	  0.037	  vs	  0.059,	  respectively).	  Additionally,	  two	  factors	  associated	  with	  muscle	  protein	  catabolism,	  myostatin	  and	  MAFBx,	  are	  expressed	  at	  higher	  levels	  in	  smokers,	  suggesting	  smoking	  suppresses	  muscle	  regeneration	  via	  these	  pathways	  (276).	  Second,	  a	  recent	  study	  reported	  muscle	  membrane	  damage	  and	  sarcomeric	  disruption	  at	  4	  and	  48h	  after	  smoke	  exposure	  in	  rats	  (93).	  These	  rats	  experienced	  significantly	  increased	  expression	  of	  MyoD	  (937±491%)	  and	  myogenin	  (1029±477%)	  at	  4h	  compared	  to	  controls,	  further	  indicating	  altered	  muscle	  turnover.	  With	  repeated	  exposure,	  sarcolemmal	  disruptions	  remained,	  with	  approximately	  15	  and	  10%	  of	  fibers	  showing	  signs	  of	  disruption	  at	  5	  and	  30d,	  respectively	  (compared	  to	  28	  and	  16%	  at	  0h	  and	  4h	  post-­‐exposure,	  respectively).	  Sarcomere	  damage	  increased	  over	  time	  from	  3.8%	  at	  0h	  to	  4.8%	  at	  48h	  and	  up	  to	  25.8	  and	  16.4%	  at	  5	  and	  30d,	  respectively.	  In	  the	  third	  study,	  mice	  exposed	  to	  smoke	  over	  a	  period	  of	  up	  to	  32wk	  initially	  (within	  8wk)	  experienced	  enhanced	  pro-­‐inflammatory	  signaling	  including	  intracellular	  adhesion	  molecule-­‐1	  (ICAM-­‐1)	  in	  lymphocytes	  and	  muscle	  C-­‐reactive	  protein	  (162).	  However,	  more	  prolonged	  exposure	  resulted	  in	  suppressed	  expression	  of	  these	  genes.	  By	  32	  weeks	  of	  smoke	  exposure,	  muscle	  cross	  sectional	  area	  was	  significantly	  smaller	  and	  Type	  I	  oxidative	  fibers	  were	  less	  prevalent.	  Peroxisome	  proliferator-­‐activated	  receptor	  (PPAR)	  pathway	  gene	  expression,	  which	  enhances	  oxidative	  metabolism,	  was	  suppressed.	  These	  data	  support	  a	  potential	  mechanism	  through	  which	  smokers	  may	  be	  more	  fatigable,	  and	  suggest	  that	  individuals	  exposed	  to	  cigarette	  smoke	  may	  experience	  negative	  effects	  on	  muscle	  with	  every	  cigarette	  inhaled.	  Over	  time,	  they	  would	  be	  less	  able	  to	  repair	  muscle,	  more	  prone	  to	  injury,	  and	  experience	  impaired	  recovery.	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However,	  the	  effects	  of	  smoking	  on	  muscle	  damage	  and	  recovery	  responses	  have	  yet	  to	  be	  tested	  in	  a	  controlled	  laboratory	  experiment.	  Understanding	  the	  mechanisms	  that	  increase	  risks	  for	  injury	  and	  impaired	  healing	  in	  smokers	  is	  important	  for	  improving	  recovery	  and	  helping	  to	  reduce	  injury	  rates	  and	  improve	  productivity	  and	  overall	  quality	  of	  life.	  Furthermore,	  knowing	  the	  underlying	  mechanisms	  that	  lead	  to	  these	  effects	  in	  smokers	  may	  help	  us	  to	  better	  understand	  potential	  modifiers	  of	  damage	  and	  repair	  processes	  in	  skeletal	  muscle.	  	  	  
Skeletal	  Muscle	  Damage	  Skeletal	  muscle	  is	  a	  plastic	  tissue	  with	  the	  ability	  to	  repair	  and	  regenerate	  in	  response	  to	  damage.	  A	  unique	  aspect	  of	  skeletal	  muscle	  is	  that	  small	  damaging	  stimuli	  (such	  as	  those	  imposed	  by	  alterations	  in	  activity)	  typically	  lead	  to	  adaptation,	  which	  can	  result	  in	  enhanced	  size,	  specific	  contractile	  properties,	  overall	  function,	  and/or	  performance.	  The	  muscle	  damage	  response	  has	  been	  studied	  to	  gain	  insight	  into	  muscle	  health,	  function,	  and	  performance.	  Although	  much	  remains	  to	  be	  understood	  with	  regard	  to	  the	  muscle	  damage	  response,	  regeneration,	  and	  adaptation,	  it	  is	  clear	  that	  there	  is	  a	  coordinated,	  established,	  and	  sequential	  series	  of	  events	  drives	  muscle’s	  response	  to	  damaging	  stimuli.	  	  Muscle	  damage	  can	  occur	  naturally	  in	  response	  to	  a	  variety	  of	  stimuli,	  including	  traumatic	  injury	  (such	  as	  impact	  (contusion,	  crushing)	  or	  environmental	  extremes	  (such	  as	  freeze)),	  exposure	  to	  toxins,	  and	  mechanical	  (or	  strain-­‐induced)	  injury.	  Strain	  injuries	  can	  range	  from	  traumatic,	  as	  in	  the	  case	  of	  a	  “pulled	  muscle,”	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to	  low	  level	  chronic	  strains	  induced	  by	  deliberate	  exercise.	  The	  most	  common	  type	  of	  exercise	  that	  causes	  strain	  injuries	  is	  muscle-­‐lengthening	  (eccentric)	  actions.	  	  Following	  injurious	  stimuli,	  the	  response	  of	  muscle	  can	  be	  categorized	  as	  three	  principal	  phases:	  damage,	  repair,	  and	  regeneration.	  Generally,	  the	  damage/repair	  cycle	  is	  resolved	  within	  several	  weeks	  of	  the	  initial	  stimulus.	  Repair	  and	  regeneration	  can	  occur	  simultaneously,	  and	  may	  also	  be	  followed	  by	  remodeling	  of	  the	  muscle.	  The	  damage	  phase	  can	  be	  further	  categorized	  into	  “primary”	  and	  “secondary”	  damage;	  the	  former	  primarily	  results	  directly	  from	  the	  initial	  stimulus,	  while	  secondary	  damage	  can	  be	  an	  unintended	  consequence	  of	  inflammatory	  processes	  critical	  to	  the	  ultimate	  recovery	  of	  the	  muscle.	  	  The	  type	  of	  stimulus	  that	  evokes	  muscle	  damage	  affects	  the	  overall	  response,	  including	  the	  timing	  and	  magnitude	  of	  responses,	  the	  contributions	  of	  primary	  versus	  secondary	  damage,	  the	  amount	  of	  damage	  to	  secondary	  tissues	  (blood	  supply,	  nerve,	  bone,	  connective	  tissue),	  inflammation,	  and	  the	  underlying	  molecular	  mechanisms	  that	  ultimately	  control	  the	  effectiveness	  of	  the	  repair	  and	  regeneration.	  To	  better	  understand	  the	  damage/repair	  process,	  several	  laboratory	  experimental	  models	  of	  muscle	  damage	  have	  been	  developed.	  	  
Experimental	  Models	  of	  Muscle	  Damage	  Much	  of	  our	  understanding	  of	  muscle	  injury	  and	  repair	  comes	  from	  animal	  and	  cell	  culture	  models	  due	  to	  the	  greater	  ability	  to	  control	  independent	  variables.	  These	  models	  include:	  chemical	  exposure	  (for	  example	  taipoxin,	  cardiotoxin	  or	  notexin	  injection	  (90,	  202,	  292));	  environmental	  insult	  (freezing	  (304,	  324,	  361,	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362)),	  traumatic	  injury	  (crushing	  or	  penetrating	  injury	  (37,	  211,	  319));	  and	  mechanical	  strain	  (stretch/strain	  (178,	  341)).	  Injury	  can	  also	  occur	  during	  exercise	  and	  different	  exercise	  models	  have	  been	  used	  to	  evoke	  mechanical	  damage	  in	  both	  human	  subjects	  (63,	  192,	  222,	  239)	  and	  animals	  (16,	  121,	  125),	  especially	  exercise	  protocols	  that	  utilize	  eccentric,	  or	  lengthening,	  muscle	  actions.	  	  Eccentric	  exercise	  (ECC)	  elicits	  transient	  exercise-­‐induced	  muscle	  damage	  (EIMD),	  followed	  by	  repair,	  regeneration,	  and	  adaptation	  of	  the	  muscle	  (reviewed	  in	  (39,	  60)).	  The	  manifestations	  of	  EIMD	  include	  loss	  of	  strength,	  delayed	  onset	  muscle	  soreness,	  swelling,	  increased	  stiffness,	  and	  the	  release	  of	  muscle-­‐specific	  proteins	  into	  the	  bloodstream.	  Repeated	  bouts	  of	  the	  same	  activity	  result	  in	  attenuated	  responses	  (reviewed	  in	  Howatson	  (129)).	  Popular	  methods	  for	  inducing	  EIMD	  include	  metabolically	  challenging	  models,	  such	  as	  downhill	  or	  downstairs	  running	  or	  stair	  stepping,	  and	  isolated	  eccentric	  exercise,	  for	  example	  squats	  or	  performance	  of	  maximal,	  eccentric,	  single	  joint	  movements.	  The	  last	  model	  allows	  researchers	  to	  isolate	  a	  specific	  muscle	  group	  to	  test	  the	  damage	  response	  and	  control,	  as	  much	  as	  possible,	  independent	  variables.	  The	  responses	  to	  ECC,	  including	  the	  manifestations	  and	  cellular	  and	  molecular	  signaling	  underlying	  these	  responses,	  vary	  depending	  on	  a	  number	  of	  factors,	  including	  the	  type	  of	  model	  (e.g.,	  metabolically	  challenging	  vs	  isolated	  actions),	  the	  muscle	  group	  (e.g.,	  elbow	  flexors	  vs	  knee	  extensors),	  and	  submaximal	  vs	  maximal	  actions.	  Generally,	  the	  most	  robust	  damage	  responses	  are	  those	  produced	  by	  isolated,	  maximal	  actions	  (reviewed	  in	  (60)).	  There	  are	  numerous	  benefits	  of	  the	  ECC	  model,	  which	  can	  be	  used	  in	  a	  controlled,	  laboratory	  setting.	  The	  damage	  from	  ECC	  is	  transient	  and	  generally	  quite	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safe,	  with	  subjects	  returning	  to	  normal	  activity	  within	  1-­‐2	  weeks.	  As	  well,	  eccentric	  actions	  (and	  the	  resultant	  responses)	  are	  more	  common	  among	  everyday	  life	  than	  traumatic	  injury,	  making	  information	  gleaned	  through	  such	  models	  more	  applicable	  to	  the	  general	  population.	  Consequently,	  I	  chose	  to	  use	  an	  established	  ECC	  model	  to	  evoke	  damage	  and	  then	  study	  the	  effects	  of	  smoking	  on	  the	  damage	  response.	  The	  remainder	  of	  this	  chapter	  reviews	  this	  model	  in	  detail	  and	  postulates	  how	  smoking	  is	  could	  modify	  the	  response	  to	  ECC.	  	  	  
Eccentric	  Exercise	  Damage	  Response	  In	  1902,	  Theodore	  Hough	  first	  postulated	  that	  delayed	  onset	  muscle	  soreness	  following	  exercise	  was	  the	  product	  of	  micro-­‐tears	  in	  muscle,	  elicited	  through	  mechanical	  stimuli	  such	  as	  exercise	  (128).	  Subsequent	  delayed	  onset	  muscle	  soreness	  (DOMS)	  studies	  found	  that	  soreness	  is	  greatest	  following	  primarily	  eccentric,	  rather	  than	  concentric	  or	  isometric	  actions	  (10,	  327).	  In	  the	  1980s,	  electron	  microscopy	  studies	  finally	  demonstrated	  direct	  evidence	  of	  physical	  muscle	  damage	  following	  ECC	  (100).	  	  Current	  knowledge	  suggests	  that	  ECC	  places	  mechanical	  stress	  on	  the	  muscle,	  resulting	  in	  primary	  damage.	  In	  the	  days	  that	  follow,	  enhanced	  disruption	  to	  the	  muscle	  can	  occur,	  referred	  to	  as	  “secondary	  damage”	  and	  is	  commonly	  thought	  to	  result	  from	  inflammation.	  Inflammatory	  cells	  and	  molecules	  also	  stimulate	  signaling	  within	  the	  muscle	  to	  control	  the	  repair	  process.	  Remodeling	  and	  repair	  typically	  take	  10-­‐14d	  to	  complete,	  and	  healthy	  muscle	  typically	  adapts	  such	  that	  further	  bouts	  of	  the	  same	  exercise	  elicit	  less	  damage	  and	  less	  dramatic	  responses	  to	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eccentric	  exercise	  (known	  as	  the	  repeated	  bout	  effect).	  The	  most	  commonly	  characterized	  responses	  to	  ECC	  are	  those	  that	  indirectly	  indicate	  damage:	  loss	  of	  strength,	  swelling,	  muscle	  soreness,	  and	  the	  leakage	  of	  muscle-­‐specific	  proteins	  into	  the	  blood.	  The	  sections	  below	  briefly	  summarize	  each	  of	  these	  markers.	  Those	  markers	  that	  are	  significantly	  linked	  to	  inflammatory	  processes	  (such	  as	  swelling	  and	  DOMS)	  are	  also	  described	  in	  greater	  detail	  later	  in	  this	  chapter.	  	  
Indirect	  Markers	  of	  Damage	  	  
Loss	  of	  Force	  Production	  Prolonged	  loss	  of	  force	  production	  (strength	  loss)	  is	  generally	  considered	  the	  best	  indirect	  measure	  of	  muscle	  damage,	  as	  it	  moderately	  correlates	  with	  direct	  measurements	  of	  damage.	  Force	  production	  decreases	  during	  ECC	  and	  usually	  resolves	  fully	  by	  5-­‐6d	  post-­‐exercise,	  but	  in	  some	  cases	  can	  persist	  for	  months	  (299).	  Strength	  loss	  can	  be	  described	  into	  two	  phases:	  early	  loss	  (comprised	  of	  both	  metabolic	  fatigue	  from	  the	  exercise	  itself	  and	  potential	  mechanical	  damage	  to	  the	  muscle)	  and	  prolonged	  loss	  (due	  to	  structural	  damage	  and	  altered	  signaling).	  Strength	  loss	  can	  vary	  depending	  on	  the	  mode	  of	  exercise,	  muscle	  group,	  submaximal	  versus	  maximal	  actions,	  angle	  and	  speed	  of	  contraction,	  total	  time	  spent	  under	  tension,	  and	  the	  total	  volume	  of	  exercise,	  as	  well	  as	  between	  individual	  subjects.	  	  The	  relative	  level	  of	  post-­‐exercise	  strength	  loss	  tends	  to	  be	  greatest	  with	  maximal,	  forced	  eccentric	  actions	  of	  the	  elbow	  flexors,	  and	  can	  reach	  up	  to	  90%	  decrease	  from	  baseline	  with	  higher	  numbers	  of	  actions	  (59).	  The	  time	  to	  full	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recovery	  is	  generally	  linked	  to	  the	  amount	  of	  damage	  and	  magnitude	  of	  initial	  force	  loss.	  The	  ability	  to	  maintain	  force	  also	  drops	  off	  rapidly	  with	  muscle	  damage;	  thus,	  the	  initial	  force	  output	  can	  be	  sustained	  for	  only	  a	  short	  period	  of	  time,	  after	  which	  force	  decreases	  more	  quickly	  than	  in	  undamaged	  muscle	  (reviewed	  by	  Warren	  (359)	  and	  Hyldahl	  and	  Hubal	  (135)).	  	  	  
Swelling	  Swelling	  of	  the	  exercised	  limb	  typically	  peaks	  3-­‐6d	  after	  ECC	  (63,	  123,	  222).	  As	  edema	  resolves,	  the	  swelling	  moves	  distally	  along	  the	  limb	  as	  the	  additional	  fluid	  is	  reabsorbed.	  Swelling	  may	  not	  be	  noticeable,	  depending	  on	  the	  affected	  muscle	  compartment.	  For	  example,	  the	  elbow	  flexors	  are	  more	  prone	  to	  obvious	  signs	  of	  swelling	  than	  muscles	  of	  the	  anterior	  upper	  leg—this	  may	  be	  due	  in	  part	  to	  the	  expandability	  of	  the	  muscle	  compartment	  as	  well	  as	  the	  amount	  of	  damage	  to	  the	  muscle.	  There	  is	  also	  high	  variability	  in	  the	  extent	  of	  swelling.	  Because	  swelling	  does	  not	  correlate	  well	  with	  any	  other	  response	  to	  ECC,	  the	  reason	  for	  this	  variability	  is	  currently	  unknown.	  Swelling	  is	  believed	  to	  be	  the	  result	  of	  inflammatory	  processes	  that	  take	  part	  in	  the	  regeneration	  of	  a	  fully	  functioning	  muscle	  after	  ECC,	  which	  will	  be	  summarized	  in	  more	  detail	  later	  in	  this	  chapter.	  
	  
Delayed	  Onset	  Muscle	  Soreness	  	  Delayed	  onset	  muscle	  soreness	  (DOMS)	  is	  a	  phenomenon	  specific	  to	  muscle	  damage	  and	  describes	  hyperalgesia	  (increased	  sensitivity	  to	  pain)	  that	  is	  delayed	  in	  its	  onset	  (occurring	  some	  hours	  after	  exercise)	  and	  typically	  resolves	  within	  less	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than	  a	  week	  of	  the	  initial	  damaging	  event.	  Reported	  soreness	  can	  be	  severe	  and	  may	  interfere	  with	  activities	  of	  daily	  living.	  The	  overall	  magnitude	  and	  duration	  of	  DOMS	  does	  not	  correlate	  well	  to	  the	  level	  of	  muscle	  damage	  incurred	  (via	  direct	  measure);	  however,	  the	  level	  of	  peak	  soreness	  does	  grossly	  relate	  to	  the	  level	  of	  damage,	  with	  higher	  peak	  soreness	  occurring	  with	  greater	  muscle	  damage.	  	  Current	  theory	  suggests	  the	  hyperalgesia	  underlying	  DOMS	  is	  mainly	  caused	  by	  inflammatory	  mediators	  and	  related	  signaling	  proteins	  (reviewed	  in	  Hyldahl	  and	  Hubal	  (135)).	  Thus	  far,	  attempts	  to	  suppress	  DOMS	  have	  been	  largely	  unsuccessful,	  with	  the	  primary	  exception	  being	  the	  use	  of	  non-­‐steroidal	  anti-­‐inflammatory	  drugs	  (NSAIDs).	  However,	  NSAID	  use	  during	  muscle	  recovery	  can	  attenuate	  functional	  regain	  and	  suppress	  adaptation	  (168,	  223).	  The	  failure	  to	  adapt	  with	  use	  of	  NSAIDs	  illustrates	  how	  enmeshed	  the	  underlying	  mechanisms	  of	  response	  to	  ECC	  are—by	  suppressing	  inflammation	  and	  therefore	  DOMS,	  muscle	  recovery	  and	  adaptation	  can	  be	  inhibited.	  For	  additional	  information,	  the	  reader	  is	  referred	  to	  reviews	  by	  Baldwin	  Lanier	  (14);	  Schoenfeld	  (303);	  and	  Stone	  and	  colleagues	  (321).	  Specific	  mechanisms	  of	  inflammation	  that	  drive	  DOMS	  are	  explored	  in	  greater	  detail	  later	  in	  this	  chapter.	  	  
Elevated	  Blood	  Levels	  of	  Muscle-­‐Specific	  Proteins	  The	  leakage	  of	  muscle-­‐specific	  proteins	  into	  the	  bloodstream	  through	  the	  damaged	  membrane	  is	  another	  indirect	  indicator	  of	  muscle	  damage.	  The	  most	  commonly	  measured	  proteins	  in	  blood	  after	  ECC	  are	  creatine	  kinase	  (CK)	  and	  myoglobin.	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CK	  is	  a	  two-­‐subunit	  enzyme	  critical	  for	  energy	  (ATP)	  production.	  Originally,	  the	  CK-­‐MB	  variant	  was	  used	  to	  confirm	  myocardial	  infarction.	  In	  the	  middle	  of	  the	  20th	  century,	  the	  association	  of	  skeletal	  muscle	  damage	  with	  increased	  CK	  (MM	  variant)	  was	  noted,	  and	  in	  the	  1960s	  altered	  blood	  CK	  activity	  was	  associated	  with	  exercise.	  After	  ECC,	  serum	  CK	  activity	  peaks	  approximately	  5d	  post-­‐exercise,	  though	  the	  level	  of	  release	  varies	  widely	  among	  specific	  models	  of	  eccentric	  exercise	  and	  among	  individuals	  (61).	  While	  a	  good	  indicator	  that	  damage	  has	  occurred,	  CK	  activity	  in	  the	  blood	  does	  not	  correlate	  well	  with	  the	  level	  of	  muscle	  damage	  itself	  (203),	  nor	  with	  other	  indirect	  markers	  of	  muscle	  damage	  like	  strength	  loss.	  	  Myoglobin	  transports	  oxygen	  and	  carbon	  dioxide	  within	  muscle	  tissue.	  After	  ECC,	  myoglobin	  leaks	  into	  the	  bloodstream,	  where	  it	  then	  travels	  to	  the	  kidneys	  for	  excretion.	  Unlike	  high	  CK	  levels,	  which	  are	  considered	  relatively	  harmless,	  high	  levels	  of	  myoglobin	  outside	  of	  skeletal	  muscle	  can	  be	  dangerous,	  if	  not	  deadly—if	  not	  cleared	  effectively,	  myoglobin	  can	  precipitate	  in	  the	  kidneys,	  leading	  to	  renal	  failure,	  a	  phenomenon	  called	  exertional	  rhabdomyolysis.	  Myoglobin	  peaks	  in	  the	  bloodstream	  after	  ECC	  at	  approximately	  the	  same	  time	  as	  CK,	  although	  it	  can	  peak	  slightly	  later.	  Myoglobin	  release	  is	  also	  much	  lower	  in	  magnitude	  than	  CK,	  though	  the	  accumulation	  of	  the	  two	  proteins	  tends	  to	  correlate	  well.	  Because	  myoglobin	  is	  expensive	  to	  measure	  and	  post-­‐ECC	  CK	  and	  myoglobin	  levels	  correlate	  well,	  CK	  is	  often	  used	  as	  a	  surrogate	  for	  myoglobin.	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Direct	  Markers	  of	  Damage	  	  In	  1988,	  Friden	  (100)	  first	  reported	  histochemical	  evidence	  that	  ECC	  resulted	  in	  muscle	  damage.	  In	  the	  following	  years,	  a	  number	  of	  other	  researchers	  reported	  similar	  findings	  with	  ultrastructural	  damage	  and	  loss	  of	  sarcomere	  organization	  (z-­‐line	  streaming)	  (98,	  146,	  240).	  Disturbances	  to	  both	  the	  sarcolemma	  and	  extracellular	  matrix	  (muscle	  connective	  tissue)	  have	  been	  reported	  (159,	  181).	  It	  was	  hypothesized	  in	  1990	  that,	  during	  lengthening	  actions,	  damage	  is	  caused	  when	  sarcomeres	  are	  stretched	  beyond	  the	  point	  where	  actin	  and	  myosin	  cross-­‐bridges	  can	  hold.	  Known	  as	  the	  “popping”	  sarcomere	  hypothesis	  (228,	  230),	  this	  theory	  does	  not	  explain	  the	  additional,	  or	  secondary,	  disruption	  to	  muscle	  structure	  seen	  in	  the	  days	  following	  exercise.	  	  In	  the	  early	  2000s,	  Yu	  and	  colleagues	  noted	  significant	  structural	  disruption	  to	  a	  number	  of	  structural	  proteins,	  including	  desmin	  (380,	  381,	  383),	  following	  ECC.	  These	  alterations	  persisted	  and	  even	  worsened	  over	  the	  course	  of	  approximately	  one	  week	  after	  exercise	  before	  resolving.	  These	  disruptions	  occurred	  in	  areas	  with	  sarcomere	  insertions,	  indicating	  sarcomerogenesis	  and	  restructuring	  of	  proteins,	  rather	  than	  damage,	  in	  the	  muscle.	  Another	  large	  difference	  between	  ECC	  and	  other	  models	  of	  muscle	  damage	  is	  the	  lack	  of	  associated	  cell	  death.	  In	  humans	  under	  voluntary	  exercise	  conditions,	  there	  is	  little	  evidence	  to	  suggest	  that	  ECC	  results	  in	  disruption	  to	  the	  sarcolemma	  to	  the	  extent	  that	  would	  result	  in	  the	  overt	  death	  of	  the	  muscle	  cell	  (reviewed	  in	  Malm	  (197)).	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Adaptation	  	  Healthy	  muscle	  adapts	  to	  repeated	  exposure	  to	  ECC.	  Remodeling	  of	  the	  muscle	  has	  been	  reported	  at	  the	  ultrastructural	  level,	  with	  sarcomere	  insertions	  (229)	  and	  alterations	  to	  intermediate	  filaments	  (97).	  Further,	  there	  is	  remodeling	  of	  the	  connective	  tissue	  (167)	  and	  the	  extracellular	  matrix,	  the	  network	  of	  proteins	  that	  connect	  the	  contractile	  elements	  to	  the	  surrounding	  connective	  tissue	  (189).	  Over	  time,	  these	  changes	  in	  protein	  likely	  lead	  to	  larger	  adaptations	  (including	  the	  insertion	  of	  sarcomeres)	  and	  can	  drive	  muscle	  hypertrophy.	  Other	  adaptations	  may	  occur	  depending	  on	  the	  specific	  nature	  of	  the	  exercise	  utilized,	  such	  as	  shifts	  in	  metabolic	  preference.	  	  These	  alterations	  to	  ultrastructure	  and	  connective	  tissue	  provide	  evidence	  of	  not	  only	  repair,	  but	  also	  remodeling	  and	  adaptation	  to	  the	  structure	  and	  function	  of	  the	  muscle.	  Repeated	  bouts	  of	  ECC	  within	  several	  months	  yield	  a	  reduction	  of	  gross	  responses	  (62,	  246,	  249,	  323).	  This	  protective	  “repeated	  bout	  effect”	  (RBE)	  was	  first	  characterized	  in	  the	  1980s	  and	  it	  is	  now	  widely	  recognized	  that	  repeated	  performance	  of	  the	  same	  ECC	  activity	  results	  in	  attenuated	  DOMS,	  muscle	  protein	  release,	  and	  strength	  loss	  (41,	  127,	  129,	  246).	  More	  recently,	  the	  cellular	  and	  molecular	  changes	  that	  may	  influence	  RBE	  have	  been	  investigated,	  including	  inflammatory	  signaling	  (133,	  323)	  and	  the	  effect	  of	  ECC	  on	  the	  contralateral	  limb	  (130,	  372),	  yet	  the	  underlying	  mechanisms	  remain	  poorly	  understood.	  Still,	  long-­‐term	  gross	  adaptations	  to	  consistent	  application	  of	  eccentric	  actions,	  such	  as	  hypertrophy	  (122,	  170)	  and	  increased	  strength	  (122,	  147,	  170),	  are	  well	  documented.	  For	  additional	  information,	  the	  reader	  is	  referred	  to	  reviews	  by	  Proske	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and	  Morgan	  (283)	  and	  Vogt	  and	  Heppeler	  (352)	  on	  muscle	  adaptation	  and	  McHugh	  (213)	  regarding	  RBE.	  Specific	  roles	  for	  inflammation	  in	  skeletal	  muscle	  adaptation	  will	  be	  discussed	  later	  in	  this	  chapter.	  	  	  
Mechanisms	  Driving	  Damage	  and	  Repair	  	  The	  following	  section	  provides	  a	  framework	  to	  understand	  the	  processes	  driving	  the	  EIMD	  response	  (55,	  67,	  116,	  133,	  137,	  156,	  192,	  194).	  An	  early	  review	  by	  Armstrong	  (7)	  proposed	  a	  four-­‐stage	  response	  to	  muscle	  injury:	  initial,	  autogenic,	  phagocytic,	  and	  regenerative.	  Since	  that	  time,	  our	  understanding	  of	  these	  processes	  has	  evolved	  to	  the	  following	  three-­‐stage	  theoretical	  framework	  of	  the	  EIMD	  response:	  1)	  the	  initial	  stimulus	  stresses	  the	  muscle	  and	  results	  in	  “primary”	  (mechanical)	  muscle	  damage;	  2)	  a	  “secondary”	  damage	  stage,	  driven	  by	  alterations	  to	  the	  inflammatory	  balance,	  that	  eventually	  resolves	  with	  repair	  and	  regeneration;	  and	  3)	  remodeling	  to	  the	  muscle	  ultrastructure	  that	  occurs	  along	  with	  and	  following	  secondary	  damage,	  and	  is	  an	  important	  component	  to	  regeneration	  and	  adaptation	  to	  future	  perturbations.	  Primary	  EIMD	  is	  largely	  the	  result	  of	  mechanical	  mechanisms.	  The	  experimental	  model	  used	  to	  evoke	  damage	  will	  greatly	  vary	  the	  extent	  and	  characteristics	  of	  the	  damage	  response	  including	  the	  specific	  underlying	  signaling	  pathways,	  though	  the	  major	  events	  that	  follow	  generally	  remain	  consistent	  among	  models	  of	  muscle	  damage.	  These	  events	  have	  some	  common	  elements	  with	  damage	  induced	  via	  non-­‐exercise	  means	  (crush,	  freeze,	  or	  toxin-­‐induced	  injury),	  though	  other	  aspects	  of	  the	  response	  are	  unique	  to	  the	  damage-­‐inducing	  stimulus.	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Secondary	  damage	  can	  be	  generally	  split	  into	  two	  phases:	  the	  “early”	  (mostly	  pro-­‐inflammatory)	  phase,	  characterized	  by	  increased	  damage	  to	  muscle;	  and	  the	  “late”	  (mainly	  anti-­‐inflammatory)	  phase,	  typically	  associated	  with	  the	  stimulation	  of	  tissue	  repair.	  A	  critical	  component	  of	  the	  damage/repair	  cycle	  is	  a	  shift	  in	  the	  inflammatory	  balance—from	  early	  pro-­‐inflammatory	  processes	  towards	  favoring	  anti-­‐inflammatory	  processes	  for	  subsequent	  repair	  and	  regeneration.	  Without	  this	  natural	  progression,	  repair	  and	  regeneration	  would	  be	  more	  prolonged	  and	  adaptation	  likely	  attenuated,	  if	  not	  completely	  abolished.	  Therefore,	  understanding	  the	  processes	  that	  drive	  secondary	  damage,	  regeneration,	  and	  remodeling,	  such	  as	  inflammation,	  is	  critical	  to	  promoting	  effective	  muscle	  healing	  and	  function,	  and	  is	  a	  major	  focus	  of	  this	  dissertation	  and	  the	  remainder	  of	  this	  chapter.	  	  
Inflammation	  and	  Muscle	  Damage	  In	  1962,	  Brendstrup	  (31)	  suggested	  that	  inflammation	  occurred	  after	  ECC	  as	  a	  result	  of	  muscle	  damage,	  specifically	  noting	  the	  presence	  of	  edema	  in	  rabbit	  triceps	  surae	  post-­‐exercise.	  The	  infiltration	  of	  inflammatory	  (specifically	  mononuclear)	  cells	  into	  damaged	  muscle	  was	  first	  noted	  approximately	  20	  years	  later	  (8,	  146).	  Since	  that	  time,	  our	  knowledge	  of	  inflammation	  in	  muscle	  damage	  and	  regeneration	  has	  grown	  substantially.	  However,	  the	  diverse	  type	  and	  nature	  of	  muscle	  damage	  models	  used	  in	  research	  (for	  example,	  downhill	  running,	  submaximal	  vs	  maximal	  isolated	  actions,	  voluntary	  vs	  electrically	  stimulated)	  result	  in	  high	  variability	  within	  the	  overall	  inflammatory	  response,	  making	  understanding	  the	  role	  of	  inflammation	  in	  EIMD	  more	  challenging.	  What	  is	  clear	  is	  that	  a	  sequential	  
	  	  30	  
cascade	  of	  inflammatory	  events	  occurs	  in	  response	  to	  a	  damaging	  stimulus	  and	  that	  this	  inflammatory	  process	  can	  cause	  secondary	  damage	  to	  tissue.	  	  The	  conspicuous	  manifestations	  of	  inflammation	  after	  ECC	  are	  swelling	  of	  the	  injured	  muscle	  or	  limb	  and	  hyperalgesia	  (increased	  sensitivity	  to	  pain).	  The	  hyperalgesia	  is	  delayed,	  and	  is	  associated	  with	  the	  sensation	  of	  prolonged	  soreness	  that	  peaks	  24-­‐48h	  post-­‐ECC	  (DOMS).	  Swelling	  and	  DOMS	  are	  believed	  to	  be	  a	  result	  of	  inflammation,	  although	  they	  do	  not	  relate	  to	  one	  another	  in	  magnitude	  or	  temporally.	  As	  mentioned	  previously,	  swelling	  typically	  peaks	  3-­‐6d	  after	  ECC	  while	  DOMS	  generally	  peaks	  at	  24-­‐48h	  post-­‐exercise.	  	  At	  the	  cellular	  level,	  inflammation	  is	  characterized	  by	  the	  release	  of	  pro-­‐	  and	  anti-­‐inflammatory	  cytokines	  and	  chemokines	  (for	  example	  tumor	  necrosis	  factor	  (TNF)-­‐α	  and	  interleukin	  (IL)-­‐10)	  into	  circulation.	  These	  chemical	  messengers	  stimulate	  the	  migration	  of	  leukocyte	  populations	  to	  the	  site	  of	  injury,	  their	  extravasation	  into	  the	  muscle,	  and	  their	  activity.	  Neutrophils	  and	  macrophages	  are	  the	  primary	  leukocytes	  involved	  in	  EIMD.	  Neutrophils	  are	  primarily	  pro-­‐inflammatory,	  and	  neutrophil	  buildup	  can	  enhance	  damage	  to	  the	  area.	  Macrophages	  can	  be	  predominantly	  either	  pro-­‐	  or	  anti-­‐inflammatory,	  playing	  diverse	  roles	  in	  the	  balance	  between	  damage	  and	  regeneration.	  Macrophages	  in	  the	  early	  stages	  after	  ECC	  are	  predominantly	  pro-­‐inflammatory	  (known	  as	  ED1	  or	  M1),	  while	  at	  later	  stages	  they	  tend	  to	  be	  anti-­‐inflammatory	  (ED2	  or	  M2).	  	  The	  underlying	  molecular	  signals	  that	  control	  inflammation,	  secondary	  damage,	  and	  regeneration	  across	  time	  after	  ECC	  are	  complex	  and	  poorly	  understood.	  A	  number	  of	  important	  signaling	  pathways	  have	  been	  reported	  to	  play	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important	  roles,	  such	  as	  the	  nuclear	  factor	  kappa	  beta	  (NFκB),	  and	  the	  mitogen	  activated	  protein	  kinases	  (MAPKs)	  pathways	  including	  the	  extracellular	  regulated	  kinases	  (ERKs),	  as	  well	  as	  related	  cytokines	  and	  extracellular	  signaling	  proteins	  such	  as	  the	  interleukins	  and	  nerve	  growth	  factor	  (NGF).	  These	  pathways	  and	  proteins	  will	  be	  explored	  in	  more	  detail	  later	  in	  this	  chapter.	  The	  following	  section	  summarizes	  a	  typical	  post-­‐ECC	  inflammatory	  profile,	  including	  how	  inflammation	  is	  related	  to	  damage	  markers	  (soreness,	  swelling),	  cellular	  level	  changes	  (cytokine	  and	  chemokine	  release,	  leukocyte	  activity	  and	  numbers)	  and	  changes	  taking	  place	  at	  the	  molecular	  level	  (gene	  and	  protein	  expression	  in	  muscle).	  	  	  
Inflammation	  and	  Swelling	  	   Swelling	  after	  ECC	  can	  be	  considerable	  and	  is	  sometimes	  recognizable	  to	  the	  naked	  eye.	  Initially,	  and	  most	  commonly,	  this	  inflammatory	  response	  was	  measured	  by	  recording	  changes	  in	  limb	  circumference,	  although	  attempts	  to	  determine	  the	  specific	  location	  and	  source	  of	  the	  increased	  limb	  circumference	  has	  led	  to	  the	  use	  of	  muscle	  biopsy	  to	  test	  for	  swelling	  of	  individual	  muscle	  fibers	  (99,	  382),	  slit	  catheter	  technique	  (99),	  and	  the	  non-­‐invasive	  practices	  of	  magnetic	  resonance	  to	  test	  cross-­‐sectional	  area	  as	  well	  as	  tissue	  density	  with	  transverse	  relaxation	  (T2)	  and	  ultrasound	  (57,	  247).	  Research	  suggests	  that	  swelling	  can	  result	  from:	  1)	  the	  increase	  in	  fluid	  around	  the	  site	  of	  injury,	  either	  within	  the	  muscle	  or	  subcutaneous	  tissues	  (57,	  94,	  247);	  and/or	  2)	  swelling	  within	  individual	  muscle	  fibers	  (99,	  382).	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Swelling	  is	  most	  commonly	  reported:	  1)	  with	  a	  greater	  extent	  of	  damage;	  2)	  with	  models	  that	  utilize	  maximal	  exertion	  and	  are	  less	  metabolically	  challenging;	  and	  3)	  in	  the	  elbow	  flexors	  (which	  are	  within	  an	  elastic	  and	  expandable	  compartment	  as	  compared	  to	  muscles	  in	  tighter	  compartments	  such	  as	  the	  plantar	  flexors).	  Extreme	  cases	  of	  swelling	  after	  ECC	  have	  been	  reported	  that	  were	  not	  related,	  either	  temporally	  or	  by	  magnitude,	  to	  other	  indicators	  of	  damage	  such	  as	  strength	  loss,	  DOMS,	  or	  CK	  release.	  However,	  in	  some	  of	  these	  cases,	  the	  subjects	  were	  high	  responders	  for	  most,	  if	  not	  all,	  muscle	  damage	  indicator	  parameters	  (300).	  As	  previously	  mentioned,	  swelling	  generally	  appears	  to	  be	  unrelated	  to	  other	  indicators	  of	  muscle	  damage,	  and	  this	  makes	  it	  difficult	  to	  determine	  the	  underlying	  cause	  for	  such	  changes.	  	  Swelling	  has	  also	  been	  studied	  using	  imaging	  techniques.	  Changes	  to	  tissue	  density	  immediately	  after	  ECC	  have	  been	  reported	  in	  MR	  studies	  examining	  alterations	  in	  T2	  relaxation	  time,	  essentially	  a	  measure	  of	  fluid	  within	  tissue	  or	  tissue	  density.	  Early	  alterations	  in	  tissue	  density	  are	  followed	  by	  a	  second,	  delayed	  T2	  peak	  that	  typically	  arises	  12-­‐24h	  after	  ECC	  and	  generally	  peaks	  3-­‐6d	  post-­‐ECC	  (57,	  61,	  94,	  247,	  326).	  Overt	  swelling	  typically	  resolves	  by	  moving	  down	  the	  limb	  in	  the	  direction	  of	  gravity	  and	  fluid	  is	  eventually	  resorbed	  by	  the	  lymphatic	  system	  (247).	  However,	  changes	  in	  T2	  can	  persist	  up	  to	  23d	  post-­‐ECC,	  when	  all	  other	  signs	  of	  swelling	  have	  dissipated,	  suggesting	  that	  changes	  to	  tissue	  density	  after	  ECC	  may	  be	  a	  sign	  of	  remodeling	  (247),	  or	  that	  T2	  is	  a	  more	  sensitive	  measure	  than	  others	  to	  detect	  persistent	  alterations	  of	  fluid	  within	  muscle.	  While	  these	  studies	  have	  indicated	  the	  physical	  source	  of	  changes	  in	  limb	  circumferences	  (fluid	  increase	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within	  the	  muscle,	  within	  the	  fibers	  themselves,	  and	  in	  subcutaneous	  tissues),	  the	  mechanisms	  that	  result	  in	  swelling	  have	  yet	  to	  be	  specifically	  identified.	  Furthermore,	  swelling	  is	  not	  strongly	  related	  to	  hyperalgesia	  and	  DOMS	  (which	  tend	  to	  resolve	  before	  significant	  swelling	  occurs).	  	  
Inflammation	  and	  Delayed	  Onset	  Muscle	  Soreness	  One	  of	  the	  hallmark	  effects	  of	  ECC	  that	  is	  related	  to	  inflammation	  is	  delayed	  onset	  muscle	  soreness	  (DOMS),	  delayed	  hyperalgesia	  that	  typically	  appears	  within	  12h,	  peaks	  24-­‐48h,	  and	  resolves	  by	  4	  to	  7d.	  DOMS	  is	  often	  the	  most	  noticeable	  and	  bothersome	  “symptom”	  of	  muscle	  damage.	  Previous	  exposure	  to	  the	  same	  eccentrically-­‐biased	  activity	  within	  ~6mo	  (RBE)	  attenuates	  the	  magnitude	  of	  DOMS,	  making	  earlier	  exposure	  to	  ECC	  the	  most	  effective	  protection	  against	  future	  DOMS.	  The	  magnitude	  and	  timing	  of	  DOMS	  reported	  varies	  widely	  among	  individuals	  and	  can	  depend	  on	  the	  level	  of	  damage,	  the	  model	  of	  ECC,	  and	  the	  muscle	  group	  exercised.	  Magnitude	  and	  duration	  are	  typically	  (but	  not	  always)	  linked,	  such	  that	  greater	  peak	  soreness	  tends	  to	  be	  more	  prolonged.	  Generally,	  greater	  muscle	  damage	  results	  in	  greater	  soreness,	  although	  the	  level	  of	  soreness	  does	  not	  always	  reflect	  the	  magnitude	  of	  damage	  (251).	  DOMS	  is	  also	  affected	  by	  the	  model	  of	  ECC—greater	  perturbations	  yield	  more	  soreness.	  For	  example,	  downhill	  running	  typically	  elicits	  lower	  soreness	  than	  concentrated	  eccentric	  actions	  of	  the	  knee	  extensors,	  and	  maximal	  contractions	  lead	  to	  greater	  soreness	  than	  submaximal	  ones.	  	  	   As	  previously	  discussed,	  interruption	  of	  DOMS	  through	  the	  use	  of	  NSAIDs	  can	  interfere	  with	  muscle	  healing	  time	  and	  adaptation	  (221,	  223).	  This	  indicates	  the	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importance	  of	  the	  complex	  and	  coordinated	  inflammatory	  response	  post-­‐exercise	  to	  muscle	  regeneration.	  Post-­‐ECC	  cellular	  and	  molecular	  alterations	  have	  been	  identified	  (55,	  67,	  116,	  133,	  137,	  156,	  192,	  194),	  including	  those	  involving	  inflammation	  and	  secondary	  damage	  that	  have	  furthered	  our	  knowledge	  of	  muscle	  damage	  and	  repair	  considerably.	  The	  current	  understanding	  regarding	  the	  mechanisms	  that	  mediate	  DOMS	  are	  briefly	  summarized	  below.	  For	  a	  more	  detailed	  review,	  the	  reader	  may	  also	  see	  Hyldahl	  and	  Hubal	  (135).	  The	  following	  sections	  summarize	  inflammatory	  changes	  following	  ECC	  that	  take	  place	  at	  the	  cellular	  level.	  
	  
Cellular	  Inflammation	  Associated	  with	  Muscle	  Damage	  Leukocyte	  infiltration	  into	  injured	  muscle	  generally	  peaks	  within	  the	  first	  3-­‐24h	  post-­‐exercise	  for	  neutrophils	  (216)	  and	  24-­‐48h	  post-­‐exercise	  for	  macrophages	  (21,	  88,	  120,	  267).	  These	  cells	  serve	  to	  remove	  debris	  (50,	  79)	  and	  can	  signal	  molecules	  to	  promote	  remodeling	  and	  regeneration	  (325).	  Macrophages	  are	  classified	  as	  either	  ED1/M1	  (primarily	  pro-­‐inflammatory	  action)	  or	  ED2/M2	  (primarily	  anti-­‐inflammatory	  action)	  macrophages.	  Earlier	  research	  classified	  the	  polarization	  of	  macrophages	  into	  ED1	  or	  ED2	  by	  the	  presence	  or	  absence	  of	  two	  antigen	  markers	  on	  the	  cell	  surface:	  CD68+/CD163-­‐	  (ED1)	  or	  CD68-­‐/CD163+	  (ED2).	  More	  recent	  research	  has	  revealed	  greater	  specificity	  and	  complexity	  in	  phenotypic	  characteristics	  of	  skeletal	  muscle	  macrophages	  after	  ECC;	  therefore,	  macrophages	  involved	  in	  skeletal	  muscle	  damage	  are	  now	  most	  commonly	  classified	  as	  M1	  or	  M2.	  M1	  macrophages	  peak	  approximately	  24h	  post-­‐ECC	  and	  are	  involved	  in	  phagocytosis	  and	  cytokine	  signaling	  as	  part	  of	  the	  early	  phase	  of	  inflammation.	  The	  
	  	  35	  
the	  late	  phase	  of	  inflammation	  emerges	  at	  approximately	  2d	  post-­‐ECC,	  with	  a	  shift	  from	  pro-­‐	  to	  anti-­‐inflammatory	  cytokine	  signaling	  (for	  example,	  a	  decrease	  in	  TNF-­‐α	  and	  increase	  of	  IL-­‐10)	  that	  is	  brought	  about	  by	  the	  appearance	  of	  a	  second	  wave	  of	  M2	  macrophages.	  Macrophage	  polarization	  shifting	  from	  M1	  to	  M2	  likely	  plays	  a	  role	  in	  the	  shift	  from	  potentially	  causing	  secondary	  damage	  to	  rebuilding	  because	  M2	  macrophages	  outnumber	  M1	  macrophages	  around	  the	  same	  time	  as	  gene	  expression	  of	  satellite	  cells	  shifts	  from	  proliferation	  to	  differentiation.	  Furthermore,	  M2	  macrophages	  produce	  and	  release	  growth	  factors	  that	  play	  a	  significant	  role	  in	  regeneration,	  such	  as	  TGF-­‐	  β	  (86).	  For	  extensive	  reviews	  of	  cellular	  inflammatory	  changes	  following	  muscle	  damage,	  the	  reader	  is	  referred	  to	  reviews	  by	  Peake	  and	  colleagues	  (270);	  Pillon	  and	  colleagues	  (280);	  Butterfield	  and	  colleagues	  (40);	  and	  Chargé	  and	  Rudnicki	  (46).	  	  
	  
Early	  Phase	  Inflammation	  The	  early	  phase	  of	  inflammation	  in	  the	  ECC	  model	  begins	  during	  exercise	  and	  typically	  lasts	  up	  to	  approximately	  2d	  post-­‐ECC.	  Under	  normal	  conditions,	  skeletal	  muscle	  contains	  resident	  macrophages	  that	  are	  quiescent	  within	  the	  epimysium	  and	  perimysium.	  As	  previously	  mentioned,	  macrophages	  are	  heterogeneous,	  particularly	  among	  tissue-­‐specific	  resident	  macrophages.	  The	  classification	  of	  skeletal	  muscle	  resident	  macrophages	  in	  humans	  remains	  poorly	  defined,	  save	  that	  they	  differ	  from	  invading	  inflammatory	  (M1/M2)	  macrophages	  in	  their	  antigen	  presentation.	  	  After	  ECC,	  resident	  macrophages	  are	  activated	  and,	  along	  with	  muscle	  fibers	  and	  other	  non-­‐muscle	  cells,	  release	  chemical	  messengers	  (such	  as	  monocyte	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chemoattractant	  protein	  (MCP)-­‐1	  (133,	  166,	  255))	  to	  evoke	  the	  activation,	  movement,	  and	  extravasation	  of	  inflammatory	  cells	  from	  circulation	  into	  the	  site	  of	  injury.	  The	  first	  cellular	  responders	  (peaking	  at	  6h	  post-­‐ECC)	  are	  the	  neutrophils,	  polymorphic	  leukocytes	  that	  serve	  to	  identify	  and	  break	  down	  damaged	  tissue	  through	  phagocytosis	  and	  respiratory	  bursts,	  resulting	  in	  damage	  and	  death	  to	  foreign	  pathogens,	  damaged	  tissue,	  and	  healthy	  neighboring	  tissue.	  Neutrophils	  are	  pro-­‐inflammatory	  and	  their	  accumulation	  post-­‐ECC	  can	  result	  in	  secondary	  tissue	  damage.	  After	  neutrophils	  accumulate,	  monocytes	  begin	  to	  infiltrate	  and	  make	  the	  phenotypic	  transformation	  into	  macrophages.	  During	  the	  early	  inflammatory	  phase,	  M1	  macrophages	  propagate	  pro-­‐inflammatory	  processes.	  	  
Early	  Phase:	  Cytokine	  and	  Chemokine	  Signaling	  The	  physical	  movement	  of	  circulating	  leukocytes	  is	  initiated	  by	  	  stretch-­‐activated	  calcium	  channels	  (69)	  that	  result	  in	  the	  release	  of	  cytokines	  and	  chemokines	  into	  circulation.	  These	  molecules	  initiate	  the	  proliferation	  and	  chemotaxis	  (movement)	  of	  leukocytes	  to	  the	  site	  of	  injury.	  The	  first	  cytokines	  to	  be	  released	  during	  the	  first	  ~48h	  after	  maximal	  ECC	  in	  humans	  are	  the	  	  pro-­‐inflammatory	  cytokines	  TNF-­‐α,	  MCP	  (325,	  358),	  and	  IL-­‐1	  (188,	  248),	  followed	  by	  IL-­‐6	  (34,	  112,	  313),	  and	  the	  colony	  stimulating	  factors	  (CSFs)	  (123,	  266,	  313)	  from	  resident	  macrophages,	  skeletal	  muscle,	  and	  infiltrating	  leukocytes.	  Together,	  these	  cytokines	  promote	  activation,	  proliferation,	  and	  chemotaxis	  by	  altering	  gene	  expression	  and	  presentation	  of	  adhesion	  molecules	  of	  leukocytes,	  stimulating	  them	  to	  roll	  along	  the	  surface	  of	  the	  vasculature	  and	  extravasate	  into	  the	  muscle.	  It	  is	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important	  to	  note	  that	  not	  all	  studies	  have	  shown	  an	  increase	  in	  TNF-­‐α	  (123,	  313),	  although	  this	  may	  be	  a	  function	  of	  the	  location	  and	  timing	  of	  measurement	  and	  differences	  in	  exercise	  mode.	  	  Systemic	  alterations	  in	  cytokine	  levels	  may	  be	  more	  difficult	  to	  detect	  due	  to	  dilution	  in	  circulation.	  Furthermore,	  research	  has	  consistently	  shown	  that	  the	  extent	  to	  which	  cytokines	  are	  expressed	  varies	  according	  to	  the	  type	  and	  intensity	  of	  exercise	  performed,	  as	  well	  as	  temporally.	  Because	  of	  this	  variability,	  it	  is	  not	  clear	  whether	  altered	  levels	  of	  circulating	  cytokines	  are	  sufficient	  or	  necessary	  to	  evoke	  major	  responses	  after	  ECC,	  though	  changes	  to	  cytokines	  near	  the	  site	  of	  injury	  can	  still	  affect	  regeneration.	  TNF-­‐α	  functions	  by	  chemoattracting	  satellite	  cells	  to	  damaged	  regions	  of	  muscle	  in	  mice	  (340).	  IL-­‐6	  stimulates	  proliferation	  of	  satellite	  cells	  after	  ECC	  (356),	  though	  this	  cytokine	  also	  plays	  both	  anti-­‐	  and	  pro-­‐inflammatory	  roles	  under	  other	  conditions.	  	  	  
Early	  Phase:	  Neutrophil	  Migration	  and	  Infiltration	  	   Neutrophils	  are	  the	  first	  leukocytes	  to	  arrive	  at	  the	  damaged	  muscle	  (187,	  188,	  210),	  infiltrating	  within	  an	  hour	  after	  ECC.	  After	  ECC,	  there	  is	  a	  transient	  increase	  in	  neutrophil	  counts,	  which	  peaks	  in	  circulation	  at	  approximately	  3-­‐6h	  post-­‐exercise	  (89,	  198,	  266,	  281,	  298).	  Enhanced	  levels	  of	  cytokines	  and	  chemokines	  in	  plasma,	  such	  as	  TNF-­‐α	  (273,	  337)	  and	  G-­‐CSF	  (266),	  result	  in	  the	  chemotaxis	  and	  diapedesis	  of	  neutrophils	  into	  the	  muscle.	  Physical	  alterations	  assist	  diapedesis,	  including	  the	  deformation	  and	  reorganization	  of	  neutrophils	  (376,	  377)	  and	  the	  endothelium	  (264)	  through	  modifying	  adherent	  junctions	  between	  cells	  (73).	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Muscular	  accumulation	  of	  neutrophils	  peaks	  between	  6-­‐24h	  after	  ECC,	  as	  measured	  by	  biopsy	  (21,	  88,	  207,	  284,	  323)	  and	  the	  use	  of	  radio-­‐labeling	  (186).	  Following	  entry	  into	  the	  muscle,	  neutrophils	  contribute	  to	  pro-­‐inflammatory	  processes	  through	  the	  release	  of	  cytokines	  and	  chemokines,	  as	  well	  as	  signaling	  stimulated	  by	  respiratory,	  or	  oxidative,	  bursts.	  Accumulation	  of	  neutrophils	  can	  also	  stimulate	  secondary	  tissue	  damage.	  	  Neutrophils	  mediate	  two	  important	  processes:	  degranulation	  and	  phagocytosis.	  In	  direct	  phagocytosis,	  debris	  is	  engulfed	  by	  neutrophils	  and	  sequestered	  in	  phagolysosomes,	  where	  noxious	  substances	  destroy	  the	  debris.	  Any	  leftover	  material	  is	  then	  released	  from	  the	  neutrophil	  for	  further	  degradation	  or	  recycling	  via	  degranulation.	  Neutrophils	  also	  release	  noxious	  substances	  into	  the	  extracellular	  space	  through	  several	  types	  of	  degranulation.	  These	  noxious	  substances,	  released	  as	  part	  of	  respiratory	  bursts,	  can	  result	  in	  damage	  to	  surrounding	  healthy	  tissue	  (secondary	  damage)	  and	  include	  nitric	  oxide	  (241),	  although	  others	  are	  involved.	  For	  example,	  myeloperoxidase	  (MPO)	  release	  from	  neutrophils	  modulates	  membrane	  disruption	  by	  way	  of	  nitric	  oxide	  and	  its	  derivatives.	  	  Generally,	  neutrophils	  break	  down	  damaged	  tissue	  and	  remove	  debris.	  However,	  the	  release	  of	  TNF-­‐α	  from	  neutrophils	  assists	  in	  the	  chemoattraction	  of	  satellite	  cells	  and	  M1	  macrophages	  (340),	  both	  of	  which	  are	  important	  in	  the	  regeneration	  process	  but	  serve	  opposing	  purposes	  of	  regeneration	  and	  (primarily)	  additional	  damage,	  respectively.	  Oxidative	  molecules	  signal	  cascades	  related	  to	  muscle	  repair	  (148)	  and	  growth	  such	  as	  insulin-­‐like	  growth	  factor	  (IGF)-­‐1,	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phosphoinositide	  3-­‐kinase/protein	  kinase	  B	  (PI3-­‐K/AKT),	  NFκB,	  and	  the	  MAPKs	  (114,	  141,	  302),	  and	  may	  therefore	  play	  an	  important	  role	  in	  subsequent	  regeneration.	  Therefore,	  neutrophils	  may	  also	  indirectly	  assist	  in	  muscle	  regeneration	  through	  the	  release	  of	  radical	  species.	  Neutrophils	  ultimately	  initiate	  apoptosis	  and	  die	  between	  1-­‐2d	  after	  ECC.	  These	  apoptotic	  cells	  are	  then	  phagocytosed	  by	  infiltrating	  macrophages	  (289).	  	  
Early	  Phase:	  Macrophage	  Activation,	  Mobilization	  and	  Infiltration	  	   After	  an	  early	  period	  of	  neutrophil	  invasion,	  the	  extravasation	  of	  monocytes	  begins	  (267).	  Following	  their	  entry	  into	  the	  muscle,	  they	  transform	  into	  inflammatory	  macrophages.	  Monocyte	  classifications	  are	  reviewed	  in	  Yona	  (379).	  In	  mice,	  monocytes	  are	  classified	  by	  the	  expression	  of	  the	  cell	  surface	  marker	  Ly-­‐6C;	  monocytes	  that	  are	  Ly-­‐6C(high)	  are	  classified	  as	  pro-­‐inflammatory	  while	  those	  that	  are	  Ly-­‐6C(low)	  are	  classified	  as	  anti-­‐inflammatory.	  In	  humans,	  the	  expression	  of	  the	  cell	  markers	  CD14	  and	  CD16	  generally	  determines	  the	  classification	  of	  monocytes:	  pro-­‐inflammatory	  express	  CD14(high)/CD16(neg),	  while	  CD14(low)/CD16(high)	  are	  considered	  anti-­‐inflammatory.	  However,	  monocytes	  and	  macrophages	  are	  a	  highly	  heterogeneous	  population	  in	  terms	  of	  their	  actions	  and	  antigen	  expression,	  both	  of	  which	  can	  vary	  substantially	  depending	  upon	  the	  tissue	  type	  in	  which	  they	  reside,	  and	  therefore	  caution	  must	  be	  taken	  to	  classify	  these	  cells.	  In	  humans,	  the	  classification	  of	  monocytes	  based	  on	  their	  expression	  of	  CD14	  and	  CD16	  is	  not	  well	  characterized	  and	  therefore	  I	  discuss	  them	  here	  by	  Ly-­‐6C	  expression,	  only.	  In	  response	  to	  injury,	  Ly-­‐6C(high)	  monocytes	  extravasate	  first	  and	  are	  most	  likely	  the	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pro-­‐inflammatory	  precursors	  to	  the	  phenotypically	  pro-­‐inflammatory	  macrophage	  population	  (M1)	  (154).	  Once	  they	  have	  infiltrated	  the	  muscle,	  these	  monocytes	  transform	  into	  macrophages	  through	  the	  expression	  of	  specific	  antigens,	  including	  CD68	  and	  CD86	  (M1),	  and	  CD206	  and	  CD163	  (M2);	  most	  macrophages	  that	  enter	  muscle	  during	  the	  early	  inflammatory	  phase	  become	  M1	  phenotype	  (reviewed	  in	  Tidball	  (337)).	  	  	   The	  majority	  of	  macrophages	  in	  this	  early	  phase	  (M1)	  phagocytose	  debris,	  although	  they	  are	  also	  involved	  in	  cytokine	  signaling	  through	  the	  release	  of	  IL-­‐6	  and	  TNF-­‐α.	  In	  addition	  to	  their	  roles	  as	  phagocytic	  cells,	  M1	  macrophages	  have	  been	  shown	  in	  vitro	  to	  promote	  the	  proliferation	  and	  suppress	  the	  differentiation	  of	  muscle	  progenitor	  cells	  (9).	  Thus,	  M1	  macrophages	  may	  assist	  muscle	  regeneration.	  	  At	  early	  stages	  of	  healing	  in	  other	  tissues,	  macrophages	  may	  play	  other	  roles	  in	  addition	  to	  or	  instead	  of	  phagocytosis	  and	  cytokine	  signaling—for	  example,	  they	  have	  been	  shown	  to	  release	  TGF-­‐β	  and	  vascular	  endothelial	  growth	  factor	  (VEGF)-­‐α	  during	  wound	  healing,	  proteins	  that	  stimulate	  muscle	  cell	  differentiation	  and	  angiogenesis,	  respectively	  (185).	  However,	  the	  timing	  of	  events	  may	  be	  different	  between	  healing	  in	  other	  tissues	  and	  muscle	  regeneration.	  For	  instance,	  when	  macrophages	  are	  co-­‐cultured	  with	  necrotic	  muscle	  progenitor	  cells	  in	  vitro,	  the	  phagocytosis	  of	  muscle	  cell	  debris	  leads	  to	  macrophage	  production	  of	  TGF-­‐β	  and	  a	  subsequent	  phenotypic	  shift	  to	  M2	  macrophages.	  Generally,	  M2	  macrophages	  express	  TGF-­‐β	  to	  a	  greater	  extent	  than	  M1	  cells,	  and,	  in	  vivo,	  M2	  macrophages	  are	  most	  prevalent	  during	  the	  later	  stage	  of	  inflammation	  (9),	  resulting	  in	  an	  increase	  of	  TGF-­‐β	  and	  enhanced	  muscle	  regeneration.	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M1	  macrophages	  can	  undergo	  a	  phenotypic	  change	  in	  response	  to	  their	  phagocytic	  activity—particularly	  phagocytosis	  of	  apoptotic	  neutrophils	  or	  debris	  caused	  by	  neutrophilic	  degranulation	  (9).	  These	  cells	  are	  considered	  to	  be	  primarily	  anti-­‐inflammatory	  in	  nature	  and	  begin	  to	  express	  cytokine	  profiles	  more	  similar	  to	  M2	  macrophages,	  including	  increased	  expression	  of	  TGF-­‐β	  and	  IL-­‐10	  and	  decreased	  expression	  of	  TNF-­‐α	  and	  IL-­‐1β	  (9).	  The	  phenotypic	  shift	  from	  M1	  to	  M2	  is	  a	  part	  of	  an	  important	  turning	  point	  in	  the	  post-­‐injury	  response—a	  tipping	  of	  the	  inflammatory	  balance	  from	  primarily	  pro-­‐inflammatory	  to	  anti-­‐inflammatory,	  as	  well	  as	  a	  shift	  in	  muscle	  progenitor	  cell	  proliferation	  to	  differentiation,	  and	  ultimately	  an	  attenuation	  of	  secondary	  damage	  and	  promotion	  of	  tissue	  regeneration.	  Shifts	  to	  this	  final	  stage	  begin	  at	  approximately	  2d	  after	  injury	  or	  stress	  to	  the	  muscle	  and	  are	  orchestrated	  in	  part	  by	  the	  M2	  macrophages.	  
	  
The	  Shift	  from	  Early	  to	  Late	  Phase	  of	  Inflammation	  following	  Damage	  	   At	  approximately	  2d	  post-­‐ECC,	  the	  shift	  from	  pro-­‐	  to	  anti-­‐inflammatory	  cytokines	  coincides	  with	  the	  increases	  in	  the	  expression	  of	  IL-­‐1	  receptor-­‐α(R-­‐α),	  IL-­‐4,	  and	  IL-­‐10	  (272,	  313),	  which	  collectively	  block	  the	  production	  of	  IL-­‐1,	  -­‐6,	  and	  -­‐8.	  Corresponding	  temporally	  with	  these	  cytokine	  changes	  is	  a	  shift	  in	  macrophage	  phenotype	  (337).	  Toward	  the	  end	  of	  the	  early	  phase,	  the	  neutrophils	  have	  either	  undergone	  apoptosis	  or	  degranulation	  and	  the	  debris	  is	  either	  shunted	  out	  of	  the	  cell	  in	  lysosomes	  or	  engulfed	  by	  the	  M1	  macrophages.	  Research	  suggests	  that	  the	  phagocytosis	  of	  neutrophilic	  debris	  by	  M1	  macrophages	  stimulates	  a	  shift	  in	  the	  macrophage	  polarization,	  resulting	  in	  their	  phenotypic	  transformation	  to	  M2	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macrophages	  (289).	  A	  heterogeneous	  population	  of	  both	  macrophage	  phenotypes	  exists	  at	  this	  transitional	  phase.	  As	  the	  transition	  period	  progresses,	  the	  balance	  tips	  such	  that	  the	  M2	  macrophages	  predominate	  over	  M1	  cells.	  M2	  macrophages	  release	  additional	  anti-­‐inflammatory	  cytokines,	  further	  enhancing	  anti-­‐inflammatory	  activity,	  quenching	  pro-­‐inflammatory	  actions,	  and	  limiting	  secondary	  damage.	  	  	  
Late	  Phase	  Inflammation	  	   The	  late	  phase	  of	  inflammation	  is	  less	  well	  understood	  than	  the	  early	  phase	  and	  is	  a	  major	  focus	  of	  this	  dissertation.	  Fewer	  studies	  have	  been	  performed	  beyond	  the	  first	  24h	  post-­‐ECC,	  and	  the	  high	  variability	  among	  responses	  to	  ECC	  is	  most	  exaggerated	  in	  the	  late	  phase,	  due,	  in	  part,	  to	  the	  wide	  variety	  of	  models	  used	  to	  elicit	  muscle	  damage	  and	  variability	  in	  response	  timing,	  and	  partly	  to	  the	  phenotypic	  heterogeneity	  of	  the	  macrophage	  population	  at	  this	  time	  point.	  The	  overall	  inflammatory	  events	  taking	  place	  two	  or	  more	  days	  after	  ECC	  have	  been	  identified;	  yet	  the	  specific	  underlying	  mechanisms	  can	  vary,	  and	  ultimately	  may	  significantly	  alter	  the	  course	  of	  recovery	  and	  regeneration.	  
	  
Late	  Phase:	  Cytokines	  and	  Chemokines	  	   As	  previously	  discussed,	  at	  approximately	  2d	  after	  ECC	  there	  is	  a	  shift	  in	  the	  inflammatory	  balance	  to	  attenuate	  pro-­‐inflammatory	  action	  and	  promote	  regeneration.	  This	  occurs	  with	  the	  combined	  release	  of	  IL-­‐1Rα,	  IL-­‐4,	  and	  IL-­‐10	  to	  block	  the	  production	  of	  pro-­‐inflammatory	  cytokines	  including	  IL-­‐1	  and	  IL-­‐6	  (337).	  IL-­‐13,	  which	  plays	  a	  role	  in	  macrophage	  phenotype	  determination,	  may	  also	  be	  
	  	  43	  
released	  at	  this	  time.	  Both	  TGF-­‐β	  and	  IL-­‐10	  are	  released	  at	  this	  time,	  which	  serve	  to	  enhance	  myogenesis.	  In	  addition,	  TGF-­‐β	  may	  promote	  angiogenesis	  and	  rebuilding	  of	  the	  extracellular	  matrix	  (ECM)	  (84,	  295).	  The	  role	  of	  these	  cytokines	  appears	  critical	  to	  effective	  healing,	  such	  that	  dysregulation	  of	  TGF-­‐β	  or	  IL-­‐1β	  may	  promote	  fibrosis	  within	  skeletal	  muscle,	  leading	  to	  decreased	  function	  and	  increased	  risk	  of	  future	  injury	  (179,	  204).	  	  
Late	  Phase:	  M2	  Macrophages,	  Inflammatory	  Resolution,	  and	  Regeneration	  During	  late	  phase	  inflammation,	  the	  primary	  macrophage	  population	  is	  M2,	  which	  most	  likely	  originate	  from	  the	  extant	  M1	  population	  via	  polarization	  change	  or	  from	  newly	  infiltrating	  monocytes	  (most	  likely	  CD14(low)/CD16(high)).	  Resident	  macrophages	  could	  conceivably	  proliferate	  and	  contribute	  to	  the	  M2	  population,	  although	  this	  possibility	  has	  yet	  to	  gain	  substantive	  support.	  	  There	  are	  three	  subtypes	  of	  M2	  macrophages,	  each	  with	  different	  functions.	  These	  subtypes	  are	  the	  result	  of	  the	  specific	  cytokine	  environment	  at	  the	  time	  of	  differentiation	  and	  promote	  distinct	  healing	  outcomes.	  For	  example,	  IL-­‐13	  is	  thought	  to	  result	  in	  macrophage	  phenotypes	  that	  suppress	  inflammation,	  while	  those	  activated	  by	  IL-­‐4	  and	  IL-­‐10	  are	  thought	  to	  promote	  tissue	  repair	  (107).	  M2a	  macrophages	  result	  in	  fibrotic	  deposition,	  play	  a	  role	  in	  the	  rebuilding	  of	  ECM	  and	  other	  connective	  tissues,	  and	  appear	  during	  the	  most	  advanced	  stages	  of	  healing	  (351,	  371).	  This	  population	  of	  macrophages	  is	  thought	  to	  result	  from	  activation	  via	  IL-­‐4	  or	  -­‐13	  signaling,	  which	  in	  turn	  results	  in	  the	  activation	  of	  STAT6	  (113,	  183).	  M2b	  macrophages	  have	  immune	  regulatory	  functions	  and	  are	  less	  likely	  to	  play	  a	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significant	  role	  in	  skeletal	  muscle	  repair,	  although	  they	  can	  be	  anti-­‐inflammatory	  through	  their	  expression	  of	  IL-­‐10	  (29).	  Finally,	  M2c	  macrophages	  result	  from	  stimulation	  by	  IL-­‐10	  or	  glucocorticoids.	  They	  appear	  relatively	  early	  within	  the	  late	  phase,	  and	  are	  primarily	  anti-­‐inflammatory	  through	  the	  release	  of	  IL-­‐10	  and	  TGF-­‐β	  (9).	  These	  findings	  indicate	  the	  importance	  of	  quenching	  pro-­‐inflammatory	  pathways	  to	  resolve	  inflammation	  and	  promote	  healing.	  Macrophages	  are	  critical	  to	  regeneration,	  as	  the	  ablation	  of	  monocytes	  impairs	  regeneration	  (9).	  In	  addition,	  there	  must	  be	  a	  resolution	  of	  inflammation.	  Without	  the	  deactivation	  of	  pro-­‐inflammatory	  activity,	  tissue	  remodeling	  is	  attenuated	  and	  this	  can	  result	  in	  fibrosis	  rather	  than	  myogenesis	  (204).	  In	  addition	  to	  previously	  described	  roles,	  inflammatory	  macrophages	  participate	  in	  muscle	  regeneration	  through	  enhancing	  proliferation	  of	  myogenic	  cells,	  shown	  in	  vitro	  (9,	  50,	  315)	  and,	  in	  vivo	  (22).	  Tidball	  and	  Wehling-­‐Henricks	  (338)	  reported	  in	  vivo	  macrophage	  depletion	  at	  2d	  after	  muscle	  re-­‐loading	  resulted	  in	  impaired	  muscle	  regeneration	  and	  suppressed	  expression	  of	  myogenic	  genes	  in	  muscle	  progenitor	  cells	  (MPCs).	  It	  is	  thought	  that	  M1	  macrophages	  stimulate	  MPC	  proliferation	  while	  M2	  macrophages	  support	  their	  differentiation	  (9,	  275).	  Furthermore,	  the	  signaling	  molecules	  released	  by	  macrophages	  and	  neutrophils,	  such	  as	  TNF-­‐α,	  help	  drive	  MPC	  activation.	  	  
The	  Role	  of	  Muscle	  Progenitor	  Cells	  in	  Inflammation	  Upon	  activation,	  muscle	  progenitor	  cells	  (MPCs;	  primarily	  satellite	  cells)	  proliferate,	  migrate	  toward	  the	  site	  of	  injury	  or	  stress,	  and	  can	  directly	  fuse	  with	  the	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damaged	  myofiber	  and	  release	  growth	  factors	  and	  other	  signaling	  molecules	  to	  enhance	  regeneration	  and	  remodeling.	  Generally,	  satellite	  cell	  numbers	  increase	  by	  24h	  post-­‐ECC	  and	  remain	  elevated	  up	  to	  or	  beyond	  8d,	  indicating	  a	  possible	  role	  in	  the	  rebuilding	  process	  (66,	  67,	  78,	  221,	  256,	  268)	  (214,	  215).	  These	  cells	  can	  also	  be	  induced	  without	  obvious	  signs	  of	  muscle	  damage	  or	  growth	  (66,	  67,	  190,	  221).	  Several	  inflammatory	  mediators	  alter	  the	  behavior	  of	  satellite	  cells.	  IL-­‐6	  deficiency	  in	  mice	  significantly	  attenuated	  satellite	  cell	  proliferation	  following	  muscle	  damage,	  which	  was	  rescued	  via	  paracrine	  IL-­‐6	  production	  by	  myotubes,	  in	  
vitro	  (308).	  These	  data	  suggest	  that	  IL-­‐6	  signaling	  is	  critical	  to	  satellite	  cell	  activity	  in	  muscle	  repair.	  Exogenous	  TNF-­‐α	  application	  in	  vitro	  and	  injection	  in	  vivo	  enhances	  satellite	  cell	  activation	  and	  proliferation,	  suggesting	  that	  it	  plays	  a	  role	  in	  satellite	  cell	  proliferation	  (180).	  	  A	  number	  of	  inflammatory	  pathways	  that	  affect	  satellite	  cell	  activity	  after	  ECC	  also	  sensitize	  nerve	  endings	  and	  are	  therefore	  implicated	  in	  hyperalgesia.	  The	  most	  studied	  of	  these	  pathways	  is	  the	  cyclooxygenase	  (COX)	  pathway	  (25,	  26,	  219),	  which	  stimulates	  prostaglandin	  synthesis.	  However,	  it	  is	  unclear	  if	  COX	  is	  necessarily	  related	  to	  muscle	  regeneration,	  as	  there	  is	  evidence	  that	  both	  supports	  (35,	  36,	  365)	  and	  refutes	  (38,	  221)	  a	  role	  for	  the	  COX	  pathway	  in	  regeneration	  after	  ECC.	  Another	  nerve-­‐sensitizing	  molecule	  implicated	  in	  MPC	  activity	  is	  nerve	  growth	  factor	  (NGF).	  In	  vitro	  treatment	  with	  NGF	  suppresses	  differentiation	  of	  MPCs,	  yet	  improves	  the	  efficiency	  of	  MPC	  engraftment	  when	  these	  cells	  are	  transplanted	  into	  mouse	  dystrophic	  muscle	  (171).	  Other	  research	  suggests	  that	  NGF	  may	  promote	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MPC	  fusion	  through	  the	  NGF	  low-­‐affinity	  receptor,	  p75NTR,	  the	  expression	  of	  which	  is	  increased	  throughout	  regeneration.	  The	  sections	  above	  explored	  the	  responses	  of	  muscle	  to	  ECC	  at	  the	  gross	  physiological	  and	  cellular	  levels.	  To	  further	  delineate	  what	  specific	  factors	  drive	  damage	  and	  repair,	  we	  must	  tease	  apart	  molecular	  mechanisms	  that	  underlie	  changes	  at	  the	  more	  macroscopic	  level.	  After	  ECC,	  alterations	  to	  mRNA	  and	  protein	  expression	  occur,	  not	  only	  within	  skeletal	  muscle	  but	  also	  a	  variety	  of	  cell	  types	  such	  as	  MPCs,	  fibroblasts,	  and	  inflammatory	  cells.	  	  	  
Molecular	  Mediators	  of	  Muscle	  Damage	  and	  Inflammation	  A	  number	  of	  studies	  investigating	  skeletal	  muscle	  damage	  mechanisms	  have	  resulted	  in	  the	  generation	  of	  large	  gene	  and	  protein	  expression	  profiles	  through	  the	  use	  of	  high	  throughput	  technologies	  such	  as	  microarrays	  (transcriptomic)	  (55,	  137,	  161,	  192,	  195)	  and	  2-D DIGE (proteomic)	  (200)(reviewed	  in	  Gelfi	  (105)).	  Key	  pathways	  that	  are	  differentially	  regulated	  early	  after	  ECC	  include	  those	  involved	  in	  the	  stress	  response	  (195,	  346),	  such	  as	  the	  heat-­‐shock	  proteins	  (161),	  and	  the	  ubiquitin-­‐proteasome	  pathway	  (161,	  195,	  346).	  At	  24h	  the	  expression	  of	  structural	  proteins	  is	  also	  upregulated	  (161),	  suggesting	  that	  it	  may	  be	  a	  part	  of	  the	  remodeling	  process.	  The	  expression	  of	  inflammatory	  genes	  is	  altered	  early	  after	  ECC	  (55,	  195),	  although	  only	  a	  small	  number	  of	  studies	  have	  investigated	  the	  early	  to	  late	  shift	  and	  later	  stages	  of	  inflammation	  (191,	  192,	  335).	  	  The	  use	  of	  varied	  damage	  models	  is	  a	  major	  challenge	  to	  understanding	  the	  underlying	  molecular	  mechanisms	  that	  mediate	  responses	  to	  ECC,	  including	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inflammation,	  secondary	  damage,	  and	  repair.	  For	  example,	  downhill	  running	  stimulates	  a	  different	  inflammatory	  profile	  as	  compared	  to	  isolated	  maximal	  eccentric	  actions,	  due	  to	  differing	  mechanical	  and	  metabolic	  demands.	  Therefore,	  caution	  must	  be	  taken	  in	  generalizing	  results	  based	  on	  the	  data	  from	  the	  small	  number	  of	  studies	  performed	  at	  later	  time	  points.	  	  Nevertheless,	  a	  set	  of	  genes	  and	  pathways	  important	  to	  muscle	  remodeling	  have	  been	  identified,	  including	  those	  involved	  in	  muscle	  formation	  (such	  as	  the	  myogenic	  regulatory	  factors	  (MRFs)	  Myf5,	  MyoD,	  myogenin,	  and	  MRF4),	  modulation	  of	  transcription	  that	  play	  roles	  in	  damage	  and	  repair,	  and	  inflammation	  (including	  cytokines	  and	  chemokines).	  Due	  to	  the	  complex	  nature	  of	  signaling	  and	  the	  variety	  in	  models,	  it	  is	  difficult	  to	  clarify	  how	  inflammation	  exerts	  its	  actions	  upon	  repair	  after	  ECC.	  However,	  several	  inflammatory	  mediators	  and	  pathways	  have	  been	  identified	  as	  possible	  major	  players	  in	  muscle	  regeneration,	  including	  several	  of	  the	  interleukins,	  TGF-­‐β,	  the	  COX-­‐2	  pathway,	  ERK,	  and	  NFκB.	  	  
Inflammatory	  Pathways	  Mediating	  EIMD	  	   The	  production	  of	  inflammation-­‐related	  mRNAs	  and	  proteins	  can	  change	  without	  typical	  signs	  of	  inflammation	  or	  damage,	  including	  swelling,	  circulating	  cytokines	  and	  chemokines,	  or	  the	  infiltration	  of	  leukocytes	  at	  the	  site	  of	  injury	  or	  muscle	  stress.	  The	  specific	  roles	  inflammation	  may	  play	  in	  ECC	  recovery	  are	  not	  well	  understood,	  though	  several	  have	  been	  identified.	  For	  example,	  the	  expression	  of	  cytokines,	  including	  IL-­‐8	  (35),	  IL-­‐1β	  (43,	  112),	  TGF-­‐β	  (112),	  is	  altered	  following	  ECC,	  the	  production	  and	  release	  of	  which	  have	  been	  previously	  discussed.	  IL-­‐6	  and	  its	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receptors	  (mRNA	  and	  protein)	  tend	  to	  increase	  after	  ECC,	  and	  may	  play	  a	  dual	  role	  as	  both	  pro-­‐	  and	  anti-­‐inflammatory	  mediators	  (35,	  112,	  214).	  This	  inflammatory	  molecule	  is	  released	  not	  only	  by	  skeletal	  muscle	  and	  satellite	  cells,	  but	  also	  fibroblasts	  (43)—cells	  that	  also	  release	  IL-­‐1	  and	  IL-­‐8,	  suggesting	  a	  potential	  role	  in	  promoting	  inflammation	  (43).	  	  Inflammatory	  signaling,	  including	  but	  not	  limited	  to	  IL-­‐6,	  TNF-­‐α,	  COX-­‐2,	  ERK,	  and	  NFκB,	  is	  involved	  in	  promoting	  cell	  proliferation,	  an	  important	  aspect	  of	  regeneration.	  Differentiation	  may	  be	  facilitated	  by	  both	  the	  suppression	  of	  proliferative	  pathways	  (such	  as	  ERK	  and	  NFκB),	  as	  well	  as	  the	  activation	  of	  other	  pathways	  including	  TGF-­‐β	  and	  VEGF-­‐α.	  Other	  signaling	  pathways,	  such	  as	  those	  mediated	  by	  NGF,	  may	  promote	  proliferation	  or	  differentiation	  through	  the	  activity	  of	  downstream	  targets	  dependent	  on	  factors	  including	  which	  receptor	  the	  protein	  binds.	  Transcription	  factors,	  such	  as	  ERK	  and	  NFκB,	  may	  also	  promote	  the	  transcription	  of	  structural	  proteins	  for	  remodeling.	  While	  many	  pathways	  exert	  inflammatory	  signaling	  that	  mediates	  EIMD,	  below	  I	  focus	  on	  the	  effects	  of	  ERK	  and	  NFκB.	   	  
Nuclear	  Factor	  Kappa	  Beta	  Signaling	  Related	  to	  Inflammation	  and	  EIMD	  NFκB	  pathway	  activity	  increases	  in	  response	  to	  ECC	  and	  plays	  a	  role	  in	  muscle	  regeneration.	  NFκB	  is	  a	  family	  of	  transcription	  factors	  that,	  upon	  activation,	  translocate	  to	  the	  nucleus	  and	  drive	  changes	  in	  gene	  expression	  for	  a	  variety	  of	  physiological	  processes,	  including	  proliferation,	  differentiation	  and	  apoptosis.	  There	  are	  two	  primary	  pathways	  through	  which	  NFκB	  acts:	  the	  canonical	  (classical)	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pathway,	  which	  is	  characterized	  by	  the	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A	  (Rel-­‐A)/p65	  subunit	  binding	  to	  either	  p52	  or	  p50,	  and	  the	  non-­‐canonical	  pathway	  in	  which	  Rel-­‐B	  binds	  with	  p52.	  For	  the	  purposes	  of	  this	  literature	  review,	  I	  will	  refer	  to	  these	  pathways	  as	  p65	  (canonical)	  and	  Rel-­‐B	  (non-­‐canonical).	  The	  two	  pathways	  act	  upon	  different	  downstream	  targets	  and	  it	  is	  hypothesized	  that	  both	  pathways	  play	  a	  role	  in	  muscle	  remodeling	  after	  damage.	   	  The	  activity	  of	  p65	  is	  increased	  shortly	  after	  muscle	  damage	  (136)	  and	  then	  declines	  over	  time	  (13).	  The	  p65	  complex	  inhibits	  muscle	  cell	  differentiation	  (13),	  can	  suppress	  myogenesis	  by	  inhibiting	  MyoD	  expression	  (110)	  and	  promoting	  the	  expression	  of	  Cyclin	  D1	  (109),	  and	  may	  play	  a	  role	  in	  enhancing	  proliferation	  (132)	  (reviewed	  in	  Dolcet	  (76)).	  The	  role	  of	  Rel-­‐B	  in	  muscle	  regeneration	  is	  less	  well	  characterized	  than	  that	  of	  p65.	  Rel-­‐B	  activity	  increases	  as	  p65	  activity	  decreases	  (13).	  Current	  research	  does	  not	  yet	  suggest	  a	  direct	  role	  of	  Rel-­‐B	  in	  muscle	  regeneration,	  though	  p65	  may	  promote	  proliferation	  of	  MPCs	  by	  interacting	  with	  other	  pathways	  that	  act	  in	  myogenesis,	  such	  as	  PI3K/AKT	  and	  ERK	  pathways	  (33,	  83,	  205).	  	  The	  canonical	  NFκB	  pathway	  is	  an	  important	  inflammatory	  regulator	  and	  is	  considered	  by	  many	  to	  be	  a	  keystone	  for	  pro-­‐inflammatory	  processes.	  This	  pathway	  is	  associated	  with	  a	  number	  of	  chronic	  inflammatory	  conditions	  including	  inflammatory	  bowel	  disease	  and	  rheumatoid	  arthritis	  (reviewed	  in	  (18)).	  p65	  is	  activated	  by	  pro-­‐inflammatory	  cytokines,	  including	  TNF-­‐α	  and	  IL-­‐1,	  leading	  to	  the	  production	  of	  a	  number	  of	  inflammatory	  molecules	  after	  injury	  or	  muscle	  stress,	  including	  the	  cytokines	  and	  chemokines	  IL-­‐1,	  IL-­‐6,	  IL-­‐8,	  MCP-­‐1,	  and	  G-­‐CSF	  (24,	  175).	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Through	  this	  signaling,	  NFκB	  acts	  in	  a	  positive	  feedback	  loop	  to	  promote	  additional	  pro-­‐inflammatory	  signaling	  and	  NFκB	  activation.	  It	  has	  also	  been	  implicated	  in	  macrophage	  activity,	  polarization,	  and	  the	  transformation	  from	  monocytes	  to	  macrophages.	  	  Rel-­‐B	  activity	  has	  been	  associated	  with	  the	  resolution	  of	  pro-­‐inflammatory	  processes.	  Specifically,	  inhibition	  of	  Rel-­‐B	  results	  in	  continued	  activity	  of	  the	  p65	  NFκB	  pathway	  as	  well	  as	  the	  continued	  production	  of	  pro-­‐inflammatory	  cytokines	  (11,	  334).	  Furthermore,	  overexpression	  of	  Rel-­‐B	  suppresses	  pro-­‐inflammatory	  mediators	  including	  IL-­‐6	  and	  COX-­‐2	  (218).	  These	  data,	  along	  with	  knowledge	  that	  activation	  of	  the	  canonical	  and	  non-­‐canonical	  pathways	  shift	  along	  with	  the	  inflammatory	  balance	  after	  ECC,	  strongly	  support	  the	  role	  of	  the	  NFκB	  pathways	  in	  the	  development	  and	  resolution	  of	  inflammation	  after	  ECC.	  These	  pathways	  also	  interact	  with	  other	  regulators	  of	  inflammation	  that	  are	  induced	  after	  ECC,	  including	  the	  ERK	  pathway.	  	  
Extracellular-­‐Signal	  Regulated	  Kinase	  Signaling:	  Inflammation	  and	  EIMD	  	  During	  and	  following	  ECC,	  there	  is	  an	  increase	  in	  ERK	  pathway	  activity.	  ERK	  is	  part	  of	  the	  MAPK	  family,	  which	  consists	  of	  three	  related	  serine/threonine	  kinase	  groups:	  p38	  Kinase,	  JNK	  (c-­‐Jun	  N-­‐terminal	  Kinase),	  and	  ERK.	  These	  kinases	  are	  ubiquitously	  expressed	  and	  play	  critical	  and	  diverse	  roles	  in	  proliferation,	  migration,	  differentiation,	  and	  apoptosis	  through	  transduction	  of	  extracellular	  signals	  to	  regulate	  gene	  expression.	  When	  an	  extracellular	  signal	  is	  received,	  a	  series	  of	  kinases	  are	  activated	  resulting	  in	  the	  translocation	  of	  ERK	  to	  the	  nucleus	  to	  drive	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expression	  of	  a	  wide	  variety	  of	  genes.	  The	  ERK	  pathway	  is	  complex	  in	  that	  interacts	  with	  a	  number	  of	  other	  pathways,	  including	  the	  other	  MAPKs	  and	  NFκB.	  	  The	  ERKs,	  specifically	  ERK1	  and	  2	  (ERK1/2),	  are	  the	  most	  widely	  studied	  of	  the	  MAPK	  family	  and,	  when	  over-­‐activated,	  are	  strongly	  linked	  to	  unchecked	  cellular	  proliferation	  and	  cancer.	  The	  ERK1/2	  pathway,	  like	  other	  MAPKs	  p38	  and	  JNK,	  can	  be	  activated	  via	  phosphorylation	  by	  a	  variety	  of	  factors,	  including	  cytokines,	  mechanotransduction	  via	  the	  integrins	  and	  extracellular	  matrix,	  growth	  factors	  including	  early	  growth	  factor	  (EGF)	  and	  NGF,	  and	  G-­‐coupled	  protein	  receptors	  (126,	  164,	  279,	  314,	  349,	  369,	  373).	  As	  previously	  mentioned,	  a	  consequence	  of	  secondary	  damage	  after	  eccentric	  exercise	  is	  the	  release	  of	  cytokines	  and	  chemokines	  (133)	  that	  recruit	  and	  stimulate	  the	  proliferation	  in	  MPCs,	  chemoattract	  and	  activate	  leukocytes,	  and	  activate	  the	  ERK1/2	  signaling	  pathway.	  The	  ERK1/2	  pathway	  plays	  a	  critical	  role	  in	  MPC	  activation	  and	  mobilization	  (83,	  353).	  Furthermore,	  ERK1/2	  activates	  downstream	  signaling	  targets	  that	  regulate	  muscle	  size	  such	  as	  mammalian	  target	  of	  rapamycin	  (mTOR)	  (205).	  Due	  to	  its	  role	  in	  MPC	  activation	  and	  regulating	  transcription	  of	  genes	  relating	  to	  muscle	  remodeling,	  ERK1/2	  may	  be	  critical	  to	  effective	  repair	  after	  muscle	  damage.	  ERK1/2	  can	  be	  activated	  by	  muscle	  tension,	  including	  eccentric	  actions	  (209,	  235,	  263,	  335,	  369).	  Activation	  after	  exercise	  is	  rapid	  and	  has	  been	  shown	  to	  occur	  immediately	  and	  at	  6h	  (209,	  235,	  263,	  369),	  as	  well	  as	  at	  48h	  after	  ECC	  (335).	  The	  early	  activation	  is	  primarily	  due	  to	  mechanotransduction	  and	  free	  radical	  signaling,	  as	  the	  level	  of	  ERK1/2	  activation	  is	  related	  to	  the	  amount	  of	  muscle	  tension	  (209,	  369)	  and	  is	  attenuated	  by	  anti-­‐oxidant	  treatment	  during	  concentric	  contractions	  
	  	  52	  
(369).	  Enhanced	  activation	  of	  ERK1/2	  occurs	  at	  48h	  after	  high	  force	  ECC	  of	  the	  biceps	  muscles	  but	  not	  after	  downhill	  running	  (335),	  a	  less	  damaging	  exercise	  that	  typically	  does	  not	  induce	  infiltration	  of	  inflammatory	  cells	  (199).	  These	  results	  indicate	  that	  ERK1/2	  is	  activated	  roughly	  coincident	  with	  inflammatory-­‐mediated	  secondary	  damage	  following	  high	  force	  eccentric	  exercise.	  	  Although	  we	  know	  little	  about	  the	  role	  of	  ERK1/2	  and	  inflammation	  after	  ECC	  in	  humans,	  results	  of	  an	  in	  vitro	  study	  suggested	  that	  inflammation	  may	  be	  the	  mechanism	  through	  which	  ERK1/2	  is	  activated	  and	  mediates	  muscle	  damage	  and	  subsequent	  healing	  (373).	  In	  that	  study,	  CC	  family	  chemokines	  stimulated	  ERK1/2	  activation	  and	  proliferation	  in	  vitro	  and	  ectopic	  expression	  of	  these	  chemokines	  sped	  healing	  time	  after	  wounding	  in	  vitro.	  Using	  an	  in	  vivo	  model	  of	  skeletal	  muscle	  damage	  induced	  by	  cardiotoxin,	  they	  found	  that	  proliferation	  was	  prolonged	  when	  these	  chemokines	  were	  overexpressed.	  The	  authors	  theorized	  that	  the	  CC	  chemokines	  acted	  through	  Ras,	  Raf,	  and	  MEK	  to	  activate	  ERK1/2,	  resulting	  in	  increased	  proliferation	  and	  more	  rapid	  healing.	  Furthermore,	  ERK1/2	  activity	  is	  affected	  by	  a	  wide	  variety	  of	  cytokines,	  including	  CD40L,	  CCL2,	  IL1-­‐6,	  -­‐10,	  -­‐13,	  and	  -­‐17,	  thereby	  acting	  as	  signal-­‐transducer	  for	  a	  number	  of	  inflammatory	  pathways.	  Although	  primarily	  activated	  through	  pro-­‐inflammatory	  cytokines	  and	  inhibited	  by	  anti-­‐inflammatory	  signalers,	  ERK1/2	  is	  thought	  to	  play	  different	  roles	  depending	  on	  the	  length	  of	  activation	  (transient	  versus	  sustained)(296).	  Finally,	  ERK1/2	  is	  strongly	  implicated	  in	  the	  development	  of	  inflammatory-­‐mediated	  hyperalgesia,	  although	  no	  studies	  have,	  as	  of	  yet,	  linked	  ERK1/2	  with	  DOMS.	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Molecular	  Inflammatory	  Mediators	  Related	  to	  Hyperalgesia	  (DOMS)	  Changes	  to	  inflammatory	  signaling	  also	  are	  critical	  to	  the	  development	  and	  resolution	  of	  DOMS.	  Although	  a	  recognized	  response	  to	  unaccustomed	  ECC	  for	  over	  a	  century,	  the	  mechanisms	  behind	  DOMS	  are	  still	  poorly	  understood.	  Current	  theory	  suggests	  multiple	  contributing	  inflammatory	  mechanisms	  lead	  to	  enhanced	  sensitivity	  of	  nociceptors—specifically	  group	  IV	  afferents	  (206).	  Some	  of	  the	  signaling	  molecules	  thought	  to	  mediate	  post-­‐ECC	  hyperalgesia	  include	  bradykinin	  (234),	  COX-­‐2	  (233),	  prostaglandin	  E2	  (PGE2)	  (331),	  and	  nerve	  growth	  factor	  (NGF)	  (118,	  234,	  242).	  IL-­‐6	  (75,	  222)	  and	  IL-­‐1β	  (28)	  play	  roles	  in	  hyperalgesia.	  For	  an	  additional	  review,	  the	  reader	  is	  referred	  to	  Hyldahl	  and	  Hubal	  (135)	  and	  Paulsen	  (269).	  	  Recent	  research	  has	  implicated	  NGF	  as	  an	  important	  mediator	  of	  hyperalgesia.	  In	  humans,	  injection	  of	  NGF	  into	  the	  trapezius	  muscle	  increases	  DOMS	  and	  temporal	  summation	  of	  pain	  after	  ECC	  of	  the	  shoulder	  (242)	  and	  leads	  to	  progressive	  muscle	  hyperalgesia	  and	  pressure	  pain	  under	  non-­‐exercise	  or	  injury	  conditions	  (118).	  Murase	  and	  colleagues	  (2010)	  found	  that	  ECC	  results	  in	  the	  upregulation	  of	  NGF	  transcripts	  in	  rat	  muscle,	  as	  well	  as	  sensitizing	  thin-­‐fiber	  afferents	  to	  hyperalgesia	  (234).	  The	  source	  of	  NGF	  is	  not	  yet	  known,	  though	  it	  may	  be	  released	  from	  muscle	  fibers,	  macrophages,	  or	  other	  cells.	  	  The	  increase	  in	  NGF	  may	  be	  due	  to	  bradykinin	  release	  (B2	  bradykinin	  was	  also	  shown	  to	  trigger	  hyperalgesia	  shortly	  after	  ECC)	  and	  blocking	  the	  receptor,	  negating	  both	  the	  upregulation	  of	  NGF	  and	  hyperalgesia	  (234).	  B2	  bradykinin	  may	  act	  by	  promoting	  the	  activity	  of	  COX-­‐2,	  which	  has	  also	  been	  implicated	  in	  DOMS.	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Attenuating	  or	  blocking	  COX-­‐2	  activity,	  which	  normally	  leads	  to	  the	  productions	  of	  PGE2,	  inhibits	  hyperalgesia	  in	  part,	  suggesting	  that	  this	  may	  be	  a	  secondary	  mechanism	  through	  which	  hyperalgesia	  and	  DOMS	  develop	  (234,	  268).	  PGE2	  injection	  also	  stimulates	  hyperalgesia	  (75),	  and	  levels	  of	  PGE2	  are	  increased	  after	  eccentric	  exercise	  (331).	  	  Other	  inflammatory	  factors	  may	  play	  a	  role	  in	  hyperalgesia	  and	  DOMS.	  For	  example,	  mechanical	  hyperalgesia	  (heightened	  sensitivity	  to	  physical	  stimulus	  such	  as	  pressure	  or	  pin	  prick)	  IL-­‐6	  injection	  stimulated	  mechanical	  hyperalgesia	  in	  rats,	  and	  increased	  its	  duration	  after	  PGE2	  injection	  (75).	  IL-­‐1β,	  which	  may	  stimulate	  the	  production	  of	  NGF	  (96),	  is	  produced	  after	  ECC	  in	  mice	  (28).	  Blocking	  the	  binding	  of	  IL-­‐1β	  to	  its	  receptor	  IL-­‐1ra,	  suppresses	  not	  only	  the	  production	  of	  IL-­‐1β	  but	  also	  mechanical	  hyperalgesia	  and	  decreases	  the	  production	  of	  MPO,	  muscle	  glutathione,	  spinal	  cord	  glutathione,	  and	  circulating	  creatine	  kinase	  activity.	  These	  findings	  suggest	  that	  IL-­‐1β	  enhances	  secondary	  damage	  and	  induces	  hyperalgesia	  by	  stimulating	  NGF	  production.	  Two	  inflammatory	  signaling	  factors	  that	  were	  previously	  discussed	  (NFκB	  and	  ERK),	  are	  also	  implicated	  in	  hyperalgesia.	  ERK	  is	  a	  well-­‐established	  mediator	  of	  varying	  types	  of	  hyperalgesia	  including	  thermal,	  inflammatory,	  and	  mechanical	  hyperalgesia,	  as	  well	  as	  referred	  pain.	  Depending	  on	  the	  type	  of	  hyperalgesia,	  ERK	  is	  stimulated	  upstream	  by	  a	  variety	  of	  stimuli	  including	  integrin-­‐mediated	  mechanotransduction,	  cytokines,	  and	  NGF	  (85,	  335,	  369,	  373).	  Indeed,	  NGF-­‐mediated	  mechanical	  hyperalgesia	  is	  thought	  to	  be	  regulated	  through	  ERK	  in	  non-­‐exercise	  models	  of	  mechanically-­‐induced	  pain	  (196).	  The	  activity	  of	  ERK	  can	  be	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attenuated	  or	  enhanced	  by	  analgesics,	  such	  as	  NSAIDs	  and	  opioids	  (176,	  260).	  In	  contrast,	  acupuncture	  is	  an	  analgesic	  and	  activates	  ERK.	  When	  ERK	  activity	  is	  suppressed	  so	  are	  the	  analgesic	  effects	  of	  needling,	  suggesting	  that	  ERK	  may	  also	  play	  a	  role	  in	  analgesic	  signaling	  as	  was	  as	  promoting	  hyperalgesia	  (262).	  Canonical	  (p65)	  NFκB	  activity,	  which	  also	  interacts	  with	  the	  ERK	  pathway,	  is	  similarly	  implicated	  in	  hyperalgesia	  of	  varying	  causes	  (111,	  173,	  355).	  This	  pathway	  is	  stimulated	  by	  multiple	  upstream	  factors	  including	  pro-­‐inflammatory	  cytokines	  such	  as	  IL-­‐1β	  and	  TNF-­‐α	  (258).	  NFκB	  p65,	  in	  turn,	  stimulates	  the	  activity	  and	  production	  of	  proteins	  associated	  with	  hyperalgesia,	  including	  NGF	  and	  the	  COX-­‐2	  pathway	  (173,	  368).	  The	  inhibition	  of	  the	  p65	  NFκB	  pathway	  results	  in	  suppressed	  pain	  sensation,	  lending	  further	  support	  that	  p65	  as	  a	  mediator	  of	  hyperalgesia	  (70,	  330).	  Interestingly,	  Rel-­‐B	  activity	  may	  act	  to	  suppress	  COX-­‐2	  activity	  (11,	  218),	  suggesting	  a	  role	  of	  the	  alternative	  NFκB	  pathway	  in	  the	  resolution	  of	  hyperalgesia.	  Taken	  together,	  these	  data	  suggest	  a	  number	  of	  interrelated	  molecular	  pathways	  leading	  to	  the	  activation	  and	  resolution	  of	  hyperalgesia,	  although	  to	  my	  knowledge	  NFκB	  and	  ERK	  have	  yet	  to	  be	  specifically	  linked	  to	  DOMS.	  	   	  At	  the	  beginning	  of	  this	  literature	  review,	  I	  presented	  data	  indicating	  that	  cigarette	  smokers	  experience	  increased	  musculoskeletal	  injury	  and	  prolonged	  healing.	  Inflammation	  following	  muscle	  injury	  is	  critical	  to	  muscle	  recovery,	  regeneration,	  and	  adaptation.	  The	  final	  sections	  of	  this	  literature	  review	  discuss	  the	  specific	  effects	  of	  smoking	  on	  inflammation	  (and	  the	  specific	  molecular	  inflammatory	  pathways	  discussed	  above),	  as	  it	  pertains	  to	  muscle	  damage.	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Smoking	  as	  an	  Inflammatory	  Response	  Modifier	  Altered	  inflammatory	  and	  immune	  responses	  and	  dysregulation	  of	  the	  inflammatory	  balance	  widely	  reported	  and	  are	  characteristic	  of	  chronic	  smokers	  (71,	  81,	  220,	  320,	  329,	  348).	  Smokers	  exhibit	  abnormalities	  in	  their	  inflammatory	  response	  both	  at	  rest	  and	  in	  response	  to	  invading	  pathogens	  and	  injury	  (317).	  These	  alterations	  lead	  to	  increased	  susceptibility,	  prolonged	  illness	  duration,	  and	  impaired	  recovery	  (64,	  153,	  182,	  253).	  Since	  smoking	  produces	  a	  pro-­‐inflammatory	  environment,	  and	  a	  controlled	  inflammatory	  balance	  is	  important	  to	  effective	  muscle	  function	  and	  recovery	  after	  injury,	  it	  is	  possible	  that	  dysregulated	  inflammation	  in	  cigarette	  smokers	  places	  them	  at	  a	  higher	  risk	  for	  injury	  and	  suppresses	  recovery.	  	  
Smoking	  Effects	  on	  Cellular	  Inflammation	  Smoking	  increases	  susceptibility	  to,	  and	  prolongs	  recovery	  from,	  viral	  and	  bacterial	  invasion	  (64,	  153,	  253)	  and	  prolongs	  healing	  after	  injury	  or	  surgery	  (163,	  182).	  The	  majority	  of	  studies	  report	  that	  there	  is	  an	  increase	  of	  pro-­‐inflammatory	  cytokines	  and	  chemokines	  in	  the	  blood	  and	  airway	  of	  smokers	  (17,	  44,	  140,	  329),	  as	  well	  as	  increased	  white	  blood	  cell	  counts	  (101,	  139,	  236).	  Of	  the	  many	  inflammatory	  cell	  types	  that	  are	  altered	  in	  smokers,	  of	  interest	  are	  neutrophils	  and	  macrophages,	  due	  to	  their	  roles	  in	  muscle	  remodeling.	  The	  number	  and	  chemotaxis	  of	  circulating	  neutrophils	  is	  higher	  in	  smokers	  (32,	  165,	  220,	  252,	  305-­‐307).	  Conversely,	  neutrophil	  respiratory	  burst	  activity	  (important	  for	  molecular	  signaling	  and	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phagocytosis	  of	  debris)	  is	  suppressed	  by	  smoking	  (297,	  307,	  316).	  In	  addition,	  neutrophil	  gene	  expression	  is	  affected.	  For	  example,	  a	  study	  conducted	  by	  Morozumi	  and	  colleagues	  (231)	  found	  that	  neutrophil	  gene	  expression,	  including	  that	  of	  inflammatory	  cytokines	  IL-­‐1β,	  IL-­‐8,	  and	  TNF-­‐α,	  was	  repressed	  in	  smokers.	  Raw	  counts	  for	  monocytes	  also	  tend	  to	  be	  higher	  in	  smokers	  than	  non-­‐smokers	  despite	  the	  observation	  that	  differentiated	  monocytes	  (macrophages)	  display	  impaired	  activity	  (52,	  124,	  217,	  245,	  312,	  316,	  320).	  	  Compared	  to	  non-­‐smokers,	  smoking	  produces	  a	  pro-­‐inflammatory	  environment	  through	  enhanced	  pro-­‐inflammatory	  signaling	  and	  greater	  cell	  counts.	  At	  the	  same	  time,	  smoking	  decreases	  the	  beneficial	  activities	  of	  inflammatory	  cells	  and	  prevents	  or	  delays	  the	  normal	  resolution	  of	  pro-­‐inflammatory	  signaling.	  Taken	  together,	  these	  data	  suggest	  that,	  in	  smokers,	  dysregulated	  inflammation	  may	  impact	  repair	  after	  muscle	  damage	  and	  increase	  susceptibility	  to	  future	  musculoskeletal	  injury.	  	  
Smoking	  Effects	  on	  Muscle	  Molecular	  Signaling:	  NFκB	  and	  ERK1/2	  Only	  two	  published	  studies	  directly	  investigated	  the	  effects	  of	  smoking	  on	  skeletal	  muscle	  in	  healthy,	  non-­‐COPD	  smokers.	  In	  a	  report	  by	  Montes	  de	  Oca	  (226),	  smokers,	  relative	  to	  non-­‐smokers,	  exhibited	  smaller	  cross	  sectional	  area	  of	  type	  I	  muscle	  fibers	  with	  a	  trend	  toward	  the	  same	  in	  type	  IIa	  fibers.	  Petersen	  and	  colleagues	  (276)	  investigated	  gene	  expression	  of	  muscle	  size	  regulatory	  genes	  as	  well	  as	  protein	  synthesis	  rate	  in	  skeletal	  muscle	  of	  smokers,	  finding	  in	  them	  higher	  mRNA	  transcripts	  of	  myostatin	  and	  muscle	  atrophy	  F-­‐box	  (MAFBx),	  negative	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regulators	  of	  muscle	  size,	  as	  well	  as	  lower	  protein	  synthesis	  rates.	  These	  data	  suggest	  a	  mechanism	  through	  which	  smoking	  may	  impact	  the	  muscle	  injury	  response.	  Because	  data	  on	  the	  effects	  of	  smoking	  on	  muscle	  gene	  expression	  are	  limited,	  I	  expanded	  my	  analysis	  to	  include	  data	  from	  other	  tissues	  to	  build	  hypotheses	  on	  how	  smoking	  could	  affect	  expression	  of	  genes	  related	  to	  muscle	  regeneration.	  As	  detailed	  above,	  the	  activity	  of	  the	  inflammatory	  proteins	  NFκB	  and	  ERK1/2	  following	  ECC	  is	  enhanced	  early	  after	  ECC.	  Smoking	  activates	  both	  of	  these	  pathways.	  	  Both	  smoke	  extract	  and	  nicotine	  can	  induce	  NFκB	  activation	  in	  a	  variety	  of	  cell	  types	  (53,	  56,	  115,	  138,	  374,	  385).	  Peripheral	  white	  blood	  cells	  exposed	  to	  smoke	  or	  nicotine	  responded	  with	  heightened	  NFκB	  activation	  in	  neutrophils	  (138),	  macrophages	  (374),	  and	  lymphocytes	  (115).	  In	  neutrophils,	  NFκB	  activation	  was	  associated	  with	  increased	  IL-­‐8	  release,	  suggesting	  NFκB	  may	  play	  a	  role	  in	  elevated	  white	  blood	  cell	  counts	  in	  smokers	  (138).	  NFκB	  activation,	  via	  IKK/IκBα	  phosphorylation,	  is	  induced	  by	  smoke	  extract	  (6),	  while	  several	  studies	  have	  shown	  NFκB	  activation	  in	  response	  to	  smoke	  that	  coincides	  with	  enhanced	  activation	  of	  the	  ERK1/2	  pathway	  (56,	  385).	  Furthermore,	  smoke-­‐induced-­‐NFκB	  activation	  was	  attenuated	  after	  ERK1/2	  activity	  was	  inhibited,	  and	  therefore	  ERK1/2	  may	  be	  important	  in	  NFκB	  activation	  in	  smokers.	  	  	  Because	  the	  ERK	  pathway	  is	  a	  potential	  mediator	  of	  cancer	  development	  via	  enhanced	  proliferation,	  ERK1/2	  has	  been	  studied	  extensively	  in	  cell	  culture	  and	  animal	  models	  exposed	  to	  smoke	  extract	  and	  components	  or	  by-­‐products	  of	  smoke.	  ERK1/2	  is	  rapidly	  activated	  on	  a	  consistent	  basis	  with	  treatment	  by	  nicotine	  (54,	  91,	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131,	  149,	  244),	  cigarette	  smoke	  extract	  (CSE)	  (177,	  208,	  232,	  243),	  or	  cigarette	  smoke	  by-­‐products	  acrolein	  (91)	  or	  benzo[a]pyrene	  (244),	  with	  phosphorylation	  peaking	  15	  minutes	  after	  treatment.	  In	  several	  studies,	  this	  phosphorylation	  led	  to	  cell	  proliferation	  (54,	  158,	  244).	  Smoking-­‐induced	  activation	  of	  the	  ERK1/2	  pathway	  may	  be	  initiated	  by	  various	  extracellular	  signaling	  molecules,	  including	  smoke	  by-­‐products	  binding	  to	  nicotinic	  acetylcholine	  receptors	  (nAChR,	  for	  example	  α7	  and	  α4/β2	  or	  β-­‐adrenoceptors)	  (54,	  244)	  and	  to	  the	  epidermal	  growth	  factor	  receptor	  (EGFR)	  (149).	  The	  downstream	  effects	  of	  ERK1/2	  activation	  by	  smoking	  are	  variable,	  likely	  due	  to	  differences	  in	  upstream	  mediators	  and	  the	  cell	  types	  investigated.	  Nicotine-­‐stimulated	  ERK1/2	  activation	  in	  vascular	  smooth	  muscle	  cells	  led	  to	  VEGF-­‐α	  release	  via	  MEK	  (149).	  CSE	  treatment	  resulted	  in	  ERK1/2-­‐mediated	  release	  of	  signaling	  molecules	  such	  as	  PGE2	  (via	  COX-­‐2)	  (208)	  and	  interleukin-­‐8	  (177)	  in	  human	  lung	  fibroblasts	  and,	  in	  concert	  with	  NFκB,	  murine	  analogs	  of	  TNF-­‐α	  and	  IL-­‐8	  in	  mast	  cells	  (232).	  Huang	  and	  colleagues	  (131)	  suggested	  that	  ERK1/2	  activation	  by	  nicotine	  may	  be	  mediated	  by	  COX-­‐2,	  oxidative	  stress	  (indicated	  by	  glutathione),	  NFκB,	  and	  activator	  protein-­‐1	  (AP-­‐1)	  and	  tyrosine	  kinase.	  These	  data	  indicate	  that	  a	  feedback	  mechanism	  through	  which	  these	  inflammatory	  mediators	  perpetuate	  a	  pro-­‐inflammatory	  environment	  in	  response	  to	  smoking.	  In	  addition	  to	  activating	  the	  NFκB	  and	  ERK	  pathways,	  smoking	  also	  enhances	  production	  of	  other	  hyperalgesia-­‐related	  molecules	  including	  COX-­‐2	  (6,	  208)	  and	  NGF	  (95,	  104,	  332,	  368),	  although	  to	  my	  knowledge	  no	  data	  exist	  regarding	  these	  factors	  in	  skeletal	  muscle	  of	  smokers.	  Smokers	  are	  also	  more	  likely	  to	  experience	  chronic	  (265,	  287,	  386)	  and	  acute	  (68,	  103)	  pain.	  Furthermore,	  the	  use	  of	  nicotine	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by	  smokers	  enhances	  pain,	  while	  suppressing	  it	  in	  non-­‐smokers,	  suggesting	  that	  smoking	  results	  in	  chronic	  alterations	  to	  gene	  expression	  related	  to	  pain	  (288).	  Hyperalgesia	  in	  DOMS	  is	  generally	  considered	  to	  result	  from	  inflammatory	  mechanisms,	  further	  supporting	  altered	  inflammation	  in	  smokers.	  Taken	  together,	  the	  data	  presented	  here	  suggest	  alterations	  in	  gene	  and	  protein	  expression	  in	  smokers	  that	  could	  relate	  to	  muscle	  regeneration	  and	  inflammation.	  Underlying	  changes	  to	  these	  pathways	  in	  response	  to	  tobacco	  use	  could	  potentially	  suppress	  normal	  muscle	  protein	  turnover	  and	  healing	  after	  damage.	  Furthermore,	  ineffective	  remodeling	  of	  muscle,	  either	  during	  normal,	  everyday	  processes	  or	  in	  response	  to	  injury,	  could	  increase	  the	  risk	  for	  future	  muscle	  injury	  in	  smokers.	  Thus,	  a	  more	  complete	  understanding	  of	  the	  direct	  effects	  of	  chronic	  smoking	  on	  skeletal	  muscle	  signaling	  is	  warranted.	  	  
Summary	  In	  this	  review	  of	  literature,	  the	  negative	  effects	  of	  smoking	  on	  musculoskeletal	  injury	  risk	  and	  healing	  after	  injury	  were	  summarized.	  ECC	  as	  a	  transient	  model	  of	  muscle	  injury	  was	  discussed,	  along	  with	  the	  roles	  of	  inflammation	  in	  repair	  and	  adaptation.	  Additionally,	  effects	  of	  ECC	  and	  smoking	  on	  inflammatory-­‐related	  signaling	  pathways	  were	  outlined,	  with	  a	  focus	  on	  ERK	  and	  NFκB.	  	  The	  goal	  of	  this	  dissertation	  is	  to	  understand	  how	  smoking	  affects	  muscle	  damage	  and	  recovery.	  In	  the	  first	  study,	  I	  examined	  the	  effects	  of	  smoking	  on	  muscle	  after	  ECC	  at	  the	  gross,	  functional	  level.	  The	  second	  study	  served	  to	  elucidate	  specific	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ECC-­‐responsive	  pathways	  in	  non-­‐smokers	  that	  could	  be	  affected	  by	  smoking	  during	  EIMD	  and	  recovery.	  In	  the	  final	  study,	  I	  directly	  tested	  the	  ECC	  response	  of	  these	  pathways	  in	  both	  smokers	  and	  non-­‐smokers	  to	  identify	  smoking	  effects	  on	  the	  muscle	  damage	  response.
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CHAPTER	  III	  
SMOKING	  DECREASES	  MUSCLE	  FUNCTION	  DURING	  ECCENTRIC	  EXERCISE	  AND	  
INCREASES	  DELAYED	  ONSET	  MUSCLE	  SORENESS	  	  
	  
Introduction	  Cigarette	  smoking	  has	  wide-­‐ranging	  impacts	  on	  health	  and	  is	  closely	  associated	  with	  airway	  diseases,	  such	  as	  chronic	  obstructive	  pulmonary	  disease	  (COPD)	  and	  lung	  cancer.	  Recent	  research	  suggests	  that	  smoking	  also	  has	  adverse	  effects	  on	  skeletal	  muscle	  health.	  Epidemiological	  studies	  have	  shown	  that	  smoking	  is	  associated	  with	  increased	  risk	  for	  musculoskeletal	  injury	  (5,	  150,	  157,	  285,	  286,	  343,	  363),	  including	  joint	  and	  muscle	  tissue	  injury.	  Smoking	  is	  also	  associated	  with	  a	  prolonged	  healing	  process	  after	  injury	  (3,	  82,	  310,	  317)	  and	  increased	  disability	  (145,	  157,	  163,	  182).	  The	  specific	  mechanisms	  driving	  the	  relationships	  among	  smoking,	  injury,	  healing,	  and	  disability	  are	  unknown.	  A	  greater	  understanding	  of	  the	  relationship	  between	  smoking	  and	  increased	  risk	  of	  injury	  may	  lead	  to	  the	  development	  of	  better	  prevention	  and	  intervention	  strategies.	  Because	  the	  majority	  of	  existing	  data	  supporting	  these	  associations	  are	  from	  epidemiological	  studies,	  identifying	  specific	  regulatory	  mechanisms	  has	  been	  difficult.	  In	  this	  study,	  I	  used	  an	  established,	  controlled	  laboratory	  model	  of	  inducible	  skeletal	  muscle	  damage	  to	  test	  specific	  hypotheses	  concerning	  the	  effects	  of	  smoking	  on	  muscle	  injury	  and	  recovery.	  	  Eccentric	  exercise	  is	  a	  safe,	  laboratory-­‐based	  model	  designed	  to	  induce	  transient	  muscle	  damage	  (55,	  58,	  246,	  249).	  These	  types	  of	  muscle	  actions,	  where	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the	  muscle	  is	  lengthening	  under	  tension,	  place	  high	  mechanical	  stresses	  on	  the	  tissue	  and	  typically	  lead	  to	  injury,	  as	  indicated	  by	  decrements	  in	  muscle	  function,	  delayed	  onset	  muscle	  soreness	  (DOMS),	  and	  the	  release	  of	  muscle-­‐specific	  proteins	  (including	  creatine	  kinase	  and	  myoglobin)	  into	  the	  circulation.	  The	  injury	  is,	  in	  healthy	  subjects,	  subclinical	  with	  regard	  to	  kidney	  function	  and	  is	  typically	  followed	  by	  full	  recovery	  within	  7-­‐10d	  post-­‐exercise,	  although	  there	  can	  be	  a	  great	  deal	  of	  inter-­‐individual	  variability	  in	  the	  magnitude	  and	  timing	  of	  the	  damage	  response.	  	  In	  healthy	  individuals,	  a	  coordinated	  sequence	  of	  inflammatory	  events	  is	  critical	  to	  effective	  muscle	  repair	  and	  is	  orchestrated,	  in	  part,	  by	  cross-­‐talk	  between	  muscle	  and	  the	  circulatory	  system.	  Smoking	  status	  is	  a	  potential	  modifier	  of	  inflammation	  and	  damage,	  and	  this	  may	  increase	  risk	  for	  prolonged	  healing	  (3,	  82,	  310,	  317,	  357)	  and	  future	  injury	  (5,	  47,	  48,	  150,	  157,	  212,	  286,	  343,	  363).	  Indeed,	  smokers	  are	  not	  only	  at	  risk	  for	  acute	  and	  repetitive	  strain	  (5,	  285)	  injury,	  but	  also	  chronic	  injury	  or	  disability	  (157,	  182),	  suggesting	  impaired	  healing	  and	  recovery	  in	  these	  individuals.	  Dysregulation	  of	  inflammation	  is	  a	  hallmark	  of	  chronic	  injury	  and	  disability.	  Smoking	  can	  interfere	  with	  the	  normal	  inflammatory	  response	  to	  injury,	  which	  could	  in	  turn	  exacerbate	  damage	  responses	  and/or	  extend	  recovery	  time.	  The	  greater	  incidence	  of	  musculoskeletal	  injury	  and	  disability	  in	  smokers	  suggests	  these	  individuals	  may	  experience	  impaired	  muscle	  function	  and	  repair,	  which	  may	  in	  turn	  increase	  susceptibility	  to	  muscle	  damage	  and	  compromise	  healing.	  To	  yield	  insight	  into	  muscle	  healing	  in	  smokers,	  I	  compared	  responses	  to	  the	  eccentric	  exercise	  model	  in	  smokers	  and	  non-­‐smokers—well	  characterized	  in	  non-­‐smokers,	  but	  not	  yet	  studied	  in	  a	  smoking	  population.	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I	  propose	  that,	  when	  exposed	  to	  a	  standardized	  laboratory-­‐based	  exercise	  challenge,	  smokers	  would	  experience	  greater	  damage	  and	  impaired	  healing	  as	  compared	  to	  non-­‐smokers.	  To	  directly	  test	  the	  effects	  of	  smoking	  on	  the	  muscle	  damage	  and	  recovery	  response,	  I	  measured	  muscle	  function	  and	  standard	  indicators	  of	  muscle	  damage	  before,	  during,	  and	  following	  standardized	  laboratory-­‐based	  eccentric	  exercise	  and	  compared	  responses	  between	  smokers	  and	  non-­‐smokers.	  I	  hypothesized	  that,	  compared	  to	  non-­‐smokers,	  smokers	  would	  have	  a	  more	  pronounced	  damage	  response,	  experiencing:	  1)	  greater	  expression	  of	  circulating	  stress	  hormones	  but	  suppressed	  inflammatory	  molecules;	  2)	  greater	  creatine	  kinase	  release;	  3)	  greater	  muscle	  fatigue;	  4)	  more	  prolonged	  strength	  loss;	  and	  5)	  greater	  soreness	  (both	  peak	  and	  prolonged)	  in	  response	  to	  eccentric	  exercise.	  
	  
Methods	  
Subjects	  Twenty	  healthy	  men,	  ages	  18-­‐35,	  were	  recruited	  into	  the	  study.	  Subjects	  had	  no	  known	  chronic	  or	  concurrent	  ailments,	  were	  sedentary	  (performed	  no	  activity	  above	  5	  Metabolic	  Equivalent	  of	  Tasks	  (METs)	  on	  a	  regular	  basis),	  and	  had	  not	  engaged	  in	  resistance	  training	  exercise	  of	  the	  legs	  or	  heavy	  lifting/lowering	  of	  materials	  using	  the	  legs	  for	  at	  least	  six	  months	  prior	  to	  enrolling	  in	  the	  study.	  Self-­‐reported	  physical	  activity	  levels	  were	  verified	  using	  the	  Paffenbarger	  activity	  questionnaire	  (259)	  at	  the	  initial	  study	  visit.	  The	  use	  of	  anti-­‐inflammatory	  and	  analgesic	  medications,	  alcohol,	  caffeine,	  and	  new	  physical	  activities	  were	  not	  permitted	  during	  the	  course	  of	  the	  study.	  Ten	  subjects	  were	  non-­‐smokers,	  defined	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as	  no	  history	  of	  regular	  tobacco	  use.	  The	  remaining	  10	  participants	  were	  current	  smokers	  who	  had	  smoked	  at	  least	  ½	  pack	  (10	  cigarettes)	  each	  day	  for	  the	  previous	  five	  years	  or	  longer	  with	  no	  history	  of	  other	  tobacco	  use.	  In	  addition	  to	  maintaining	  their	  normal	  smoking	  habits	  throughout	  the	  study,	  smokers	  smoked	  a	  cigarette	  approximately	  10	  minutes	  before	  each	  visit	  to	  reduce	  potential	  variability	  due	  to	  time	  from	  the	  last	  cigarette.	  All	  participants	  completed	  a	  medical	  history	  questionnaire	  and	  gave	  written	  informed	  consent	  as	  approved	  by	  the	  University	  of	  Massachusetts	  Amherst	  Institutional	  Review	  Board	  prior	  to	  participation.	  	  
Study	  Design	  The	  study	  consisted	  of	  eight	  visits	  over	  the	  course	  of	  7-­‐11d	  (Figure	  3.1).	  At	  the	  first	  visit,	  blood	  was	  drawn	  to	  test	  creatine	  kinase	  activity.	  In	  addition,	  baseline	  soreness	  was	  evaluated,	  and	  initial	  strength	  testing	  of	  the	  knee	  flexors	  and	  extensors	  was	  performed.	  Within	  1-­‐4d	  after	  visit	  1,	  the	  subjects	  returned	  to	  the	  laboratory	  in	  the	  morning	  (visit	  2)	  for	  repeated	  baseline	  strength	  testing,	  eccentric	  exercise	  of	  the	  knee	  extensors,	  and	  post-­‐exercise	  strength	  testing.	  Recovery	  was	  measured	  from	  visits	  3-­‐8.	  Blood	  was	  collected	  six	  hours	  after	  visit	  2	  (visit	  3).	  Each	  morning	  from	  1-­‐5d	  post-­‐exercise	  (visits	  4-­‐8),	  subjects	  returned	  to	  the	  laboratory	  for	  blood	  collection,	  soreness	  assessment,	  and	  strength	  testing.	  For	  all	  morning	  visits	  (visits	  1	  and	  4-­‐8),	  participants	  were	  fasted	  overnight	  except	  for	  water.	  At	  visit	  2,	  a	  standardized	  meal	  was	  provided	  that	  consisted	  of	  400	  kcals	  (approximately	  55%	  carbohydrate,	  30%	  fat,	  and	  15%	  protein),	  after	  which	  all	  subjects	  were	  required	  to	  fast	  until	  they	  returned	  for	  visit	  3	  (6h	  later).	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Salivary	  Cortisol,	  IL-­‐6,	  and	  Cotinine	  Saliva	  was	  collected	  by	  passive	  drool	  technique	  at	  all	  visits,	  including	  two	  morning	  pre-­‐exercise	  samples,	  one	  afternoon	  pre-­‐exercise	  sample,	  and	  six	  post-­‐exercise	  samples	  (6h	  and	  1-­‐5d).	  Subjects	  were	  fasted	  for	  8-­‐12h	  prior	  to	  collection.	  All	  subjects	  refrained	  from	  any	  actions	  that	  might	  result	  in	  bleeding	  within	  the	  mouth,	  such	  as	  vigorous	  brushing	  of	  teeth	  or	  flossing,	  in	  the	  hour	  prior	  to	  collection.	  Upon	  entering	  the	  laboratory,	  subjects	  rinsed	  their	  mouths	  with	  water	  and	  then	  rested	  in	  a	  seated	  position	  for	  10min.	  For	  saliva	  collection,	  subjects	  were	  asked	  to	  lean	  forward	  slightly,	  head	  down,	  to	  encourage	  saliva	  to	  pool	  under	  the	  tongue	  at	  the	  front	  of	  the	  mouth.	  A	  straw	  was	  provided,	  and	  subjects	  allowed	  the	  pooled	  saliva	  to	  move	  through	  the	  straw	  into	  a	  small	  collection	  tube.	  All	  samples	  were	  visually	  inspected	  for	  blood	  contamination—no	  samples	  had	  visual	  contamination.	  The	  saliva	  was	  briefly	  centrifuged	  to	  eliminate	  bubbles	  and	  shipped	  to	  a	  clinical	  laboratory	  for	  analysis	  of	  the	  stress	  hormone	  cortisol,	  cytokine	  interleukin-­‐6	  (IL-­‐6),	  and	  cotinine;	  the	  latter	  is	  a	  nicotine	  derivative	  used	  to	  confirm	  smoking	  status	  (Salimetrics,	  State	  College,	  PA,	  USA).	  	  
Blood	  Creatine	  Kinase	  Activity	  and	  Cytokine	  Analysis	  At	  all	  visits	  except	  the	  exercise	  visit	  (visit	  2),	  blood	  was	  collected	  by	  venipuncture	  at	  the	  antecubital	  region	  using	  standard	  aseptic	  technique	  (one	  morning	  and	  one	  afternoon	  pre-­‐exercise	  sample,	  six	  post-­‐exercise	  samples	  at	  6h	  and	  1-­‐5d).	  Blood	  was	  drawn	  after	  saliva	  collection	  and	  under	  fasting	  conditions.	  For	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plasma	  isolation,	  blood	  was	  drawn	  into	  vacutainers	  containing	  either	  the	  anticoagulant	  EDTA	  or	  sodium	  heparin.	  After	  sitting	  at	  room	  temperature	  for	  15min,	  whole	  blood	  samples	  were	  centrifuged	  at	  1000Xg	  for	  10min	  and	  the	  supernatant	  collected.	  The	  resultant	  plasma	  was	  stored	  at	  -­‐80°C	  for	  later	  analysis.	  Plasma	  separated	  with	  EDTA	  was	  shipped	  to	  a	  clinical	  laboratory	  for	  creatine	  kinase	  (CK)	  activity	  analysis	  (Holyoke	  Hospital,	  Holyoke,	  MA,	  USA).	  Sandwich	  enzyme-­‐linked	  immunosorbant	  assays	  (ELISAs	  (R&D	  Systems,	  Minneapolis,	  MN,	  USA))	  were	  used	  according	  to	  manufacturer’s	  instructions	  to	  analyze	  circulating	  cytokines	  in	  the	  blood	  before	  and	  after	  exercise.	  Plasma	  separated	  using	  the	  anticoagulants	  EDTA	  or	  sodium	  heparin	  was	  used	  based	  on	  the	  instructions	  from	  the	  specific	  kit.	  Briefly,	  plasma	  samples	  were	  added	  to	  96-­‐well	  plates	  to	  which	  a	  primary	  antibody	  against	  the	  cytokine	  of	  interest	  was	  attached	  and	  samples	  incubated	  at	  room	  temperature.	  The	  plate	  was	  washed,	  an	  enzyme-­‐linked	  antibody	  against	  the	  cytokine	  of	  interest	  was	  added,	  and	  samples	  incubated	  again	  at	  room	  temperature.	  The	  plate	  was	  washed	  and	  a	  substrate	  solution	  added.	  After	  the	  specified	  amount	  of	  time,	  a	  stop	  solution	  was	  added	  to	  halt	  the	  colorimetric	  reaction,	  at	  which	  time	  the	  absorbance	  of	  each	  well	  was	  read	  on	  a	  Labsystems	  Multiskan	  RC	  plate	  reader	  (Thermo-­‐Fisher	  Scientific,	  Rockford	  IL,	  USA)	  at	  450nm	  with	  a	  correction	  wavelength	  of	  540nm.	  The	  samples	  were	  run	  in	  duplicate.	  The	  resulting	  averages	  were	  quantified	  by	  comparing	  against	  a	  set	  of	  standards	  run	  on	  the	  same	  plate.	  ELISA	  kits	  were	  used	  to	  test	  plasma	  levels	  of	  targets	  c-­‐reactive	  protein	  (CRP),	  interleukin-­‐1β	  (IL-­‐1β),	  IL-­‐6,	  interleukin-­‐8	  (IL-­‐8),	  tumor	  necrosis	  factor-­‐α	  (TNF-­‐α),	  vascular	  endothelial	  growth	  factor-­‐D	  (VEGF-­‐D).	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Isometric	  Strength	  Muscle	  strength	  was	  assessed	  on	  a	  Biodex	  System	  3	  dynamometer	  (Biodex	  Medical	  Systems,	  Shirley,	  NY,	  USA)	  as	  described	  previously	  (137,	  372).	  Because	  the	  knee	  extensors	  were	  the	  exercised	  muscle	  group,	  changes	  in	  flexion	  strength	  were	  not	  expected;	  however,	  strength	  of	  the	  flexors	  was	  also	  evaluated	  to	  test	  if	  post-­‐ECC	  changes	  to	  the	  agonist/antagonist	  force	  output	  ratio	  differed	  between	  smokers	  and	  non-­‐smokers.	  Briefly,	  participants	  were	  positioned	  in	  the	  dynamometer	  in	  a	  seated	  position	  and	  straps	  were	  placed	  across	  the	  chest,	  hips,	  and	  thigh	  of	  the	  exercised	  leg	  to	  reduce	  the	  use	  of	  muscles	  not	  under	  examination.	  The	  pivot	  point	  of	  the	  dynamometer	  arm	  was	  aligned	  with	  the	  lateral	  epicondyle	  of	  the	  femur.	  Prior	  to	  testing,	  the	  subject’s	  relaxed	  leg	  was	  moved	  through	  passive	  range	  of	  motion	  by	  a	  study	  investigator.	  The	  dynamometer	  was	  set	  to	  0°	  when	  the	  leg	  was	  fully	  extended	  at	  the	  knee,	  and	  isometric	  (0°/sec)	  strength	  was	  measured	  at	  70°	  of	  knee	  flexion.	  Participants	  contracted	  maximally	  against	  an	  immovable	  lever	  for	  4sec	  either	  by	  kicking	  at	  the	  knee	  (extension)	  or	  pulling	  (flexion),	  followed	  by	  a	  60sec	  rest.	  Six	  repetitions	  were	  performed,	  alternating	  extension	  and	  flexion	  (3	  repetitions	  each).	  All	  repetitions	  in	  a	  set	  within	  10%	  coefficient	  of	  variation	  were	  retained	  for	  analyses.	  Prolonged	  loss	  of	  strength	  (i.e.	  in	  the	  days	  following	  exercise)	  is	  generally	  considered	  the	  best	  indirect	  indicator	  of	  muscle	  damage	  incurred	  through	  eccentric	  exercise	  (360).	  However,	  early	  (i.e.	  within	  a	  few	  minutes)	  post-­‐exercise	  strength	  loss	  is	  a	  combination	  of	  both	  fatigue	  due	  to	  the	  exertion	  during	  the	  exercise	  session	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and	  any	  damage	  to	  the	  muscle	  itself	  incurred	  during	  exercise.	  Therefore,	  strength	  loss	  was	  tested	  in	  two	  phases:	  early	  (5min	  post-­‐exercise)	  and	  prolonged	  (1-­‐5d	  post-­‐exercise),	  also	  referred	  to	  here	  as	  “recovery”.	  These	  data	  were	  analyzed	  separately	  for	  each	  phase.	  	  Biodex	  torque	  (N•m)	  data	  for	  isometric	  and	  eccentric	  strength	  were	  exported	  and	  analyzed	  using	  a	  custom-­‐written	  Matlab	  program	  (version	  R2009b;	  Mathworks,	  Natick,	  MA).	  To	  eliminate	  noise,	  a	  20-­‐Hz	  low-­‐pass	  Butterworth	  filter	  was	  applied	  to	  each	  channel.	  For	  some	  contractions,	  there	  was	  a	  slight	  signal	  offset	  such	  that	  baseline	  (no	  torque	  produced)	  measured	  either	  above	  or	  below	  0	  torque;	  therefore,	  to	  remove	  the	  signal	  offset,	  the	  baseline	  for	  each	  contraction	  was	  manually	  identified	  using	  plotted	  data.	  Manual	  identification	  was	  then	  used	  to	  outline	  the	  following	  critical	  points	  of	  each	  contraction:	  1)	  initiation	  of	  torque	  production;	  and	  2)	  start	  and	  3)	  stop	  points	  for	  the	  plateau	  phase	  of	  contraction—the	  phase	  during	  which	  maximal	  torque	  production	  was	  roughly	  maintained.	  The	  Matlab	  program	  used	  these	  points	  to	  identify	  additional	  variables,	  including:	  the	  time	  to	  peak	  torque,	  peak	  torque	  and	  work,	  and	  the	  end	  of	  contraction.	  This	  process	  was	  repeated	  for	  all	  contractions.	  These	  results	  were	  exported	  into	  Microsoft	  Excel	  to	  be	  organized	  for	  further	  analysis	  using	  SAS	  statistical	  software	  version	  9.3.	  	  	  
Eccentric	  Exercise	  The	  exercise	  consisted	  of	  100	  (10	  sets	  of	  10	  repetitions)	  maximal	  eccentric	  contractions	  of	  the	  knee	  extensors	  performed	  on	  the	  Biodex	  dynamometer.	  Participants	  were	  positioned	  as	  described	  above.	  The	  exercise	  leg	  was	  moved	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passively	  to	  35°	  of	  flexion	  by	  the	  study	  investigator,	  and	  participants	  were	  instructed	  to	  kick	  with	  maximal	  effort.	  The	  dynamometer	  elicited	  greater	  force	  against	  the	  leg	  than	  the	  subject	  could	  produce	  in	  resistance,	  causing	  the	  knee	  to	  bend	  and	  move	  into	  full	  flexion.	  The	  complete	  range	  of	  motion	  was	  ~75°	  for	  each	  participant	  and	  set	  prior	  to	  exercise	  using	  passive	  resistance	  points.	  Repetitions	  were	  approximately	  4sec	  in	  length,	  followed	  by	  a	  10sec	  rest.	  Subjects	  also	  rested	  for	  1min	  after	  each	  10-­‐repetition	  set.	  After	  the	  last	  set	  there	  was	  a	  5min	  rest	  period,	  followed	  by	  isometric	  strength	  testing	  (early	  phase).	  Throughout	  the	  exercise	  and	  testing	  sessions,	  the	  subjects	  were	  verbally	  encouraged	  to	  perform	  at	  maximal	  effort	  and	  all	  procedures	  were	  executed	  using	  the	  non-­‐dominant	  leg.	  	  The	  exercise	  session	  was	  designed	  to	  both	  elicit	  fatigue	  and	  to	  stress	  the	  muscle	  eccentrically	  so	  as	  to	  result	  in	  prolonged	  damage	  and	  recovery.	  I	  also	  collected	  data	  during	  the	  exercise	  (torque	  and	  work)	  to	  determine	  if	  differences	  in	  exercise-­‐induced	  strength	  loss	  could	  be	  explained	  by	  differences	  in	  muscle	  performance	  during	  the	  exercise	  session.	  	  	  
Soreness	  Soreness	  was	  assessed	  at	  the	  initial	  (baseline)	  visit	  and	  on	  each	  day	  from	  1-­‐5d	  after	  the	  exercise	  visit	  (55,	  58,	  246).	  Soreness	  was	  evaluated	  prior	  to	  strength	  testing	  in	  order	  to	  eliminate	  any	  effect	  of	  strength	  testing	  on	  soreness.	  Participants	  were	  instructed	  to	  perform	  two	  controlled	  one-­‐legged	  squats	  on	  the	  non-­‐dominant	  (exercise)	  leg	  from	  standing	  to	  sitting	  in	  a	  chair	  and	  back	  to	  standing,	  with	  each	  portion	  of	  the	  movement	  lasting	  approximately	  one	  second	  for	  a	  total	  of	  two	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seconds	  for	  each	  squat.	  Upon	  completing	  the	  squats,	  participants	  marked	  a	  single	  vertical	  line	  on	  a	  100mm	  visual	  analog	  scale	  (VAS)	  to	  indicate	  peak	  soreness	  during	  the	  squats.	  A	  “0”	  indicated	  no	  soreness,	  “100”	  indicated	  maximal	  soreness.	  The	  distance	  (mm)	  from	  the	  beginning	  of	  the	  line	  to	  the	  vertical	  mark	  was	  measured	  and	  recorded.	  
	  
Statistical	  Analyses	  For	  early	  strength	  loss,	  a	  2-­‐factor	  analysis	  of	  variance	  (ANOVA)(92)	  was	  used	  (group*exercise)	  for	  absolute	  values	  and	  the	  values	  normalized	  to	  bodyweight.	  A	  Student’s	  T-­‐Test	  was	  used	  to	  analyze	  these	  data	  when	  expressed	  as	  percent	  baseline	  (322).	  For	  recovery	  visits,	  data	  were	  analyzed	  using	  a	  2-­‐factor	  (group*exercise)	  repeated-­‐measures	  ANOVA,	  with	  repeated	  subject	  ID	  measures	  and	  a	  group*time	  interaction	  term	  for	  absolute	  values,	  those	  normalized	  to	  bodyweight,	  and	  when	  expressed	  as	  percent	  baseline.	  	  For	  the	  exercise	  session,	  each	  statistically-­‐analyzed	  point	  represented	  the	  average	  of	  three	  repetitions:	  baseline	  was	  repetitions	  3-­‐5	  (to	  account	  for	  any	  learning	  or	  ramp	  up	  in	  the	  first	  few	  contractions)	  and	  all	  other	  points	  represent	  the	  average	  of	  the	  last	  three	  repetitions	  of	  each	  set.	  Strength	  values	  for	  each	  set	  were	  analyzed	  using	  a	  2-­‐factor	  (group*exercise)	  repeated-­‐measures	  ANOVA,	  with	  repeated	  subject	  ID.	  The	  repeated-­‐measures	  ANOVA	  was	  also	  used	  to	  analyze	  soreness	  and	  CK	  activity.	  Post-­‐hoc	  differences	  were	  assessed	  using	  Tukey’s	  HSD	  testing.	  Student’s	  T-­‐Tests	  were	  used	  to	  compare	  both	  total	  work	  done	  between	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groups	  (345)	  and	  peak	  soreness.	  Blood	  and	  salivary	  measures	  were	  analyzed	  by	  2-­‐factor	  ANOVA	  (group*time)	  for	  baseline	  differences;	  when	  there	  were	  differences,	  baselines	  were	  included	  as	  a	  co-­‐variate	  as	  appropriate	  in	  further	  testing.	  The	  full	  dataset	  for	  each	  analyte	  was	  tested	  using	  either	  a	  2-­‐factor	  RM-­‐ANOVA	  or	  analysis	  of	  co-­‐variance	  (ANCOVA)(group*exercise),	  as	  appropriate.	  Significance	  was	  set	  as	  p<0.05	  and	  all	  testing	  was	  performed	  using	  SAS	  statistical	  software	  (Version	  9.3;	  SAS	  Institute,	  Cary,	  NC).	  All	  data	  are	  presented	  as	  means	  ±	  standard	  error.	  
	  
Results	  All	  subjects	  (N=10	  smokers	  and	  10	  non-­‐smokers)	  successfully	  completed	  the	  exercise	  protocol	  and	  complied	  with	  study	  requirements.	  Final	  subject	  characteristics	  are	  presented	  in	  Table	  3.1.	  
	  
Salivary	  Cortisol,	  IL-­‐6,	  and	  Cotinine	  Salivary	  cotinine,	  cortisol,	  and	  IL-­‐6	  were	  measured	  before	  and	  after	  exercise.	  Smoking	  status	  was	  verified	  using	  salivary	  cotinine	  measures,	  collected	  at	  every	  visit,	  and	  corroborated	  that	  all	  subjects	  were	  categorized	  appropriately	  and	  maintained	  regular	  smoking	  (or	  non-­‐smoking)	  habits	  throughout	  the	  course	  of	  the	  study	  (Table	  2)	  (p<0.05).	  Levels	  of	  cortisol	  differed	  significantly	  (p<0.05)	  between	  the	  morning	  and	  afternoon	  baseline	  measures	  for	  both	  non-­‐smokers	  (0.511±0.07	  and	  0.209±0.04ug/dl,	  respectively)	  and	  smokers	  (0.417±0.05	  and	  0.224±0.04).	  This	  finding	  was	  expected,	  as	  cortisol	  presents	  with	  strong	  diurnal	  rhythmicity;	  cortisol	  levels	  are	  highest	  in	  the	  morning	  and	  decrease	  throughout	  the	  day.	  Therefore,	  the	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afternoon	  (6h	  post-­‐exercise)	  visit	  was	  compared	  to	  the	  afternoon	  baseline,	  only,	  and	  the	  morning	  measures	  (1-­‐5d	  post-­‐exercise)	  compared	  to	  the	  morning	  baseline.	  There	  were	  no	  differences	  between	  group	  responses,	  after	  exercise,	  or	  overall	  between	  groups	  when	  comparing	  between	  the	  afternoon	  visits	  or	  among	  the	  morning	  visits.	  IL-­‐6	  salivary	  measures	  were	  highly	  variable	  and	  levels	  were	  undetectable	  for	  a	  number	  of	  samples,	  leaving	  five	  non-­‐smokers	  and	  nine	  smokers	  in	  the	  final	  analysis.	  Baseline	  levels	  did	  not	  differ	  between	  visits	  and	  were	  therefore	  averaged	  for	  the	  remaining	  analyses.	  These	  baseline	  levels	  were	  significantly	  higher	  in	  non-­‐smokers	  (40.86±10.97pg/mL	  as	  compared	  to	  smokers,	  11.85±2.04),	  yet	  there	  was	  no	  overall	  effect	  of	  smoking,	  exercise,	  or	  interaction.	  However,	  given	  the	  number	  of	  samples	  eliminated	  because	  levels	  were	  below	  detection,	  these	  data	  must	  be	  given	  little	  weight.	  
	  
Creatine	  Kinase	  Activity	  Plasma	  creatine	  kinase	  activity	  after	  exercise	  was	  used	  as	  an	  indirect	  marker	  of	  acute	  skeletal	  muscle	  injury.	  The	  data	  supported	  the	  effectiveness	  of	  the	  exercise,	  as	  there	  was	  a	  significant	  increase	  in	  creatine	  kinase	  activity	  in	  both	  groups	  following	  exercise	  that	  peaked	  at	  5d	  (p<0.05;	  Figure	  3.2).	  However,	  there	  were	  no	  significant	  differences	  between	  smokers	  and	  non-­‐smokers	  in	  their	  response	  to	  the	  exercise	  (p=0.76)	  or	  between	  groups	  overall	  (p=0.62),	  denoting	  similar	  overall	  responses.	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  Plasma	  Cytokines	  Levels	  of	  IL-­‐8	  and	  IL-­‐1β	  were	  below	  the	  level	  of	  detection	  and	  therefore	  could	  not	  be	  analyzed.	  For	  all	  other	  plasma	  cytokines,	  pre-­‐exercise	  levels	  were	  similar	  between	  the	  two	  baseline	  visits	  (morning	  and	  afternoon)	  and	  were	  therefore	  averaged	  for	  all	  of	  the	  following	  analyses.	  There	  was	  no	  difference	  between	  smokers	  and	  non-­‐smokers	  overall	  (group	  difference)	  or	  difference	  between	  groups	  in	  their	  exercise	  response	  (interaction)	  for	  any	  of	  the	  cytokines	  tested.	  However,	  levels	  of	  all	  four	  cytokines	  were	  affected	  by	  the	  exercise	  session.	  Plasma	  IL-­‐6	  was	  significantly	  higher	  at	  6h	  compared	  to	  all	  other	  time	  points	  (non-­‐smokers:	  222.6±37.2%	  baseline;	  smokers:	  180.0±27.2%)	  and	  this	  response	  did	  not	  differ	  between	  groups.	  TNF-­‐α	  levels	  for	  both	  groups	  were	  subtly	  yet	  significantly	  different	  between	  6h	  and	  2d	  post-­‐exercise	  (p<0.05;	  non-­‐smokers:	  92.9±4.2	  vs	  104.6±5.4%;	  smokers:	  91.5±4.0	  vs	  98.4±3.5%).	  For	  both	  groups,	  CRP	  levels	  significantly	  differed	  from	  baseline	  at	  all	  post-­‐exercise	  visits	  (p<0.05),	  peaking	  at	  1d	  (non-­‐smokers:	  200.6±46.9%	  baseline;	  smokers:	  232.6±55.5).	  There	  were	  no	  significant	  effects	  of	  group,	  alone,	  and	  the	  interaction	  term	  did	  not	  reach	  significance.	  Levels	  of	  VEGF-­‐D	  for	  both	  groups	  were	  significantly	  lower	  at	  1	  and	  2d	  after	  exercise	  as	  compared	  to	  pre-­‐exercise	  levels	  (p<0.05;	  non-­‐smokers:	  93.6±1.7	  and	  92.3±2.4%	  of	  baseline;	  smokers:	  91.9±3.3	  and	  92.0±2.4%).	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Isometric	  Strength	  
Baseline	  	  Before	  exercise,	  smokers	  appeared	  to	  be	  slightly	  stronger	  for	  extensor	  strength	  than	  non-­‐smokers	  (p<0.05;	  Figure	  3.3a),	  but	  this	  did	  not	  reach	  significance	  when	  normalized	  to	  bodyweight	  (p=0.13;	  Figure	  3.3b).	  Baseline	  flexor	  strength	  was	  not	  different	  between	  non-­‐smokers	  and	  smokers,	  for	  absolute	  values	  (non-­‐smokers:	  95±8.4N•m;	  smokers:	  108±5.8N•m;	  p=0.22)	  or	  when	  normalized	  bodyweight	  (non-­‐smokers:	  1.28±0.09N•m/kg;	  smokers:	  1.35±0.09N•m/kg;	  p=0.61).	  
	  
Early	  Strength	  Loss	  Isometric	  strength	  was	  tested	  five	  minutes	  after	  completing	  the	  eccentric	  exercise	  session.	  This	  early	  strength	  loss	  is	  generally	  composed	  of	  temporary	  fatigue	  from	  the	  exercise	  plus	  any	  damage	  that	  has	  occurred.	  For	  extension,	  strength	  significantly	  decreased	  after	  the	  exercise	  for	  both	  non-­‐smokers	  (29±6.6%	  loss)	  and	  smokers	  (44±4.2%	  loss)	  (Figure	  3.4a;	  p<0.01).	  There	  was	  no	  main	  effect	  of	  group	  (p=0.15);	  however,	  there	  was	  an	  interaction	  between	  smoking	  and	  exercise	  such	  that	  smokers	  lost	  significantly	  greater	  strength	  after	  the	  exercise	  than	  did	  non-­‐smokers	  (p=0.04).	  When	  normalized	  to	  bodyweight,	  the	  significant	  effect	  of	  exercise	  remained	  (Figure	  3.4b;	  p<0.01),	  with	  no	  overall	  effect	  of	  smoking	  (p=0.61).	  The	  interaction	  also	  remained	  significant,	  with	  smokers	  experiencing	  a	  greater	  loss	  of	  strength	  after	  exercise	  than	  non-­‐smokers	  (p=0.04).	  Finally,	  when	  expressed	  as	  a	  percent	  of	  baseline,	  there	  was	  a	  trend	  for	  greater	  strength	  loss	  after	  exercise	  in	  smokers	  (Figure	  3.4c;	  p=0.07).	  
	  	  76	  
For	  flexion,	  both	  groups	  lost	  similar	  amounts	  of	  strength	  early	  after	  exercise	  (not	  shown;	  non-­‐smokers:	  baseline	  95±8.4	  vs	  post-­‐exercise	  88±8.1N•m;	  smokers:	  108±5.8	  vs	  94±4.7N•m;	  exercise:	  p<0.01;	  group	  p=0.33;	  interaction	  p=0.25).	  Normalizing	  to	  bodyweight	  did	  not	  alter	  results,	  with	  a	  significant	  effect	  of	  exercise	  (p<0.01),	  no	  effect	  of	  smoking	  (p=0.90),	  and	  no	  interaction	  (p=0.21).	  Expressing	  flexion	  strength	  as	  a	  percent	  of	  baseline	  also	  did	  not	  modify	  results	  (not	  shown;	  non-­‐smokers:	  94±5.4%;	  smokers:	  87±2.5%;	  p=0.27).	  	  
Prolonged	  Strength	  Loss	  The	  “strength	  recovery	  phase”	  consisted	  of	  visits	  4-­‐8	  and	  spanned	  the	  time	  from	  1-­‐5d	  post-­‐exercise.	  Because	  there	  was	  a	  24h	  period	  between	  the	  exercise	  session	  and	  the	  first	  recovery	  measure,	  any	  effect	  of	  metabolic	  fatigue	  on	  torque	  production	  was	  minimized.	  Isometric	  strength	  at	  each	  time	  point	  was	  compared	  to	  baseline	  and	  between	  groups.	  For	  peak	  isometric	  extension	  torque	  (Figure	  3.5a;	  p<0.01),	  strength	  decreased	  significantly	  and	  most	  profoundly	  at	  1d	  post-­‐exercise	  (percent	  loss	  from	  baseline:	  non-­‐smokers,	  33%;	  smokers:	  38%),	  with	  a	  linear	  increase	  in	  strength	  to	  5d	  toward	  baseline	  (non-­‐smokers,	  6%;	  smokers	  14%	  loss	  from	  baseline).	  There	  was	  no	  effect	  of	  smoking	  (p=0.27)	  and	  no	  group*exercise	  interaction	  (p=0.37).	  When	  normalized	  to	  bodyweight,	  the	  effect	  of	  exercise	  remained	  (Figure	  3.5b;	  p<0.01),	  with	  no	  effect	  of	  smoke	  (p=0.67)	  and	  no	  interaction	  (0.41).	  As	  a	  percent	  of	  baseline,	  the	  effect	  of	  exercise	  persisted	  (Figure	  3.5c;	  p<0.01),	  but,	  again,	  there	  was	  no	  effect	  of	  smoke	  (p=0.15)	  and	  no	  interaction	  (p=0.24).	  These	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data	  indicate	  that	  the	  exercise	  was	  effective	  at	  inducing	  damage,	  and	  that	  smokers	  and	  non-­‐smokers	  exhibited	  similar	  prolonged	  strength	  loss.	  	  As	  with	  extension,	  flexion	  peak	  torque	  during	  recovery	  had	  a	  significant	  effect	  of	  exercise	  (Table	  3.3;	  p<0.01),	  with	  no	  effect	  of	  smoking	  (p=0.15)	  or	  interaction	  (p=0.35).	  These	  patterns	  remained	  with	  normalization	  to	  bodyweight	  and	  percent	  baseline.	  
	  
Muscle	  Function	  During	  Eccentric	  Exercise	  
Eccentric	  Peak	  Torque	  Loss	  	  Eccentric	  peak	  torque	  was	  plotted	  at	  baseline	  and	  the	  last	  3	  contractions	  of	  each	  set.	  Eccentric	  torque	  decreased	  significantly	  from	  baseline	  for	  both	  groups	  beginning	  in	  set	  4	  (p<0.05)	  and	  continuing	  through	  the	  end	  of	  exercise	  (sets	  5-­‐10,	  p<0.01)	  in	  absolute	  values	  (Figure	  3.6a),	  when	  normalized	  to	  bodyweight	  (Figure	  3.6b),	  and	  when	  expressed	  as	  a	  percent	  of	  baseline	  (Figure	  3.6c).	  There	  was	  no	  overall	  effect	  of	  group	  for	  absolute	  (p=0.14),	  normalized	  (0.54),	  or	  percent	  baseline	  values	  (p=0.1).	  Smokers	  (26%	  loss)	  had	  a	  more	  dramatic	  decrease	  in	  eccentric	  peak	  torque	  from	  baseline	  to	  the	  end	  of	  exercise	  than	  non-­‐smokers	  (36%	  loss)	  for	  absolute	  and	  normalized	  torque	  values	  and	  when	  expressed	  as	  a	  percent	  of	  baseline	  (interaction:	  p≤0.01).	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Eccentric	  Work	  	  
Total	  Work	  To	  determine	  if	  the	  difference	  in	  strength	  loss	  during	  and	  5min	  post-­‐exercise	  could	  be	  explained	  by	  differences	  in	  work	  done	  during	  the	  exercise,	  work	  was	  analyzed	  between	  groups.	  Over	  the	  course	  of	  the	  exercise,	  smokers	  did	  significantly	  more	  total	  work	  (~30%	  for	  absolute	  values,	  ~20%	  when	  adjusted	  for	  BW)	  than	  did	  non-­‐smokers	  in	  absolute	  values	  (Figure	  3.7a;	  p=0.03).	  However,	  when	  differences	  in	  bodyweight	  were	  accounted	  for,	  total	  work	  done	  did	  not	  differ	  between	  non-­‐smokers	  and	  smokers,	  each	  group	  producing	  614J/kg	  and	  731J/kg,	  respectively	  (Figure	  3.7b;	  p=0.13).	  	  
	  
Work	  Capacity	  over	  Exercise	  Bout	  	  While	  the	  total	  volume	  of	  work	  did	  not	  differ	  between	  groups,	  the	  pattern	  of	  work	  done	  over	  the	  course	  of	  the	  exercise	  could	  explain	  differences	  in	  the	  exercise	  response.	  Therefore,	  I	  analyzed	  work	  done	  in	  each	  set	  throughout	  the	  exercise	  session	  and	  compared	  these	  changes	  between	  groups.	  	  Work	  capacity	  decreased	  over	  the	  course	  of	  the	  10-­‐set	  exercise	  session,	  with	  work	  during	  the	  final	  set	  at	  23%	  and	  30%	  loss	  from	  baseline	  for	  non-­‐smokers	  and	  smokers,	  respectively	  (Figure	  3.8a;	  p<0.01).	  While	  there	  were	  no	  overall	  differences	  between	  smokers	  and	  non-­‐smokers	  in	  absolute	  values	  over	  the	  course	  of	  the	  exercise	  session,	  there	  was	  an	  interaction	  (p<0.01),	  with	  smokers	  decreasing	  work	  capacity	  to	  a	  greater	  degree	  than	  non-­‐smokers.	  The	  effect	  of	  set	  and	  the	  interaction	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term	  remained	  significant	  when	  work	  was	  normalized	  to	  bodyweight	  (Figure	  3.8b;	  p<0.01)	  or	  expressed	  as	  a	  percent	  of	  baseline	  (Figure	  3.8c;	  p<0.01).	  	  
	  
Delayed	  Onset	  Muscle	  Soreness	  As	  expected,	  exercise	  significantly	  increased	  soreness	  in	  both	  groups	  (p<0.01;	  Figure	  3.9)	  that	  peaked	  at	  2d	  (non-­‐smokers:	  41.5mm;	  smokers:	  58.3mm).	  The	  interaction	  term	  was	  non-­‐significant	  (p=0.16),	  as	  the	  pattern	  of	  soreness	  development	  was	  not	  different	  between	  groups	  after	  exercise.	  Both	  groups	  followed	  the	  pattern	  of	  DOMS	  typically	  seen	  in	  this	  exercise	  model.	  However,	  smokers	  reported	  greater	  soreness	  overall	  (p=0.01)	  across	  the	  entire	  time	  course	  post-­‐exercise	  as	  well	  as	  greater	  peak	  soreness	  (non-­‐smokers:	  43.4±5.5mm;	  smokers:	  59.0±4.7mm;	  p<0.05).	  	  
	  
Discussion	  This	  study	  tested	  the	  relationship	  between	  smoking	  and	  muscle	  injury	  by	  comparing	  responses	  to	  damage-­‐inducing	  eccentric	  exercise.	  Epidemiological	  studies	  have	  reported	  greater	  risk	  for	  injury,	  disability,	  and	  prolonged	  healing	  in	  smokers	  relative	  to	  non-­‐smokers.	  Given	  these	  observations,	  I	  hypothesized	  that	  smokers	  would	  have:	  1)	  greater	  expression	  of	  circulating	  stress	  hormones	  but	  suppressed	  inflammatory	  molecules;	  2)	  greater	  creatine	  kinase	  release;	  3)	  greater	  early	  strength	  loss;	  4)	  more	  prolonged	  strength	  loss;	  and	  5)	  greater	  soreness	  (both	  peak	  and	  prolonged)	  in	  response	  to	  eccentric	  exercise.	  The	  findings	  of	  this	  study	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support	  hypotheses	  3	  and	  5:	  smokers	  had	  greater	  eccentric	  strength	  loss	  during	  and	  isometric	  strength	  loss	  following	  ECC	  and	  greater	  peak	  soreness.	  Based	  on	  previously	  published	  reports	  linking	  smoking	  to	  dysregulated	  inflammatory	  signaling,	  I	  hypothesized	  that	  ECC-­‐mediated	  changes	  to	  circulating	  levels	  of	  stress	  hormones	  and	  inflammatory	  molecules	  would	  be	  altered	  in	  smokers.	  With	  the	  expected	  exception	  of	  cotinine	  (a	  product	  of	  nicotine	  degradation)	  and	  baseline	  levels	  of	  salivary	  IL-­‐6,	  levels	  of	  circulating	  factors	  tested	  did	  not	  differ	  between	  smokers	  and	  non-­‐smokers.	  While	  previous	  studies	  have	  shown	  differences	  in	  some	  of	  these	  factors	  in	  chronic	  smokers	  at	  rest	  (17,	  23,	  277),	  the	  majority	  of	  studies	  use	  older	  smokers	  or	  those	  who	  have	  already	  developed	  smoking-­‐related	  diseases	  such	  as	  COPD.	  It	  is	  important	  to	  note	  that	  the	  population	  of	  smokers	  in	  this	  study	  was	  young	  and	  relatively	  healthy;	  it	  may	  take	  a	  longer	  period	  of	  regular	  exposure	  to	  cigarette	  smoke	  to	  result	  in	  the	  changes	  to	  circulating	  factors	  seen	  in	  other	  studies.	  	  In	  support	  of	  previously	  published	  literature,	  there	  was	  a	  significant	  increase	  of	  IL-­‐6	  after	  exercise	  (34,	  112,	  313).	  TNF-­‐α	  levels	  were	  significantly	  lower	  at	  6h	  compared	  to	  2d	  (non-­‐smokers:	  11.7%	  difference;	  smokers:	  6.9%).	  CRP	  levels	  were	  also	  affected	  by	  exercise	  in	  both	  groups,	  peaking	  1d	  post-­‐ECC	  (non-­‐smokers:	  ~201%	  of	  baseline;	  smokers:	  ~233%).	  Alterations	  to	  TNF-­‐α	  and	  CRP	  are	  not	  always	  found	  after	  eccentric	  exercise	  (36,	  123,	  199,	  222,	  254,	  313),	  although	  some	  studies	  have	  reported	  altered	  levels	  of	  these	  analytes	  (42,	  266,	  278).	  Both	  CRP	  and	  TNF-­‐α	  stimulate	  phagocytosis	  by	  macrophages;	  the	  results	  presented	  here	  indicate	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potential	  phases	  of	  macrophage	  activity	  that	  support	  the	  progression	  through	  the	  primarily	  pro-­‐inflammatory	  phase	  of	  the	  eccentric	  exercise	  response.	  	  VEGF-­‐D	  levels	  were	  suppressed	  slightly,	  but	  significantly,	  at	  1	  (~93%	  of	  baseline)	  and	  2d	  (~92%)	  post-­‐ECC.	  To	  my	  knowledge,	  this	  is	  the	  first	  study	  to	  report	  changes	  to	  VEGF-­‐D	  levels	  in	  circulation	  in	  response	  to	  muscle	  damage.	  VEGF-­‐D	  is	  typically	  associated	  with	  lymphangiogenesis,	  although	  some	  evidence	  supports	  its	  role	  in	  angiogenesis	  (151).	  It	  is	  possible	  that	  the	  decrease	  in	  circulating	  VEGF-­‐D	  indicate	  either:	  a)	  enhanced	  binding	  of	  this	  protein,	  decreasing	  circulating	  (free)	  levels;	  or	  b)	  a	  suppression	  of	  angiogenesis	  during	  the	  initial	  stages	  of	  the	  muscle	  damage	  response.	  Recent	  research	  suggests	  that	  a	  single	  bout	  of	  eccentric	  can	  suppress	  angiogenesis	  during	  the	  initial	  stages	  of	  post-­‐exercise	  recovery	  (134),	  though	  little	  research	  currently	  exists	  regarding	  the	  vascular	  response	  to	  eccentric	  exercise.	  Additional	  research	  is	  therefore	  required	  to	  understand	  how	  VEGF-­‐D	  may	  impact	  muscle	  recovery.	  It	  initially	  appeared	  that	  the	  smokers	  in	  this	  cohort	  were	  stronger	  at	  baseline	  (19%	  higher	  in	  smokers)	  and	  experienced	  greater	  overall	  loss	  of	  force	  production	  during	  (final	  set,	  10%	  greater	  loss	  in	  smokers)	  and	  following	  exercise	  (5min	  post-­‐exercise,	  ~15%	  greater	  in	  smokers).	  However,	  when	  modest	  bodyweight	  differences	  were	  taken	  in	  to	  account,	  differences	  between	  groups	  were	  no	  longer	  present	  for	  baseline	  strength	  or	  sustained	  strength	  loss,	  while	  strength	  losses	  during	  and	  5min	  post-­‐exercise	  remained	  significantly	  greater	  in	  smokers.	  	  These	  data	  support	  the	  first	  hypothesis	  (greater	  early	  strength	  loss	  in	  smokers)	  and	  revealed	  greater	  muscle	  fatigue	  in	  smokers	  during	  the	  exercise.	  In	  
	  	  82	  
contrast,	  the	  second	  and	  third	  hypotheses	  were	  refuted.	  Smokers	  did	  not	  differ	  from	  non-­‐smokers	  in	  their	  prolonged	  strength	  loss	  or	  CK	  activity,	  suggesting	  a	  suppressive	  effect	  of	  smoking	  on	  fatigue	  rather	  than	  greater	  overt	  muscle	  damage.	  The	  data	  confirmed	  the	  fourth	  hypothesis	  and	  I	  found	  that	  smokers	  reported	  higher	  peak	  soreness	  (~15%	  greater	  in	  smokers)	  and	  overall	  greater	  DOMS,	  which	  is	  indicative	  of	  differences	  in	  the	  damage	  response,	  such	  as	  dysregulated	  inflammation.	  Taken	  together,	  these	  data	  showed	  that	  smokers	  fatigued	  more	  with	  eccentric	  exercise	  and	  experienced	  great	  levels	  of	  soreness,	  but	  indirect	  markers	  of	  muscle	  damage	  other	  than	  soreness	  (prolonged	  strength	  loss	  and	  creatine	  kinase	  release)	  were	  not	  significantly	  affected.	  Smokers	  experienced	  greater	  early	  strength	  loss	  (fatigue),	  coupled	  with	  a	  more	  substantial	  loss	  of	  force	  production	  during,	  and	  shortly	  following,	  eccentric	  exercise.	  Previous	  studies	  have	  shown	  greater	  muscle	  fatigue	  in	  response	  to	  electrically	  stimulated	  contractions	  following	  chronic	  smoke	  exposure	  in	  mice	  (290)	  and	  in	  humans	  (370).	  This	  is	  the	  first	  study	  to	  my	  knowledge	  documenting	  greater	  fatigue	  in	  smoking	  during	  and	  after	  voluntary	  eccentric	  contractions.	  Mechanisms	  that	  may	  explain	  this	  phenomenon	  include:	  1)	  changes	  in	  blood	  flow	  due	  to	  smoking	  leading	  to	  altered	  clearance	  of	  metabolic	  by-­‐products	  and/or	  decreased	  O2	  delivery;	  2)	  suppressed	  oxidative	  metabolism	  (162,	  290,	  328);	  and	  3)	  fiber	  type	  distribution	  differs	  between	  smokers	  and	  non-­‐smokers,	  with	  smokers	  having	  a	  lower	  prevalence	  of	  fatigue-­‐resistant	  Type	  I	  muscle	  fibers	  (169,	  290,	  328).	  	  Immediately	  after	  smoking,	  muscle	  blood	  flow	  is	  acutely	  increased	  for	  a	  brief	  period	  (approximately	  5min)(364),	  although	  smoking	  is	  conversely	  known	  to	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decrease	  overall	  blood	  flow,	  more	  pertinently	  within	  muscle	  during	  stimulated	  contractions	  (370).	  In	  addition,	  previous	  reports	  have	  shown	  impairments	  to	  oxidative	  metabolism	  in	  individuals	  exposed	  to	  cigarette	  smoke	  (169,	  328).	  However,	  in	  the	  study	  subjects	  were	  performing	  maximal	  eccentric	  contractions,	  which	  rely	  more	  heavily	  on	  anaerobic,	  rather	  than	  oxidative,	  metabolism.	  Given	  on	  these	  prior	  studies,	  it	  is	  unlikely	  that	  limited	  blood	  flow	  or	  suppressed	  oxidative	  metabolism	  contributed	  significantly	  to	  the	  greater	  fatigue	  found	  during	  and	  shortly	  following	  maximal	  eccentric	  exercise	  in	  the	  smoking	  group,	  although	  this	  was	  not	  tested	  directly.	  	  While	  I	  did	  not	  examine	  muscle	  fiber	  types	  in	  these	  subjects,	  data	  in	  the	  literature	  support	  the	  hypothesis	  that	  differences	  in	  fiber-­‐type	  distribution	  might	  explain	  the	  greater	  fatigue	  in	  smokers.	  Anaerobic	  (Type	  II)	  muscle	  fibers	  are	  more	  prone	  to	  fatigue	  than	  those	  that	  rely	  primarily	  on	  oxidative	  phosphorylation	  (Type	  I).	  A	  shift	  in	  fiber	  type	  distribution	  away	  from	  Type	  I	  and	  corresponding	  greater	  fatigue	  has	  been	  found	  in	  several	  studies	  using	  animal	  models	  of	  long-­‐term	  cigarette	  smoke	  exposure	  (290,	  328).	  Furthermore,	  Type	  I	  fibers	  from	  human	  smokers	  are	  smaller	  in	  both	  cross-­‐sectional	  area	  (169,	  226)	  and	  number	  (169)	  relative	  to	  non-­‐smokers.	  These	  differences	  appear	  to	  be	  reversible,	  since	  fiber	  type	  distribution	  in	  former	  smokers	  was	  no	  different	  than	  non-­‐smokers.	  	  Fiber-­‐type	  shifts	  in	  smokers	  away	  from	  Type	  I	  fibers	  may	  result	  from	  the	  more	  hypoxic	  environment	  caused	  by	  carbon	  monoxide	  inhalation	  during	  smoking	  (294,	  311).	  In	  addition,	  nicotine	  and	  other	  components	  of	  smoke	  may	  influence	  fiber	  type	  independent	  from	  carbon	  monoxide	  exposure.	  Taken	  together,	  these	  data	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suggest	  that	  smoking	  impacts	  fiber	  type	  distribution	  such	  that	  smokers	  rely	  more	  on	  anaerobic	  fibers	  and	  are	  therefore	  more	  susceptible	  to	  fatigue,	  especially	  since	  the	  high	  forces	  involved	  in	  eccentric	  exercise	  bias	  recruitment	  to	  Type	  II	  fibers.	  In	  the	  current	  study,	  the	  smokers	  may	  have	  been	  unable	  to	  sustain	  eccentric	  work	  production	  over	  time	  due	  to	  a	  lower	  percentage	  of	  smaller	  Type	  I	  fibers	  and	  decreased	  fatigue	  resistance,	  resulting	  in	  greater	  immediate	  strength	  loss.	  This	  would	  not,	  however,	  impact	  muscle	  damage	  and	  therefore	  prolonged	  strength	  loss	  was	  unaffected	  by	  smoking.	  Prolonged	  strength	  loss	  (an	  indirect	  indicator	  of	  damage)	  did	  not	  differ	  between	  smokers	  and	  non-­‐smokers,	  and	  both	  groups	  performed	  a	  similar	  amount	  of	  work	  overall.	  I	  found,	  though,	  that	  while	  force	  production	  remained	  similar	  between	  groups	  during	  the	  first	  5	  sets	  of	  the	  exercise	  session,	  it	  then	  decreased	  over	  the	  second	  half	  of	  the	  exercise	  session	  to	  a	  greater	  extent	  in	  smokers.	  While	  an	  indicator	  of	  fatigue,	  this	  force	  reduction	  also	  means	  that	  smokers	  were	  exposed	  to	  a	  lower	  number	  of	  relative	  high-­‐force	  contractions	  (those	  that	  result	  in	  the	  greatest	  amount	  of	  strain	  and	  muscle	  damage	  (250))	  later	  in	  the	  exercise	  period.	  Nevertheless,	  smokers	  responded	  to	  the	  exercise	  session	  with	  a	  similar	  pattern	  of	  prolonged	  strength	  loss,	  indicating	  greater	  muscle	  dysfunction	  proportionate	  to	  the	  number	  of	  relative	  high-­‐force	  contractions	  when	  the	  muscle	  is	  fatigued.	  Therefore,	  while	  these	  data	  do	  not	  obviously	  point	  to	  greater	  muscle	  damage	  sustained	  in	  smokers	  (using	  indirect	  markers),	  they	  do	  suggest	  that	  smokers	  could	  be	  more	  susceptible	  to	  damage	  on	  a	  relative	  scale.	  In	  combination	  with	  greater	  fatigue,	  this	  subtle	  increase	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in	  susceptibility	  to	  injury	  in	  smokers	  could	  contribute	  to	  their	  higher	  risk	  for	  injury	  and	  promote	  disability	  in	  smokers.	  	  Creatine	  kinase	  activity	  (a	  biochemical	  marker	  of	  damage)	  increased	  after	  exercise	  but	  did	  not	  differ	  between	  groups	  after	  exercise.	  This	  may	  be	  due	  to	  the	  high	  intra-­‐subject	  variability	  in	  CK	  activity	  following	  eccentric	  exercise	  (248),	  which	  makes	  modest	  effects	  difficult	  to	  detect.	  Furthermore,	  while	  CK	  activity	  is	  a	  good	  indicator	  that	  muscle	  damage	  has	  occurred,	  it	  does	  not	  correlate	  well	  with	  the	  level	  of	  muscle	  damage.	  Therefore,	  while	  counter	  to	  my	  hypothesis,	  the	  lack	  of	  significant	  differences	  may	  not	  be	  surprising.	  Unlike	  the	  persistent	  strength	  loss	  and	  CK	  activity	  parameters,	  another	  indirect	  marker	  of	  muscle	  damage	  was	  found	  to	  be	  significantly	  different	  between	  groups.	  Smokers	  reported	  higher	  overall	  soreness	  (2d	  post-­‐exercise,	  15.6%	  greater	  in	  smokers)	  as	  well	  as	  peak	  muscle	  soreness	  (16.8%	  greater	  in	  smokers)	  compared	  to	  the	  non-­‐smokers.	  While	  post-­‐hoc	  differences	  at	  individual	  time	  points	  were	  not	  significant,	  modest	  differences	  at	  each	  time	  point	  may	  have	  been	  difficult	  to	  pick	  up	  due	  to	  high	  variability	  in	  soreness	  responses.	  Peak	  soreness	  and	  the	  magnitude	  of	  muscle	  damage	  generally	  tend	  to	  be	  positively	  correlated.	  Inflammation	  is	  widely	  considered	  to	  drive	  DOMS	  after	  lengthening	  contractions.	  	  It	  is	  worth	  noting	  that	  smokers	  are	  known	  to	  have	  dysregulated	  inflammatory	  responses	  to	  injury	  (reviewed	  in	  (108)).	  Although	  data	  from	  the	  current	  study	  did	  not	  directly	  address	  inflammation,	  one	  possibility	  is	  that	  greater	  overall	  and	  peak	  soreness	  in	  the	  smoking	  group	  after	  eccentric	  exercise	  may	  be	  a	  result	  of	  dysregulated	  inflammatory	  processes	  during	  muscle	  recovery.	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Inflammation	  is	  highly	  regulated	  and	  critical	  to	  muscle	  regeneration	  (190,	  221,	  223).	  Muscle	  stress	  stimulates	  pro-­‐inflammatory	  signaling,	  which	  is	  followed	  by	  anti-­‐inflammatory	  signaling	  and	  then	  a	  full	  resolution	  of	  inflammation	  (336,	  337).	  Current	  knowledge	  points	  to	  pro-­‐inflammatory	  signaling	  stimulating	  the	  release	  of	  chemical	  nerve	  sensitizers	  and	  increased	  intramuscular	  pressure	  from	  edema,	  together	  resulting	  in	  hyperalgesia	  and	  manifesting	  as	  DOMS	  (135).	  Disruptions	  to	  the	  inflammatory	  process	  (such	  as	  the	  use	  of	  non-­‐steroidal	  anti-­‐inflammatory	  drugs)	  result	  in	  delayed	  healing	  and	  attenuate	  adaptation	  (190,	  221,	  223),	  indicating	  the	  importance	  of	  inflammation	  in	  muscle	  recovery.	  In	  this	  study,	  smokers	  reported	  higher	  overall	  DOMS	  without	  obvious	  signs	  of	  greater	  muscle	  damage,	  suggesting	  alterations	  to	  inflammation	  after	  eccentric	  exercise.	  	  Inflammatory	  responses	  are	  altered	  in	  smokers	  after	  traumatic	  injury	  and	  surgery,	  variances	  that	  are	  thought	  to	  interfere	  with	  normal	  healing.	  Inflammation	  after	  muscle	  injury	  has	  yet	  to	  be	  investigated	  in	  smokers.	  At	  rest,	  smokers	  have	  greater	  numbers	  of	  circulating	  neutrophils	  and	  macrophages	  (32,	  165,	  220,	  252,	  305-­‐307),	  but	  leukocyte	  activity	  is	  generally	  suppressed,	  including	  neutrophil	  respiratory	  bursts	  (297,	  307,	  316)	  and	  activity	  of	  macrophages	  (52,	  124,	  217,	  245,	  312,	  316,	  320).	  Leukocytes	  from	  smokers	  tend	  to	  be	  pro-­‐inflammatory,	  although	  an	  abnormal	  prevalence	  of	  anti-­‐inflammatory	  leukocyte	  sub-­‐types	  has	  also	  been	  reported	  (71,	  309).	  I	  theorize	  that	  dysregulated	  inflammation	  could	  interfere	  with	  normal	  muscle-­‐recovery	  signaling,	  leading	  to	  greater	  soreness,	  less	  effective	  healing,	  and	  higher	  risk	  for	  injury.	  Since	  inflammatory	  responses	  to	  muscle	  injury	  in	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smokers	  have	  yet	  to	  be	  studied,	  it	  remains	  to	  be	  seen	  if	  altered	  inflammation	  may	  explain	  the	  higher	  soreness	  found	  in	  this	  study.	  I	  believe	  the	  greater	  soreness	  in	  smokers	  to	  be	  indicative	  of	  a	  dysregulated	  inflammatory	  response	  after	  exercise,	  which	  could	  lead	  to	  suppressed	  healing	  and	  greater	  future	  risk	  for	  injury.	  I	  also	  believe	  the	  similar	  damage	  sustained	  (indicated	  by	  prolonged	  strength	  loss	  and	  CK	  activity)	  while	  exposed	  to	  fewer	  relative	  high-­‐force	  contractions,	  combined	  with	  greater	  peak	  soreness,	  indicate	  a	  greater	  susceptibility	  to	  muscle	  damage	  in	  smokers.	  The	  primary	  findings	  indicate	  two	  possible	  mechanisms	  behind	  the	  higher	  risk	  for	  injury	  in	  smokers:	  1)	  greater	  fatigue	  in	  smokers	  may	  increase	  risk	  for	  acute	  injury,	  and	  2)	  higher	  soreness	  may	  indicate	  dysregulated	  inflammation,	  which	  could	  interfere	  with	  normal	  healing	  and	  promote	  disability.	  Based	  on	  these	  data,	  I	  speculate	  that	  smokers	  may	  be	  at	  greater	  risk	  of	  injury	  from	  physical	  activities	  that	  are	  novel	  and	  impose	  high	  muscular	  stress,	  particularly	  to	  those	  individuals	  who	  experience	  high	  levels	  of	  fatigue	  and	  soreness.	  I	  cannot	  make	  public	  health	  recommendations	  based	  on	  the	  size	  of	  this	  study;	  however,	  additional	  study	  is	  justified	  regarding	  whether	  acute	  injury	  risk	  may	  be	  reduced	  by	  paying	  careful	  attention	  to	  muscle	  fatigue.	  Further,	  examination	  of	  the	  effect	  of	  time	  between	  bouts	  of	  exercise,	  allowing	  additional	  time	  for	  recovery	  and	  possible	  reduced	  risk	  for	  disability,	  is	  warranted.	  Greater	  soreness	  in	  smokers	  may	  influence	  these	  individuals	  against	  participation	  in	  stressful	  physical	  activity.	  Over	  time,	  lower	  fitness	  levels	  could	  lead	  to	  increased	  risk	  for	  health	  consequences	  associated	  with	  low	  physical	  activity	  such	  as	  cardiovascular	  disease	  and	  diabetes.	  Further	  research	  is	  needed	  to	  understand	  the	  molecular	  mechanisms	  that	  may	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underlie	  greater	  fatigue	  and	  higher	  soreness	  in	  order	  to	  more	  effectively	  reduce	  risk	  for	  injury	  and	  promote	  effective	  musculoskeletal	  healing	  in	  smokers.	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Tables	  and	  Figures	  
Figure	  3.1:	  Study	  Timeline.	  	  Over	  the	  course	  of	  8	  visits,	  there	  were	  8	  blood	  draws,	  maximal	  voluntary	  contraction	  (MVC;	  strength	  measure)	  testing	  at	  7	  visits,	  and	  one	  eccentric	  exercise	  session	  (visit	  2).	  	  
	  	  
Table	  3.1:	  Subject	  Characteristics.	  There	  were	  no	  significant	  differences	  between	  groups	  for	  height,	  weight,	  body	  mass	  index	  (BMI),	  or	  age.	  Pack-­‐years	  is	  a	  product	  of	  packs	  of	  cigarettes	  smoked	  per	  day	  and	  years	  of	  smoking.	  Data	  are	  mean±SEM.	  
	   Height	  (cm)	   Weight	  (kg)	   BMI	   Age	   Pack-­‐years	  Non-­‐smokers	   176.0	  ±	  1.3	   74.8	  ±	  4.6	   24.2	  ±	  1.5	   25.5	  ±	  1.0	   N/A	  Smokers	   178.6	  ±	  2.6	   82.1	  ±	  4.8	   25.8	  ±	  1.6	   25.3	  ±	  1.6	   4.4	  ±	  0.5	  
	  
	  
Table	  3.2:	  Salivary	  Cotinine	  Levels.	  	  Smoking	  status	  was	  verified	  using	  cotinine	  (ng/mL),	  measured	  in	  saliva	  that	  was	  collected	  at	  all	  visits.	  Baseline	  is	  average	  of	  V1	  and	  V2,	  which	  did	  not	  differ.	  Smokers	  maintained	  their	  regular	  smoking	  habits	  throughout	  the	  course	  of	  the	  study.	  Data	  are	  mean±SEM.	  *	  p<0.05	  effect	  of	  group	  (smoking).	  
	  	   Baseline	   6h	   1d	   2d	   3d	   4d	   5d	  Non-­‐smokers	   1.6±0.3*	   1.6±0.3*	   1.2±0.3*	   2.0±0.7*	   1.8±0.3*	   1.2±0.2*	   1.3±0.2*	  Smokers	   308.3±44.4	   355.6±72.4	   326.2±67.5	   265.2±45.2	   291.7±57.1	   315.5±65.8	   351.7±67.1	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Figure	  3.2:	  Creatine	  Kinase.	  	  Blood	  CK	  before	  and	  after	  ECC.	  Non-­‐smokers	  	  	  	  	  	  	  	  	  	  	  	  	  	  ;	  smokers	  	  	  	  	  	  	  	  	  	  	  	  	  	  .	  Data	  are	  mean±SEM.	  *	  p<0.05	  effect	  of	  exercise	  (compared	  to	  baseline).	  CK,	  creatine	  kinase.	  
	  	  



































































	  	  91	  
Figure	  3.4:	  Isometric	  Peak	  Torque	  Extension:	  5min	  Post-­‐ECC.	  Peak	  torque	  at	  baseline	  and	  5min	  after	  ECC,	  expressed	  as	  (a)	  absolute	  values,	  (b)	  normalized	  to	  bodyweight,	  and	  (c)	  percent	  baseline.	  Non-­‐smokers	  	  	  	  	  ;	  smokers	  	  	  	  	  .	  Data	  are	  mean±SEM.	  *	  p<0.05	  effect	  of	  exercise	  (compared	  to	  baseline);	  †	  p<0.05	  effect	  of	  group	  (smoking).	  ECC,	  eccentric	  exercise.	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Table	  3.3:	  Isometric	  Peak	  Torque	  Flexion:	  Recovery.	  Peak	  torque	  during	  recovery	  (1-­‐5d	  post-­‐ECC),	  expressed	  as	  absolute	  values	  (N•m),	  normalized	  to	  bodyweight	  (N•m/kg),	  and	  percent	  baseline.	  *	  p<0.05	  effect	  of	  exercise	  (compared	  to	  baseline).	  ECC,	  eccentric	  exercise.	  	  
	   	   Baseline	   1d	   2d	   3d	   4d	   5d	  
Flexion	  
torque	  
Non-­‐smokers	   95±8.4	   90±8.8*	   88±7.7	   87±6.9	   98±7.4	   97±6.9	  Smokers	   108±5.8	   98±6.0*	   105±6.6	   109±7.3	   109±6.4	   111±8.1	  
Torque/	  
bodyweight	  
Non-­‐smokers	   1.29±0.09	   1.21±0.10*	   1.20±0.10	   1.19±0.09	   1.34±0.10	   1.37±0.10	  Smokers	   1.35±0.09	   1.22±0.09*	   1.29±0.09	   1.35±0.11	   1.35±0.09	   1.37±0.10	  
Percent	  loss	  
from	  baseline	  
Non-­‐smokers	   0	   6±2.9	   7±	  3.0	   6±4.1	   -­‐1±6.6	   -­‐2±4.4	  Smokers	   0	   10±3.4	   5±3.7	   0±4.9	   -­‐1±3.2	   -­‐2±3.9	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Figure	  3.7:	  Total	  Eccentric	  Work	  Done:	  Exercise	  Session.	  The	  sum	  of	  work	  done	  during	  the	  exercise	  session	  expressed	  as	  (a)	  absolute	  values	  and	  (b)	  normalized	  to	  bodyweight.	  Non-­‐smokers	  	  	  	  	  ;	  smokers	  	  	  	  	  	  .	  Data	  are	  mean±SEM.	  †	  p<0.05	  effect	  of	  group	  (smoking).	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Figure	  3.8:	  Eccentric	  Work	  during	  the	  Exercise	  Session.	  	  Eccentric	  work	  done	  in	  each	  set	  over	  the	  exercise	  session	  expressed	  as	  (a)	  absolute	  values,	  (b)	  normalized	  to	  bodyweight,	  and	  (c)	  percent	  baseline.	  Non-­‐smokers	  	  	  	  	  	  	  	  	  	  	  	  	  ;	  smokers	  	  	  	  	  	  	  	  	  	  	  	  	  	  .	  Data	  are	  mean	  ±	  SEM.	  *	  p<0.05	  vs	  baseline;	  §	  p<0.05	  interaction	  (exercise*smoking,	  response	  compared	  to	  baseline).	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Figure	  3.9:	  Soreness	  Post-­‐ECC.	  	  Soreness	  measured	  by	  VAS	  at	  baseline	  and	  1-­‐5d	  post-­‐ECC.	  Non-­‐smokers	  	  	  	  	  	  	  	  	  	  	  	  	  	  ;	  smokers	  	  	  	  	  	  	  	  	  	  	  	  	  	  .	  Data	  are	  mean	  ±	  SE.	  *	  p<0.05	  effect	  of	  exercise	  (compared	  to	  baseline);	  †	  p<0.05	  effect	  of	  smoking	  (compared,	  overall,	  to	  non-­‐smokers).	  VAS,	  visual	  analog	  scale;	  ECC,	  eccentric	  exercise.	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CHAPTER	  IV	  
TRANSCRIPTOME	  ANALYSIS	  OF	  SKELETAL	  MUSCLE	  AT	  EARLY	  (3H)	  AND	  LATE	  
(48H)	  TIME	  POINTS	  AFTER	  ECCENTRIC	  EXERCISE	  
	  
Introduction	  	   Muscle-­‐lengthening	  (eccentric)	  contractions	  (ECC)	  stimulate	  a	  damage/repair	  process	  that	  can	  be	  described	  in	  three	  stages.	  Primary	  damage	  via	  mechanical	  strain	  during	  exercise	  is	  followed	  over	  the	  subsequent	  hours	  and	  days	  by	  secondary	  damage,	  caused	  by	  infiltrating	  inflammatory	  cells	  and	  free	  radical	  molecules.	  The	  final	  stage,	  repair	  and	  regeneration,	  can	  last	  for	  a	  week	  or	  more	  post-­‐exercise.	  This	  stage	  overlaps	  somewhat	  with	  the	  secondary	  damage	  stage	  both	  temporally	  and	  in	  its	  underlying	  molecular	  mechanisms.	  Pathways	  implicated	  in	  early	  changes	  after	  ECC	  have	  been	  previously	  reported,	  yet	  mechanisms	  that	  drive	  secondary	  damage	  and	  repair	  are	  poorly	  understood,	  especially	  the	  critical	  shift	  from	  damage	  to	  resolution	  and	  repair/regeneration.	  Understanding	  the	  molecular	  mechanisms	  that	  mediate	  these	  processes	  may	  help	  reduce	  healing	  time,	  minimize	  permanent	  consequences	  to	  muscle	  such	  as	  fibrosis,	  and	  protect	  against	  future	  injury.	  	   Neutrophils	  dominate	  in	  the	  early	  phase	  of	  inflammation	  following	  ECC	  (up	  to	  2d	  post-­‐exercise),	  where	  they	  degrade	  necrotic	  and	  (sometimes	  healthy)	  neighboring	  tissue.	  Yet,	  free	  radical	  molecules	  produced	  during	  this	  phase	  can	  also	  promote	  regeneration,	  for	  example	  H2O2	  stimulates	  protein	  kinase	  c	  (PKC)	  activation	  (160).	  Pro-­‐inflammatory	  processes	  include	  the	  activation	  of	  signaling	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molecules	  such	  as	  nuclear	  factor	  kappa–B	  (NFκB)	  (reviewed	  in	  Haddad	  (111))	  and	  cytokine	  release	  such	  as	  interleukin-­‐6	  (IL-­‐6	  (271,	  313))	  and	  macrophage	  chemoattractant	  protein-­‐1	  (MCP-­‐1(133,	  166,	  255)).	  Next,	  M1	  macrophages,	  which	  act	  in	  a	  similar	  manner	  to	  neutrophils,	  infiltrate	  and	  continue	  to	  promote	  pro-­‐inflammatory	  activity.	  The	  late	  phase	  of	  post-­‐ECC	  inflammation	  (roughly	  2d+	  post-­‐ECC	  and	  onward)	  is	  characterized	  by	  anti-­‐inflammatory	  (M2)	  macrophages	  and	  other	  signaling	  that	  quenches	  pro-­‐inflammatory	  signaling	  and	  cell	  activity,	  which	  suppresses	  further	  damage	  and	  stimulating	  repair	  and	  adaptation.	  At	  the	  end	  of	  this	  phase,	  inflammation	  generally	  resolves	  back	  to	  baseline.	  If	  this	  progression	  of	  inflammatory	  events	  favors	  the	  pro-­‐inflammatory	  environment,	  secondary	  damage	  can	  occur.	  However,	  effective	  repair	  and	  adaptation	  can	  be	  suppressed	  when	  inflammation	  is	  attenuated,	  indicating	  that	  pro-­‐inflammatory	  processes	  are	  critical	  to	  muscle	  recovery	  (168,	  190,	  221,	  223).	  	  	   The	  molecular	  mechanisms	  controlling	  the	  balance	  between	  secondary	  damage	  and	  muscle	  repair	  are	  poorly	  understood,	  particularly	  during	  the	  transitional	  period	  (~2d	  post-­‐ECC).	  ECC	  is	  an	  excellent	  laboratory	  model	  that	  instigates	  transient	  muscle	  damage,	  repair,	  and	  adaptation	  to	  investigate	  the	  underlying	  processes.	  Physiological	  changes	  following	  ECC	  include	  the	  loss	  of	  strength,	  increased	  muscle-­‐derived	  proteins	  in	  the	  blood	  (such	  as	  creatine	  kinase),	  and	  delayed	  onset	  muscle	  soreness	  (DOMS).	  DOMS	  is	  a	  form	  of	  transient,	  mechanically-­‐induced	  hyperalgesia	  that	  typically	  manifests	  in	  the	  hours	  after	  ECC,	  peaks	  24-­‐48h	  post-­‐exercise	  and	  resolves	  within	  ~5d.	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In	  a	  recent	  study,	  I	  found	  that	  chronic	  cigarette	  smokers	  experienced	  25%	  greater	  DOMS	  than	  non-­‐smokers	  after	  ECC.	  Smokers	  also	  have	  greater	  risk	  for	  musculoskeletal	  injury	  (5,	  47,	  48,	  150,	  157,	  212,	  286,	  343,	  363)	  impaired	  healing	  after	  injury	  or	  surgery	  (3,	  82,	  310,	  317,	  357),	  and	  dysregulated	  inflammatory	  signaling	  (32,	  101,	  165,	  305,	  306,	  316,	  320).	  DOMS	  is	  driven	  (in	  part)	  by	  inflammatory	  signaling,	  and	  research	  indicates	  that	  nerve-­‐sensitizing	  factors,	  such	  as	  prostaglandins,	  bradykinin,	  and	  nerve	  growth	  factor	  (NGF)	  may	  be	  important	  in	  the	  development	  of	  both	  hyperalgesia	  and	  DOMS	  (233,	  234).	  However,	  the	  specific	  mechanisms	  underlying	  the	  DOMS	  response	  have	  yet	  to	  be	  fully	  elucidated.	  Thus,	  before	  investigating	  the	  reason	  for	  heightened	  DOMS	  in	  smokers,	  it	  was	  necessary	  to	  first	  gain	  a	  better	  understanding	  of	  the	  molecular	  mechanisms	  mediating	  DOMS	  and	  the	  damage/repair	  cycle	  in	  non-­‐smokers.	  Because	  of	  the	  complexity	  of	  the	  molecular	  pathways	  that	  regulate	  DOMS,	  and	  the	  paucity	  of	  data	  in	  the	  later	  phase	  of	  secondary	  damage	  (during	  which	  DOMS	  peaks),	  I	  used	  a	  genome-­‐wide	  transcriptomic	  analysis	  to	  identify	  pathways	  likely	  to	  affect	  secondary	  muscle	  damage	  and	  DOMS.	  Global	  transcriptional	  profiling	  coupled	  with	  subsequent	  biological	  pathway	  analysis	  can	  be	  used	  to	  better	  understand	  muscle	  damage,	  repair,	  and	  DOMS.	  From	  publically	  available	  gene	  expression	  profiles,	  I	  selected	  two	  robust	  skeletal	  muscle	  gene	  expression	  profile	  sets	  to	  compare	  early	  and	  later	  inflammatory	  phases	  in	  skeletal	  muscle	  after	  ECC.	  Molecular	  pathways	  of	  interest	  from	  this	  analysis	  were	  then	  validated	  in	  skeletal	  muscle	  biopsy	  samples	  from	  a	  new	  48h	  post-­‐ECC	  cohort.	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In	  this	  study,	  I	  tested	  the	  hypotheses	  that:	  1)	  at	  3h	  post-­‐ECC,	  gene	  expression	  downstream	  of	  related	  to	  pro-­‐inflammatory	  signaling	  such	  as	  IL1,	  and	  IL6,	  and	  would	  stimulate	  NFκB	  and	  related	  pathways	  to	  promote	  additional	  pro-­‐inflammatory	  signaling;	  2)	  at	  48h	  post-­‐ECC,	  gene	  expression	  would	  relate	  to	  greater	  anti-­‐	  and	  reduced	  pro-­‐inflammatory	  signaling,	  for	  example	  increased	  gene	  expression	  downstream	  of	  anti-­‐inflammatory	  proteins	  and	  cytokines	  such	  as	  IL4	  and	  IL13;	  and	  3)	  expression	  of	  genes	  related	  to	  hyperalgesia	  and/or	  DOMS	  would:	  increase	  at	  3h	  and	  decrease	  but	  remain	  elevated	  above	  baseline/control	  at	  48h	  post-­‐ECC.	  These	  data	  were	  then	  used	  to	  develop	  a	  model	  of	  the	  possible	  inflammatory	  signaling	  pathways	  that	  mediate	  and	  heightened	  DOMS	  observed	  in	  smokers.	  	  	  
Methods	  This	  study	  employed	  a	  two-­‐phase	  approach,	  combining	  in	  silico	  transcriptome	  screens	  with	  targeted	  experimental	  validations.	  First,	  two	  publically	  available	  global	  gene	  expression	  (microarray)	  datasets	  were	  analyzed	  to	  identify	  important	  changes	  with	  eccentric	  exercise	  between	  the	  early	  and	  late	  phases	  of	  the	  post-­‐exercise	  response	  (Transcriptome	  Analyses,	  below).	  The	  first	  study	  was	  performed	  at	  the	  University	  of	  Massachusetts	  Amherst	  and	  samples	  were	  collected	  early	  (3h)	  after	  exercise	  (referred	  to	  here	  as	  UM-­‐3h)	  (137,	  372).	  The	  second	  selected	  study	  (referred	  to	  here	  as	  MM)	  was	  performed	  at	  McMaster	  University	  and	  samples	  were	  collected	  from	  one	  pool	  of	  subjects	  early	  (MM-­‐3h)	  and	  late	  (MM-­‐48h)	  post-­‐exercise	  (192).	  Biological	  pathway	  analysis	  (where	  groups	  of	  transcripts	  are	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related	  by	  established	  biological	  function)	  was	  used	  to	  identify	  underlying	  molecular	  pathways	  affected	  at	  each	  time	  point.	  In	  the	  second	  stage	  of	  the	  analysis,	  I	  used	  qRT-­‐PCR,	  PCR	  arrays,	  and	  protein	  analyses	  to	  validate	  changes	  in	  transcript	  abundance	  and	  protein	  activity	  predicted	  from	  the	  in	  silico	  analyses.	  These	  analyses	  were	  performed	  on	  two	  sets	  of	  samples:	  1)	  a	  sub-­‐cohort	  from	  UM-­‐3h,	  referred	  to	  here	  as	  “Validation-­‐early”	  (VAL-­‐3h);	  and	  2)	  from	  a	  new	  cohort	  in	  which	  samples	  were	  collected	  at	  48h	  (late)	  post-­‐exercise,	  referred	  to	  here	  as	  “Validation-­‐late”	  (VAL-­‐48h).	   	  	  
Subjects	  Healthy	  young	  men	  participated	  in	  two	  similar	  exercise	  paradigms	  from	  which	  muscle	  tissue	  was	  obtained	  for	  the	  microarray	  studies,	  the	  details	  of	  which	  have	  been	  previously	  reported	  and	  are	  discussed	  below	  (137,	  191,	  192,	  372).	  For	  transcript	  and	  protein	  validation	  (VAL-­‐48h),	  I	  used	  a	  new	  group	  of	  subjects.	  For	  all	  studies,	  subjects	  were	  free	  of	  disease	  or	  disorder	  that	  might	  affect	  the	  study	  results,	  did	  not	  take	  any	  medications	  that	  might	  affect	  the	  result	  of	  the	  study	  as	  determined	  by	  a	  study	  physician,	  and	  agreed	  to	  refrain	  from	  muscle	  treatments,	  such	  as	  ice	  and	  massage,	  during	  the	  duration	  of	  the	  study.	  All	  subjects	  were	  non-­‐smokers,	  and	  none	  had	  participated	  in	  resistance	  training	  of	  the	  legs	  in	  the	  six	  months	  prior	  to	  enrolling	  in	  the	  study.	  In	  UM-­‐3h,	  there	  were	  35	  sedentary	  men	  ages	  18-­‐30.	  VAL-­‐48h	  was	  comprised	  of	  9	  sedentary	  men	  ages	  18-­‐35y.	  Interviews	  were	  used	  to	  verify	  that	  the	  activity	  level	  of	  both	  subject	  pools	  was	  below	  5	  Metabolic	  Equivalent	  of	  Task	  units	  (METs)	  during	  all	  activities	  in	  which	  subjects	  regularly	  participated.	  Subjects	  in	  UM-­‐
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3h	  and	  VAL-­‐48h	  were	  allowed	  acetaminophen	  after	  the	  muscle	  biopsies,	  and	  were	  required	  to	  refrain	  from	  the	  use	  of	  alcohol	  and	  new	  physical	  activities	  until	  they	  completed	  the	  study.	  MM	  included	  9	  recreationally	  active	  (performed	  less	  than	  3h	  of	  exercise	  per	  week)	  men,	  ages	  18-­‐25.	  Before	  each	  muscle	  biopsy,	  subjects	  in	  the	  MM	  study	  were	  required	  to	  refrain	  from	  exercise	  for	  72h;	  alcohol	  for	  48h;	  caffeine	  for	  12h;	  and	  were	  requested	  to	  consumed	  their	  habitual	  diet	  for	  48h.	  All	  participants	  gave	  written	  informed	  consent	  as	  approved	  by	  the	  University	  of	  Massachusetts	  Amherst	  Institutional	  Review	  Board	  (UM-­‐3h	  and	  VAL-­‐48h)	  or	  the	  Research	  Ethics	  Board	  of	  McMaster	  University	  (MM)	  prior	  to	  participation.	  	   	  
Study	  Design	  	   A	  simplified	  outline	  of	  the	  study	  design	  is	  presented	  in	  Table	  4.1,	  with	  details	  provided	  in	  the	  text	  below.	  	  
	  
Transcriptome	  Analyses	  
UM-­‐3h	  Study	  Design	  Gene	  expression	  profiles	  were	  generated	  from	  skeletal	  muscle	  at	  3h	  post-­‐exercise	  for	  the	  UM-­‐3h	  study,	  the	  details	  of	  which	  have	  been	  reported	  previously	  (137,	  372).	  In	  addition	  to	  muscle	  biopsies,	  muscle	  soreness,	  blood	  creatine	  kinase	  activity,	  and	  strength	  loss	  were	  also	  measured	  as	  damage	  markers	  (137,	  372).	  Briefly,	  UM-­‐3h	  consisted	  of	  seven	  visits	  over	  the	  course	  of	  8-­‐11d	  (Table	  4.1).	  At	  the	  first	  study	  visit,	  participants	  came	  to	  the	  laboratory	  in	  a	  fasted	  state	  (no	  food	  or	  beverage	  except	  water	  for	  8-­‐12h),	  blood	  was	  drawn,	  and	  subjects	  underwent	  a	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familiarization	  session	  on	  the	  Biodex	  System	  3	  dynamometer	  (Biodex	  Medical	  Systems,	  Shirley,	  NY,	  USA),	  followed	  by	  baseline	  strength	  testing	  of	  the	  knee	  extensors	  of	  the	  exercised	  (non-­‐dominant)	  leg.	  Within	  2d,	  subjects	  returned	  to	  the	  laboratory	  in	  a	  fasted	  state	  and	  then	  ingested	  a	  standardized	  meal	  consisting	  of	  400	  kcals	  (approximately	  55%	  carbohydrate,	  30%	  fat,	  and	  15%	  protein).	  Baseline	  soreness	  and	  muscle	  strength	  were	  assessed,	  followed	  by	  the	  exercise	  session	  and	  underwent	  strength	  testing	  (0h	  post-­‐exercise).	  Three	  hours	  after	  the	  exercise,	  vastus	  lateralis	  biopsies	  were	  taken	  from	  the	  exercised	  and	  non-­‐exercised	  (control,	  dominant)	  legs.	  On	  each	  of	  the	  following	  5	  days,	  participants	  returned	  to	  the	  laboratory	  to	  have	  blood	  drawn	  for	  creatine	  kinase	  (CK)	  activity	  analysis,	  soreness	  assessed,	  and	  strength	  measured.	  
	  
MM	  Study	  Design	  This	  study	  was	  used	  to	  generate	  gene	  expression	  profiles	  at	  3h	  and	  48h	  post-­‐ECC.	  The	  details	  of	  this	  study	  have	  been	  reported	  previously	  (191,	  192).	  In	  brief,	  this	  study	  consisted	  of	  four	  visits	  over	  the	  course	  of	  approximately	  10d	  (Table	  4.1).	  The	  first	  visit	  served	  to	  familiarize	  subjects	  to	  the	  Biodex	  System	  3	  dynamometer,	  an	  initial	  control	  muscle	  biopsy	  (non-­‐exercised	  left	  leg)	  was	  taken,	  and	  blood	  was	  collected	  for	  CK	  analysis.	  All	  muscle	  biopsies	  were	  collected	  from	  the	  vastus	  lateralis	  and	  were	  taken	  from	  two	  distinct	  anatomical	  sites	  at	  least	  6cm	  apart.	  Eight	  days	  later,	  subjects	  returned	  to	  the	  lab	  for	  the	  exercise	  visit.	  At	  this	  visit,	  a	  second	  control	  biopsy	  was	  collected	  (non-­‐exercised	  leg,	  control	  sample	  used	  in	  the	  current	  study)	  followed	  by	  the	  exercise.	  Three	  and	  48h	  hours	  later,	  a	  muscle	  biopsy	  was	  collected	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from	  the	  exercised	  leg,	  as	  well	  as	  blood	  for	  CK	  analysis.	  At	  all	  biopsy	  visits,	  subjects	  came	  to	  the	  laboratory	  fasted	  and	  2h	  prior	  to	  the	  biopsy	  consumed	  a	  standardized	  meal	  consisting	  of	  350	  kcals	  (approximately	  57%	  carbohydrate,	  28%	  fat,	  and	  15%	  protein).	  Subjects	  also	  consumed	  a	  standardized	  235mL	  defined	  formula	  diet	  (Boost®)	  2h	  before	  the	  exercise.	  	  
VAL-­‐48h	  Study	  Design	  To	  confirm	  and	  extend	  findings	  from	  the	  transcriptomic	  analyses,	  skeletal	  muscle	  samples	  from	  VAL-­‐3h	  and	  VAL-­‐48h	  were	  tested	  using	  mRNA	  and	  protein	  analyses.	  Subjects	  in	  the	  validation	  cohort,	  VAL-­‐3h	  were	  all	  subjects	  in	  UM-­‐3h	  and	  did	  not	  differ	  significantly	  from	  the	  full	  UM-­‐3h	  cohort	  for	  subject	  demographics	  or	  ECC	  response.	  VAL-­‐48h	  consisted	  of	  six	  visits	  over	  the	  course	  of	  13-­‐15d	  (Table	  4.1).	  Briefly,	  once	  enrolled	  in	  the	  study,	  subjects	  performed	  a	  familiarization	  session	  with	  a	  Biodex	  dynamometer,	  which	  was	  later	  used	  for	  strength	  testing	  and	  exercise.	  Visit	  2,	  2-­‐4	  days	  later,	  consisted	  of	  strength	  testing	  of	  the	  knee	  flexors	  and	  extensors,	  eccentric	  exercise	  of	  the	  knee	  extensors,	  and	  post-­‐exercise	  strength	  testing.	  Two	  days	  after	  the	  exercise	  session	  (Visit	  4),	  subjects	  returned	  to	  the	  laboratory	  for	  muscle	  biopsies.	  Strength	  testing	  was	  repeated	  at	  1,	  4,	  and	  9d	  post-­‐exercise	  (1d	  pre-­‐biopsy	  and	  2	  and	  7d	  post-­‐biopsy;	  Visits	  3,	  5,	  and	  6,	  respectively).	  	  
Eccentric	  Exercise	  	  In	  each	  cohort	  (UM-­‐3h,	  MM,	  and	  VAL-­‐48h),	  subjects	  performed	  maximal	  eccentric	  exercise	  (ECC)	  of	  the	  knee	  extensors	  on	  a	  Biodex	  dynamometer.	  Subjects	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were	  verbally	  encouraged	  to	  exert	  maximal	  effort	  through.	  For	  exercise	  and	  strength	  testing,	  UM-­‐3h,	  subjects	  were	  randomized	  to	  use	  either	  their	  dominant	  or	  non-­‐dominant	  leg,	  while	  subjects	  in	  VAL-­‐48h	  used	  their	  non-­‐dominant	  leg	  only.	  All	  subjects	  performed	  100	  (10	  sets	  of	  10	  repetitions)	  contractions	  with	  the	  eccentric	  resistance	  set	  at	  30°/sec.	  The	  other	  leg	  served	  as	  a	  control	  and	  did	  not	  perform	  the	  exercise.	  Each	  repetition	  was	  approximately	  4sec	  in	  length	  with	  a	  75°	  range	  of	  motion,	  was	  followed	  by	  10sec	  of	  rest,	  and	  a	  1min	  rest	  followed	  each	  10-­‐repetition	  set.	  In	  MM,	  subjects	  performed	  the	  exercise	  at	  a	  more	  rapid	  pace	  (120°/sec)	  and	  did	  150	  (15	  sets	  of	  10	  repetitions)	  contractions	  using	  the	  right	  leg	  only	  (regardless	  of	  leg	  dominance).	  Each	  repetition	  was	  approximately	  1sec	  in	  length	  with	  a	  60°	  range	  of	  motion,	  performed	  continuously	  within	  each	  set	  (no	  rest	  between	  repetitions),	  and	  each	  15-­‐repetition	  set	  was	  separated	  by	  1min	  of	  rest.	  Additional	  information	  on	  both	  studies	  has	  been	  previously	  published	  (137,	  192,	  372).	  	  
Strength	  Loss,	  Creatine	  Kinase	  Activity	  and	  DOMS	  Subjects	  performed	  strength	  measurements	  on	  the	  Biodex	  prior	  to	  and	  following	  the	  exercise	  for	  UM-­‐3h	  (5min,	  1,	  and	  2d	  post-­‐ECC)	  and	  VAL-­‐48h	  (5min	  and	  1d	  post-­‐ECC)	  to	  verify	  the	  exercise	  caused	  muscle	  damage.	  Details	  for	  UM-­‐3h	  have	  been	  previously	  reported	  (137,	  372).	  For	  both	  UM-­‐3h	  and	  VAL-­‐48h,	  subjects	  sat	  in	  the	  Biodex	  with	  the	  exercise	  leg	  strapped	  in	  to	  prevent	  extraneous	  movement.	  Subjects	  performed	  maximal	  isometric	  (0°/sec)	  contractions	  that	  were	  four	  seconds	  in	  length,	  three	  each	  for	  extension	  and	  flexion,	  with	  a	  minute	  of	  rest	  between	  contractions.	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In	  each	  cohort,	  subjects	  had	  blood	  drawn	  and	  tested	  for	  creatine	  kinase	  (CK)	  levels	  as	  an	  indicator	  that	  the	  exercise	  had	  elicited	  damage.	  Blood	  was	  collected	  prior	  to	  exercise,	  at	  1d	  (UM-­‐3h	  and	  VAL-­‐48h)	  and	  2d	  (UM-­‐3h	  and	  MM)	  after	  ECC.	  CK	  activity	  was	  analyzed	  using	  an	  ELISA-­‐based	  activity	  assay.	  	  Post-­‐exercise	  soreness	  (previously	  reported	  (137,	  372))	  was	  assessed	  in	  UM-­‐3h	  and	  peak	  soreness	  over	  the	  course	  of	  the	  study	  was	  used	  in	  the	  current	  study	  for	  correlation	  analyses	  with	  biochemical	  data.	  Soreness	  was	  not	  evaluated	  in	  VAL-­‐48h.	  To	  evaluate	  muscle	  soreness	  prior	  to	  and	  on	  days	  1-­‐5	  post-­‐ECC,	  subjects	  performed	  two	  one-­‐legged	  squats,	  from	  standing	  to	  sitting	  in	  a	  chair	  then	  again	  to	  standing,	  at	  a	  controlled	  pace	  (approximately	  1s	  each	  portion	  of	  the	  movement)	  using	  the	  exercise	  leg,	  only.	  Subjects	  then	  marked	  a	  single,	  vertical	  line	  on	  a	  visual	  analog	  scale	  (100mm)	  corresponding	  with	  their	  amount	  of	  perceived	  peak	  soreness—no	  soreness	  was	  indicated	  by	  a	  “0”	  and	  maximal	  soreness	  was	  “100”.	  The	  distance	  (mm)	  from	  0	  provided	  a	  semi-­‐quantitative	  measure	  of	  soreness.	  	  	  
Muscle	  Biopsies	  Biopsy	  procedures	  were	  similar	  for	  all	  cohorts	  and	  have	  been	  reported	  previously	  (137,	  193).	  Briefly,	  Bergström	  percutaneous	  needle	  biopsies	  were	  obtained	  from	  the	  vastus	  lateralis	  under	  local	  anesthetic	  (lidocaine)	  with	  suction.	  Approximately	  100-­‐150mg	  of	  tissue	  was	  collected	  at	  each	  biopsy	  site.	  Once	  removed,	  fat	  and	  connective	  tissue	  was	  dissected	  from	  the	  skeletal	  muscle,	  the	  samples	  were	  flash-­‐frozen	  in	  liquid	  nitrogen,	  and	  stored	  at	  -­‐86°C	  until	  processed.	  A	  total	  of	  two	  biopsies	  were	  collected	  from	  each	  subject	  in	  UM-­‐3h	  and	  VAL-­‐48h	  (one	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from	  each	  leg—both	  collected	  at	  the	  post-­‐exercise	  visit)	  and	  four	  in	  MM	  (two	  from	  each	  leg—control	  samples	  collected	  prior	  to	  exercise).	  Control	  samples	  were	  collected	  from	  the	  non-­‐exercised	  leg	  and	  experimental	  from	  the	  exercised	  leg	  (both	  studies).	  For	  MM,	  the	  second	  pre-­‐exercise	  biopsy	  was	  used	  as	  the	  control	  sample	  for	  microarray	  analysis.	  	  
Transcriptome	  Analyses	  
RNA	  Extraction	  and	  Microarray	  Hybridization	  For	  the	  two	  microarray	  studies,	  total	  RNA	  was	  isolated	  using	  standard	  TRIzol	  extraction	  protocols	  (Invitrogen,	  Carlsbad,	  CA).	  For	  UM-­‐3h	  (137,	  372)),	  the	  Oligotex	  mRNA	  Midi	  kit	  (Qiagen,	  Valencia,	  CA)	  was	  used	  to	  isolate	  mRNA.	  The	  Ovation	  Pico	  WTA	  system	  (NuGen,	  San	  Carlos,	  CA)	  was	  used	  to	  create	  double-­‐stranded	  cDNA	  and	  subsequent	  cRNA.	  Finally,	  Cy3-­‐labeled	  cRNA	  (1.65ug)	  was	  hybridized	  to	  Agilent	  Whole	  Genome	  microarrays	  (Agilent,	  Santa	  Clara,	  CA).	  All	  procedures	  were	  performed	  at	  Gene	  Logic	  (Gaithersburg,	  MD)	  according	  to	  standard	  manufacturer	  procedures.	  This	  system	  allowed	  for	  the	  testing	  of	  ~41,000	  genes.	  Raw	  data	  from	  the	  Agilent	  system	  was	  output	  as	  “txt”	  files	  for	  import	  into	  analysis	  software.	  Gene	  expression	  changes	  were	  filtered	  by	  p-­‐value	  (p<0.01)	  and	  fold	  change.	  For	  MM,	  extracted	  RNA	  was	  treated	  with	  DNase	  I	  (Ambion	  Inc.,	  Austin,	  TX)	  and	  then	  analyzed	  for	  purity	  on	  a	  Nanodrop	  spectrophotometer	  and	  an	  Agilent	  Bioanalyzer	  Nano	  Chip	  System.	  Samples	  that	  passed	  purity	  testing	  were	  then	  hybridized	  (850ng	  biotin-­‐labeled	  cRNA)	  according	  to	  manufacturer’s	  instructions	  to	  Human	  Ref-­‐8	  BeadChips	  (Illumina).	  This	  system	  allowed	  the	  testing	  of	  ~23,000	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genes,	  and	  the	  results	  were	  obtained	  using	  a	  BeadStation	  array	  reader	  (Illumina).	  The	  signal	  was	  calculated	  using	  GenomeStudio	  (Illumina),	  and	  the	  raw	  data	  (in	  Excel	  format)	  was	  transferred	  directly	  from	  a	  study	  investigator	  at	  McMaster	  University.	  Further	  details	  can	  be	  found	  in	  a	  previous	  report	  (192).	  Gene	  expression	  changes	  were	  filtered	  by	  p-­‐value	  (p<0.01).	  	  All	  microarray	  results	  were	  re-­‐analyzed	  from	  the	  original	  raw	  data	  files	  (downloaded	  from	  the	  GEO	  website)	  to	  standardize	  the	  analysis	  methods	  across	  studies.	  The	  raw	  data	  were	  log	  transformed	  and	  then	  evaluated	  by	  analysis	  of	  variance	  (UM-­‐3h)	  and	  repeated	  measures	  analysis	  of	  variance	  (MM)	  with	  Partek	  Genomics	  Suite	  software	  (6.13.1106).	  A	  Fisher’s	  Least	  Significant	  Difference	  test	  was	  used	  as	  the	  contrast	  method	  to	  compare	  between	  samples	  for	  UM-­‐3h	  (control	  and	  exercise)	  and	  among	  three	  time	  points	  for	  MM	  (baseline	  v	  3h,	  baseline	  v	  48h,	  and	  3	  v	  48h).	  For	  MM,	  the	  second	  control	  leg	  biopsy	  (collected	  at	  the	  “exercise”	  visit)	  was	  used	  as	  the	  baseline	  sample.	  The	  datasets	  were	  then	  filtered	  for	  significance	  as	  described	  above	  and	  imported	  into	  the	  Ingenuity	  Pathway	  Analysis	  software.	  Datasets	  were	  not	  filtered	  by	  False	  Discovery	  Rate	  to	  allow	  more	  robust	  sets	  to	  be	  analyzed	  by	  pathway	  analysis,	  which	  naturally	  filters	  out	  false	  positive	  results	  (as	  random	  false	  positive	  results	  would	  not	  be	  biologically	  linked	  to	  the	  bulk	  of	  the	  true	  results).	  	  
	  
Biological	  Pathway	  Analysis	  Ingenuity	  Pathway	  Analysis	  (IPA)	  software	  (Ingenuity	  Systems,	  Redwood	  City,	  CA;	  v	  18841524)	  analyzed	  gene	  expression	  patterns	  to	  identify	  functional	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pathways	  altered	  following	  ECC	  and	  create	  a	  theoretical	  model	  to	  explain	  differences	  between	  early	  and	  late	  exercise	  responses.	  IPA	  queries	  genes	  from	  an	  imported	  dataset	  for	  inter-­‐relationships	  with	  other	  genes	  and	  functional	  pathways	  using	  existing	  literature.	  Using	  Fischer’s	  exact	  test,	  IPA	  determines	  if	  the	  probability	  of	  association	  between	  the	  uploaded	  genes	  and	  existing	  cellular	  and	  molecular	  functions	  is	  due	  to	  chance.	  	  I	  investigated	  genes,	  functions,	  and	  pathways	  that:	  1)	  were	  shared	  between	  datasets	  at	  the	  3h	  time	  point;	  and	  2)	  differed	  between	  time	  points	  (3	  and	  48h).	  To	  do	  this	  I	  first	  performed	  individual	  analyses	  on	  the	  three	  microarray	  datasets	  (each	  time	  point	  for	  all	  studies—UM-­‐3h,	  MM-­‐3h,	  and	  MM-­‐48h).	  Next,	  I	  performed	  a	  comparison	  analyses	  on	  UM-­‐3h	  and	  MM-­‐3h	  to	  determine	  similarities	  and	  differences	  in	  the	  3h	  response.	  Finally,	  I	  performed	  a	  comparison	  analysis	  on	  all	  three	  datasets	  to	  determine	  similarities	  and	  differences	  between	  time	  points.	  To	  more	  specifically	  identify	  important	  and	  novel	  functions,	  pathways,	  regulators,	  and	  genes	  for	  additional	  testing,	  I	  used	  four	  primary	  tools	  from	  IPA:	  1)	  Canonical	  Pathways	  compares	  uploaded	  datasets	  to	  previously	  defined	  and	  classically	  characterized	  elements	  in	  defined	  signaling	  pathways;	  2)	  Diseases	  and	  Bio	  Functions	  compares	  the	  uploaded	  dataset	  to	  defined	  functional	  categories	  or	  known	  groups	  of	  disease-­‐related	  genes;	  3)	  Upstream	  Regulators	  identifies	  upstream	  regulatory	  molecules	  (ie.,	  proteins,	  RNAs)	  that	  map	  to	  multiple	  uploaded	  genes;	  and	  4)	  Regulator	  Effects	  uses	  predicted	  changes	  in	  regulators	  common	  to	  multiple	  genes	  in	  the	  uploaded	  dataset	  to	  predict	  functional	  outcomes	  downstream.	  These	  tools	  categorize	  and	  organize	  the	  data	  to	  help	  identify	  overarching,	  important,	  novel,	  or	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dysregulated	  themes	  and	  relationships	  between	  signaling	  and	  functions	  throughout	  the	  datasets.	  The	  primary	  determinant	  criteria	  for	  further	  investigation	  were	  z-­‐scores,	  which	  indicate	  the	  consistency	  and	  directionality	  of	  the	  predicted	  relationship,	  and	  p-­‐value	  (significance).	  Specific	  numerical	  criteria	  (Table	  4.2)	  were	  used	  to	  filter	  results	  from	  the	  above	  tools.	  Slight	  differences	  in	  cut-­‐off	  values	  within	  specific	  criteria	  are	  due	  to	  the	  size	  of	  the	  datasets.	  The	  final,	  filtered	  data	  was	  used	  to	  create	  a	  theoretical	  model	  to	  help	  explain	  the	  differences	  between	  the	  early	  (3h)	  and	  late	  (48h)	  secondary	  damage	  phases	  and	  mechanisms	  that	  may	  underlie	  the	  development	  and	  resolution	  of	  DOMS.	  This	  model	  was	  further	  explored	  with	  focused	  RNA	  (polymerase	  chain	  reaction)	  and	  protein	  analysis.	  	  	  
Validation	  Studies	  
RNA	  Analyses	  RNA	  isolation	  and	  cDNA	  synthesis	  for	  VAL-­‐3h	  were	  described	  above.	  For	  VAL-­‐48h,	  total	  RNA	  was	  extracted	  using	  the	  standard	  TRIzol	  protocol,	  the	  quality	  and	  quantity	  of	  which	  were	  tested,	  in	  duplicate,	  using	  spectrophotometry	  (Nanodrop,	  Wilmington,	  DE).	  Samples	  were	  diluted	  in	  TE	  buffer	  (pH	  8.0)	  and	  quality	  was	  assessed	  using	  the	  260/280	  ratio	  with	  an	  optimal	  ratio	  above	  1.8—an	  additional	  clean	  up	  step	  was	  performed	  using	  the	  RNeasy	  kit	  on	  any	  samples	  below	  1.5,	  which	  raised	  ratios	  above	  the	  threshold.	  mRNA	  was	  isolated	  using	  the	  RNeasy	  RNA	  isolation	  kit	  (Qiagen,	  Valencia,	  CA)	  according	  to	  manufacturer’s	  instructions.	  The	  mRNA	  (0.5ug)	  was	  then	  transcribed	  to	  cDNA	  using	  manufacturer’s	  instructions.	  
	  	  112	  
For	  qRT-­‐PCR,	  cDNA	  was	  synthesized	  using	  the	  RT2	  First	  Strand	  cDNA	  synthesis	  kit,	  primed	  with	  random	  hexamers	  (SABiosciences,	  a	  part	  of	  Qiagen,	  Valencia,	  CA).	  For	  PCR	  arrays,	  cDNA	  synthesis	  was	  performed	  with	  a	  RevertAid	  First	  Strand	  cDNA	  synthesis	  kit,	  also	  primed	  with	  random	  hexamers	  (Fermentas,	  Thermo	  Scientific).	  	  	  
PCR	  Arrays	  PCR	  array	  analysis	  was	  used	  to	  filter	  findings	  from	  the	  transcriptome	  analyses	  to	  extend	  these	  to	  48h	  post-­‐ECC.	  A	  custom-­‐designed	  PCR	  array	  was	  used	  to	  analyze	  expression	  differences	  between	  control	  and	  exercise	  legs	  for	  44	  genes	  of	  interest	  in	  the	  VAL-­‐48h	  cohort.	  These	  genes	  were	  chosen	  to	  investigate	  categories	  of	  protein	  function	  that	  were	  hypothesized	  to	  differ	  between	  time	  points	  based	  on	  previous	  studies	  in	  muscle	  and	  the	  microarray	  data	  from	  UM-­‐3h	  and	  MM:	  apoptosis,	  cell	  cycle,	  hyperalgesia,	  inflammation,	  muscle	  structure,	  myogenesis,	  nitric	  oxide	  signaling,	  and	  vascular	  health/angiogenesis	  (27,	  55,	  65,	  133,	  136,	  148,	  190,	  335,	  346,	  369).	  	  Because	  of	  the	  large	  number	  of	  genes	  of	  interest,	  this	  assay	  was	  performed	  as	  a	  multiplex	  using	  a	  single	  well	  per	  gene	  and	  so	  was	  considered	  to	  represent	  a	  secondary	  screening	  tool.	  Therefore,	  genes	  chosen	  from	  transcriptome	  analyses	  for	  full	  validation	  and	  model	  extension	  were	  not	  included	  here	  and	  instead	  were	  tested	  directly	  via	  qRT-­‐PCR.	  After	  it	  was	  combined	  with	  the	  RT2	  SYBR	  Green	  qPCR	  master	  mix,	  cDNA	  (25ng	  final	  concentration)	  was	  added	  to	  a	  microplate	  containing	  primer	  sequence	  sets	  (10uM	  concentration)	  to	  each	  gene	  of	  interest.	  The	  average	  threshold	  cycle	  (Ct)	  was	  determined	  after	  40	  amplification	  cycles	  on	  a	  MX3000p	  Real-­‐Time	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PCR	  System	  (Stratagene,	  La	  Jolla,	  CA,	  USA)	  and	  normalized	  to	  the	  average	  of	  2	  housekeeping	  genes	  that	  are	  not	  affected	  by	  exercise:	  β-­‐actin	  and	  β-­‐2-­‐microglobulin	  (B2M)	  (193).	  The	  resultant	  ΔCt	  for	  the	  exercise	  leg	  was	  then	  subtracted	  from	  the	  ΔCt	  for	  the	  control	  leg,	  yielding	  ΔΔCt.	  This	  value	  was	  transformed	  into	  fold	  change	  for	  visualization	  purposes.	  	  
qRT-­‐PCR	  qRT-­‐PCR	  analysis	  was	  used	  on	  samples	  from	  VAL-­‐3h	  and	  VAL-­‐48h	  to	  both	  confirm	  microarray	  findings	  from	  IPA	  analyses	  and	  to	  further	  extend	  the	  understanding	  of	  which	  pathways	  were	  altered	  at	  48h	  post-­‐exercise.	  Due	  to	  limited	  sample	  availability,	  only	  mRNA	  from	  a	  sub-­‐set	  of	  subjects	  was	  used	  from	  VAL-­‐48h	  (five	  subjects)	  studies.	  Prior	  to	  qRT-­‐PCR	  analysis,	  primers	  were	  tested	  and	  the	  appropriate	  product	  size	  confirmed	  using	  2%	  agarose	  gel	  electrophoresis	  and	  ethidium	  bromide	  staining.	  SsoFast	  Evagreen	  master	  mix	  (Biorad,	  Hercules,	  CA)	  was	  used	  for	  all	  PCR	  analyses	  to	  measure	  the	  relative	  levels	  of	  TNF	  receptor-­‐associated	  factor	  6	  (TRAF6),	  NFκB	  inhibitor-­‐alpha,	  also	  known	  as	  I	  kappa	  B-­‐alpha	  (NFKBIA/IκB),	  and	  nerve	  growth	  factor	  (NGF).	  cDNA	  (25ng/uL	  final	  concentration)	  samples	  from	  control	  and	  exercised	  muscles	  were	  amplified	  in	  triplicate	  for	  each	  gene	  of	  interest	  on	  96-­‐well	  plates.	  No	  template	  controls	  were	  also	  processed.	  Melting	  curves	  were	  generated	  and	  analyzed	  for	  primer	  dimers	  following	  each	  reaction;	  no	  primer	  dimers	  or	  abnormalities	  were	  found	  in	  the	  melting	  curves	  of	  any	  of	  the	  reactions.	  The	  average	  of	  the	  triplicate	  cycle	  thresholds	  (Ct)	  values	  was	  used	  for	  time	  point	  comparisons	  with	  the	  ΔΔCt	  method.	  All	  Ct	  values	  were	  normalized	  to	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the	  housekeeping	  gene	  β-­‐2	  microglobulin	  (B2M),	  which	  has	  been	  validated	  to	  remain	  unchanged	  after	  eccentric	  exercise	  (193).	  Primers	  for	  genes	  of	  interest	  are	  shown	  in	  Table	  4.3.	  
	  
Nuclear	  Protein	  Extraction	  and	  NFκB	  Activity	  Assay	  NFκB	  activity	  was	  tested	  via	  DNA-­‐binding	  activity	  in	  the	  VAL-­‐48	  cohort	  and	  compared	  with	  prior	  measures	  from	  the	  UM-­‐3h	  cohort.	  Nuclear	  protein	  was	  extracted	  by	  homogenizing	  muscle	  samples	  in	  low-­‐salt	  lysis	  buffer	  (10uM	  HEPES,	  pH	  7.6;	  10mM	  KCl;	  1.5mM	  MgCl2;	  0.1mM	  EDTA;	  0,1mM	  DTT;	  0.5M	  PMSF;	  50uL	  protease	  inhibitor	  cocktail;	  and	  0.5mg/ml	  benzamidine).	  This	  slurry	  was	  put	  through	  two	  freeze/thaw	  cycles	  in	  an	  ethanol/dry	  ice	  bath	  and	  a	  water	  bath	  at	  37°C,	  mixed	  briefly	  by	  vortexing,	  and	  then	  centrifuged	  for	  3min	  at	  670	  x	  g	  at	  4°C.	  Cytosolic	  proteins	  (supernatant)	  were	  removed	  and	  stored.	  The	  remaining	  nuclear	  pellet	  was	  resuspended	  in	  a	  high-­‐salt	  lysis	  buffer	  (20mM	  HEPES,	  pH	  7.6;	  420mM	  NaCl;	  1mM	  EDTA;	  25%	  glycerol;	  1mM	  DTT;	  and	  5ul	  protease	  inhibitor	  cocktail).	  After	  30min	  incubation	  on	  ice,	  the	  samples	  were	  centrifuged	  at	  4°C	  for	  5min	  at	  12,560	  x	  g.	  The	  resultant	  supernatant	  with	  nuclear	  proteins	  was	  removed	  and	  stored	  at	  -­‐80°C	  until	  later	  protein	  quantification	  with	  a	  standard	  BCA	  assay	  (Pierce,	  Rockford,	  IL,	  USA).	  NFκB	  DNA	  binding	  activity	  of	  nuclear	  proteins	  was	  analyzed	  using	  a	  commercially	  available	  ELISA-­‐based	  TransAM	  NFκB	  p65	  assay	  (Active	  Motif,	  Carlsbad,	  CA)	  per	  manufacturer’s	  instructions.	  All	  procedures	  were	  performed	  in	  duplicate	  at	  room	  temperature,	  with	  the	  average	  of	  the	  two	  values	  used	  for	  statistical	  analyses.	  Briefly,	  nuclear	  extracts	  (5ug	  of	  protein)	  were	  incubated	  for	  1h	  
	  	  115	  
in	  wells	  containing	  a	  consensus	  binding	  sequence	  for	  NFκB	  (5’-­‐GGGACTTTCC-­‐3’).	  After	  washing,	  the	  same	  wells	  were	  incubated	  for	  an	  additional	  hour	  with	  a	  primary	  antibody	  against	  the	  p65	  subunit.	  The	  wells	  were	  washed	  again,	  incubated	  with	  a	  horseradish	  peroxidase	  conjugated	  secondary	  antibody	  for	  1h,	  washed,	  and	  subjected	  to	  a	  colorimetric	  reaction	  through	  the	  addition	  of	  a	  developing	  solution	  for	  5min	  followed	  by	  the	  addition	  of	  a	  stop	  solution.	  A	  multiwell	  microplate	  reader	  (FLUOstar	  Optima;	  BMG	  Labtech,	  Offenburg,	  Germany)	  was	  used	  to	  measure	  the	  absorbance	  of	  the	  plate	  at	  450nm	  with	  a	  correction	  wavelength	  of	  655nm.	  	  
	  
Statistical	  Analyses	  for	  Validation	  Studies	  qRT-­‐PCR,	  PCR	  array,	  and	  NFκB	  activity	  assays	  were	  analyzed	  for	  significant	  differences	  with	  exercise	  and	  over	  time	  using	  a	  2-­‐factor	  (group*exercise)	  repeated-­‐measures	  analysis	  of	  variance	  (RM-­‐ANOVA	  (92)).	  For	  PCR	  array,	  qRT-­‐PCR,	  and	  NFκB	  activity	  analysis,	  the	  raw	  data	  were	  analyzed	  with	  SAS	  statistical	  software	  (Version	  9.3;	  SAS	  Institute,	  Cary,	  NC).	  Post-­‐hoc	  analysis	  was	  performed	  using	  Tukey’s	  HSD	  (345).	  Pearson	  product-­‐moment	  correlations	  were	  performed	  using	  SAS	  (274).	  Data	  are	  presented	  as	  means	  ±	  standard	  error,	  and	  significance	  was	  set	  at	  p<0.05.	  FDR	  was	  performed	  on	  PCR	  arrays	  to	  account	  for	  multiple	  testing,	  resulting	  in	  more	  stringent,	  adjusted	  significance	  criteria	  (p<0.002).	  
	  
Results	  All	  subjects	  in	  these	  studies	  conformed	  to	  their	  respective	  study	  requirements	  and	  completed	  the	  exercise	  protocols	  successfully.	  Subject	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characteristics	  are	  presented	  in	  Table	  4.4.	  There	  were	  no	  significant	  differences	  between	  study	  groups	  in	  terms	  of	  participant	  height,	  weight,	  body	  mass	  index	  (BMI),	  or	  age.	  
	  
Strength	  Loss,	  Creatine	  Kinase	  Activity,	  and	  DOMS	  Isometric	  strength	  was	  tested	  before	  and	  after	  exercise	  in	  UM-­‐3h	  and	  VAL-­‐48h,	  but	  not	  in	  MM.	  These	  data	  have	  been	  previously	  reported	  for	  UM-­‐3h	  (137,	  372),	  with	  subjects	  experiencing	  an	  average	  of	  30.1%	  and	  42.1%	  strength	  loss	  at	  5min	  and	  1d	  post-­‐ECC,	  respectively	  (p<0.05	  vs	  pre-­‐ECC).	  Subjects	  from	  the	  sub-­‐cohort	  VAL-­‐3h	  sustained	  31.6%	  loss	  at	  5min	  after	  exercise	  and,	  at	  1d,	  48.9%.	  For	  VAL-­‐48h,	  average	  strength	  loss	  was	  30.4%	  and	  22.2%	  (p<0.05)	  at	  5	  min	  and	  1d	  post-­‐ECC,	  respectively.	  Plasma	  creatine	  kinase	  (CK)	  activity	  after	  exercise	  was	  previously	  reported	  for	  UM-­‐3h	  (137,	  372)	  and	  MM	  (191,	  192),	  with	  significant	  increases	  in	  each	  study	  in	  response	  to	  exercise	  (p<0.05).	  The	  pre-­‐	  and	  post-­‐exercise	  CK	  activity	  among	  studies	  was	  comparable.	  Before	  exercise,	  CK	  activity	  levels	  were	  168.2±22.2	  for	  UM-­‐3h	  and	  141.3±31.4	  for	  the	  sub-­‐cohort	  VAL-­‐3h,	  104.1±52.4	  for	  MM,	  and	  150.4±36.8	  U/L	  for	  VAL-­‐48h.	  After	  exercise,	  CK	  activity	  increased	  at	  1d	  to	  529.9±77.7	  (UM-­‐3h),	  439.3±104.1	  (VAL-­‐3h),	  and	  477.3±85.4	  (VAL-­‐48h),	  and	  was	  elevated	  at	  2d	  with	  values	  of	  533.0±135.5	  (UM-­‐3h),	  329±56.5	  (VAL-­‐3h),	  and	  489.3±193.2	  (MM).	  Together,	  these	  data	  support	  that	  each	  exercise	  was	  effective	  at	  eliciting	  moderate	  amounts	  of	  muscle	  damage	  in	  all	  studies.	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Biological	  Pathway	  Analysis	  In	  UM-­‐3h,	  4,311	  identifiable	  genes	  met	  the	  inclusion	  criteria	  (p<0.01	  and	  ≥1.2-­‐fold	  change)	  for	  significant	  differential	  expression	  and	  were	  analyzed	  using	  IPA,	  of	  which	  1,748	  were	  upregulated	  and	  2,601	  downregulated.	  For	  MM-­‐3h,	  1,952	  genes,	  of	  approximate	  equal	  distribution	  between	  up	  and	  downregulation	  (963	  up,	  998	  down)	  met	  the	  inclusion	  criteria	  (p<0.01),	  1,433	  of	  which	  differed	  significantly	  in	  their	  expression	  from	  MM-­‐48h	  (758	  up,	  680	  down).	  There	  were	  ~8%	  fewer	  genes	  (1,792	  genes)	  that	  were	  differentially	  expressed	  in	  MM-­‐48h	  than	  in	  MM-­‐3h,	  with	  a	  skewed	  distribution	  toward	  greater	  upregulation	  (~25%:	  1025	  upregulated,	  767	  downregulated).	  Of	  these	  genes,	  1,349	  differed	  significantly	  in	  expression	  from	  MM-­‐3h.	  Biological	  pathway	  analyses	  identified	  a	  much	  greater	  breadth	  and	  number	  of	  functional	  and	  signaling	  changes	  at	  3h	  than	  at	  48h.	  In	  the	  following	  sections,	  I	  present	  overarching	  themes	  (related	  functions,	  pathways,	  and	  regulators)	  that	  were	  most	  strongly	  indicated	  in	  the	  ECC	  response—at	  3h,	  48h,	  shared	  between	  time	  points,	  and	  those	  that	  contrasted	  in	  response	  between	  3	  and	  48h.	  The	  full	  data	  that	  passed	  inclusion	  criteria	  (above	  and	  Table	  4.2)	  are	  shown	  as	  heat-­‐maps	  in	  Tables	  4.5-­‐6,	  arranged	  by	  overarching	  functions	  for	  each	  time	  point	  in	  Figures	  4.1a	  (3h)	  and	  b	  (48h).	  	  	   	  
Early	  (3h)	  Signaling	  Post-­‐ECC	  Unless	  otherwise	  indicated,	  numerical	  data	  presented	  in	  text	  below	  are	  the	  average	  z-­‐scores	  of	  multiple,	  related	  functions	  or	  pathways	  from	  the	  two	  3h	  datasets	  (UM-­‐3h	  and	  MM-­‐3h).	  Positive	  z-­‐scores	  (indicate	  the	  directionality	  and	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consistency	  of	  a	  predicted	  relationship)	  indicate	  an	  increase	  in	  activity/expression	  and	  negative	  z-­‐scores	  indicate	  a	  decrease—the	  farther	  from	  zero,	  the	  more	  consistent	  the	  relationship	  and	  less	  likelihood	  that	  the	  predicted	  relationship	  was	  identified	  by	  chance.	  	  At	  3h	  post-­‐ECC,	  z-­‐scores	  were	  enhanced	  for	  functions	  related	  to	  cell	  survival	  and	  growth,	  specifically:	  1)	  enhanced	  proliferation;	  2)	  decreased	  cell	  death;	  3)	  greater	  cell	  migration;	  and	  4)	  greater	  cell	  survival	  (Figure	  4.1a).	  Enhanced	  cell	  migration	  was	  indicated	  by	  specific	  sub-­‐functions	  such	  as	  cell	  migration,	  movement	  and	  spreading.	  Various	  cell	  types	  were	  associated	  with	  these	  functional	  sub-­‐categories	  including	  fibroblasts,	  connective	  tissue,	  and	  smooth	  muscle	  cells.	  Cardiovascular	  development	  and	  function	  was	  also	  enhanced,	  which,	  along	  with	  proliferation	  and	  migration	  of	  smooth	  muscle	  cells,	  may	  indicate	  angiogenesis	  pathways.	  In	  UM-­‐3h	  only,	  proliferation	  and	  growth	  of	  muscle	  (z-­‐score	  3.9)	  were	  indicated,	  although	  the	  migration	  of	  smooth	  and	  skeletal	  muscle	  cells	  were	  shown	  in	  both	  datasets	  (z-­‐score:	  2.2).	  An	  inflammatory	  response	  was	  also	  indicated,	  specifically	  through	  inflammatory	  invasion,	  and	  also	  with	  enhanced	  immortalization,	  proliferation,	  and	  movement	  (including	  migration	  and	  elongation	  of	  cellular	  protrusions)	  of	  cells	  and	  tissues	  related	  to	  inflammation:	  lymphatic,	  bone	  marrow,	  blood,	  and	  hematopoietic	  progenitor	  cells.	  Pathway	  analysis	  suggested	  these	  various	  functions	  were	  driven	  by	  several	  signaling	  pathways	  that	  involved	  signaling	  mediators	  ERK1/2	  and	  NFκB	  activity.	  Analysis	  of	  the	  identified	  upstream	  pathways	  indicated	  abundant	  early	  ERK1/2	  signaling	  (Tables	  4.5a	  and	  4.6a).	  Of	  regulators	  that	  met	  inclusion	  criteria,	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nine	  are	  regulators	  within	  the	  ERK1/2	  pathway,	  including	  MAPK3	  (ERK1).	  Upstream,	  intracellular	  regulators	  of	  ERK1/2	  activity	  RAF1,	  MAP2K1,	  MAP3K1,	  and	  TRAF6	  were	  indicated	  to	  have	  increased	  activity.	  Further,	  activity	  of	  a	  downstream	  target	  of	  ERK1/2	  and	  key	  transcription	  factor,	  CREB1,	  was	  enhanced	  (z-­‐score:	  5.3).	  Six	  out	  of	  seven	  secreted	  signaling	  molecules	  indicated	  through	  these	  analyses	  to	  have	  enhanced	  activity	  are	  extracellular	  regulators	  that	  activate	  the	  ERK	  pathway,	  including	  EGF	  and	  inflammatory	  cytokines	  IL5,	  IL1β,	  and	  TNF.	  Among	  the	  top	  canonical	  pathways	  indicated	  to	  have	  enhanced	  activity	  were	  the	  ERK/MAPK	  pathway	  itself	  as	  well	  as	  extracellular	  stimulators	  of	  ERK	  (including	  IL6,	  CD40,	  HGF,	  and	  integrins),	  downstream	  products	  (IL8),	  and	  related	  inflammatory	  or	  proliferative	  pathways	  (p38	  MAPK,	  PI3K/AKT)	  (Tables	  4.5b	  and	  4.6b).	  Taken	  together,	  these	  strongly	  indicate	  enhanced	  ERK	  activity	  and	  that	  ERK	  promoted	  pro-­‐inflammatory	  signaling	  prior	  to	  and	  at	  3h	  post-­‐ECC.	  ERK	  and	  several	  interrelated	  pathways	  are	  also	  associated	  with	  pain	  or	  hyperalgesia,	  including	  the	  integrins	  and	  IL6.	  Furthermore,	  these	  analyses	  indicated	  that	  key	  3h	  regulators	  that	  coordinate	  ERK	  activity	  (including	  ERK,	  MAP3K1,	  and	  RAF1)	  suppressed	  differentiation	  (muscle	  cells),	  and	  enhanced	  viability,	  proliferation,	  and	  migration	  (various	  cell	  types).	  These	  analyses	  also	  indicated	  a	  signaling	  role	  (upstream	  and	  at	  3h	  as	  a	  key	  regulator)	  for	  the	  canonical	  (p65)	  NFκB	  pathway	  (activated).	  This	  pathway,	  critical	  to	  pro-­‐inflammatory	  signaling,	  promotes	  transcription	  involved	  in	  proliferation,	  in	  part	  by	  interacts	  with	  ERK	  and	  CREB1—both	  of	  which	  were	  activated.	  Several	  extracellular	  regulators	  of	  NFκB	  activity,	  including	  IL1β,	  were	  also	  indicated	  to	  have	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greater	  activity.	  Intracellular	  regulators	  that	  enhance	  NFκB	  activity	  were	  also	  activated,	  including	  MAP2K1	  and	  TRAF6.	  Although	  the	  NFκB	  canonical	  pathway	  itself	  did	  not	  meet	  inclusion	  criteria,	  other	  canonical	  pathways	  strongly	  associated	  with	  NFκB	  activity	  (primarily	  to	  promote	  its	  activity)	  were	  indicated	  such	  as	  ERK,	  IL8,	  p38	  MAPK,	  and	  CD40.	  Key	  regulators	  identified	  at	  3h	  that	  directly	  relate	  to	  or	  are	  involved	  in	  activating	  the	  NFκB	  pathway	  included	  the	  NFκB	  itself,	  RelA,	  NFKBIB,	  and	  AREG.	  These	  regulators	  were	  identified	  in	  multiple	  pathways	  or	  functions	  and	  are	  also	  related	  to	  ERK	  activity.	  Enhanced	  activity	  of	  other	  inflammatory	  pathways	  at	  3h	  post-­‐ECC	  was	  identified,	  although	  not	  as	  strongly	  as	  ERK	  and	  NFκB,	  including	  upstream	  regulation	  via	  the	  monocyte	  chemotaxis	  ligand	  CXCL12	  and	  receptor	  CXCR4,	  JNK,	  and	  p38	  MAPK.	  Beyond	  the	  pathways	  discussed	  above,	  no	  other	  inflammatory	  canonical	  pathways	  were	  identified	  to	  have	  increased	  or	  decreased	  activity	  at	  3h.	  However,	  analysis	  indicated	  that	  activity	  of	  other	  inflammatory	  regulators	  was	  enhanced	  at3h,	  many	  involved	  in	  ERK	  and	  NFκB	  signaling	  either	  up	  or	  downstream,	  including	  JAK2,	  CXCL12/CXCR4,	  IL2,	  IL2RB,	  IL1,	  CYR61,	  and	  F2RL.	  Downstream	  targets	  of	  these	  and	  the	  aforementioned	  ERK/NFκB-­‐related	  regulators	  were	  upregulated	  and	  are	  involved	  in	  cell	  cycle	  progression	  and	  proliferation	  (e.g.,	  FOS,	  CDKN1B,	  EGFR),	  extracellular	  matrix	  and	  connective	  tissue	  development	  (e.g.,	  CTGF,	  CD44),	  and,	  most	  prevalently,	  inflammation	  (e.g.,	  CYR61,	  CXCL1,	  IL1β,	  IL6,	  NFKBIA,	  NGF).	  The	  most	  dramatically	  induced	  genes	  in	  each	  dataset	  included:	  NR4A3	  (UM-­‐3h:	  30.2-­‐fold;	  MM-­‐3h:	  3.2-­‐fold;	  interacts	  with	  CREB);	  CYR61	  (29.6-­‐fold;	  7.6-­‐fold);	  and	  MAP3K8	  (13.8-­‐fold;	  11.0-­‐fold;	  interacts	  with/activates	  JNK,	  NFκB,	  and	  ERK).	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Shared	  Signaling	  at	  Early	  (3h)	  and	  Late	  (48h)	  Time	  Points	  Post-­‐ECC	  Unless	  otherwise	  indicated,	  z-­‐scores	  presented	  below	  are	  the	  average	  of	  the	  two	  3h	  datasets	  followed	  by	  the	  z-­‐score	  at	  48h	  (UM-­‐3h	  and	  MM-­‐3h/MM-­‐48h).	  Suppressed	  activity	  at	  3h	  and	  48h	  of	  the	  two	  alternative	  Wnt	  signaling	  canonical	  pathways,	  Wnt/Ca++	  (intracellular	  calcium	  signaling)	  and	  PCP	  (cell	  polarity),	  was	  inferred	  (Table	  4.5).	  Analysis	  suggested	  that	  growth	  hormone	  and	  PPAR	  signaling	  were	  also	  suppressed,	  each	  of	  which	  may	  indicate	  attenuated	  JAK/STAT	  signaling—however,	  changes	  to	  that	  pathway	  did	  not	  reach	  statistical	  significance.	  Enhanced	  upstream	  signaling	  in	  all	  three	  datasets	  may	  suggest	  anti-­‐inflammatory	  signaling	  and	  continued	  movement	  toward	  muscle	  differentiation	  at	  or	  beyond	  48h	  via	  MYOD1	  (differentiation)	  and	  anti-­‐inflammatory	  pathways	  including	  IL13,	  TGFβ,	  IL4,	  and	  IL5.	  Yet	  the	  process	  of	  secondary	  damage	  and	  recovery	  is	  a	  continuum,	  and	  upstream	  signaling	  linked	  to	  early	  processes	  were	  also	  suggested	  via	  KRAS	  (proliferation/migration)	  and	  EIF4E	  (proliferation),	  CD38	  (pro-­‐inflammatory	  leukocyte	  migration),	  and	  NFE2L2	  (oxidative	  stress).	  Identified	  functions	  neither	  supported	  nor	  refuted	  these	  data,	  although	  enhanced	  canonical	  pathway	  activity	  did	  lend	  support,	  including	  growth	  factors	  HGF	  and	  PDGF;	  acute	  phase	  response	  signaling;	  PI3K/AKT;	  and	  inflammatory	  signaling	  pathways	  IL6	  and	  p38	  MAPK,	  which	  can	  enhance	  pro-­‐	  or	  anti-­‐inflammatory	  signaling.	  	  
	  	  122	  
Contrasting	  Signaling	  at	  Early	  (3h)	  and	  Late	  (48h)	  Time	  Points	  Post-­‐ECC	  No	  canonical	  pathways	  or	  regulators	  that	  met	  inclusion	  criteria	  were	  indicated	  to	  have	  enhanced	  signaling	  at	  48h	  that	  was	  suppressed	  or	  unchanged	  at	  3h.	  Identified	  functions	  with	  this	  contrasting	  activity	  suggested	  greater	  import	  and	  metabolism	  of	  protein;	  augmented	  tissue	  development	  via	  increased	  mass	  of	  adipose	  and	  connective	  tissue;	  and	  infectious	  disease	  via	  viral	  release.	  The	  latter	  function	  may	  actually	  indicate	  the	  ejection	  of	  phagocytosed	  debris	  from	  inflammatory	  cells.	  	  Only	  a	  handful	  of	  pathways	  and	  functions	  were	  indicated	  as	  enhanced	  at	  3h	  and	  suppressed	  at	  48h.	  Upstream	  regulators	  identified	  with	  this	  activity	  pattern	  are	  involved	  in	  angiogenesis	  (VEGFA)	  and	  inflammatory	  regulation:	  FN1,	  PRL,	  CD24,	  and	  ESRRA	  (Table	  4.6a).	  FN1	  and	  PRL	  are	  generally	  considered	  pro-­‐inflammatory	  and	  PRL	  stimulates	  NFκB	  activity.	  CD24	  and	  ESRRA	  are	  considered	  anti-­‐inflammatory	  through	  their	  roles	  in	  suppressing	  NFκB	  (CD24)	  and	  PPAR	  (ESRRA)	  signaling.	  PPARG,	  a	  regulator	  with	  similar	  activity	  patterns,	  was	  suppressed	  at	  48h,	  although	  PPARG	  canonical	  pathways	  were	  attenuated	  in	  all	  three	  datasets.	  Strictly	  oppositional	  signaling	  of	  canonical	  pathways	  only	  met	  inclusion	  criteria	  for	  cardiac	  hypertrophy	  signaling	  and	  the	  canonical	  Wnt/β-­‐catenin	  pathway	  (Table	  4.6b).	  Two	  canonical	  pathways	  with	  little/no	  change	  at	  3h	  and	  suppression	  at	  48h	  did,	  however,	  meet	  inclusion	  criteria:	  androgen	  signaling	  (stimulates	  NFκB)	  and	  ultraviolet	  (UVA)-­‐induced	  MAPK	  signaling.	  Based	  on	  these	  and	  the	  remaining	  Canonical	  Pathways,	  early	  growth	  and	  pro-­‐inflammatory	  signaling	  is	  followed	  by	  later	  suppression	  of	  each	  processes.	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The	  majority	  of	  signaling	  differences	  were	  due	  to	  enhanced	  3h	  signaling	  and	  little	  or	  no	  corresponding	  changes	  were	  observed	  at	  48h,	  including	  the	  previously	  discussed	  CD40,	  CDK5,	  ERK/MAPK,	  IL8,	  and	  integrin	  signaling	  pathways	  (Table	  4.6).	  These	  pathways	  have	  also	  been	  previously	  associated	  with	  hyperalgesia,	  and	  suggest	  several	  means	  through	  which:	  1)	  there	  is	  a	  shift	  from	  primarily	  pro-­‐	  (3h)	  to	  anti-­‐inflammatory	  signaling	  (48h);	  and	  2)	  hyperalgesia	  may	  be	  stimulated	  and	  resolve	  through	  the	  enhancement	  and	  subsequent	  suppression	  of	  various	  pathways.	  Important	  mediators	  of	  hyperalgesia	  and	  downstream	  targets	  at	  3h	  but	  not	  48h	  included	  a	  number	  of	  interleukins	  and	  NGF	  (see	  Early	  Signaling,	  above).	  	  Together	  these	  data	  implicated	  ERK	  and	  NFκB	  signaling	  as	  important	  contributing	  factors	  during	  the	  secondary	  damage	  phase	  after	  ECC.	  However,	  other	  pathways,	  such	  as	  AKT1,	  and	  functions	  were	  also	  implicated.	  Therefore,	  a	  smaller	  group	  of	  genes	  was	  tested	  using	  the	  more	  directed,	  custom-­‐designed	  PCR	  arrays,	  qRT-­‐PCR,	  and	  the	  canonical	  NFκB	  pathway	  activity	  at	  48h;	  these	  tests	  were	  used	  as	  confirmation	  to	  develop	  a	  more	  specific	  model	  of	  post-­‐exercise	  responses.	  	  
Validation	  Studies	  
PCR	  Arrays	  PCR	  arrays	  indicated	  significant	  upregulation	  of	  two	  genes	  in	  the	  exercised	  leg	  at	  48h	  post-­‐exercise	  as	  compared	  to	  baseline	  (Table	  4.7,	  Supplemental).	  Of	  note,	  AKT1	  mRNA	  (V-­‐Akt	  Murine	  Thymoma	  Viral	  Oncogene	  Homolog	  1,	  also	  known	  as	  Protein	  Kinase	  B	  or	  PKB),	  was	  upregulated	  1.51±0.07-­‐fold	  (p<0.002).	  AKT1	  has	  roles	  in	  cell	  cycle	  regulation	  (inhibiting	  proliferation)	  and	  signaling	  to	  promote	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myogenesis.	  MAP2K1	  was	  upregulated	  2.48±0.36-­‐fold	  (p<0.002)	  post-­‐exercise,	  is	  involved	  in	  proliferation,	  differentiation,	  and	  inflammation	  and	  it	  influences	  downstream	  signaling	  almost	  exclusively	  through	  the	  ERK	  and	  NFκB	  pathways.	  	  
	  
qRT-­‐PCR	  qRT-­‐PCR	  was	  used	  to	  validate	  findings	  from	  the	  transcriptomic	  analyses	  that	  indicated	  potential	  involvement	  of	  NGF	  and	  of	  the	  AKT1,	  NFκB,	  and	  ERK	  pathways	  in	  the	  shift	  from	  the	  early	  to	  late	  phases	  of	  secondary	  damage.	  Samples	  from	  UM-­‐3h	  and	  VAL-­‐48h	  were	  used	  to	  test	  three	  genes:	  TRAF6,	  NFKBIA,	  and	  NGF.	  TRAF6	  regulates	  NFκB	  activity,	  stimulates	  activation	  of	  JNK,	  p38	  MAPK,	  AKT1,	  and,	  less	  commonly,	  ERK1/2	  activity	  (152).	  NFKBIA	  is	  a	  negative	  regulator	  of	  the	  NFκB	  p65	  pathway,	  and	  lies	  downstream	  of	  TRAF6.	  NGF	  can	  stimulate	  activation	  of	  the	  NFκB	  p65	  pathway	  when	  bound	  to	  the	  low-­‐affinity	  receptor,	  p75NTR,	  and	  the	  ERK5	  pathway	  when	  bound	  to	  the	  tyrosine	  receptor	  kinase	  A	  (TrkA)	  in	  endosomal	  transportation,	  and	  sustained	  activity	  of	  the	  ERK1/2	  pathway	  when	  bound	  to	  TrkA	  at	  the	  cell	  surface.	  ERK1/2	  and	  NFκB	  can	  also	  enhance	  the	  expression	  of	  NGF.	  Changes	  to	  TRAF6	  expression	  at	  48h	  could	  indicate	  changes	  to	  the	  aforementioned	  pathways,	  while	  altered	  NFKBIA	  more	  specifically	  affects	  NFκB	  (p65).	  Altered	  NGF	  could	  signal	  changes	  to	  downstream	  pathways	  NFκB	  or	  ERK.	  Due	  to	  sample	  availability,	  six	  subjects	  were	  tested	  from	  UM-­‐3h	  (VAL-­‐3h),	  and	  five	  from	  VAL-­‐48h.	  For	  analysis	  of	  NFKBIA,	  an	  outlier	  was	  removed	  from	  UM-­‐3h.	  Each	  subset	  remained	  statistically	  similar	  to	  the	  total	  cohort	  for	  key	  demographic	  differences	  and	  strength	  loss.	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TRAF6	  was	  not	  differentially	  expressed	  either	  between	  time	  points	  or	  in	  response	  to	  exercise	  at	  either	  3h	  or	  48h	  (fold	  changes	  of	  1.34±0.24	  and	  1.15±0.11,	  respectively).	  Expression	  of	  NFKBIA	  was	  significantly	  altered	  with	  exercise	  (p<0.01),	  with	  a	  decrease	  at	  3h	  (0.56±0.05-­‐fold)	  and	  return	  to	  pre-­‐exercise	  levels	  by	  48h	  (1.15±0.23-­‐fold).	  The	  overall	  expression	  48h	  post-­‐exercise	  was	  greater	  than	  at	  3h	  (p<0.05),	  but	  there	  was	  no	  significant	  difference	  in	  upregulation	  between	  time	  points.	  For	  NGF,	  there	  was	  a	  significant	  upregulation	  after	  exercise	  (p<0.01)	  that	  was	  greater	  at	  3h	  (7.54±2.28-­‐fold)	  than	  at	  48h	  (1.94±	  0.63-­‐fold,	  p<0.05),	  with	  no	  overall	  effect	  of	  time.	  These	  findings	  are	  depicted	  in	  Figure	  4.2.	  	  
	  
NFκB	  Activity	  The	  microarray,	  PCR	  array,	  and	  qRT-­‐PCR	  data	  pointed	  to	  a	  suppression	  of	  NFκB	  p65	  pathway	  activation	  at	  the	  48h	  time	  point.	  I	  compared	  NFκB	  DNA-­‐binding	  activity	  at	  48h	  to	  previously	  measured	  NFκB	  p65	  pathway	  activation	  at	  3h	  post-­‐exercise.	  Hyldahl	  et	  al.	  (137)	  reported	  a	  230.5±51.2%	  increase	  in	  NFκB	  activity	  at	  3h	  after	  ECC	  (Figure	  4.3).	  This	  upregulation	  was	  localized	  primarily	  (95%	  signal)	  to	  non-­‐muscle	  cells.	  In	  contrast,	  at	  48h	  after	  exercise	  NFκB	  activity	  was	  significantly	  suppressed	  (142±10.8%	  of	  the	  control	  leg,	  p<0.05),	  constituting	  an	  approximate	  315%	  difference	  in	  activity	  between	  the	  enhanced	  activation	  early	  and	  the	  later	  decrease.	  To	  test	  the	  relationship	  between	  NFκB	  and	  DOMS,	  early	  NFκB	  percent	  change	  and	  peak	  soreness	  were	  tested	  using	  correlations.	  Soreness	  was	  not	  tested	  in	  VAL-­‐48h,	  so	  later	  NFκB	  activity	  could	  not	  be	  tested	  against	  soreness	  at	  this	  time.	  There	  was	  a	  moderate	  (r=0.55)	  positive	  correlation	  between	  NFκB	  activation	  at	  3h	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and	  later	  peak	  soreness,	  which	  was	  significant	  (p<0.05).	  These	  data	  suggest	  that	  NFκB	  activity	  does	  influence	  DOMS,	  although	  the	  specific	  mechanisms	  through	  which	  this	  occurs	  are	  as	  of	  yet	  unknown.	  	  
	  
Discussion	  In	  this	  study,	  I	  tested	  the	  hypotheses	  that:	  1)	  at	  3h	  post-­‐ECC,	  gene	  expression	  downstream	  of	  pro-­‐inflammatory	  signaling	  such	  as	  IL1,	  IL6,	  and	  would	  increase,	  which	  could	  potentially	  stimulate	  NFκB	  and	  related	  pathways	  to	  promote	  additional	  pro-­‐inflammatory	  signaling;	  2)	  at	  48h	  post-­‐ECC,	  gene	  expression	  would	  favor	  greater	  anti-­‐	  and	  reduced	  pro-­‐inflammatory	  signaling,	  for	  example	  increased	  gene	  expression	  downstream	  of	  anti-­‐inflammatory	  proteins	  and	  cytokines	  such	  as	  IL4	  and	  IL13;	  and	  3)	  expression	  of	  genes	  related	  to	  hyperalgesia	  and/or	  DOMS	  would:	  a)	  increase	  at	  3h;	  and	  b)	  decrease	  but	  remain	  elevated	  above	  baseline/control	  at	  48h	  post-­‐ECC.	  These	  data	  were	  then	  used	  to	  develop	  a	  model	  of	  the	  possible	  inflammatory	  signaling	  pathways	  that	  could	  mediate	  and	  heightened	  DOMS	  observed	  in	  smokers.	  	  My	  first	  hypothesis,	  that	  early	  responses	  after	  ECC	  would	  favor	  pro-­‐inflammatory	  signaling	  including	  NFκB	  and	  related	  pathways,	  was	  supported.	  At	  3h,	  canonical	  signaling	  pathways	  that	  stimulate	  pro-­‐inflammatory	  activity	  and	  downstream	  signaling	  had	  increased	  z-­‐scores—indicating	  greater	  likelihood	  of	  activation.	  These	  pathways,	  including	  IL-­‐8,	  the	  integrins,	  and	  CD40,	  have	  all	  been	  previously	  linked	  to	  ERK1/2	  activity.	  NFκB	  activity	  was	  also	  indicated,	  primarily	  as	  a	  key	  regulator	  of	  numerous	  functions	  and	  pathways,	  although	  primarily	  in	  UM-­‐3h.	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Furthermore,	  NGF,	  which	  can	  mediate	  hyperalgesia,	  was	  identified	  as	  a	  target	  molecule	  at	  this	  time,	  was	  upregulated	  in	  both	  3h	  datasets,	  and	  is	  also	  connected	  to,	  in	  some	  cases	  integrally,	  each	  of	  the	  pro-­‐inflammatory	  signaling	  pathways	  previously	  discussed.	  	  Including	  multiple	  protocols	  enhanced	  the	  study:	  determining	  shared	  responses	  at	  the	  3h	  time	  point,	  independent	  of	  protocol	  differences,	  provides	  a	  better	  understanding	  of	  fundamental	  mechanisms	  early	  after	  muscle	  damage.	  For	  example,	  fibroblast	  growth	  factor	  (FGF)	  signaling	  was	  slightly	  suppressed	  in	  UM-­‐3h	  (z-­‐score:	  -­‐0.39)	  yet	  enhanced	  in	  MM-­‐3h	  (z-­‐score:	  2.33),	  suggesting	  it	  is	  not	  an	  inherent	  signaling	  pathway	  to	  generalized	  ECC	  response.	  Generally,	  the	  support	  for	  evidence	  of	  pro-­‐inflammatory	  signaling	  (indicated	  through	  z-­‐scores	  and	  significance)	  was	  stronger	  in	  UM-­‐3h	  than	  MM-­‐3h,	  for	  example	  IL-­‐8	  signaling	  (z-­‐scores:	  UM-­‐3h,	  1.94;	  MM-­‐3h,	  1.15)	  and	  NFκB	  (as	  an	  upstream	  regulator;	  UM-­‐3h,	  6.20;	  MM-­‐3h	  4.39).	  This	  may	  have	  been	  due	  to	  differences	  in	  study	  protocol—the	  slower	  speed	  of	  each	  eccentric	  contraction	  in	  UM-­‐3h	  (and	  both	  VAL	  groups),	  as	  compared	  to	  MM,	  meant	  a	  more	  prolonged	  time	  under	  tension	  creating	  more	  muscle	  stress	  and,	  possibly	  leading	  to	  greater	  subsequent	  damage	  and	  inflammatory	  responses.	  Altogether	  these	  data	  suggested	  that	  the	  degree	  of	  pro-­‐inflammatory	  response	  is	  dependent	  upon	  the	  level	  of	  muscle	  stress,	  and	  this	  may	  explain	  the	  discrepancy	  in	  inflammatory	  signaling	  (some	  with,	  others	  without)	  between	  reports	  of	  post-­‐ECC	  responses	  (200,	  247,	  267,	  270).	  	  Results	  from	  transcriptome	  analyses	  at	  the	  later	  time	  point	  (48h	  post-­‐ECC)	  were	  less	  clear	  than	  those	  at	  3h	  post-­‐ECC.	  I	  had	  originally	  expected	  signaling	  at	  3h	  to	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promote	  pro-­‐inflammatory	  pathways	  and	  at	  48h	  to	  directly	  oppose	  these	  pathways	  through	  enhanced	  anti-­‐inflammatory	  signaling.	  Instead,	  pro-­‐inflammatory	  pathways	  enhanced	  at	  3h	  were	  simply	  no	  longer	  differentially	  expressed	  at	  48h.	  The	  primary	  exception	  to	  this	  was	  MAPK	  signaling	  (UVA-­‐induced),	  which	  was	  suppressed	  at	  48h,	  yet	  had	  not	  been	  enhanced	  early.	  However,	  given	  that	  the	  earlier,	  induced	  pathways	  were	  related	  to	  ERK	  and	  NFκB	  signaling,	  and	  that	  these	  pathways	  appeared	  to	  have	  ceased	  their	  supranormal	  signaling	  by	  48h,	  suggests	  a	  general	  suppression	  of	  ERK-­‐	  and	  NFκB-­‐related	  signaling.	  The	  disparity	  between	  the	  results	  found	  and	  those	  expected	  may	  have	  stemmed	  from	  the	  exercise	  protocols.	  The	  MM	  study	  protocol	  (faster	  rate	  of	  contraction)	  was	  more	  similar	  to	  a	  fatiguing	  protocol	  while	  the	  UM	  and	  VAL	  study	  protocols	  (greater	  time	  under	  tension)	  were	  developed	  to	  elicit	  a	  higher	  level	  of	  muscle	  stress	  and	  damage.	  Molecular	  responses	  at	  48h	  from	  MM	  support	  greater	  effects	  of	  fatigue	  rather	  than	  high	  levels	  of	  damage.	  While	  this	  did	  provide	  a	  general	  understanding	  of	  processes	  happening	  at	  48h,	  the	  gene	  expression	  differences	  at	  3h	  indicated	  that	  other	  processes	  may	  occur	  at	  48h	  with	  greater	  perturbation.	  Thus,	  to	  more	  fully	  understand	  responses	  to	  damage,	  further	  investigation	  at	  48h	  was	  required	  using	  the	  protocol	  from	  UM/VAL.	  	  To	  filter	  candidate	  pathways	  from	  transcriptome	  analysis	  and	  extend	  these	  to	  the	  48h	  time	  point	  using	  the	  same	  exercise	  protocol	  as	  the	  UM-­‐3h	  dataset,	  PCR	  arrays	  were	  used	  to	  test	  genes	  related	  to	  pathways	  and	  functions	  indicated	  through	  transcriptome	  analysis.	  The	  immediate	  upstream	  regulator	  of	  ERK1/2,	  MAP2K1,	  was	  also	  upregulated	  at	  48h.	  To	  date,	  a	  single	  published	  study	  (335)	  has	  shown	  increased	  activity	  of	  the	  ERK	  pathway	  beyond	  the	  early	  muscle	  damage	  response	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(ERK).	  ERK	  activity	  can	  be	  transient	  or	  sustained,	  each	  of	  which	  initiates	  different	  downstream	  signaling	  (1,	  296).	  Therefore,	  the	  role	  of	  ERK	  at	  48h	  after	  ECC	  may	  differ	  from	  its	  early	  activity.	  qRT-­‐PCR	  was	  then	  used	  in	  an	  attempt	  to	  clarify	  the	  signaling	  at	  48h	  and	  	  provide	  additional	  information	  regarding	  hyperalgesia-­‐related	  signaling.	  	  To	  further	  clarify	  ERK	  and	  NFκB	  signaling	  at	  48h	  post-­‐ECC,	  I	  performed	  qPCR	  analyses	  and	  tested	  NFκB	  DNA-­‐binding	  activity.	  Suppressed	  expression	  of	  NFKBIA	  at	  3h,	  that	  was	  not	  different	  from	  baseline	  (control)	  at	  48h	  from	  baseline,	  support	  the	  transcriptome	  analysis	  results	  indicating	  suppressed	  NFκB	  activity	  at	  the	  late	  time	  point.	  NFκB	  activity	  was	  increased	  at	  3h	  but	  suppressed	  at	  48h	  compared	  to	  controls.	  This	  is	  novel	  finding	  in	  humans	  after	  ECC.	  Research	  has	  previously	  shown	  canonical	  NFκB	  pathway	  activation	  changes	  during	  muscle	  proliferation	  and	  differentiation	  (13),	  in	  which	  this	  pathway	  in	  activated	  early	  and	  stimulates	  both	  proliferation	  and	  pro-­‐inflammatory	  signaling.	  Then,	  approximately	  48h	  post-­‐ECC,	  activity	  is	  attenuated,	  pro-­‐inflammatory	  signaling	  begins	  to	  resolve,	  and	  differentiation	  ensues.	  It	  is	  therefore	  possible	  that	  the	  resolution	  of	  NFκB	  activity	  may	  be	  an	  important,	  if	  not	  critical,	  step	  in	  the	  conclusion	  of	  the	  early	  pro-­‐inflammatory	  phase	  and	  forward	  progress	  toward	  healing	  and	  regeneration.	  In	  addition	  to	  its	  role	  in	  proliferation,	  NFκB	  may	  be	  a	  hyperalgesic-­‐mediator	  (reviewed	  in	  Haddad	  (111)).	  In	  this	  study,	  I	  found	  that	  early	  NFκB	  activity	  was	  moderately	  correlated	  with	  peak	  DOMS	  expression,	  and	  therefore	  may	  be	  involved	  in	  DOMS	  signaling.	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Because	  NGF	  binding	  can	  drive	  ERK	  and	  NFκB	  signaling,	  and	  those	  pathways	  can	  in	  turn	  stimulate	  NGF	  expression,	  I	  extended	  the	  findings	  related	  to	  hyperalgesia	  by	  testing	  NGF	  expression.	  As	  anticipated,	  NGF	  expression	  was	  elevated	  at	  3h	  and,	  while	  somewhat	  attenuated	  in	  degree,	  remained	  so	  at	  48h.	  These	  data	  support	  previous	  research	  regarding	  NGF	  and	  ECC	  (233,	  234)	  and	  extend	  such	  research	  to	  humans	  at	  multiple	  time	  points	  after	  ECC.	  The	  mechanisms	  underlying	  the	  resolution	  of	  DOMS	  are	  poorly	  understood,	  yet	  these	  data	  suggest	  that	  as	  NFκB	  activity	  wanes,	  so	  do	  NGF	  expression	  and	  hyperalgesia.	  Based	  on	  the	  findings	  of	  this	  study,	  I	  have	  developed	  a	  model	  to	  explain	  the	  signaling	  shifts	  between	  early	  and	  late	  phases	  of	  inflammation	  that	  could	  influence	  DOMS.	  In	  this	  model	  (Figures	  4.4	  and	  4.5),	  early	  extracellular	  signaling,	  including	  pro-­‐inflammatory	  cytokines	  and	  NGF,	  stimulate	  activity	  of	  the	  NFκB	  and	  ERK	  pathways,	  resulting	  in	  the	  production	  of	  additional	  pro-­‐inflammatory	  signaling	  molecules.	  Later,	  as	  extracellular	  pro-­‐inflammatory	  (and	  NGF)	  signaling	  wanes,	  so	  does	  NFκB	  activity,	  resulting	  in	  further	  de-­‐activation	  of	  pro-­‐inflammatory	  signaling	  and	  hyperalgesia.	  If	  ERK	  activity	  is	  enhanced	  and,	  if	  so,	  whether	  that	  activity	  is	  transient	  or	  sustained,	  requires	  additional	  study	  in	  future.	  Furthermore,	  the	  specific	  ways	  in	  which	  NGF	  exerts	  its	  downstream	  activity	  (e.g.,	  to	  which	  receptor	  it	  binds	  and	  therefore	  which	  downstream	  pathways	  it	  activates)	  after	  ECC	  are	  currently	  unknown.	  NGF	  binds	  to	  two	  different	  receptors	  and	  can	  instigate	  disparate	  downstream	  signaling	  and	  responses	  based	  on	  that	  binding.	  Therefore,	  a	  greater	  understanding	  of	  NGF	  signaling	  after	  ECC	  is	  warranted	  to	  further	  our	  knowledge	  of	  its	  role	  in	  DOMS.	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These	  analyses	  were	  performed	  to	  develop	  a	  working	  model	  of	  mechanisms	  underlying	  muscle	  damage	  and	  repair	  responses,	  specifically	  DOMS,	  and	  to	  develop	  a	  model	  to	  use	  for	  future	  evaluation	  of	  heightened	  DOMS	  in	  cigarette	  smokers	  after	  ECC.	  In	  a	  previous	  study	  (Dissertation	  Study	  1,	  Chapter	  3)	  I	  found	  that	  smokers	  have	  greater	  peak	  DOMS.	  Smoking	  has	  also	  been	  previously	  associated	  with	  changes	  in	  NGF	  expression	  and	  activity	  (primarily	  enhanced)	  of	  both	  ERK	  and	  NFκB.	  Therefore,	  in	  the	  final	  chapter	  of	  my	  dissertation,	  I	  describe	  the	  results	  of	  a	  study	  designed	  to	  test	  this	  model	  in	  chronic	  cigarette	  smokers	  who	  engaged	  in	  ECC	  in	  order	  to	  elucidate	  the	  cause	  of	  greater	  DOMS	  and	  explore	  possible	  muscular	  consequences	  of	  smoking.
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Tables	  and	  Figures	  	  
Table	  4.1:	  Simplified	  Timeline	  of	  Study	  Visits.	  	  Studies	  were	  performed	  at	  multiple	  sites	  and	  muscle	  samples	  collected	  early	  (3h)	  or	  late	  (48h)	  after	  eccentric	  exercise	  (ECC).	  UM-­‐3h,	  University	  of	  Massachusetts	  Amherst-­‐3h;	  VAL-­‐3h,	  validation	  study	  at	  University	  of	  Massachusetts	  Amherst-­‐3h;	  MM,	  McMaster	  University,	  samples	  at	  both	  3	  and	  48h;	  VAL-­‐48h,	  validation	  study	  at	  University	  of	  Massachusetts	  Amherst-­‐48h.	  CK,	  creatine	  kinase.	  
Time	   Measure	   UM-­‐3h	  VAL-­‐3h	   MM	   VAL-­‐48h	  
Pre-­‐ECC	  	  
CK	   X	   X	   X	  Strength	   X	   	   	  Biopsy	  (control)	   	   X	   	  Soreness	   X	   	   	  
Exercise	  
Pre-­‐exercise	  strength	   X	   	   X	  Biopsy	  (control)	   	   X	   	  Exercise	   X	   X	   X	  Post-­‐exercise	  strength	   X	   	   X	  3h	  post-­‐ECC	   Biopsy	   X	   X	   	  CK	   	   X	   	  1d	  post-­‐ECC	   Soreness	   X	   	   	  CK	   X	   	   X	  Strength	   X	   	   X	  
2d	  post-­‐ECC	   Soreness	   X	   	   	  CK	   X	   X	   	  Strength	   X	   	   	  Biopsy	   	   X	   X	  	  
	  
Table	  4.2.	  Biological	  Pathway	  Analysis	  Criteria.	  	  Criteria	  used	  for	  transcriptome	  analyses	  using	  Ingenuity	  Pathway	  Analysis.	  
See	  Supplemental	  page	  1	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Table	  4.3:	  qRT-­‐PCR	  Primers.	  	  NGF,	  nerve	  growth	  factor;	  NFKBIA,	  Nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  inhibitor,	  alpha;	  TRAF6,	  TNF	  receptor-­‐associated	  factor	  6;	  B2M,	  Beta-­‐2-­‐microglobulin.	  
Target	   Primer	   Reference	  NGF	   	  Fwd:	  5'-­‐	  CAACAGGACTCACAGGAGCA	  -­‐3'	   (2)	  	  Rev:	  5'-­‐	  ACCTCTCCCAACACCATCAC	  -­‐3'	  NFKBIA	   	  Fwd:	  5'-­‐TGG	  CCT	  TCC	  TCA	  ACT	  TCC	  AGA	  ACA-­‐3'	   (137)	  Rev:	  5'-­‐CTC	  AGC	  AAT	  TTC	  TGG	  CTG	  GTT	  GGT	  -­‐3'	  TRAF6	   Fwd:	  5'-­‐TGATAGTGTGGGTGGAACTG-­‐3'	   (282)	  Rev:	  5'-­‐CTCCTTGGACAATCCTTCAG-­‐3'	  B2M	   Fwd:	  5'-­‐TGTCTGGGTTTCATCCATCCGACA-­‐3'	   (137)	  Rev:	  5'-­‐TCACACGGCAGGCATACTCATCTT-­‐3'	  	   	  	  
	  
	  
Table	  4.4:	  Subject	  Characteristics.	  	  Data	  are	  presented	  as	  mean±SEM.	  Body	  mass	  index	  (BMI)	  data	  are	  unavailable	  for	  the	  MM	  study.	  UM-­‐3h,	  University	  of	  Massachusetts	  Amherst-­‐3h;	  VAL-­‐3h,	  validation	  study	  at	  University	  of	  Massachusetts	  Amherst-­‐3h;	  MM,	  McMaster	  University;	  VAL-­‐48h,	  validation	  study	  at	  University	  of	  Massachusetts	  Amherst-­‐48h.	  
	   N	   Age	  (y)	   Height	  (cm)	   Weight	  (kg)	   BMI	  
UM-­‐3h	   35	   20.9±0.5	   178.9±1.2	   80.6±2.9	   25.2±0.8	  
VAL-­‐3h	   6	   19.3±0.6	   174.8±3.2	   78.5±5.3	   26.1±2.0	  
MM	   9	   21±2.4	   181.6±5.6	   73.4±1.5	   -­‐	  
VAL-­‐48h	   9	   22±0.8	   180.7±2.0	   82.2±2.8	   25.9±0.3	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Table	  4.5:	  Early	  and	  Late	  Time	  Points:	  Shared	  Transcriptome	  Responses.	  	  Ingenuity	  Pathway	  Analysis	  of	  microarray	  data	  at	  3	  and	  48h	  post-­‐exercise	  regarding	  (a)	  Upstream	  Regulators	  and	  (b)	  Canonical	  Pathways.	  Data	  are	  presented	  as	  z-­‐scores,	  darker	  color	  greater	  up-­‐	  or	  down-­‐regulation:	  green	  is	  decreased	  activity,	  red	  is	  increased	  activity.	  Gene	  names	  and	  symbols	  from	  the	  National	  Institute	  of	  Health	  (NIH)	  National	  Center	  of	  Biotechnology	  (NCBI)	  database,	  June	  2015.	  *	  p<0.05.	  UM,	  University	  of	  Massachusetts;	  MM,	  McMaster	  University.	  	  
Upstream	  	  
regulator	   Gene	  name	  
UM-­‐3h	   MM-­‐3h	   MM-­‐48h	  	  



















UM-­‐3h	   MM-­‐3h	   MM-­‐48h	  
z-­‐score	  Wnt/Ca+	  pathway	   -­‐1.3	  *	   -­‐1.2	  *	   -­‐2.3	  *	  PCP	  pathway	   -­‐1.6	  *	   -­‐1.7	  *	   -­‐2.2	  Growth	  hormone	  signaling	   -­‐1.2	   -­‐0.6	  *	   -­‐1.4	  PPAR	  signaling	   -­‐2.2	  *	   -­‐0.3	  *	   -­‐1.3	  IL-­‐6	  signaling	   2.5	  *	   2.4	  *	   1.2	  PI3K/AKT	  signaling	   2.2	  *	   0.8	  *	   1.2	  *	  HGF	  signaling	   0.8	  *	   1.7	   1.3	  PDGF	  signaling	   1.1	  *	   1.1	  *	   1.5	  *	  p38	  MAPK	  signaling	   2.3	  *	   1.5	  *	   1.6	  Acute	  phase	  response	  signaling	   2.4	  *	   0.8	   1.7	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Table	  4.6:	  Early	  and	  Late	  Time	  Points:	  Contrasting	  Transcriptome	  Responses.	  Ingenuity	  Pathway	  Analysis	  of	  microarray	  data	  at	  3	  and	  48h	  post-­‐exercise	  regarding	  (a)	  Upstream	  Regulators	  and	  (b)	  Canonical	  Pathways.	  Data	  are	  presented	  as	  z-­‐scores,	  darker	  color	  indicates	  more	  up-­‐	  or	  down-­‐regulation:	  green	  is	  decreased	  activity,	  red	  is	  increased	  activity.	  Gene	  names	  and	  symbols	  from	  the	  National	  Institute	  of	  Health	  (NIH)	  National	  Center	  of	  Biotechnology	  (NCBI)	  database,	  June	  2015.	  *p<0.05.	  UM,	  University	  of	  Massachusetts;	  MM,	  McMaster	  University.	  
Upstream	  
regulators	   Gene	  name	  
UM-­‐3h	   MM-­‐3h	   MM-­‐48h	  
z-­‐score	  FN1	   Fibronectin	  1	   2.9	  *	   2.8	  *	   -­‐2.4	  *	  VEGFA	   Vascular	  endothelial	  growth	  factor	  A	   4.2	  *	   3.0	  *	   -­‐2.1	  PRL	   Prolactin	   3.0	  *	   1.8	  *	   -­‐1.9	  CD24	   CD24	  molecule	   1.3	  *	   2.3	  *	   -­‐1.9	  *	  ESRRA	   Estrogen-­‐related	  receptor	  alpha	   1.9	   1.1	  *	   -­‐1.5	  *	  
	  
Canonical	  pathway	  
UM-­‐3h	   MM-­‐3h	   MM-­‐48h	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Table	  4.7:	  PCR	  Array	  Analysis.	  	  The	  array	  was	  comprised	  of	  44	  genes	  of	  interest	  normalized	  to	  two	  housekeeping	  genes.	  Gene	  names	  and	  symbols	  from	  the	  National	  Institute	  of	  Health	  (NIH)	  National	  Center	  of	  Biotechnology	  (NCBI)	  database,	  June	  2015.	  Functions	  from	  NCBI,	  UniProt,	  Genecards,	  and	  published	  literature.	  Data	  are	  presented	  as	  fold	  change	  (exercise	  vs	  control	  leg,	  mean±SEM)	  and	  were	  analyzed	  as	  ΔΔCt	  using	  repeated	  measures	  ANOVA,	  with	  significance	  based	  on	  false	  discovery	  rate:	  *	  p<0.002,	  effect	  of	  exercise.	  ANOVA,	  analysis	  of	  variance.	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Figure	  4.2:	  qRT-­‐PCR	  Validation.	  	  Post-­‐ECC	  gene	  expression.	  Early	  (3h)	  	  	  	  	  ,	  late	  (48h)	  	  	  	  	  .	  Data	  are	  presented	  as	  mean±SEM.	  *	  p<0.05	  effect	  of	  exercise;	  §	  p<0.05	  interaction	  (group*exercise).	  NGF,	  nerve	  growth	  factor;	  NFKBIA,	  nuclear	  factor	  kappa	  B	  inhibitor-­‐alpha;	  TRAF6,	  TNF-­‐associated	  factor	  6.	  	  	  
	  	  	  
Figure	  4.3:	  NFκB	  Activity.	  	  Post-­‐ECC	  NFκB	  (p65)	  DNA-­‐binding	  activity.	  Early	  (3h)	  	  	  	  	  ,	  late	  (48h)	  	  	  	  	  .	  Data	  are	  presented	  as	  mean±SEM.	  *	  p<0.05	  effect	  of	  exercise.	  NFκB,	  nuclear	  factor	  kappa	  beta;	  p65	  (REL-­‐A),	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A.	  	  
	   	  

















§	  	  	  


























	  	  139	  
Figure	  4.4:	  Proposed	  Model	  of	  Inflammatory	  Events	  at	  3h	  and	  48h	  Post-­‐ECC.	  Proposed	  pathway	  regulation	  affecting	  inflammation	  and	  DOMS	  early	  (a)	  and	  late	  (b)	  post-­‐ECC.	  DOMS,	  delayed	  onset	  muscle	  soreness;	  ECC,	  eccentric	  exercise.	  	  
	  	  	  
a Early 
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b Late 
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CHAPTER	  V	  
MOLECULAR	  EFFECTS	  OF	  SMOKING	  ON	  SKELETAL	  MUSCLE	  	  
48H	  AFTER	  ECCENTRIC	  EXERCISE	  
	  
Introduction	  The	  long-­‐term	  negative	  consequences	  of	  cigarette	  smoking	  include	  an	  increased	  risk	  for	  musculoskeletal	  injury	  (5,	  47,	  48,	  150,	  157,	  212,	  286,	  343,	  363)	  and	  prolonged	  healing	  time	  (3,	  82,	  310,	  317,	  357).	  In	  a	  previous	  study	  investigating	  smoking	  and	  injury	  risk,	  I	  used	  an	  eccentric	  exercise	  model	  (ECC)	  of	  acute	  muscle	  injury	  that	  elicits	  transient	  muscle	  damage,	  including	  delayed	  hyperalgesia	  (delayed	  onset	  muscle	  soreness,	  or	  DOMS)	  and	  functional	  losses	  (reviewed	  in	  (135).	  In	  response	  to	  ECC,	  smokers	  experienced	  greater	  muscle	  fatigue,	  as	  indicated	  by	  15%	  greater	  eccentric	  torque	  loss	  during	  and	  10%	  greater	  loss	  of	  strength	  5min	  after	  ECC,	  and	  15%	  greater	  peak	  DOMS	  than	  non-­‐smokers	  (Dissertation	  Study	  1,	  Chapter	  3).	  Since	  the	  mechanisms	  responsible	  for	  the	  link	  between	  smoking	  and	  muscle	  injury	  risk	  are	  poorly	  understood,	  I	  conducted	  a	  molecular	  analysis	  of	  muscle	  biopsies	  from	  smokers	  and	  non-­‐smokers	  after	  ECC	  to	  better	  understand	  why	  smokers	  demonstrate	  higher	  fatigue	  and	  DOMS.	  Muscle	  fatigue	  may	  be	  affected	  by	  a	  number	  of	  mechanisms	  (reviewed	  in	  Allen,	  Lamb,	  and	  Westerblad	  (4))	  including	  fiber	  type	  distribution.	  	  A	  growing	  number	  of	  studies	  have	  shown	  muscle	  of	  smokers	  to	  favor	  a	  lower	  proportion	  of	  Type	  I	  (oxidative)	  fibers	  than	  in	  non-­‐smokers	  (169,	  290,	  328).	  Type	  I	  muscle	  fibers	  are	  more	  fatigue	  resistant	  than	  Type	  II	  fibers,	  and	  therefore	  a	  fiber-­‐type	  shift	  away	  
	  	  142	  
from	  Type	  I	  fibers	  could	  predispose	  smokers	  to	  greater	  fatigue	  during	  exercise.	  Recent	  studies	  suggest	  that	  smoke	  exposure	  may	  influence	  muscle	  fiber	  type	  through	  the	  suppression	  of	  peroxisome	  proliferator-­‐activated	  receptor-­‐gamma	  (PPAR-­‐γ)	  coactivator-­‐1	  (PGC-­‐1)	  (162,	  328),	  a	  family	  of	  proteins	  that	  promote	  oxidative	  (Type	  I)	  muscle	  fiber	  development.	  The	  non-­‐canonical	  NFκB	  (REL-­‐B,	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  B)	  pathway	  regulates	  PGC1,	  promotes	  oxidative	  metabolism,	  and	  is	  enhanced	  during	  muscle	  differentiation	  (13).	  Smoking	  affects	  REL-­‐B	  activity	  (375)	  and	  may	  be	  a	  mechanism	  through	  which	  fiber	  type	  shifts	  enhance	  muscular	  fatigue	  in	  smokers.	  DOMS	  is	  driven	  in	  part	  by	  inflammatory	  signaling	  after	  ECC	  that	  is	  critical	  for	  muscle	  repair.	  Early	  pro-­‐inflammatory	  activity	  (0	  to~2d	  post-­‐exercise),	  exacerbates	  mechanical	  damage,	  while	  later	  anti-­‐inflammatory	  activity	  (>2d	  post-­‐exercise)	  quenches	  inflammation	  and	  stimulates	  healing	  and	  recovery.	  The	  resolution	  of	  pro-­‐inflammatory	  activity	  is	  critical	  to	  the	  recovery	  process,	  as	  delayed	  resolution	  can	  lead	  to	  “secondary”	  muscle	  damage	  to	  the	  surrounding	  healthy	  tissue	  and	  stimulate	  DOMS	  (reviewed	  in	  Hyldahl	  and	  Hubal	  (135)).	  	  Non-­‐ECC	  models	  of	  pain	  have	  identified	  several	  early	  pro-­‐inflammatory	  mediators	  in	  hyperalgesia	  signaling	  through	  the	  sensitization	  of	  nociceptors.	  In	  the	  well-­‐characterized	  cyclooxygenase	  (COX)	  pathway,	  COX	  stimulates	  the	  synthesis	  of	  prostaglandins,	  which	  induce	  hyperalgesia	  (87,	  201,	  233).	  Bradykinin	  (B2)	  stimulates	  hyperalgesia	  via	  ion	  channel	  activation	  and	  can	  stimulate	  the	  production	  and	  release	  of	  prostaglandins,	  which	  can,	  in	  turn,	  potentiates	  the	  nerve-­‐sensitizing	  effects	  of	  B2	  (234).	  Nerve	  growth	  factor	  (NGF),	  which	  also	  mediates	  prostaglandins	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and	  B2,	  sensitizes	  nociceptors	  directly	  and	  indirectly	  by	  stimulating	  neutrophils	  and	  mast	  cells	  to	  release	  factors	  such	  as	  tumor	  necrosis	  factor-­‐alpha	  (TNF-­‐α)	  (reviewed	  in	  (224)).	  Recent	  evidence	  indicates	  that	  NGF	  is	  an	  important	  mediator	  of	  DOMS	  (234).	  	  My	  previous	  transcriptome	  analyses	  (Dissertation	  Study	  2,	  Chapter	  4)	  suggested	  differential	  activation	  of	  the	  extracellular	  regulated	  kinase	  (ERK)	  and	  canonical	  (p65:	  REL-­‐A,	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A)	  nuclear	  factor	  kappa	  B	  (NFκB)	  pathway	  between	  3h	  (up	  vs	  control)	  and	  48h	  (down	  vs	  control)	  after	  ECC	  in	  humans.	  Both	  pathways	  can	  stimulate	  hyperalgesia	  in	  non-­‐ECC	  pain	  models	  by	  regulating	  the	  synthesis	  and	  release	  of	  other	  hyperalgesic	  and	  pro-­‐inflammatory	  factors,	  such	  as	  the	  COX2	  pathway	  and	  TNF-­‐α,	  yet	  their	  effects	  on	  DOMS	  have	  yet	  to	  be	  determined.	  ERK	  can	  promote	  pro-­‐	  or	  anti-­‐inflammatory	  signaling	  and	  regulate	  inflammatory	  cell	  survival	  or	  apoptosis	  via	  its	  activity	  in	  the	  nucleus	  (including	  inflammatory	  gene	  expression)	  and	  cytoplasm	  (where	  it	  can	  regulate	  p65	  activity).	  After	  ECC,	  ERK	  is	  activated	  early,	  yet	  later	  activation	  may	  also	  occur	  (335).	  Other	  hyperalgesic	  factors	  were	  also	  differentially	  expressed	  between	  these	  two	  time	  points.	  This	  included	  NGF,	  which	  stimulates	  ERK	  and	  p65	  activity	  and	  (separately	  and	  together)	  can	  stimulate	  the	  production	  and	  release	  of	  NGF	  (51,	  85,	  172,	  174,	  238,	  261).	  NGF	  was	  enhanced	  at	  48h,	  but	  to	  a	  greater	  extent	  at	  3h.	  Together,	  these	  pathways	  may	  promote	  DOMS,	  which	  resolves	  as	  their	  activity	  subsides.	  	  Smoking	  is	  associated	  with	  dysregulated	  inflammation,	  including	  NGF	  expression	  (elevated	  with	  smoke	  components	  (238,	  368))	  and	  ERK	  and	  p65	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activation	  (6,	  238,	  368,	  385)—all	  of	  which	  are	  associated	  with	  hyperalgesia.	  Chronic	  cigarette	  smokers	  report	  greater	  pain	  after	  traumatic	  injury	  or	  surgery	  (103,	  287),	  higher	  incidences	  of	  chronic	  pain	  (including	  musculoskeletal	  pain	  (386),	  and	  they	  require	  larger	  doses	  of	  analgesics	  to	  manage	  pain	  (68,	  288)).	  Differences	  in	  nerve-­‐sensitizing	  pathways	  may	  explain	  heightened	  DOMS	  in	  my	  previous	  research	  and	  shed	  light	  on	  enhanced	  muscle	  injury	  risk	  and	  prolonged	  recovery.	  	  The	  aims	  of	  the	  present	  study	  were	  to	  determine	  if:	  1)	  REL-­‐B	  activity	  and	  fiber	  type	  distribution	  differed	  between	  muscle	  of	  smokers	  and	  non-­‐smokers;	  and	  2)	  NFκB	  and	  ERK	  activity,	  along	  with	  NGF	  protein	  levels,	  were	  altered	  in	  smokers.	  These	  mechanisms	  may	  explain	  greater	  muscle	  fatigue	  and	  DOMS	  in	  smokers,	  respectively	  (Dissertation	  Study	  1,	  Chapter	  3).	  I	  hypothesized	  that:	  1)	  smokers	  would	  have	  a	  greater	  proportion	  of	  Type	  II	  fibers	  and	  suppressed	  REL-­‐B	  activity	  at	  48h	  post-­‐ECC	  compared	  to	  non-­‐smokers;	  2)	  after	  ECC	  the	  activity	  of	  the	  canonical	  NFκB	  pathway	  would	  be	  suppressed	  in	  non-­‐smokers	  but	  not	  in	  smokers;	  3)	  nuclear	  activity	  of	  the	  ERK	  pathway	  would	  increase	  for	  non-­‐smokers	  while	  activity	  would	  be	  concentrated	  in	  the	  cytoplasm	  for	  smokers;	  and	  4)	  NGF	  levels	  and	  receptor	  co-­‐localization	  would	  be	  more	  pronounced	  in	  smokers	  versus	  non-­‐smokers.	  	  
	  
Methods	  This	  study	  was	  comprised	  of	  two	  parts:	  1)	  an	  in	  silico	  transcriptomic	  profile	  analysis;	  and	  2)	  an	  experimental	  analysis	  validating	  key	  pathways	  identified	  through	  prior	  research	  and	  the	  in	  silico	  analyses.	  The	  in	  silico	  analysis	  was	  used	  to	  determine	  which	  damage-­‐related	  genes	  may	  also	  be	  altered	  by	  smoking	  and/or	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pain.	  Then,	  I	  tested	  the	  combined	  effects	  of	  exercise	  and	  cigarette	  smoking	  on	  signaling	  components	  of	  the	  identified	  pathways.	  	  
In	  Silico	  Expression	  Profile	  Analyses	  The	  National	  Institutes	  of	  Health	  Gene	  Expression	  Omnibus	  (GEO)	  profile	  database	  (http://www.ncbi.nlm.nih.gov/geoprofiles)	  was	  used	  to	  query	  the	  effects	  of:	  1)	  muscle	  damage;	  2)	  smoking;	  and	  3)	  pain	  on	  21	  genes	  (Table	  5.1,	  Supplemental),	  selected	  based	  on	  models	  developed	  from	  previous	  transcriptome	  analyses	  (Dissertation	  Study	  2,	  Chapter	  4).	  The	  primary	  goal	  was	  to	  identify	  which	  genes	  from	  the	  model	  may	  be	  involved	  with	  hyperalgesia	  signaling	  or	  affected	  by	  smoking.	  There	  are	  currently	  no	  studies	  in	  the	  GEO	  database	  that	  report	  on	  investigations	  of	  the	  effects	  of	  smoking	  on	  skeletal	  muscle,	  and	  datasets	  related	  to	  the	  effects	  of	  cigarette	  smoking,	  tobacco	  use,	  or	  exposure	  to	  chemicals	  associated	  with	  cigarette	  use	  on	  other	  tissues	  were	  queried.	  I	  chose	  24	  data	  sets	  for	  further	  analysis	  using	  the	  following	  search	  terms:	  1)	  muscle	  damage/injury	  (search	  input:	  muscle,	  skeletal	  muscle,	  injury,	  damage,	  eccentric,	  exercise,	  dystrophy);	  2)	  cigarette	  smoking/smoke	  exposure	  (cigarette,	  smoke,	  smoking,	  tobacco);	  and	  3)	  models	  of	  pain/hyperalgesia	  (pain,	  hyperalgesia).	  The	  raw	  data	  were	  downloaded	  and	  then	  mRNA	  expression	  was	  probed	  using	  ANOVA	  testing	  for	  statistically	  significant	  differences:	  1)	  after	  muscle	  damage;	  2)	  with	  smoke	  exposure/smoking;	  or	  3)	  with	  pain	  stimulation.	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Validation	  Study	  
Subjects	  Twenty	  healthy	  young	  men,	  ages	  18-­‐35,	  participated	  in	  this	  study.	  All	  subjects	  were	  generally	  sedentary	  (all	  regular	  activities	  below	  5	  METs)	  and	  had	  not	  performed	  resistance	  training	  with	  their	  legs	  or	  engaged	  in	  any	  heavy	  lifting/lowering	  of	  materials	  for	  the	  previous	  six	  months,	  verified	  through	  interviews	  and	  the	  Paffenbarger	  activity	  questionnaire	  (259).	  Throughout	  the	  course	  of	  the	  study,	  subjects	  refrained	  from:	  new	  physical	  activities;	  consumption	  of	  alcohol	  or	  dietary	  supplements;	  muscle	  treatments	  (including	  hot/cold	  or	  massage	  treatments)	  or	  use	  of	  any	  medications	  that	  might	  affect	  the	  study	  outcome,	  except	  acetaminophen	  after	  the	  biopsies.	  The	  non-­‐smokers	  (N=10)	  recruited	  for	  the	  study	  had	  never	  smoked	  regularly	  nor	  consumed	  any	  tobacco/nicotine	  products.	  The	  chronic	  cigarette	  smokers	  (N=10)	  had	  habitually	  smoked	  at	  least	  ½	  pack	  (10	  cigarettes)	  per	  day	  for	  five	  or	  more	  years,	  without	  the	  consumption	  of	  other	  tobacco	  products.	  The	  smokers	  were	  required	  to	  sustain	  their	  normal	  smoking	  habits,	  as	  well	  as	  consume	  one	  cigarette	  10min	  before	  each	  visit	  to	  reduce	  variability	  that	  might	  occur	  as	  a	  result	  of	  time	  from	  last	  cigarette.	  Prior	  to	  participating,	  all	  subjects	  gave	  written	  informed	  consent	  as	  approved	  by	  the	  University	  of	  Massachusetts	  Amherst	  Institutional	  Review	  Board.	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Experimental	  Design	  A	  summary	  of	  study	  events	  is	  provided	  in	  Figure	  5.1,	  with	  details	  below.	  All	  visits	  took	  place	  around	  mid-­‐day,	  except	  the	  third	  and	  fourth	  visits,	  which	  occurred	  in	  the	  morning	  (see	  below	  for	  details).	  Subjects	  fasted	  overnight	  (no	  food	  or	  drink	  except	  water)	  in	  advance	  of	  the	  first,	  third,	  and	  fourth	  visits.	  At	  V1,	  subjects	  provided	  a	  medical	  history,	  filled	  out	  the	  Paffenbarger	  activity	  questionnaire,	  performed	  a	  familiarization	  session	  with	  the	  Biodex	  dynamometer	  for	  future	  strength	  testing	  and	  exercise,	  and	  had	  a	  baseline	  blood	  draw.	  Strength	  was	  tested	  using	  a	  Biodex	  dynamometer,	  specifically	  testing	  isometric	  maximal	  voluntary	  contractions	  (MVCs).	  Within	  2-­‐4d,	  subjects	  returned	  to	  the	  laboratory	  (V2)	  and	  had	  baseline	  strength	  measured,	  performed	  the	  exercise	  session,	  and	  had	  strength	  measures	  taken	  again	  at	  5min	  post-­‐exercise.	  At	  V3,	  which	  took	  place	  the	  morning	  after	  the	  exercise	  session	  at	  approximately	  20h	  post-­‐exercise,	  blood	  was	  drawn	  and	  strength	  again	  tested.	  At	  V4	  (2d	  post-­‐exercise),	  subjects	  came	  to	  the	  laboratory	  in	  the	  morning,	  consumed	  a	  standardized	  meal	  consisting	  of	  400	  kcals	  (approximately	  55%	  carbohydrate,	  30%	  fat,	  and	  15%	  protein),	  and	  then	  remained	  resting	  the	  laboratory	  until	  the	  biopsy	  collection	  approximately	  3-­‐4h	  later.	  The	  last	  two	  visits	  took	  place	  at	  4	  and	  9d	  post-­‐exercise	  (2	  and	  7d	  post-­‐biopsy)	  and	  consisted	  of	  strength	  testing	  and	  an	  examination	  of	  the	  biopsy	  site.	  The	  sutures	  were	  removed	  at	  the	  last	  scheduled	  visit,	  or	  one	  week	  following	  the	  biopsy	  to	  allow	  additional	  healing,	  by	  the	  study	  physician.	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Blood	  Collection	  and	  Creating	  Kinase	  Activity	  Analysis	  Blood	  was	  collected	  under	  fasting	  conditions	  at	  the	  antecubital	  region	  by	  venipuncture	  using	  standard	  asceptic	  technique.	  For	  creatine	  kinase	  (CK)	  activity	  analysis,	  blood	  was	  drawn	  into	  vacutainers	  containing	  the	  anticoagulant	  EDTA.	  After	  resting	  at	  room	  temperature	  for	  15min,	  the	  vacutainers	  were	  centrifuged	  for	  10min	  at	  1000	  x	  g.	  The	  resultant	  supernatant	  (plasma)	  was	  shipped	  to	  a	  clinical	  laboratory	  for	  CK	  activity	  analysis	  using	  standard	  ELISA-­‐based	  technique	  (Holyoke	  Hospital,	  Holyoke,	  MA).	  	  	  
Isometric	  Maximal	  Strength	  Testing	  Functional	  testing	  was	  performed	  exclusively	  with	  the	  non-­‐dominant	  leg.	  Isometric	  maximal	  voluntary	  contraction	  (MVC;	  measure	  of	  muscle	  strength)	  was	  tested	  to	  verify	  the	  efficacy	  of	  the	  exercise	  protocol	  in	  eliciting	  muscle	  dysfunction	  (pre-­‐,	  5min,	  and	  ~1d	  post-­‐exercise)	  and	  to	  ensure	  proper	  recovery	  (4	  and	  9d	  post-­‐exercise).	  While	  the	  primary	  focus	  of	  the	  study	  was	  the	  knee	  extensor	  muscle	  group,	  I	  also	  examined	  the	  flexor	  muscle	  group	  (changes	  in	  flexion	  strength	  were	  not	  anticipated).	  All	  strength	  measures	  and	  eccentric	  exercise	  were	  performed	  on	  a	  Biodex	  System	  3	  dynamometer	  (Biodex	  Medical	  Systems,	  Shirley,	  NY,	  USA)	  as	  described	  previously	  (6,	  14).	  In	  brief,	  subjects	  were	  seated	  on	  the	  dynamometer	  and	  straps	  were	  placed	  across	  the	  upper	  leg	  (non-­‐dominant	  only),	  hips,	  and	  chest	  to	  moderate	  the	  use	  of	  muscles	  not	  under	  investigation.	  The	  dynamometer	  arm	  pivot	  point	  was	  aligned	  with	  the	  lateral	  epicondyle	  of	  the	  femur.	  Before	  testing,	  the	  study	  investigator	  moved	  the	  subject’s	  relaxed	  leg	  through	  passive	  range	  of	  motion.	  At	  full	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extension	  of	  the	  knee,	  the	  dynamometer	  was	  set	  to	  0°;	  isometric	  (0°/sec)	  and	  strength	  was	  measured	  at	  70°	  of	  flexion.	  Subjects	  performed	  six	  total	  contractions	  against	  the	  immovable	  dynamometer	  level	  arm,	  alternating	  between	  extension	  (kicking)	  and	  flexion	  (pulling)	  for	  a	  total	  of	  three	  contractions	  each.	  Each	  contraction	  was	  4sec	  in	  length	  and	  followed	  by	  60sec	  of	  rest.	  The	  study	  investigator	  provided	  verbal	  encouragement	  to	  reinforce	  maximal	  effort.	  For	  each	  set,	  all	  repetitions	  were	  within	  10%	  coefficient	  of	  variation.	  	  
Eccentric	  Exercise	  The	  exercise	  session	  was	  comprised	  of	  100	  (10	  sets	  of	  10	  repetitions)	  maximal	  eccentric	  contractions	  of	  the	  knee	  extensors	  on	  the	  Biodex	  dynamometer	  (6,	  14).	  Subjects	  were	  seated	  as	  described	  above	  and	  the	  leg	  moved	  passively	  to	  35°	  of	  flexion	  by	  the	  study	  investigator.	  Subjects	  then	  were	  instructed	  to	  kick	  with	  maximal	  effort	  throughout	  the	  exercise.	  Eccentric	  resistance	  was	  set	  at	  a	  moderate	  pace	  of	  30°/sec,	  such	  that	  although	  the	  subject	  provided	  maximal	  effort,	  his	  knee	  was	  forced	  to	  move	  into	  flexion.	  At	  full	  flexion,	  the	  resistance	  would	  stop,	  and	  the	  subject’s	  leg	  was	  returned	  passively	  by	  the	  study	  investigator	  to	  35°	  of	  flexion—a	  75°	  range	  of	  motion.	  Each	  contraction	  was	  approximately	  4sec	  in	  length,	  with	  10sec	  rest	  between	  repetitions.	  Each	  10-­‐repetition	  set	  was	  followed	  by	  a	  1min	  rest	  period.	  Throughout	  the	  exercise	  session,	  subjects	  were	  verbally	  encouraged	  to	  exercise	  with	  maximal	  effort.	  Work	  done	  and	  eccentric	  torque	  were	  recorded	  for	  each	  contraction.	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Muscle	  Biopsy	  Biopsy	  procedures	  have	  been	  reported	  previously	  (6).	  Briefly,	  the	  study	  physician	  collected	  percutaneous	  needle	  biopsies	  from	  the	  vastus	  lateralis	  under	  local	  anesthetic	  (lidocaine)	  using	  a	  Bergström	  needle	  with	  suction.	  Each	  biopsy	  site	  yielded	  approximately	  100-­‐150mg	  of	  tissue.	  After	  fat	  and	  connective	  tissue	  were	  removed,	  the	  skeletal	  muscle	  was	  flash-­‐frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐86oC	  until	  processed.	  Two	  biopsies	  were	  collected	  from	  each	  subject,	  first	  from	  the	  exercise	  leg	  and	  then	  immediately	  after	  from	  the	  control	  leg.	  The	  biopsy	  collection	  process	  began	  48h	  after	  the	  exercise	  session	  and	  took	  approximately	  15-­‐20min	  for	  each	  leg.	  Subjects	  were	  permitted	  use	  of	  acetaminophen	  after	  the	  biopsy	  to	  manage	  pain	  associated	  with	  the	  biopsy	  procedure;	  all	  subjects	  ceased	  use	  of	  acetaminophen	  within	  3d.	  	  
RNA	  Isolation	  Total	  RNA	  was	  extracted	  using	  the	  RNeasy	  RNA	  isolation	  kit	  (Qiagen,	  Valencia,	  CA,	  USA).	  Samples	  were	  resuspended	  in	  TE	  buffer	  (pH	  8.0)	  and	  the	  quality	  and	  quantity	  of	  RNA	  was	  tested	  in	  duplicate	  using	  spectrophotometry	  (Nanodrop,	  Willmington,	  DE).	  Samples	  with	  a	  260/280	  ratio	  below	  1.5	  were	  subjected	  to	  an	  additional	  clean	  up	  step	  using	  the	  RNeasy	  kit.	  cDNA	  was	  then	  synthesized	  for	  qRT-­‐PCR	  from	  0.5ug	  of	  total	  RNA	  with	  a	  RT2	  First	  Strand	  cDNA	  synthesis	  kit	  (SABiosciences,	  a	  part	  of	  Qiagen)	  or	  for	  PCR	  arrays	  from	  0.04ug	  total	  RNA	  with	  a	  RevertAid	  First	  Strand	  cDNA	  synthesis	  kit	  (Fermentas,	  Thermo-­‐Fisher	  Scientific,	  Rockford	  IL,	  USA).	  All	  kits	  were	  used	  per	  manufacturer’s	  instructions.	  
	  	  151	  
	  
PCR	  Arrays	  PCR	  arrays	  were	  used	  to	  quantify	  the	  mRNA	  expression	  levels	  of	  44	  genes	  (Table	  5.1)	  related	  to	  pathway	  components	  of	  the	  muscle	  damage/regeneration	  response	  and	  to	  compare	  levels	  between	  smokers	  and	  non-­‐smokers	  (SABiosciences,	  a	  part	  of	  Qiagen).	  The	  genes	  on	  this	  custom-­‐designed	  array	  were	  chosen	  to	  investigate	  hypothesized	  differences	  between	  smokers	  and	  non-­‐smokers	  based	  on	  previous	  literature	  regarding	  the	  effects	  of	  smoking	  and	  hyperalgesia,	  in	  addition	  to	  the	  microarray	  data	  explored	  in	  Dissertation	  Study	  2	  (Chapter	  4).	  These	  genes	  encode	  for	  proteins	  with	  functions	  in	  six	  overarching	  categories:	  apoptosis,	  cell	  cycle,	  hyperalgesia,	  inflammation,	  muscle	  structure,	  myogenesis,	  nitric	  oxide	  signaling,	  and	  vascular	  health/angiogenesis	  (1-­‐5,	  7,	  8,	  11-­‐13).	  	  cDNA	  (1.5ng/uL	  final	  concentration)	  combined	  with	  RT2	  SYBR	  Green	  qPCR	  master	  mix	  was	  added	  to	  a	  microtiter	  plate	  containing	  the	  primer	  sequences	  (10uM	  concentration)	  for	  each	  gene	  of	  interest	  (quality	  assurance	  testing,	  including	  melting	  curve	  analyses,	  were	  performed	  by	  Qiagen).	  After	  10min	  at	  95°C	  to	  activate	  the	  polymerase,	  samples	  were	  amplified	  over	  40	  heating/cooling	  cycles	  of	  95°C	  for	  15sec	  followed	  by	  1min	  at	  60°C;	  PCR	  was	  performed	  on	  an	  MX3000p	  Real-­‐Time	  PCR	  System	  (Stratagene,	  La	  Jolla,	  CA,	  USA).	  The	  average	  threshold	  cycle	  (Ct)	  for	  each	  gene	  of	  interest	  was	  then	  normalized	  to	  the	  average	  of	  two	  housekeeping	  genes	  that	  do	  not	  change	  in	  response	  to	  resistance	  exercise	  (9):	  β-­‐actin	  and	  β-­‐2-­‐microglobulin	  (B2M),	  yielding	  ΔCt	  for	  each	  leg.	  The	  ΔCt	  for	  the	  exercise	  leg	  was	  then	  normalized	  to	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that	  from	  the	  control	  leg,	  and	  the	  resultant	  ΔΔCt	  were	  transformed	  into	  fold-­‐change	  for	  visualization	  purposes.	  	  
qRT-­‐PCR	  To	  confirm	  and	  extend	  findings	  from	  the	  previous	  transcriptome	  work	  (Dissertation	  Study	  2,	  Chapter	  4),	  in	  silico	  data	  presented	  here,	  and	  the	  PCR	  arrays,	  I	  also	  performed	  semi-­‐quantitative	  real-­‐time	  PCR	  with	  primers	  for	  nerve	  growth	  factor	  (NGF),	  nuclear	  factor	  κ	  B	  inhibitor-­‐α	  (NFKBIA),	  and	  TNF-­‐associated	  factor-­‐6	  (TRAF6).	  The	  primer	  sequences	  with	  the	  number	  of	  subjects	  per	  group	  are	  presented	  in	  Table	  5.2.	  Primer	  sequences	  were	  utilized	  at	  a	  concentration	  of	  6uM.	  Quality	  of	  the	  primers	  was	  tested	  via	  RT-­‐PCR	  and	  agarose	  gel	  electrophoresis.	  In	  each	  case,	  ethidium	  bromide	  staining	  was	  used	  to	  verify	  the	  existence	  of	  a	  single	  product	  that	  was	  the	  anticipated	  size.	  Due	  to	  limited	  sample	  availability,	  only	  samples	  from	  a	  sub-­‐set	  of	  subjects	  were	  used	  for	  qRT-­‐PCR	  analysis.	  This	  group	  did	  not	  differ	  from	  the	  entire	  cohort	  for	  age,	  height,	  weight,	  or	  BMI.	  	  The	  relative	  abundance	  of	  the	  transcripts	  for	  the	  genes	  of	  interest	  was	  measured	  by	  qPCR	  analysis	  using	  SsoFast	  Evagreen	  master	  mix	  (Biorad,	  Hercules,	  CA).	  For	  each	  gene	  of	  interest,	  samples	  (cDNA	  final	  concentration	  of	  25ng/uL)	  were	  run	  in	  triplicate	  in	  96-­‐well	  plates	  along	  with	  no	  template	  controls.	  A	  melting	  curve	  was	  generated	  following	  each	  reaction	  in	  order	  to	  insure	  that	  no	  primer	  dimers	  were	  detected.	  The	  triplicate	  Ct	  values	  were	  averaged	  and	  normalized	  to	  the	  housekeeping	  gene	  B2M,	  validated	  previously	  to	  maintain	  expression	  after	  eccentric	  exercise	  (9).	  Time	  and	  group	  comparisons	  were	  made	  using	  the	  ΔΔCt	  method.	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Protein	  Isolation	  and	  Nuclear	  Protein	  Fractionation	  Muscle	  samples	  were	  collected	  via	  needle	  biopsy	  and	  homogenized	  on	  ice	  in	  Tissue	  Protein	  Extraction	  Reagent	  (Thermo-­‐Fisher	  Scientific)	  in	  the	  presence	  of	  Halt	  protease/phosphatase	  inhibitors	  (Thermo-­‐Fisher	  Scientific).	  The	  homogenate	  was	  centrifuged	  at	  12,000xg	  for	  5min	  at	  4°C	  and	  then	  the	  supernatant	  was	  removed.	  Total	  protein	  per	  sample	  was	  quantified	  using	  a	  standard	  bicinchoninic	  acid	  (BCA)	  kit	  with	  bovine	  serum	  albumin	  (BSA)	  as	  the	  standard	  (Thermo-­‐Fisher	  Scientific),	  and	  stored	  at	  -­‐80°C	  for	  later	  analysis.	  Nuclear	  fractions	  were	  isolated	  using	  previously	  described	  methods	  (5).	  Briefly,	  frozen	  muscle	  samples	  were	  homogenized	  in	  a	  low-­‐salt	  buffer	  solution	  (10uM	  HEPES,	  pH	  7.6;	  10mM	  KCl;	  1.5mM	  MgCl2;	  0.1mM	  EDTA;	  0.1mM	  DTT;	  0.5M	  PMSF;	  50uL	  HALT	  protease/phosphatase	  inhibitor	  cocktail	  (Thermo-­‐Fisher	  Scientific);	  and	  0.5mg/ml	  benzamidine)	  and	  then	  incubated	  on	  ice	  for	  5min.	  The	  homogenate	  was	  then	  cooled	  in	  an	  ethanol/dry	  ice	  bath	  for	  5min,	  heated	  in	  a	  37°C	  water	  bath	  for	  1min,	  and	  vortexed	  briefly.	  This	  cooling	  and	  heating	  process	  was	  repeated	  and	  the	  samples	  were	  then	  centrifuged	  at	  670	  x	  g	  in	  a	  microfuge	  for	  3min	  at	  4°C.	  The	  supernatant,	  which	  contained	  the	  cytoplasmic	  proteins,	  was	  removed	  and	  stored	  at	  -­‐80°C	  for	  later	  analysis.	  The	  remaining	  nuclear	  pellet	  was	  resuspended	  in	  an	  ice-­‐cold	  high-­‐salt	  buffer	  solution	  (20mM	  HEPES,	  pH	  7.6;	  420mM	  NaCl;	  1mM	  EDTA;	  25%	  glycerol;	  1mM	  DTT;	  and	  5ul	  protease	  inhibitor	  cocktail)	  and	  incubated	  on	  ice	  for	  30min.	  After	  centrifugation	  at	  12,560	  x	  g	  for	  5min	  at	  4°C,	  the	  supernatant	  was	  removed	  and	  stored	  as	  the	  cytoplasmic	  protein.	  All	  protein	  samples	  (total	  and	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nuclear)	  were	  quantified	  using	  a	  standard	  BCA	  kit	  (Thermo-­‐Fisher	  Scientific)	  prior	  to	  the	  NFκB	  activity	  assay	  and	  Western	  blotting.	  	  	  
NFκB	  Activity	  Components	  of	  the	  NFκB	  canonical	  (p65)	  and	  non-­‐canonical	  (Rel-­‐B)	  pathways	  were	  measured	  for	  DNA	  binding	  activity	  using	  a	  DNA-­‐binding	  ELISA	  kit	  (Active	  Motif,	  Carlsbad,	  CA).	  All	  procedures	  were	  performed	  at	  room	  temperature.	  Nuclear	  fractions	  (12ug,	  in	  duplicate)	  were	  incubated	  in	  a	  96-­‐well	  plate	  containing	  a	  NFκB	  consensus	  sequence	  (5´-­‐GGGACTTTCC-­‐3´)	  for	  1h.	  After	  washing,	  the	  plates	  were	  incubated	  for	  1h	  with	  the	  primary	  antibody	  (1:1000)	  against	  p65	  or	  Rel-­‐B	  and	  then	  washed.	  The	  plates	  were	  then	  incubated	  with	  an	  HRP-­‐conjugate	  secondary	  antibody	  (1:1000)	  for	  1h	  and	  again	  washed.	  A	  developing	  solution	  was	  added,	  producing	  a	  colorimetric	  reaction	  that	  was	  allowed	  to	  develop	  over	  5min.	  The	  reaction	  was	  halted	  with	  the	  addition	  of	  a	  stop	  solution	  and	  absorbance	  was	  read	  at	  450nm	  with	  a	  correction	  wavelength	  of	  655nm	  on	  a	  multi-­‐well	  plate	  reader	  (FLUOstar	  Optima;	  BMG	  Labtech,	  Offenburg,	  Germany).	  	  
Western	  Blotting	  	   Western	  blotting	  was	  used	  to	  quantify	  differences	  in	  protein	  levels	  of	  phosphorylated	  and	  total	  ERK	  between	  smokers	  and	  non-­‐smokers	  and	  their	  responses	  to	  exercise.	  40ug	  protein	  samples	  were	  loaded	  into	  a	  4-­‐15%	  TGX	  polyacrylamide	  gel	  (Bio-­‐Rad,	  Hercules	  CA),	  and	  electrophoresis	  performed	  at	  300V	  for	  18min	  to	  separate	  proteins.	  These	  proteins	  were	  transferred	  for	  60min	  at	  50V	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onto	  Immun-­‐Blot	  polyvinylidene	  diflouride	  membrane	  (Biorad).	  Membrane	  were	  washed	  with	  Tris-­‐buffered	  saline	  and	  0.2%	  tween	  (TBS-­‐T)	  and	  blocked	  with	  5%	  milk	  in	  TBS-­‐T	  for	  1h	  at	  room	  temperature.	  After	  blocking,	  membranes	  were	  washed	  with	  TBS-­‐T	  and	  incubated	  with	  primary	  antibody	  in	  blocking	  solution	  overnight	  at	  4°C	  with	  rocking	  motion.	  Following	  primary	  antibody	  incubation,	  the	  membrane	  was	  washed	  and	  incubated	  at	  room	  temperature	  for	  1h	  with	  HRP-­‐conjugated	  secondary	  antibodies	  (Biorad).	  After	  washing,	  Supersignal	  West	  Pico	  enhanced	  chemiluminesence	  agent	  (Thermo-­‐Fisher	  Scientific)	  was	  applied	  and	  blots	  imaged	  using	  a	  ChemiDoc	  XRS+	  (Bio-­‐Rad,	  Hercules	  CA).	  The	  blot	  was	  then	  stripped	  for	  8min	  with	  Restore	  Western	  Blot	  Stripping	  Buffer	  (Thermo-­‐Fisher	  Scientific),	  washed	  with	  TBS-­‐T,	  and	  the	  process	  repeated	  for	  additional	  antibodies	  from	  the	  blocking	  step.	  The	  initial	  blot	  was	  probed	  for	  phosphorylated	  ERK	  (pERK,	  rabbit	  polyclonal,	  1:2000,	  Cell	  Signaling,	  Danvers,	  MA,	  USA)	  followed	  by	  total	  ERK	  (ERK,	  rabbit	  polyclonal,	  1:1000,	  Cell	  Signaling),	  and	  finally	  GAPDH,	  which	  served	  as	  a	  loading	  control	  (mouse	  monoclonal,	  1:1000,	  Abcam,	  Cambridge,	  MA,	  USA).	  The	  resulting	  images	  were	  analyzed	  using	  ImageJ	  software	  (National	  Institutes	  of	  Health	  (NIH),	  Bethesda,	  MD,	  USA)	  (234).	   	  
Immunohistochemistry	  Skeletal	  muscle	  samples	  collected	  from	  the	  control	  and	  exercised	  legs	  were	  analyzed	  for	  relative	  protein	  expression	  of	  myosin	  heavy	  chain-­‐1	  (MHC-­‐1)	  tenascin-­‐C	  (TNC),	  NGF,	  tyrosine	  receptor	  kinase	  A	  (TrkA)	  and	  p75	  neurotrophin	  receptor	  (p75NTR);	  and	  localization/co-­‐localization	  of	  NGF,	  TrkA,	  and	  p75NTR	  using	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immunohistochemistry.	  Samples	  were	  embedded	  in	  Tissue-­‐Tex	  O.C.T.	  compound	  (Sakura	  Finetek,	  Torrance,	  CA,	  USA),	  flash-­‐frozen	  in	  liquid	  nitrogen,	  and	  stored	  at	  -­‐86°C.	  12uM	  cross-­‐sections	  were	  generated	  on	  a	  Microm	  HM	  505E	  cryostat	  at	  -­‐20°C	  (Richard	  Allan	  Scientific,	  Kalamazoo,	  MI,	  USA)	  and	  mounted	  on	  Superfrost	  slides	  (Fisher	  Scientific,	  Pittsburgh,	  PA,	  USA).	  After	  air-­‐drying	  for	  30min,	  the	  sections	  were	  rehydrated	  for	  5min	  with	  1X	  PBS	  and	  0.1%	  tween	  (PBS-­‐T)	  for	  5min	  at	  room	  temperature.	  After	  15min	  blocking	  in	  7%	  normal	  goal	  serum	  (Thermo-­‐Fisher	  Scientific)	  at	  room	  temperature,	  sections	  were	  incubated	  overnight	  at	  4°C	  with	  two	  primary	  antibodies	  simultaneously	  (as	  noted	  below)	  in	  PBS-­‐T.	  The	  sections	  were	  then	  washed	  three	  times	  for	  5min	  in	  PBS-­‐T	  and	  incubated	  for	  30min	  at	  room	  temperature	  with	  the	  appropriate	  secondary	  antibodies	  plus	  DAPI	  (1:100,	  Sigma,	  St.	  Louis,	  MO,	  USA).	  The	  slides	  were	  washed	  three	  times	  in	  PBS-­‐T	  and	  once	  in	  ddH20	  for	  5min	  each	  before	  being	  mounted	  with	  Vectashield	  (Vector	  Laboratories,	  Burlingame,	  CA,	  USA).	  Sections	  were	  then	  imaged	  with	  a	  Nikon	  model	  TMS	  inverted	  microscope	  (Nikon,	  Tokyo,	  Japan)	  and	  a	  SPOT	  Insight	  imaging	  color	  camera	  (Diagnostic	  Instruments,	  Sterling	  Heights,	  MI,	  USA).	  Images	  were	  analyzed	  using	  ImageJ	  analysis	  software.	  The	  following	  primary	  antibodies	  were	  used:	  MHC-­‐1	  (mouse	  monoclonal,	  1:3	  dilution,	  Developmental	  Studies	  Hybridoma	  Bank,	  Iowa	  City,	  IA,	  USA);	  TNC	  (rabbit	  polyclonal,	  1:100	  dilution,	  EMD	  Millipore,	  Billerica,	  MA,	  USA);	  NGF	  (rabbit	  polyclonal,	  1:100	  dilution,	  Abcam);	  TrkA	  (mouse	  monoclonal,	  1:50,	  Abcam);	  p75NTR	  (mouse	  monoclonal,	  1:50	  dilution,	  Abcam).	  The	  following	  secondary	  antibodies	  were	  all	  used	  at	  1:100	  dilution:	  Dylight	  488	  goat	  anti-­‐mouse	  iGg2b	  (for	  MHC-­‐1;	  Jackson	  Immuno-­‐Research	  Laboratories,	  West	  Grove,	  PA),	  Dylight	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549	  goat	  anti-­‐rabbit	  (for	  MHC-­‐1;	  Jackson	  Immuno-­‐Research	  Laboratories,	  West	  Grove,	  PA),	  FITC-­‐conjugated	  goat	  anti-­‐mouse	  (TrkA	  and	  p75NTR;	  Biorad),	  and	  TRITC-­‐conjugated	  goat	  anti-­‐rabbit	  (NGF).	  	   	  
Statistics	  Unless	  otherwise	  noted	  above,	  data	  were	  analyzed	  statistically	  using	  a	  repeated-­‐measures	  analysis	  of	  variance	  (RM	  ANOVA)	  (92),	  with	  time	  as	  the	  repeated	  factor	  and	  comparing	  the	  main	  effects	  of	  group	  (non-­‐smokers	  vs	  smokers),	  exercise	  (control	  and	  exercise),	  and	  the	  group	  by	  exercise	  interaction.	  When	  baselines	  were	  different	  between	  groups	  due	  to	  an	  effect	  of	  smoking	  on	  non-­‐exercised	  muscle,	  the	  baseline	  was	  applied	  as	  a	  covariate	  to	  investigate	  specific	  effects	  of	  the	  exercise	  on	  group	  responses.	  Tukey’s	  HSD	  (345)	  was	  used	  to	  perform	  
post-­‐hoc	  analyses.	  Pearson	  product-­‐moment	  correlations	  (274)	  were	  used	  to	  test	  correlations	  between	  protein	  and	  mRNA	  levels.	  Students	  T-­‐Tests	  (322)	  were	  used	  to	  compare	  between	  groups	  for	  MHC	  content.	  Data	  were	  analyzed	  using	  SAS	  statistical	  software,	  and	  are	  presented	  as	  means	  ±	  standard	  error,	  with	  significance	  between	  groups	  or	  conditions	  set	  at	  p<0.05.	  	  
Results	  
In	  Silico	  Expression	  Profile	  Study	  Summary	  data	  for	  the	  in	  silico	  analyses	  are	  presented	  in	  Table	  5.3.	  Of	  the	  21	  genes	  initially	  targeted	  for	  study	  using	  the	  GEO	  database,	  two	  (IL1A	  and	  IL1R1)	  were	  eliminated	  from	  consideration	  because	  smoking	  and/or	  pain	  were	  not	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associated	  with	  changes	  to	  their	  expression.	  Of	  the	  remaining	  19	  targets	  selected	  for	  study,	  elevated	  expressions	  of	  four	  transcripts	  (CCL2,	  IL18,	  NGF,	  and	  TGFB1)	  were	  found	  in	  studies	  testing	  the	  effects	  of:	  1)	  smoke	  exposure;	  and	  2)	  pain.	  NGFR	  (p75NTR)	  and	  IL1β	  were	  elevated	  in	  some	  datasets	  but	  suppressed	  in	  at	  least	  one	  study	  after	  smoke	  exposure,	  indicating	  differential	  effects	  based	  on	  tissue	  or	  cell	  type.	  Both	  of	  these	  genes	  have	  been	  reported	  to	  enhance	  hyperalgesia	  through	  greater	  protein	  expression	  of	  IL1β	  (28)	  or	  binding	  by	  NGF	  to	  either	  p75NTR	  or	  TrkA	  (reviewed	  in	  Mizumura	  and	  Murase	  (224)).	  NTRK1	  (TrkA),	  the	  high-­‐affinity	  NGF	  receptor,	  was	  not	  affected	  by	  pain	  or	  smoking	  in	  any	  studies	  using	  the	  search	  criteria,	  although	  it	  is	  well	  established	  that	  binding	  with	  NGF	  produces	  hyperalgesia.	  	  Twelve	  genes	  were	  differentially	  expressed	  after	  smoke	  exposure.	  Although	  associated	  with	  pain	  in	  other	  published	  works	  (30,	  74,	  75,	  184,	  262,	  318,	  330,	  331,	  344,	  350,	  367,	  378,	  384),	  expression	  of	  these	  genes	  was	  not	  associated	  with	  pain	  in	  the	  existing	  transcription	  profiles:	  cytokines	  CXCL1,	  CXCL2,	  CXCL10,	  IL6,	  IL6R,	  and	  IL18;	  TRAF6;	  ERK-­‐related	  proteins	  MAP3K14	  and	  MAP3K8;	  and	  NFκB	  pathway	  components	  IKBKB,	  NFKBIA,	  and	  CHUK.	  Changes	  in	  the	  expression	  of	  cytokines	  CXCL1	  and	  CXCL2	  were	  equivocal	  (Table	  5.3)	  while	  studies	  testing	  CXCL10,	  IL6,	  and	  IL6R	  showed	  elevated	  responses,	  only.	  Published	  reports	  indicate	  that	  IL-­‐6	  stimulates	  hyperalgesia	  (74,	  75).	  TRAF6,	  which	  acts	  upstream	  of	  ERK	  and	  NFκB,	  was	  elevated	  with	  smoke	  exposure	  in	  two	  published	  studies	  and	  may	  serve	  to	  maintain	  hyperalgesia	  (184).	  In	  the	  in	  silico	  analyses,	  smokers	  had	  elevated	  expression	  of	  ERK	  pathway	  components	  MAP3K14	  (one	  study)	  and	  MAP3K8	  (two	  studies)—activity	  of	  each	  protein	  result	  in	  downstream	  activation	  of	  ERK	  and	  NFκB	  (MAP3K14	  only).	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IKBKB,	  an	  inhibitor	  of	  the	  canonical	  NFκB	  pathway,	  was	  suppressed	  in	  one	  study;	  another	  inhibitor,	  NFKBIA,	  was	  also	  suppressed	  in	  one	  study	  but	  elevated	  by	  smoking	  in	  five	  studies.	  Expression	  of	  CHUK,	  which	  activates	  the	  non-­‐canonical	  NFκB	  pathway,	  was	  enhanced	  in	  two	  studies.	  Together,	  these	  data	  suggest	  an	  effect	  of	  smoking	  on	  NFκB	  activity,	  but	  the	  direction	  of	  this	  putative	  activity	  is	  unknown	  in	  muscle.	  Four	  of	  these	  genes	  (MAP3K14,	  MAP3K8,	  IKBKB,	  and	  NFKBIA)	  are	  not	  directly	  associated	  with	  hyperalgesia,	  although	  their	  downstream	  targets,	  ERK	  and	  NFκB,	  are	  associated	  with	  hyperalgesia	  (85,	  111,	  173,	  196,	  335,	  355,	  369,	  373).	  	  Together,	  the	  GEO	  profile	  analyses	  indicate	  that	  the	  interrelated	  NGF,	  ERK,	  and	  NFκB	  pathway	  activities	  may	  be	  altered	  in	  smokers.	  Given	  that	  these	  pathways	  are	  also	  involved	  in	  the	  post-­‐exercise	  muscle	  response,	  hyperalgesia,	  and	  that	  smokers	  had	  greater	  DOMS	  in	  my	  previous	  study,	  I	  hypothesized	  that	  their	  activity	  would	  be	  affected	  by	  eccentric	  exercise.	  Specifically,	  I	  hypothesized	  that	  at	  48h	  post-­‐ECC:	  1)	  activity	  of	  the	  canonical	  NFκB	  pathway	  would	  be	  suppressed	  in	  non-­‐smokers	  but	  not	  in	  smokers,	  while	  the	  non-­‐canonical	  (alternative)	  pathway	  would	  increase	  in	  non-­‐smokers	  but	  not	  in	  smokers;	  2)	  nuclear	  activity	  of	  the	  ERK	  pathway	  would	  increase	  for	  non-­‐smokers	  while	  activity	  would	  be	  concentrated	  in	  the	  cytoplasm	  for	  smokers;	  and	  3)	  NGF	  levels	  and	  binding	  with	  receptors	  would	  be	  more	  pronounced	  in	  smokers.	  Based	  on	  the	  GEO	  profile	  analyses,	  I	  validated	  key	  targets	  (including	  NFκB,	  ERK,	  and	  NGF)	  by	  subjecting	  non-­‐smokers	  and	  smokers	  to	  ECC	  and	  tested	  muscle	  biopsy	  samples	  for	  mRNA	  and	  protein	  expression,	  protein	  activity,	  and	  protein	  localization.	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Validation	  Study	  
Subjects	  All	  subjects	  conformed	  to	  the	  study	  requirements	  and	  successfully	  completed	  the	  exercise	  protocol.	  One	  subject	  was	  removed	  from	  analyses	  after	  experiencing	  an	  intramuscular	  hematoma.	  Characteristics	  for	  the	  remaining	  subjects	  are	  presented	  in	  Table	  5.4.	   	  
Creatine	  Kinase	  Activity	  The	  two	  groups	  had	  similar	  plasma	  activity	  of	  creating	  kinase	  (CK)	  prior	  to	  exercise,	  with	  pre-­‐exercise	  levels	  of	  150.4±36.8U/L	  for	  non-­‐smokers	  and	  122.3±24.0	  for	  smokers.	  The	  groups	  responded	  to	  the	  exercise	  similarly:	  increased	  activity	  post-­‐exercise	  (p<0.05)	  for	  both	  non-­‐smokers	  (477.3±85.4)	  and	  smokers	  (581.3±140.8),	  with	  no	  significant	  group	  differences	  (p=0.4).	  	  	  
Eccentric	  Exercise	  and	  Isometric	  Maximal	  Voluntary	  Contractions	  (MVC)	  During	  the	  exercise	  session,	  non-­‐smokers	  and	  smokers	  did	  similar	  amounts	  of	  work,	  with	  average	  work	  performed	  per	  repetition	  of	  288.8±5.7	  for	  non-­‐smokers	  and	  282.9±9.2	  for	  smokers.	  There	  was	  an	  effect	  of	  exercise	  set,	  with	  a	  reduction	  of	  work	  produced	  as	  the	  sets	  progressed	  (p<0.05).	  There	  was	  no	  interaction	  between	  set	  and	  smoking	  group	  (p=0.45)	  or	  main	  effect	  of	  smoking	  status	  (p=0.2).	  Peak	  eccentric	  torque	  also	  decreased	  over	  the	  course	  of	  the	  session	  with	  a	  significant	  interaction	  (p<0.05)	  and	  main	  effect	  of	  set	  (p<0.05),	  but	  no	  main	  effect	  of	  smoking	  status	  (p=0.16).	  Smokers	  decreased	  peak	  eccentric	  torque	  more	  rapidly,	  while	  non-­‐
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smokers	  declined	  more	  gradually.	  However,	  when	  expressed	  as	  a	  percent	  of	  baseline	  (Figure	  5.2),	  the	  significant	  effect	  of	  set	  remained	  (p<0.05),	  while	  the	  interaction	  (p=0.10)	  and	  group	  effect	  (p=0.98)	  did	  not	  reach	  significance.	  	  Before	  exercise,	  there	  were	  no	  significant	  differences	  for	  baseline	  extension	  isometric	  strength	  (MVC,	  non-­‐smokers:	  264.6±14.3N•m;	  smokers:	  234.9±17.2N•m,	  p=0.2).	  The	  exercise*smoking	  interaction	  effect	  was	  non-­‐significant	  when	  data	  were	  expressed	  as	  raw	  numbers	  (p=0.37)	  or	  percent	  of	  pre-­‐exercise	  levels	  (p=0.4),	  and	  there	  was	  no	  effect	  of	  smoking	  status	  (raw:	  p=0.16;	  percent	  baseline:	  p=0.64).	  There	  was	  a	  significant	  effect	  of	  exercise	  on	  both	  raw	  and	  normalized	  MVC	  (p<0.05).	  At	  5min	  post-­‐exercise,	  both	  groups	  experienced	  approximately	  25-­‐30%	  strength	  loss	  (Figure	  5.3).	  At	  4d	  after	  exercise,	  recovery	  was	  significantly	  suppressed	  for	  both	  groups	  (p<0.05;	  non-­‐smokers:	  1d	  77.8±5.5N•m	  vs	  4d	  78.6±7.2;	  smokers:	  1d	  76.4±6.4N•m	  vs	  4d	  68.7±7.6).	  This	  may	  have	  been	  a	  side	  effect	  of	  the	  muscle	  biopsy,	  which	  was	  obtained	  at	  48h	  post-­‐exercise.	  At	  9d,	  MVC	  were	  no	  longer	  significantly	  different	  from	  pre-­‐exercise	  levels	  for	  both	  raw	  values	  (p=0.59)	  and	  percent	  of	  pre-­‐exercise	  levels	  (p=0.58).	  As	  with	  extension,	  there	  were	  no	  significant	  differences	  for	  flexion	  strength	  before	  exercise	  (MVC,	  non-­‐smokers:	  121.3±8.3;	  smokers:	  106.1±4.0).	  The	  exercise*smoking	  interaction	  term	  was	  significant	  for	  both	  raw	  and	  data	  normalized	  to	  pre-­‐exercise	  levels	  (p<0.05),	  and	  there	  was	  a	  significant	  main	  effect	  of	  smoking	  status	  for	  raw	  data	  (p<0.05)	  but	  not	  for	  exercise	  (p=0.06);	  when	  normalized	  to	  pre-­‐exercise	  levels,	  the	  effect	  of	  smoking	  did	  not	  persist	  (p=0.40)	  while	  the	  effect	  of	  exercise	  was	  significant	  (p<0.05).	  Both	  the	  exercise*smoking	  interaction	  term	  and	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exercise	  effect	  were	  driven	  by	  differences	  in	  exercise	  response	  at	  4d	  post-­‐exercise	  (2d	  post-­‐biopsy),	  when	  non-­‐smokers	  remained	  at	  pre-­‐exercise	  levels	  while	  smokers	  decreased	  in	  flexion	  to	  approximately	  81%	  of	  baseline.	  As	  with	  extension	  measures,	  this	  effect	  had	  resolved	  by	  9d.	  These	  data	  are	  presented	  in	  Table	  5.5.	  
	  
PCR	  Arrays	  mRNA	  quantification	  via	  PCR	  array	  are	  presented	  as	  fold	  change	  (Table	  5.6,	  Supplemental),	  with	  significantly	  dysregulated	  genes	  shown	  in	  Figure	  5.4.	  Expression	  for	  five	  genes	  was	  significantly	  different	  with	  exercise	  overall,	  with	  upregulation	  of	  AKT1,	  CDKN1A,	  and	  MAP2K1,	  and	  downregulation	  of	  PDK2	  and	  VEGFA.	  There	  was	  no	  effect	  of	  group	  (smoking)	  for	  any	  gene	  of	  interest.	  There	  was	  a	  significant	  exercise*group	  interaction	  for	  three	  genes,	  such	  that	  smokers	  experienced	  a	  reduced	  fold	  change	  in	  comparison	  to	  non-­‐smokers:	  ACTA1	  (27%	  lower),	  FIGF	  (encodes	  for	  the	  VEGF-­‐D	  protein,	  50%	  lower),	  and	  PDPK1	  (26%	  lower).	  Smokers	  had	  lower	  expression	  of	  these	  genes	  after	  ECC,	  while	  non-­‐smokers	  displayed	  either	  baseline	  levels	  of	  expression	  or	  an	  increase.	  Similar	  expression	  patterns	  occurred	  after	  ECC	  (smokers	  down-­‐regulated,	  non-­‐smokers	  up-­‐regulated	  or	  no	  change)	  for	  components	  of	  the	  ERK1/2	  (MAP2K1,	  MAPK1,	  MAPK3)	  and	  NFκB	  (CHUK,	  NFKBIA,	  REL)	  pathways,	  although	  these	  did	  not	  reach	  the	  more	  stringent	  significance	  levels	  required	  when	  testing	  multiple	  genes.	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qRT-­‐PCR	  The	  steady	  state	  levels	  of	  three	  transcripts	  identified	  previously	  (Dissertation	  Study	  2,	  Chapter	  4)	  were	  also	  analyzed	  by	  qRT-­‐PCR:	  TRAF6,	  NFKBIA	  (an	  inhibitor	  of	  NFκB),	  and	  NGF	  (Figure	  5.5).	  In	  the	  control	  leg,	  the	  expression	  of	  these	  genes	  did	  not	  differ	  between	  smokers	  and	  non-­‐smokers,	  suggesting	  that	  there	  were	  no	  baseline	  differences	  in	  expression.	  TRAF6	  is	  involved	  in	  the	  activation	  of	  numerous	  pathways,	  including	  ERK1/2	  and	  NFκB.	  TRAF6	  expression	  in	  response	  to	  exercise	  was	  not	  significantly	  different	  between	  groups	  (p=0.16)	  and	  did	  not	  differ	  in	  response	  to	  exercise	  (p=0.35)	  or	  between	  groups	  (0.52).	  Because	  TRAF6	  activation	  stimulates	  ERK	  and	  NFκB	  activity	  and	  TRAF6	  was	  upregulated	  early	  (3h)	  post-­‐ECC,	  no	  difference	  in	  expression	  at	  48h	  versus	  control	  may	  indicate	  a	  decrease	  in	  activation	  of	  ERK1/2,	  NFκB,	  and	  other	  related	  pathways	  by	  virtue	  of	  decreased	  TRAF6	  expression.	  NFKBIA	  expression	  in	  response	  to	  exercise	  was	  similar	  between	  groups	  (p=0.24).	  Furthermore,	  NFKBIA	  expression	  was	  not	  significantly	  changed	  with	  exercise	  (p=0.69)	  or	  as	  a	  result	  of	  smoking	  status	  (p=0.29).	  The	  exercise	  response	  of	  NGF	  was	  also	  similar	  between	  smokers	  and	  non-­‐smokers	  (p=0.88),	  and	  there	  was	  no	  overall	  effect	  of	  smoking	  (p=0.93).	  While	  both	  groups	  appeared	  to	  have	  higher	  NGF	  expression	  after	  exercise,	  this	  did	  not	  reach	  significance	  (p=0.09).	  	  	  
NFκB	  activity	  Nuclear	  activity	  of	  the	  canonical	  (p65)	  and	  non-­‐canonical	  (REL-­‐B)	  NFκB	  pathways	  revealed	  differences	  between	  smokers	  and	  non-­‐smokers	  in	  response	  to	  exercise	  (Figure	  5.6).	  There	  were	  no	  differences	  in	  baseline	  (control	  leg)	  REL-­‐B	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activity	  between	  groups	  (3.8%	  lower	  in	  smokers).	  There	  was	  a	  significant	  interaction	  between	  exercise	  and	  smoking	  (p<0.05):	  non-­‐smokers	  experienced	  enhanced	  REL-­‐B	  activity	  in	  the	  exercised	  leg	  (148%	  greater)	  while	  smokers	  failed	  to	  display	  a	  difference	  between	  exercised	  and	  control	  legs	  (102%).	  There	  was	  no	  overall	  effect	  of	  exercise	  on	  REL-­‐B	  activity,	  although	  smokers	  had	  significantly	  lower	  REL-­‐B	  activity	  (~21%	  lower,	  p<0.05).	  In	  the	  control	  leg,	  non-­‐smokers	  had	  a	  higher	  level	  of	  p65	  activity	  as	  compared	  to	  smokers	  (60%	  greater	  in	  non-­‐smokers,	  p<0.05).	  In	  response	  to	  the	  exercise,	  smokers	  and	  non-­‐smokers	  differed	  significantly	  in	  p65	  activity	  (p<0.05).	  When	  compared	  to	  control,	  non-­‐smokers	  had	  considerably	  lower	  p65	  activity	  in	  the	  exercised	  legs	  (14%	  of	  control),	  whereas	  smokers	  did	  not	  differ	  significantly	  between	  legs	  (exercise	  leg:	  6%	  lower	  than	  control).	  The	  overall	  effect	  of	  exercise	  on	  p65	  activity	  did	  not	  reach	  significance	  (p=0.07),	  and	  there	  was	  no	  overall	  effect	  of	  smoking	  status.	  	  	  
ERK	  Activity	  ERK	  is	  activated	  through	  phosphorylation	  (pERK),	  which	  in	  turn	  activates	  distinct	  signaling	  pathways	  in	  the	  cytosol	  and	  nucleus.	  The	  amount	  of	  total	  ERK,	  and	  therefore	  the	  total	  capacity	  for	  activation,	  generally	  remains	  unchanged	  in	  response	  to	  a	  variety	  of	  stimuli	  and	  is	  often	  used	  as	  a	  secondary	  control	  for	  ERK	  activity	  (ERK	  activity	  ratio).	  However,	  total	  ERK	  may	  differ	  between	  smokers	  and	  non-­‐smokers.	  Both	  pERK	  and	  total	  ERK	  protein	  levels	  were	  normalized	  to	  the	  loading	  control	  GAPDH.	  Because	  pERK	  and	  total	  ERK	  were	  probed	  using	  different	  antibodies,	  their	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values	  could	  not	  be	  compared	  directly.	  However,	  normalization	  relative	  to	  GAPDH	  is	  possible,	  and	  these	  normalized	  data	  are	  discussed	  below	  and	  presented	  in	  Figure	  5.7.	  	   Exercise	  did	  not	  affect	  the	  relative	  levels	  of	  pERK	  or	  total	  ERK—overall	  or	  as	  an	  interaction	  with	  smoking.	  In	  nuclear	  fractions,	  there	  was	  greater	  total	  (45%,	  p<0.05)	  and	  pERK	  (290%,	  p<0.05)	  compared	  to	  cytosol,	  which	  did	  not	  differ	  with	  exercise.	  Smokers	  had	  lower	  total	  ERK	  than	  non-­‐smokers,	  specifically	  in	  the	  nuclear	  compartment	  (38%	  of	  non-­‐smokers,	  p<0.05).	  Therefore,	  the	  ERK	  activity	  ratio	  could	  not	  be	  used;	  rather,	  total	  ERK	  was	  included	  as	  a	  covariate	  in	  the	  pERK	  statistical	  model,	  yielding	  pERKtotal	  (the	  amount	  of	  pERK	  relative	  to	  total	  ERK	  levels).	  	  Without	  total	  ERK	  as	  covariate,	  the	  sole	  significant	  finding	  was	  lower	  cytosolic	  pERK	  in	  smokers	  when	  compared	  to	  non-­‐smokers	  (59%	  of	  non-­‐smokers,	  p<0.05).	  When	  expressed	  as	  pERKtotal,	  this	  no	  longer	  met	  significance	  criteria	  (p=0.09).	  Yet	  differences	  in	  pERKtotal	  indicated	  that	  smokers	  had	  greater	  ERK	  activity	  relative	  to	  the	  total	  amount	  of	  ERK	  available	  in	  the	  nuclear	  compartment	  than	  non-­‐smokers	  (p<0.05).	  	  Together,	  these	  data	  indicate	  that	  smokers	  had	  a	  lower	  capacity	  for	  ERK	  activity,	  specifically	  in	  the	  nucleus,	  yet	  used	  a	  greater	  percentage	  of	  available	  ERK	  for	  signaling	  within	  the	  nucleus.	  However,	  there	  was	  no	  difference	  in	  overall	  pERK	  between	  groups	  in	  the	  nucleus	  (p=0.37).	  Smokers	  did	  have	  less	  pERK	  in	  the	  cytosol	  (p<0.05),	  indicating	  that	  there	  may	  be	  a	  general	  suppression	  of	  cytosol-­‐specific	  ERK	  signaling.	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Immunohistochemistry	  Sample	  availability	  was	  limited	  for	  immunohistochemical	  analyses	  so	  samples	  from	  only	  three	  non-­‐smokers	  and	  four	  smokers	  were	  used	  to	  test	  the	  following	  parameters:	  1)	  fiber	  type	  distribution	  via	  myosin	  heavy	  chain-­‐I;	  2)	  muscle	  damage	  via	  tenascin-­‐c	  expression;	  3)	  protein	  levels	  of	  NGF	  and	  its	  receptors,	  TrkA	  and	  p75NTR;	  and	  4)	  co-­‐localization	  of	  NGF	  and	  each	  of	  its	  receptors	  (TrkA	  and	  p75NTR).	  	  
Fiber	  Type	  Distribution:	  Myosin	  Heavy	  Chain-­‐I	  Anti-­‐MHC-­‐I	  immunofluorescence	  analysis	  of	  skeletal	  muscle	  sections	  revealed	  that	  there	  were	  differences	  in	  fiber	  type	  composition	  between	  groups	  (p<0.05):	  non-­‐smokers	  had	  significantly	  greater	  fibers	  positively	  stained	  for	  MHC-­‐I	  (Type	  I	  oxidative)	  than	  smokers	  (p<0.05,	  Figure	  5.8).	  Both	  groups	  had	  similar	  numbers	  of	  fibers	  (non-­‐smokers:	  183±17	  fibers;	  smokers	  202±25	  fibers),	  but	  while	  non-­‐smokers	  had	  an	  approximately	  equal	  fiber	  type	  distribution,	  smokers	  had	  13%	  lower	  MHC-­‐I-­‐positive	  fibers.	  	  	  
Tenascin-­‐C	  Tenascin-­‐c	  (TNC)	  was	  used	  as	  an	  indicator	  of	  muscle	  damage	  and	  remodeling.	  It	  appeared	  that	  smokers	  had	  greater	  TNC	  levels	  post-­‐exercise	  (non-­‐smokers	  control	  vs	  exercise:	  5276±1701	  pixels	  vs	  15917±5630;	  smokers:	  2700±1195	  pixels	  vs	  23150±12732,	  p=0.88,	  Figure	  5.9).	  However,	  this	  was	  a	  small	  sample	  size	  with	  high	  variability	  for	  TNC	  expression,	  and	  the	  exercise	  response	  did	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not	  differ	  significantly	  between	  smokers	  and	  non-­‐smokers,	  nor	  was	  there	  a	  significant	  effect	  of	  group.	  TNC	  levels	  were,	  however,	  significantly	  higher	  after	  exercise	  in	  both	  groups	  (p<0.05),	  indicating	  that	  the	  exercise	  was	  sufficient	  to	  elicit	  damage.	  	  	  
NGF,	  TrkA,	  and	  p75NTR	  NGF	  localized	  primarily	  to	  the	  muscle	  membrane,	  although	  staining	  of	  some	  nuclei	  was	  evident	  (Figure	  5.10,	  center).	  There	  were	  no	  significant	  effects	  of	  smoking	  or	  exercise,	  and	  no	  significant	  interaction	  between	  the	  two	  (Figure	  5.12a).	  When	  data	  from	  control	  and	  exercised	  muscle	  were	  combined,	  differences	  between	  smokers	  and	  non-­‐smokers	  remained	  insignificant	  (p=0.10).	  NGF	  elicits	  different	  responses	  based	  on	  which	  of	  two	  receptors	  it	  binds,	  and	  therefore	  differences	  in	  the	  number	  of	  receptors	  and	  co-­‐localization	  may	  contribute	  to	  DOMS	  and	  other	  downstream	  signaling.	  Therefore,	  I	  examined	  the	  expression	  of	  the	  low-­‐affinity	  receptor	  p75NTR	  and	  the	  high	  affinity	  receptor	  TrkA	  and	  their	  presumptive	  binding	  to	  NGF	  using	  co-­‐localization.	  Low-­‐level	  signal	  of	  TrkA	  appeared	  to	  be	  localized	  to	  the	  membrane	  (Figure	  5.10,	  right).	  There	  was	  a	  significant	  interaction	  (p<0.05)	  between	  smoking	  and	  exercise,	  indicating	  that	  smokers	  had	  greater	  levels	  of	  TrkA	  after	  ECC,	  while	  non-­‐smokers	  had	  slightly	  lower	  levels	  after	  ECC	  (Figure	  5.12a).	  There	  was	  no	  overall	  effect	  of	  exercise	  or	  group.	  TrkA	  and	  NGF	  were	  co-­‐localized	  (Figure	  5.10,	  left;	  Figure	  5.12b)	  in	  25%	  of	  the	  total	  signal	  volume	  of	  the	  sections	  for	  both	  groups.	  Roughly	  55%	  of	  total	  TrkA	  signal	  was	  co-­‐localized	  with	  NGF,	  and	  57%	  of	  total	  NGF	  signal	  was	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co-­‐localized	  with	  TrkA.	  There	  were	  no	  significant	  differences	  in	  co-­‐localization	  of	  these	  proteins	  with	  exercise,	  smoking,	  or	  their	  interaction,	  and	  the	  co-­‐localization	  correlation	  was	  weak	  for	  exercise	  (non-­‐smokers:	  r=0.31;	  smokers:	  r=0.32)	  and	  moderate	  for	  control	  (non-­‐smokers:	  r=0.44;	  smokers:	  r=0.50).	  The	  tissue	  distribution	  of	  p75NTR	  was	  similar	  to	  that	  of	  NGF	  (Figure	  5.11,	  center).	  There	  was	  no	  interaction	  between	  exercise	  and	  smoking	  and	  no	  effect	  of	  exercise	  for	  p75NTR	  expression.	  However,	  smokers	  had	  significantly	  greater	  p75NTR	  expression	  overall	  (p<0.05,	  Figure	  5.12a).	  There	  was	  a	  significant	  interaction	  (p<0.05)	  between	  smoking	  and	  exercise	  for	  the	  percent	  volume	  of	  co-­‐localization	  between	  p75NTR	  and	  NGF	  (Figure	  5.11a,	  Figure	  5.12c).	  Co-­‐localization	  of	  p75NTR	  and	  NGF	  in	  non-­‐smokers	  was	  40%	  of	  the	  total	  signal	  volume	  in	  the	  control	  leg	  and	  decreased	  to	  31%	  in	  the	  exercised	  leg.	  Compared	  to	  non-­‐smokers,	  co-­‐localization	  of	  p75NTR	  and	  NGF	  was	  greater	  in	  the	  control	  leg	  (59%	  of	  total	  signal	  volume)	  and	  increased	  to	  72%	  in	  the	  exercise	  leg.	  Overall,	  co-­‐localization	  did	  not	  differ	  significantly	  between	  smokers	  and	  non-­‐smokers	  (p=0.07).	  There	  was	  an	  overall	  effect	  of	  smoking	  on	  the	  percent	  of	  total	  signal	  co-­‐localized	  for	  p75NTR	  (p<0.05)	  and	  NGF	  (p<0.05).	  In	  control	  legs,	  74%	  of	  total	  p75NTR	  and	  NGF	  signals	  were	  co-­‐localized	  in	  non-­‐smokers,	  with	  86%	  co-­‐localization	  in	  smokers.	  In	  the	  exercised	  legs	  of	  non-­‐smokers,	  56%	  of	  total	  p75NTR	  signal	  co-­‐localized	  with	  70%	  of	  NGF	  signal;	  for	  smokers,	  this	  co-­‐localization	  was	  93%	  for	  p75NTR	  and	  90%	  for	  NGF.	  The	  co-­‐localization	  correlation	  was	  strong	  for	  control	  and	  exercise	  in	  both	  groups	  (control,	  smokers	  and	  non-­‐smokers:	  r=0.70;	  exercise:	  non-­‐smokers	  r=0.73,	  smokers	  r=0.66).	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NGF	  is	  a	  secreted	  factor	  that	  can	  translocation	  into	  the	  cytoplasm	  via	  endosomal	  transportation	  and	  may	  play	  a	  role	  in	  the	  nucleus	  as	  a	  transcription	  factor	  in	  conjunction	  with	  other	  signaling	  molecules.	  In	  this	  study,	  I	  found	  significant	  co-­‐localization	  of	  NGF	  with	  nuclei	  that	  decreased	  after	  exercise	  (p<0.05,	  data	  not	  shown).	  There	  was	  also	  a	  significant	  interaction	  between	  smoking	  status	  and	  exercise:	  after	  ECC,	  non-­‐smokers	  experienced	  a	  significant	  decrease	  in	  NGF-­‐nuclear	  co-­‐localization	  (p<0.05),	  while	  the	  decrease	  for	  smokers	  did	  not	  reach	  significance	  (control:	  non-­‐smokers,	  6.8%	  total	  signal	  volume;	  smokers,	  5.1%;	  exercise:	  non-­‐smokers,	  4.0%;	  smokers,	  3.5%).	  These	  are	  preliminary	  findings,	  however,	  that	  require	  additional	  study	  to	  determine	  the	  specific	  cell	  types	  in	  which	  this	  co-­‐localization	  occurs.	  	  
Discussion	  This	  study	  tested	  mechanisms	  hypothesized	  to	  explain	  greater	  muscle	  fatigue	  and	  DOMS	  in	  smokers	  after	  ECC	  (Dissertation	  Study	  1,	  Chapter	  3),	  specifically	  if:	  1)	  REL-­‐B	  activity	  and	  fiber	  type	  distribution	  differed	  between	  muscle	  of	  smokers	  and	  non-­‐smokers	  (fatigue);	  and	  2)	  NFκB	  and	  ERK	  activity,	  along	  with	  NGF	  protein	  levels,	  were	  altered	  in	  smokers	  (DOMS).	  I	  hypothesized	  that:	  1)	  smokers	  would	  have	  a	  greater	  proportion	  of	  Type	  II	  fibers	  and	  suppressed	  REL-­‐B	  activity	  at	  48h	  post-­‐ECC	  compared	  to	  non-­‐smokers;	  2)	  after	  ECC	  the	  activity	  of	  the	  canonical	  NFκB	  pathway	  would	  be	  suppressed	  in	  non-­‐smokers	  but	  not	  in	  smokers;	  3)	  nuclear	  activity	  of	  the	  ERK	  pathway	  would	  increase	  for	  non-­‐smokers	  while	  activity	  would	  be	  concentrated	  in	  the	  cytoplasm	  for	  smokers;	  and	  4)	  NGF	  levels	  and	  receptor	  co-­‐localization	  would	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be	  more	  pronounced	  in	  smokers	  versus	  non-­‐smokers.	  To	  my	  knowledge,	  this	  was	  the	  first	  study	  to	  investigate	  the	  effects	  of	  chronic	  cigarette	  smoking	  on	  molecular	  responses	  of	  skeletal	  muscle	  to	  ECC	  in	  humans.	  	  I	  hypothesized	  that	  smokers	  would	  have	  a	  greater	  ratio	  of	  Type	  II:Type	  I	  muscle	  fibers	  and	  suppressed	  REL-­‐B	  activity	  when	  compared	  to	  smokers.	  In	  the	  current	  study,	  histochemical	  analysis	  revealed	  a	  greater	  prevalence	  of	  Type	  II	  muscle	  fibers	  in	  smokers	  (~60%	  total	  fibers),	  while	  non-­‐smokers	  had	  ~1:1	  ratio	  of	  Type	  I	  and	  Type	  II	  fibers.	  While	  still	  equivocal,	  other	  studies	  have	  reported	  similar	  fiber	  type	  shifts	  with	  cigarette	  smoke	  exposure	  (72,	  162,	  169,	  290,	  328).	  Other	  potential	  mechanisms	  underlying	  muscle	  fatigue	  in	  smokers	  have	  been	  reviewed	  in	  greater	  detail	  previously	  (Dissertation	  Study	  1,	  Chapter	  3).	  I	  provide	  evidence	  that	  supports	  the	  sparse	  published	  research	  linking	  smoking	  to	  muscle	  fatigue	  and	  fiber	  type	  shift	  and,	  further,	  provide	  a	  potential	  mechanism:	  REL-­‐B	  pathway	  activation	  post-­‐ECC	  (which,	  among	  its	  functions,	  promotes	  oxidative	  metabolism	  (12,	  13)),	  was	  suppressed	  in	  smokers.	  Shifts	  in	  fiber	  type	  distribution	  (greater	  Type	  II	  than	  controls)	  in	  response	  to	  smoke	  exposure	  (162,	  328)	  and	  greater	  muscle	  fatigue	  (328)	  have	  been	  associated	  with	  suppressed	  PGC-­‐1	  expression.	  The	  PGC-­‐1	  protein	  family	  promotes	  the	  development	  of	  Type	  I	  muscle	  fibers	  (12,	  328)	  and	  can	  be	  activated	  by	  REL-­‐B,	  and,	  therefore,	  the	  suppressed	  REL-­‐B	  response	  in	  smokers	  may	  attenuate	  PGC-­‐1	  signaling	  and	  lead	  to	  a	  predominance	  of	  Type	  II	  fibers.	  Given	  that	  smokers	  had	  fewer	  Type	  I	  oxidative	  fibers	  and,	  in	  Dissertation	  Study	  1	  (Chapter	  3),	  smokers	  experienced	  less	  fatigue	  resistance	  during	  ECC	  than	  non-­‐smokers,	  my	  data	  suggest	  a	  mechanism	  through	  which	  smoking	  promotes	  a	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fiber	  type	  shift	  in	  favor	  of	  more	  fatigable	  Type	  II	  fibers.	  This	  fiber	  type	  distribution	  could	  predispose	  smokers	  to	  greater	  risk	  for	  injury:	  smokers	  may	  rely	  on	  other,	  weaker	  muscles	  and/or	  muscles	  may	  fail	  to	  perform	  tasks	  safely.	  Type	  II	  fibers	  are	  more	  susceptible	  to	  injury,	  possibly	  through	  lower	  fatigue	  resistance,	  greater	  potential	  loads	  imposed	  upon	  these	  fibers,	  or	  other	  as	  of	  yet	  unknown	  mechanisms.	  These	  data	  therefore	  may	  explain	  the	  greater	  risk	  for	  injury	  in	  smokers.	  Smoking-­‐suppressed	  REL-­‐B	  activity	  in	  non-­‐muscle	  cells	  is	  also	  associated	  with	  increased	  pro-­‐inflammatory	  signaling	  including	  COX2	  activity,	  while	  overexpression	  of	  REL-­‐B	  rescues	  cigarette	  smoke-­‐induced	  pro-­‐inflammatory	  responses	  and	  reduces	  COX2	  and	  prostaglandin	  E2	  expression(218).	  These	  data	  indicate	  that	  suppressed	  REL-­‐B	  activity	  in	  smokers	  may	  also	  contribute	  to	  DOMS	  in	  smokers.	  Based	  on	  previously	  published	  reports	  and	  findings	  from	  Dissertation	  Study	  2	  (Chapter	  4),	  I	  hypothesized	  that	  the	  canonical	  NFκB	  pathway	  would	  be	  suppressed	  in	  non-­‐smokers,	  but	  not	  in	  smokers.	  In	  Dissertation	  Study	  2,	  p65	  DNA	  binding	  activity	  (pro-­‐inflammatory)	  was	  suppressed	  at	  48h	  post-­‐ECC	  in	  non-­‐smokers.	  In	  the	  current	  study,	  p65	  activity	  did	  not	  change	  after	  ECC	  in	  smokers.	  This	  finding	  is	  novel,	  as	  NFκB	  activity	  had	  yet	  to	  be	  tested	  in	  the	  skeletal	  muscle	  of	  smokers	  after	  ECC.	  Skeletal	  muscle	  activity	  of	  the	  pro-­‐inflammatory	  canonical	  NFκB	  pathway	  has	  been	  tested	  in	  only	  a	  small	  handful	  of	  studies,	  with	  equivocal	  results	  (119,	  291).	  Recent	  research	  has	  shown	  increased	  NFκB	  activity	  in	  vitro	  during	  proliferation	  of	  myoblasts	  that	  decreases	  during	  differentiation	  (13),	  and	  enhanced	  activity	  early	  (3h)	  after	  ECC	  (137).	  Enhanced	  activity	  of	  the	  canonical	  pathways	  is	  well	  established	  in	  response	  to	  smoking,	  although	  it	  had	  not	  yet	  been	  evaluated	  in	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skeletal	  muscle	  of	  smokers.	  p65	  is	  considered	  a	  keystone	  of	  inflammation,	  the	  activity	  of	  which	  promotes	  pro-­‐inflammatory	  signaling.	  The	  current	  data	  suggest	  a	  lack	  of	  pro-­‐inflammatory	  resolution	  at	  48h	  in	  smokers,	  which	  may	  negatively	  impact	  healing	  and	  adaptation.	  Failed	  inflammatory	  resolution	  could	  also	  prolong	  hyperalgesic	  signaling.	  ERK	  stimulates	  gene	  expression	  (including	  anti-­‐inflammatory	  genes)	  and	  can	  affect	  canonical	  NFκB	  pathway	  activity	  in	  the	  cytoplasm.	  Therefore	  I	  hypothesized	  that	  nuclear	  ERK	  activity	  would	  increase	  for	  non-­‐smokers	  and	  remain	  concentrated	  in	  the	  cytoplasm	  for	  smokers.	  Because	  pERK	  was	  not	  affected	  by	  ECC	  at	  48h,	  these	  data	  do	  not	  explain	  suppressed	  p65	  activity	  in	  non-­‐smokers.	  pERK	  may	  have	  suppressed	  p65	  activity	  before	  48h,	  yet	  this	  change	  in	  activity	  could	  have	  resulted	  through	  other	  mechanisms.	  In	  the	  current	  study,	  pERK	  was	  suppressed	  in	  the	  cytosol	  of	  smokers	  (both	  legs).	  Cigarette	  smoke	  extract	  or	  components,	  including	  nicotine,	  invoke	  rapid	  and	  transient	  activation	  of	  ERK1/2	  in	  non-­‐muscle	  tissue	  (177,	  243).	  The	  majority	  of	  studies	  report	  transient	  (~15min)	  ERK	  activation	  after	  smoke	  exposure,	  yet	  sustained	  changes	  to	  activity	  (333)	  may	  occur.	  In	  the	  current	  study	  smokers	  were	  required	  to	  have	  a	  cigarette	  10min	  prior	  to	  the	  muscle	  biopsy	  procedure	  (>30-­‐40min	  before	  sample	  collection),	  indicating	  that,	  after	  transient	  activation,	  smoking	  may	  induce	  chronic	  pERK	  suppression.	  Smokers	  also	  had	  lower	  total	  nuclear	  ERK	  compared	  to	  non-­‐smokers.	  To	  my	  knowledge,	  only	  one	  published	  study	  has	  reported	  changes	  to	  total	  ERK	  protein	  levels	  (144).	  Lower	  total	  ERK	  may	  limit	  the	  capacity	  for	  ERK	  activity;	  therefore,	  to	  maintain	  normal	  nuclear	  ERK	  signaling	  (indicated	  by	  similar	  nuclear	  pERK),	  smokers	  must	  activate	  a	  greater	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proportion	  of	  available	  ERK.	  Thus,	  smokers	  may	  have	  a	  lower	  ceiling	  for	  the	  extent	  of	  pERK	  activity	  and	  so	  when	  a	  more	  substantial	  ERK	  response	  is	  required,	  be	  unable	  to	  meet	  the	  demands.	  I	  originally	  postulated	  that	  NFκB	  and	  ERK	  affect	  hyperalgesia	  and,	  therefore,	  might	  contribute	  to	  greater	  DOMS	  experienced	  in	  smokers.	  It	  is	  possible	  that	  differences	  in	  NFκB	  and	  ERK	  activity	  early	  after	  ECC	  affected	  hyperalgesia,	  yet	  their	  early	  activity	  was	  not	  tested.	  NFκB	  activity	  did	  remain	  elevated	  compared	  to	  non-­‐smokers,	  and	  so	  may	  contribute	  to	  greater	  DOMS	  in	  smokers.	  However,	  the	  lack	  of	  change	  in	  ERK	  activity	  in	  smokers	  at	  48h,	  coupled	  with	  its	  suppressed	  activity	  compared	  with	  non-­‐smokers,	  suggests	  that	  ERK	  may	  not	  play	  a	  significant	  role	  in	  greater	  DOMS	  reported	  by	  smokers.	  NGF,	  which	  promotes	  hyperalgesia,	  is	  elevated	  in	  smokers,	  and	  so	  I	  hypothesized	  that	  levels	  of	  NGF	  and	  co-­‐localization	  with	  its	  receptors	  would	  be	  more	  pronounced	  in	  smokers	  than	  non-­‐smokers.	  An	  important	  factor	  in	  the	  development	  of	  hyperalgesia	  and	  specifically	  DOMS	  (reviewed	  in	  (224)),	  NGF	  exerts	  disparate	  downstream	  signaling	  by	  bindings	  to	  TrkA	  (ERK1/2)	  and	  p75NTR	  (canonical	  NFκB	  pathway)	  receptors,	  and	  both	  are	  implicated	  in	  hyperalgesia.	  Although	  evidence	  better	  supports	  TrkA	  in	  this	  role,	  p75NTR	  also	  can	  stimulate	  hyperalgesia	  (155).	  NGF	  can	  also	  bind	  simultaneously	  with	  p75NTR	  and	  TrkA	  and	  stimulate	  hyperalgesia	  (reviewed	  in	  (20)).	  Due	  to	  technical	  limitations,	  the	  co-­‐localization	  of	  NGF	  with	  both	  TrkA	  and	  p75NTR	  was	  not	  possible	  in	  the	  current	  study.	  	  In	  the	  current	  study,	  NGF	  was	  unaffected	  by	  smoking	  or	  exercise.	  While	  a	  limited	  sample,	  increased	  TrkA	  expression	  with	  exercise	  in	  smokers	  may	  indicate	  a	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greater	  potential	  for	  NGF	  binding.	  However,	  co-­‐localization	  with	  NGF	  was	  unchanged,	  suggesting	  that	  signaling	  downstream	  of	  TrkA	  was	  not	  affected.	  However,	  neurotrophin	  3	  (NTF-­‐3),	  another	  neutrophin,	  can	  bind,	  less	  efficiently	  than	  NGF,	  to	  TrkA	  and	  the	  location	  of	  that	  binding	  can	  either	  agonize	  or	  antagonize	  NGF	  effects	  (reviewed	  in	  (20)).	  It	  is	  therefore	  possible	  that,	  after	  ECC,	  NTF-­‐3	  also	  binds	  TrkA	  in	  smokers	  and	  this	  binding	  enhances	  its	  hyperalgesia.	  Future	  study	  should	  therefore	  include	  co-­‐localization	  of	  these	  neurotrophins	  to	  TrkA.	  	  Smokers	  experienced	  greater	  overall	  p75NTR	  expression	  and	  NGF	  co-­‐localization	  with	  p75NTR	  than	  TrkA	  in	  the	  current	  study.	  Further,	  co-­‐localization	  decreased	  in	  non-­‐smokers	  with	  exercise,	  and	  increased	  in	  smokers—indicating	  a	  mechanism	  through	  which	  smoking	  could	  result	  in	  greater	  DOMS.	  Greater	  expression	  of	  p75NTR	  and	  co-­‐localization	  with	  NGF	  suggest	  a	  “priming”	  effect,	  whereby	  nociceptors	  are	  already	  at	  a	  lower	  activation	  threshold.	  These	  nerves	  would	  respond	  more	  intensely	  to	  NGF	  and	  other	  signals,	  such	  as	  COX2.	  Unfortunately,	  the	  limited	  samples	  available	  for	  analysis	  did	  not	  allow	  me	  to	  investigate	  specifically	  the	  expression,	  localization,	  and	  co-­‐localization	  of	  NGF	  and	  its	  receptors	  to	  nerves	  within	  the	  muscle	  sections,	  and	  so	  specific	  effects	  of	  smoking	  to	  the	  nerve	  signaling	  of	  these	  proteins	  must	  be	  left	  for	  future	  study.	  Smoking	  likely	  enhances	  nerve	  sensitivity	  through	  multiple	  mechanisms:	  for	  example,	  COX2	  signaling	  (6)	  and	  transient	  receptor	  potential	  vanilloid	  1	  (TRPV1)(102),	  other	  hyperalgesic	  mediators,	  may	  play	  a	  role	  in	  greater	  DOMS	  in	  smokers	  and	  therefore	  additional	  study	  is	  needed.	  However,	  data	  from	  Dissertation	  Study	  2	  (Chapter	  4)	  and	  the	  current	  study	  do	  not	  support	  those	  pathways.	  Rather,	  these	  data,	  specifically	  the	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increase	  in	  NGF	  and	  p75NTR	  co-­‐localization	  after	  ECC	  in	  smokers,	  provide	  a	  mechanism	  through	  which	  DOMS	  is	  enhanced	  in	  smokers,	  possibly	  through	  continued	  NFκB	  activation	  (rather	  than	  suppression,	  as	  seen	  in	  non-­‐smokers)	  at	  48h	  after	  ECC.	  	  In	  summary,	  I	  found	  that	  smokers	  had	  a	  greater	  percentage	  of	  the	  less	  fatigue	  resistant	  Type	  II	  fibers,	  which	  may	  be	  a	  result	  of	  attenuated	  activation	  of	  the	  non-­‐canonical	  (REL-­‐B)	  NFκB	  pathway.	  Smokers	  also	  had	  suppressed	  ERK	  signaling	  and	  canonical	  (p65)	  NFκB	  activity,	  as	  well	  as	  a	  lack	  of	  NFκB	  response	  to	  ECC.	  These	  signaling	  differences	  may	  attenuate	  proliferation	  and	  muscle	  regeneration,	  prolong	  pro-­‐inflammatory	  signaling,	  and,	  potentially,	  suppress	  inflammatory	  resolution	  and	  healing.	  p75NTR	  levels	  were	  greater	  in	  smokers,	  as	  was	  its	  co-­‐localization	  with	  NGF,	  which	  increased	  after	  ECC.	  Taken	  together,	  this	  Dissertation	  suggests	  several	  mechanisms	  through	  which	  smokers	  are	  predisposed	  to	  greater	  muscle	  fatigue,	  soreness,	  and	  susceptibility	  to	  musculoskeletal	  injury.
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Tables	  and	  Figures	  
	  
Table	  5.1:	  In	  Silico	  Expression	  Profile	  Analysis.	  
See	  Supplemental	  page	  3	  
	  
	  
Figure	  5.1:	  Study	  Timeline.	  	  Blood	  was	  drawn	  at	  2	  visits,	  maximal	  voluntary	  contractions	  (MVCs;	  strength	  measure)	  were	  tested	  at	  4	  visits	  with	  a	  familiarization	  session	  at	  the	  initial	  visit,	  and	  eccentric	  exercise	  and	  biopsies	  were	  performed	  at	  one	  visit,	  each.	  	  
	  	  	  
Table	  5.2:	  qRT-­‐PCR	  Primers.	  	  NGF,	  nerve	  growth	  factor;	  NFKBIA,	  Nuclear	  factor	  of	  kappa	  light	  polypeptide	  gene	  enhancer	  in	  B-­‐cells	  inhibitor,	  alpha;	  TRAF6,	  TNF	  receptor-­‐associated	  factor	  6;	  B2M,	  Beta-­‐2-­‐microglobulin.	  
Target	   Primer	   Reference	  NGF	   Fwd:	  5'-­‐	  CAACAGGACTCACAGGAGCA	  -­‐3'	   (2)	  Rev:	  5'-­‐	  ACCTCTCCCAACACCATCAC	  -­‐3'	  NFKBIA	   Fwd:	  5'-­‐TGG	  CCT	  TCC	  TCA	  ACT	  TCC	  AGA	  ACA-­‐3'	   (137)	  Rev:	  5'-­‐CTC	  AGC	  AAT	  TTC	  TGG	  CTG	  GTT	  GGT	  -­‐3'	  TRAF6	   Fwd:	  5'-­‐TGATAGTGTGGGTGGAACTG-­‐3'	   (282)	  Rev:	  5'-­‐CTCCTTGGACAATCCTTCAG-­‐3'	  
B2M	   Fwd:	  5'-­‐TGTCTGGGTTTCATCCATCCGACA-­‐3'	   (137)	  Rev:	  5'-­‐TCACACGGCAGGCATACTCATCTT-­‐3'	  	  Rev:	  5'-­‐TCACACGGCAGGCATACTCATCTT-­‐3'	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Table	  5.3:	  Subject	  Characteristics.	  	  There	  were	  no	  significant	  differences	  between	  groups	  for	  height,	  weight,	  body	  mass	  index	  (BMI),	  or	  age.	  Data	  are	  presented	  as	  mean±SEM.	  	   N	   Age	  (y)	   Height	  (cm)	   Weight	  (kg)	   BMI	  Non-­‐smokers	   9	   22.0±0.8	   180.7±3.3	   82.2±2.8	   25.2±0.7	  Smokers	   10	   23.3±1.2	   173.2±2.0	   75.0±3.9	   25.0±1.2	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Table	  5.4:	  Isometric	  Flexion	  Maximal	  Voluntary	  Contraction.	  	  Data	  are	  presented	  as	  Nm,	  and	  are	  mean±SEM.	  *	  p<0.05	  effect	  of	  exercise;	  †	  p<0.05	  effect	  of	  group	  (smoke).	  
	   	   Time	  Post-­‐exercise	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Table	  5.5:	  Gene	  Expression	  after	  Eccentric	  Exercise.	  	  Arrays	  were	  comprised	  of	  44	  genes	  of	  interest,	  normalized	  to	  two	  housekeeping	  genes.	  Gene	  names	  and	  symbols	  from	  the	  National	  Institute	  of	  Health	  (NIH)	  National	  Center	  of	  Biotechnology	  (NCBI)	  database,	  June	  2015.	  Functions	  from	  NCBI,	  UniProt,	  Genecards,	  and	  published	  literature.	  Data	  are	  presented	  as	  fold	  change	  (exercise	  vs	  control	  leg)	  and	  were	  analyzed	  as	  ΔΔCt	  using	  repeated	  measures	  ANOVA,	  with	  significance	  based	  on	  false	  discovery	  rate	  (FDR):	  *	  p<0.007,	  effect	  of	  exercise;	  §	  p<0.003,	  interaction	  (group*exercise).	  No	  genes	  were	  significant	  (p<0.002)	  for	  the	  effect	  of	  group	  (smoke).	  	  
See	  Supplemental	  page	  4	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Figure	  5.4:	  PCR	  Array—Expression	  Affected	  by	  Exercise.	  	  Non-­‐smokers	  	  	  	  	  ;	  	  smokers	  	  	  	  	  .	  Data	  are	  presented	  as	  fold-­‐change	  (mean±SEM)	  and	  were	  analyzed	  (as	  ΔΔCt)	  using	  repeated	  measures	  ANOVA,	  with	  significance	  based	  on	  false	  discovery	  rate	  (FDR):	  *	  p<0.007,	  effect	  of	  exercise;	  §	  p<0.003,	  interaction	  (group*exercise).
	  	  	  
Figure	  5.5:	  qRT-­‐PCR	  Analyses—TRAF6,	  NFKBIA,	  and	  NGF.	  	  Non-­‐smokers	  	  	  	  	  ;	  smokers	  	  	  	  	  .	  Data	  are	  presented	  as	  fold	  change	  (mean±SEM).	  There	  were	  no	  significant	  effects	  of	  group	  or	  time.	  NGF,	  nerve	  growth	  factor;	  NFKBIA,	  nuclear	  factor	  kappa	  B	  inhibitor-­‐alpha;	  TRAF6,	  TNF-­‐associated	  factor	  6.	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Figure	  5.6:	  NFκB	  Activity	  Changes	  with	  Eccentric	  Exercise.	  	  Activity	  of	  (a)	  the	  canonical	  p65	  pathway;	  and	  (b)	  the	  non-­‐canonical	  REL-­‐B	  pathway	  at	  48h	  after	  ECC.	  Control	  	  	  	  	  ;	  exercise	  	  	  	  .	  §	  p<0.05,	  interaction	  (group*exercise);	  †	  p<0.05,	  effect	  of	  group	  (smoke).	  NFκB,	  nuclear	  factor	  kappa	  beta;	  p65	  (REL-­‐A),	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A;	  REL-­‐B,	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  B.	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Figure	  5.8:	  Myosin	  Heavy	  Chain	  Isoform	  Distribution.	  	  The	  percent	  of	  total	  fiber	  counts	  positive	  (	  	  	  	  )	  or	  negative	  (	  	  	  	  )	  for	  MHC-­‐I	  are	  shown	  (a),	  with	  average	  fiber	  counts	  per	  section	  displayed.	  Representative	  images	  of	  cross	  sections	  at	  12uM	  for	  non-­‐smokers	  (b)	  and	  smokers	  (c)	  are	  shown,	  with	  MHC-­‐I	  positive	  fibers	  in	  green	  and	  nuclei	  stained	  blue	  (DAPI).	  †	  p<0.05,	  effect	  of	  group	  (smoke).	  MHC,	  myosin	  heavy	  chain;	  DAPI,	  DAPI,	  4',6-­‐diamidino-­‐2-­‐phenylindole.	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Figure	  5.10:	  NGF	  and	  TrkA	  Co-­‐Localization.	  	  Representative	  images	  of	  muscle	  cross-­‐sections	  at	  12uM:	  non-­‐smoker	  (control:	  a-­‐c;	  exercise:	  d-­‐f)	  and	  smoker	  (control:	  g-­‐i,	  exercise:	  j-­‐l).	  Co-­‐localization	  are	  shown	  far	  left	  (a,	  d,	  g,	  j),	  NGF	  in	  center	  (green,	  b,	  e,	  h,	  k),	  and	  TrkA	  at	  right	  (c,	  f,	  i,	  l).	  NGF,	  nerve	  growth	  factor;	  TrkA,	  tyrosine	  receptor	  kinase	  A;	  DAPI,	  4',6-­‐diamidino-­‐2-­‐phenylindole.	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Figure	  5.11:	  NGF	  and	  p75NTR	  Co-­‐Localization.	  	  Representative	  images	  of	  cross	  sections	  at	  12uM:	  non-­‐smoker	  (control:	  a-­‐c;	  exercise:	  d-­‐f)	  and	  smoker	  (control:	  g-­‐i,	  exercise:	  j-­‐l).	  Co-­‐localization	  are	  shown	  far	  left	  (a,	  d,	  g,	  j),	  NGF	  in	  center	  (green:	  b,	  e,	  h,	  k),	  and	  p75NTR	  at	  right	  (red:	  c,	  f,	  i,	  l).	  NGF,	  nerve	  growth	  factor;	  p75NTR,	  p75	  neurotrophin	  receptor;	  DAPI,	  4',6-­‐diamidino-­‐2-­‐phenylindole.	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CHAPTER	  VI	  
SUMMARY	  The	  primary	  goal	  of	  this	  dissertation	  was	  to	  understand	  how	  smoking	  affects	  muscle	  damage	  and	  recovery.	  Data	  primarily	  from	  large-­‐scale	  epidemiological	  studies	  indicate	  that	  smokers	  are	  at	  greater	  risk	  for	  musculoskeletal	  injury	  (5,	  145,	  157,	  182,	  286)	  (145,	  157).	  Further,	  smokers	  have	  a	  greater	  risk	  for	  complications	  and	  prolonged	  healing	  time	  after	  injury	  or	  surgery	  (82,	  117,	  163).	  The	  mechanisms	  underlying	  these	  phenomena	  in	  skeletal	  muscle	  damage	  had	  not	  yet	  been	  explored,	  although	  dysregulated	  inflammatory	  responses	  are	  potential	  candidates	  (17,	  307,	  312,	  316).	  To	  investigate	  muscle	  injury	  and	  recovery	  in	  smokers,	  I	  used	  eccentric	  exercise	  contractions	  (ECC),	  a	  model	  of	  transient	  muscle	  damage,	  to	  elicit	  muscle	  stress.	  Prior	  to	  this	  dissertation,	  the	  effects	  of	  smoking	  on	  the	  response	  to	  ECC	  were	  unknown.	  Therefore,	  the	  first	  goal	  of	  this	  dissertation	  was	  to	  test	  if	  the	  functional	  responses	  of	  smokers	  to	  muscle	  stress	  were	  different	  from	  non-­‐smokers.	  I	  found	  that	  smokers	  experienced	  greater	  fatigue	  during	  exercise	  as	  well	  as	  greater	  delayed	  hyperalgesia,	  in	  the	  form	  of	  delayed	  onset	  muscle	  soreness	  (DOMS),	  after	  exercise.	  These	  novel	  findings	  provide	  insight	  into	  not	  only	  functional	  changes	  that	  may	  place	  smokers	  at	  a	  higher	  risk	  for	  injury	  when	  performing	  fatiguing	  tasks,	  but	  also	  suggests	  that	  there	  are	  molecular	  differences	  between	  smokers	  and	  non-­‐smokers	  that	  may	  affect	  their	  ability	  to	  recover	  from	  such	  strain.	  Soreness	  typically	  peaks	  in	  smokers	  at	  2d	  post-­‐ECC,	  a	  stage	  of	  flux	  after	  ECC	  during	  which	  the	  inflammatory	  balance	  shifts	  from	  favoring	  pro-­‐inflammatory	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actions	  (early)	  to	  favor	  anti-­‐inflammatory	  ones	  (late).	  However,	  little	  is	  known	  regarding	  the	  molecular	  responses	  of	  muscle	  to	  ECC	  at	  48h	  after	  exercise.	  Therefore,	  the	  second	  goal	  of	  this	  dissertation	  was	  to	  identify	  differences	  in	  the	  skeletal	  muscle	  transcriptome	  between	  the	  early	  and	  late	  inflammatory	  phases	  in	  non-­‐smokers	  and	  to	  use	  these	  results	  to	  identify	  candidate	  genes	  and	  pathways	  that	  may	  explain	  findings	  (greater	  soreness,	  less	  fatigue	  resistance)	  from	  Dissertation	  Study	  1	  (Chapter	  3)	  for	  further	  study.	  Transcriptome	  analysis	  indicated	  that	  canonical	  (p65:	  REL-­‐A,	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  A)	  nuclear	  factor	  kappa-­‐beta	  (NFκB),	  extracellular	  regulated	  kinase	  (ERK)1/2,	  and	  nerve	  growth	  factor	  (NGF)-­‐related	  signaling	  were	  all	  enhanced	  early	  and	  suppressed	  later.	  These	  pathways	  may	  act	  early	  to	  promote	  pro-­‐inflammatory	  signaling,	  proliferation,	  and	  DOMS.	  Thus,	  their	  reduced	  signaling	  activity	  at	  the	  later	  time	  point	  could	  indicate	  a	  return	  toward	  inflammatory	  balance	  and	  subsequent	  DOMS	  resolution.	  These	  pathways	  are	  also	  altered	  in	  various	  non-­‐muscle	  tissues/cells	  with	  smoke	  exposure,	  and	  so	  were	  further	  indicated	  for	  study	  in	  smokers.	  The	  final	  goal	  of	  this	  dissertation	  was	  to	  test	  potential	  mechanisms	  underlying	  the	  greater	  muscle	  fatigue	  found	  in	  Dissertation	  Study	  1	  (Chapter	  3)	  and	  to	  test	  the	  pathways	  identified	  in	  Study	  2	  (Chapter	  4)	  in	  smokers	  at	  48h	  after	  ECC.	  Smokers	  had	  a	  lower	  percentage	  of	  Type	  I	  (oxidative,	  fatigue	  resistant)	  muscle	  fibers.	  In	  addition,	  activity	  of	  the	  non-­‐canonical	  NFκB	  pathway	  (REL-­‐B,	  v-­‐rel	  avian	  reticuloendotheliosis	  viral	  oncogene	  homolog	  B),	  which	  stimulates	  oxidative	  metabolism	  and	  was	  increased	  in	  non-­‐smokers,	  also	  showed	  no	  change	  for	  smokers.	  The	  suppressed	  REL-­‐B	  activity	  suggests	  a	  mechanism	  through	  which	  smokers	  may	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suppress	  oxidative	  metabolism	  and,	  over	  time,	  muscle	  may	  adapt	  by	  shifting	  fiber	  types	  to	  favor	  the	  less	  fatigue-­‐resistant	  Type	  II	  fibers.	  These	  data	  support	  a	  mechanism	  through	  which	  smoking	  results	  in	  the	  higher	  muscle	  fatigability.	  	  I	  found	  that	  the	  activity	  of	  the	  canonical	  (p65)	  NFκB	  pathway,	  suppressed	  in	  non-­‐smokers	  after	  ECC,	  was	  unchanged	  in	  smokers.	  Smokers	  also	  had	  a	  lower	  nuclear	  ERK	  activity	  capacity	  and	  ERK	  activity	  in	  the	  cytosol,	  which	  could	  blunt	  signaling	  downstream	  of	  ERK	  and	  limit	  the	  overall	  ERK	  activity	  response.	  However,	  this	  difference	  from	  non-­‐smokers	  does	  not	  appear	  to	  relate	  to	  the	  NFκB	  signaling,	  as	  exercise	  did	  not	  affect	  ERK	  activity.	  Taken	  together,	  these	  data	  suggest	  that	  smokers	  may	  have	  baseline	  suppression	  of	  proliferation	  and	  inflammatory	  signaling	  downstream	  of	  ERK,	  and	  an	  impaired	  inflammatory	  response	  to	  muscle	  damage.	  These	  effects	  could	  attenuate	  proliferation,	  undermine	  inflammatory	  resolution,	  and	  blunt	  recovery,	  repair,	  and	  adaptation	  to	  muscle	  damage	  in	  smokers.	  Although	  there	  were	  no	  differences	  in	  overall	  NGF	  expression,	  smokers	  expressed	  higher	  protein	  levels	  of	  the	  low-­‐affinity	  NGF	  receptor,	  p75NTR.	  In	  addition,	  NGF	  co-­‐localization	  to	  p75NTR	  was	  greater	  in	  smokers	  after	  exercise	  yet	  decreased	  in	  non-­‐smokers.	  These	  data	  may	  explain	  why	  NFκB	  activity,	  which	  occurs	  downstream	  of	  p75NTR,	  fails	  to	  decrease	  at	  48h	  after	  ECC	  in	  smokers,	  and	  suggests	  a	  way	  in	  which	  there	  is	  a	  break	  down	  of	  pro-­‐inflammatory	  resolution.	  These	  data	  further	  suggest	  that	  smoking	  affects	  NGF	  signaling	  after	  muscle	  damage	  and	  provide	  a	  mechanism	  through	  which	  smoking	  increases	  DOMS.	  	  With	  this	  dissertation,	  I	  provided	  evidence	  that	  smoking	  attenuates	  fatigue	  resistance	  and	  enhances	  hyperalgesia,	  and	  mechanisms	  through	  which	  each	  of	  these	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gross	  responses	  may	  be	  affected.	  These	  data	  suggest	  two	  mechanisms	  that	  may	  increase	  heightened	  risk	  for	  muscle	  injury.	  Further,	  understanding	  the	  effects	  of	  smoking	  on	  muscle	  response	  to	  injury	  may	  lead	  to	  more	  specific	  recommendations	  for	  fitness	  interventions	  in	  smokers.	  Finally,	  these	  data	  may	  lead	  to	  the	  development	  of	  strategies	  to	  reduce	  overall	  risk	  for	  injury	  and	  promote	  muscle	  healing	  and	  regeneration.
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